backgroundcas
studi
recent
public
report
red
cell
transfus
previous
pregnant
femal
donor
markedli
increas
mortal
transfus
male
patient
find
wouldif
truehav
farreach
clinic
administr
implic
manag
blood
suppli
howev
result
may
influenc
bias
introduc
statist
analysi
studi
designmethod
separ
analyz
data
three
link
blood
donor
recipi
cohort
includ
data
us
scandinavia
long
time
period
patient
follow
time
first
red
cell
transfus
occurr
inhospit
longterm
mortal
use
separ
cox
regress
model
estim
associ
number
red
cell
transfus
femal
donor
previous
pregnant
donor
donor
sexdiscord
recipiental
treat
timedependentand
risk
death
control
total
number
red
cell
transfus
receiv
use
stratifi
cox
model
analys
perform
overal
effect
stratifi
recipi
sex
age
resultsfind
includ
total
patient
death
patient
death
patient
death
longer
follow
cohort
ii
iii
respect
associ
donor
characterist
inhospit
mortal
three
cohort
tabl
hazard
ratio
per
transfus
unit
parou
femal
donor
nonsignific
rang
result
similar
effect
donor
sex
sexdiscord
inhospit
mortal
tabl
well
longterm
mortal
two
cohort
data
shown
effect
estim
differ
recipi
sex
andor
age
categor
analys
show
neg
effect
heavili
expos
patient
conclus
joint
analysi
data
three
larg
cohort
transfus
patient
found
evid
associ
donor
sex
pariti
either
inhospit
longterm
patient
surviv
null
find
use
similar
statist
approach
across
million
patient
heterogen
clinic
set
differ
countri
indic
prior
find
seem
unlik
reflect
true
biolog
effect
backgroundcas
studi
platelet
essenti
optim
haemostasi
preserv
endotheli
glycocalyx
resuscit
shock
howev
day
shelflif
convent
roomtemperatur
store
platelet
mean
usual
avail
outsid
larg
hospit
cryopreserv
dimethylsuphoxid
extend
shelflif
year
reconstitut
plasma
requir
minim
time
specialis
equip
train
howev
despit
encourag
preclin
phase
data
one
phase
ii
trial
patient
receiv
cryopreserv
platelet
publish
clip
trial
program
seek
provid
suffici
phase
iii
trial
data
regulatori
approv
studi
designmethod
juli
decemb
hospit
enrol
cardiac
surgic
patient
particularli
high
risk
periop
bleed
identifi
use
trust
criteria
alghamdi
et
al
transfus
clipi
pilot
trial
patient
randomis
receiv
either
cryopreserv
liquidstor
platelet
treat
clinician
decid
platelet
transfus
indic
cryopreserv
platelet
prepar
australian
red
cross
blood
servic
use
method
base
netherland
militari
blood
bank
modif
origin
protocol
describ
us
navi
resultsfind
total
patient
randomis
receiv
platelet
transfus
studi
group
wellmatch
baselin
signific
differ
effect
outcom
trend
cryopreserv
group
requir
fewer
red
blood
cell
unit
transfus
median
iqr
vs
unit
trend
toward
cryopreserv
group
less
blood
chest
drain
median
iqr
vs
ml
composit
outcom
defin
bleed
academ
research
consortium
barc
trend
superior
cryopreserv
platelet
group
vs
clinic
import
differ
measur
advers
event
conclus
pilot
trial
cryopreserv
platelet
associ
evid
harm
small
nonsignific
trend
reduc
requir
red
cell
transfus
reduc
postop
blood
loss
light
data
clear
logist
advantag
cryopreserv
definit
studi
noninferior
design
test
volum
postop
bleed
primari
outcom
warrant
improv
identif
patient
high
risk
platelet
transfus
use
plateletspecif
transfus
risk
predict
score
increas
effici
phase
iii
trial
commun
assum
criteria
remain
accept
includ
absenc
msm
prior
year
follow
telephon
call
tollfre
number
reinstat
donor
also
recruit
donat
base
current
elig
reinstat
donor
requir
meet
donor
requir
donor
rate
id
marker
reinstat
donor
compar
chisquar
test
gener
donor
popul
donat
resultsfind
donor
return
donat
indefinit
msm
deferr
remov
donor
id
deferr
follow
reinstat
confirm
syphili
antihbcreact
occas
histori
prior
reinstat
antihbc
reactiv
post
reinstat
note
antihbc
reactiv
donor
also
incid
hiv
nat
convert
addit
donor
return
donat
subsequ
msm
deferr
id
deferr
follow
reinstat
confirm
syphili
one
donor
also
hiv
antibodynat
posit
acknowledg
ongo
msm
overal
rate
id
marker
routin
donor
compar
reinstat
indefinit
defer
msm
donor
p
odd
ratio
confid
interv
ci
reinstat
defer
msm
donor
p
ci
conclus
feder
fund
program
investig
variat
hbv
hcv
hiv
preval
incid
yet
detect
signific
chang
indic
compar
safeti
preand
postmsm
polici
chang
howev
review
msm
reinstat
donor
idmark
versu
gener
donor
show
trend
requir
care
monitor
incid
red
blood
cell
alloimmun
impact
prophylact
antigen
match
patient
warm
autoantibodi
meghan
delaney
torunn
oveland
apelseth
carolina
bonet
bub
claudia
cohn
nanci
dunbar
jose
kutner
michael
murphi
kathleen
selleng
juli
stave
silvano
wendel
alyssa
ziman
backgroundcas
studi
recent
assess
massiv
transfus
protocol
outcom
identifi
earli
transfus
plasma
result
improv
hemostasi
shorter
ventil
time
increas
surviv
infus
use
plasma
red
blood
cell
also
demonstr
signific
decreas
morbid
mortal
freezedri
plasma
fdp
product
success
use
altern
freshfrozen
plasma
ffp
howev
current
fdp
product
prepar
glass
bottl
limit
widespread
adopt
fdp
environ
battlefield
new
fdp
product
contain
reconstitut
plastic
blood
bag
use
ml
usp
steril
water
inject
within
less
two
minut
recent
develop
studi
designmethod
prospect
pair
open
label
singlecent
doseescal
phase
studi
determin
safeti
autolog
infus
whole
blood
cpd
deriv
fdp
plasmapheresi
acd
deriv
fdp
normal
healthi
subject
fdp
product
manufactur
minimum
volum
ml
ffp
three
cohort
subject
per
cohort
includ
result
infus
ml
cohort
cpd
acd
fdp
infus
ml
cohort
cpd
acd
fdp
infus
ml
cohort
acd
fdp
acd
ffp
infus
cohort
random
doubleblind
crossov
studi
compar
clinic
laboratori
level
thrombogenesi
biomark
fdp
vs
ffp
infus
clinic
laboratori
followup
perform
minut
hour
hour
day
postinfus
vitro
biochem
coagul
paramet
includ
ph
osmol
aptt
naptt
inr
factor
v
viii
viia
protein
antithrombin
iii
total
protein
level
also
analyz
data
safeti
monitor
board
review
subject
data
complet
infus
cohort
resultsfind
date
total
subject
screen
subject
enrol
assign
treatment
cohort
subject
infus
fdp
product
fdp
unit
reconstitut
less
two
minut
subject
seriou
advers
event
sae
relat
product
infus
occurr
predetermin
treatment
emerg
advers
event
teae
includ
thromboembol
event
infect
evid
unusu
bleedingbruis
elev
ddimer
level
observ
physic
examin
show
signific
chang
vital
sign
well
score
four
ae
relat
fdp
product
infus
observ
cohort
rhiniti
transient
weakli
posit
dat
hyperglycaemia
transient
mild
increas
liver
transaminas
ae
identifi
cohort
sign
either
local
system
allerg
reaction
observ
infus
cohort
infus
ongo
result
cohort
present
conclus
preliminari
data
suggest
fdp
well
toler
normal
healthi
volunt
sae
safeti
concern
backgroundcas
studi
substanti
donortodonor
variabl
well
store
human
rbc
circul
posttransfus
howev
basi
variabl
poorli
understood
report
like
human
rbc
genet
distinct
strain
mice
store
differ
genet
element
respons
differ
storag
mice
store
well
fvb
mice
store
poorli
map
studi
designmethod
individu
mice
gener
fvb
cross
analyz
regard
posttransfus
rbc
recoveri
ptr
high
resolut
metabolom
snp
base
genotyp
phenotyp
driven
backcross
also
carri
poorli
store
progeni
cross
mice
gener
congen
strain
new
transgen
mice
engin
overexpress
rbc
known
human
variant
human
clone
express
cho
cell
activ
measur
resultsfind
quantit
trait
locu
qtl
analysi
mice
identifi
mb
region
chr
associ
ptr
narrow
mb
contain
code
gene
mrna
level
quantifi
gene
rtpcr
erythroid
precursor
one
gene
show
significantli
differ
express
fvb
mice
compar
p
anova
bonferroni
correct
two
mrna
transcript
variant
mice
compar
fvb
fvb
mice
wild
type
transcript
fold
higher
transcript
fold
lower
p
p
respect
anova
bonferroni
correct
rbc
fvb
mice
twice
activ
fold
higher
protein
level
rbc
overexpress
transgen
mice
result
signific
decreas
ptr
store
rbc
compar
wildtyp
p
lipid
oxid
correl
poor
ptr
cohort
refin
cluster
oxylipin
carri
strain
transgen
mice
known
natur
variant
human
wide
varieti
activ
conclus
multipl
line
evid
use
differ
approach
identifi
genet
element
regul
ptr
ferrireductas
convert
suggest
mechan
promot
fenton
reaction
ensu
oxid
lipid
human
mice
share
orthologu
ident
amino
acid
level
null
mice
defici
human
similar
anemia
knowledg
report
first
indic
role
biolog
matur
rbc
human
variant
differ
activ
test
rbc
storag
test
hypothesi
human
would
requir
studi
ptr
rbc
donor
genet
variat
gene
involv
base
pathway
red
blood
cell
alloimmun
respons
transfus
blood
requir
splenic
margin
zone
macrophag
abhinav
arneja
juan
salazar
manjula
santhanakrishnan
jeann
hendrickson
chanc
j
luckey
univers
virginia
yale
univers
backgroundcas
studi
alloimmun
nonabo
red
blood
cell
rbc
antigen
remain
signific
clinic
problem
transfus
medicin
presenc
rbc
alloantibodi
lead
delay
transfus
reaction
result
signific
morbid
occasion
mortal
transfus
rbc
repres
uniqu
immun
stimulu
lack
tradit
pathogen
signal
stimul
innat
immun
respons
molecular
cellular
mechan
involv
stimul
immun
respons
transfus
rbc
remain
unclear
recent
work
mous
model
shown
storag
rbc
prior
transfus
lead
signific
enhanc
alloimmun
studi
independ
implic
macrophag
spleen
critic
immun
respons
store
rbc
splenic
margin
zone
macrophag
mzm
report
stimul
innat
immun
also
promot
adapt
immun
respons
certain
bloodborn
pathogen
addit
splenic
mzm
specif
phagocytos
intraven
inject
apoptot
cell
result
immun
suppress
toward
apoptot
cell
antigen
uptak
apoptot
cell
mzm
critic
depend
exposur
phosphatidylserin
ps
cell
surfac
exposur
ps
surfac
rbc
increas
rbc
age
significantli
enhanc
storag
hypothes
splenic
mzm
phagocytos
transfus
store
rbc
unlik
apoptot
cell
stimul
innat
adapt
immun
respons
rbc
antigen
studi
designmethod
investig
role
mzm
rbc
alloantibodi
gener
util
hod
mous
model
compar
alloimmun
wildtyp
wt
liver
x
receptor
knockout
ko
mice
transcript
factor
essenti
gener
backgroundcas
studi
prophylact
administr
polyclon
antirhd
women
prevent
matern
alloimmun
howev
certain
condit
prepar
antirhd
paradox
enhanc
alloimmun
underli
mechan
behind
modul
humor
alloimmun
antirhd
unknown
howev
recent
becom
appreci
differ
igg
subtyp
antibodi
may
differenti
regul
alloimmun
herein
take
reductionist
approach
passiv
immun
mice
monoclon
alloantibodi
wherebi
antibodi
specif
differ
igg
subtyp
test
igg
subtyp
regul
rbc
alloimmun
studi
designmethod
new
monoclon
antiduffi
isol
sequenc
classswitch
differ
mous
igg
subtyp
individu
subtyp
passiv
infus
mice
follow
transfus
pack
leukoreduc
rbc
consist
hod
label
lipophil
dye
allow
track
hod
rbc
express
rbcspecif
tripl
fusion
protein
consist
hen
egg
lysozym
ovalbumin
ova
human
duffi
recipi
receiv
adopt
transfer
otii
cell
recogn
ova
contain
within
hod
present
recipi
mhcii
alloantibodi
assess
day
measur
flow
crossmatch
hod
control
rbc
target
resultsfind
passiv
immun
enhanc
antihod
alloantibodi
product
experi
p
led
increas
neither
modul
alloimmun
compar
control
addit
mechanist
studi
focus
passiv
immun
acceler
hod
rbc
clearanc
circul
everi
time
point
analyz
compar
syngen
rbc
addit
treatment
led
signific
increas
hod
rbc
consumpt
p
experi
increas
observ
dendrit
cell
dc
red
pulp
macrophag
lesser
extent
plasmacytoid
dc
neutrophil
cumul
effect
alter
rbc
consumpt
pattern
mice
result
signific
increas
otii
prolifer
p
experi
conclus
current
find
indic
preexist
antirbc
alloantibodi
modul
futur
rbc
alloantibodi
product
particular
enhanc
alloantibodi
product
acceler
rbc
clearanc
shift
pattern
consumpt
individu
immunostimulatori
antigen
present
cell
subset
cumul
effect
chang
enhanc
cell
activ
prolifer
lead
increas
rbc
alloantibodi
polyclon
antirhd
contain
multipl
antibodi
subtyp
vari
ratio
find
may
provid
insight
prepar
rhd
certain
condit
enhanc
alloimmun
paurvi
shind
krystalyn
e
hudson
ariel
hay
jenna
lebedev
heather
l
howi
ellen
van
der
schoot
gestur
vidarsson
xiaohong
wang
jame
c
zimr
bloodworksnw
research
institut
sanquin
blood
suppli
research
sanquin
research
backgroundcas
studi
addit
better
known
effector
function
antibodi
also
known
regul
primari
immun
respons
eg
administr
polyclon
antirhd
prevent
matern
alloimmun
attempt
gener
monoclon
antirhd
complic
iron
prepar
enhanc
rather
suppress
human
trial
likewis
administr
plasma
deriv
antirhd
caus
enhanc
set
underli
factor
andor
mechan
regul
enhanc
suppress
poorli
understood
investig
process
use
tractabl
mous
model
express
variant
kell
rbc
allow
transfus
rbc
antigenneg
recipi
allotransfus
studi
designmethod
monoclon
isol
sequenc
recombin
dna
technolog
use
express
variabl
domain
differ
mous
igg
subtyp
isol
subtyp
infus
mice
follow
transfus
one
unit
rbc
microlit
alloimmun
measur
test
serum
igm
day
igg
day
via
flow
crossmatch
rbc
recipi
mice
includ
target
delet
common
gamma
chain
fcgr
fcgri
fcgriii
tradit
cellular
surfac
plasmon
reson
spr
assay
perform
assess
affin
differ
fcgr
resultsfind
significantli
enhanc
alloimmun
exampl
combin
data
experi
treat
vs
control
mice
igm
vs
p
igg
vs
p
enhanc
observ
use
antibodi
thirdparti
antigen
likewis
signal
detect
mice
receiv
antibodi
transfus
addit
mechanist
studi
focus
subtyp
enhanc
lost
mice
delet
common
fc
gamma
chain
fcgr
suggest
fcgri
fcgriii
fcgriv
combin
requir
enhanc
enhanc
elimin
fcgri
mice
unalt
fcgriii
mice
addit
spr
analysi
reveal
affin
highest
fcgri
find
demonstr
fcgri
fcgriii
requir
mediat
enhanc
alloantibodi
respons
rbc
conclus
current
find
indic
antirbc
antibodi
influenc
humor
alloimmun
process
depend
upon
igg
subtyp
enhanc
alloimmun
mechanist
enhanc
requir
fcgri
enhanc
lost
fcgri
null
mice
none
fcgr
suffici
enhanc
rule
may
involv
backgroundcas
studi
transfusionassoci
circulatori
overload
taco
one
lead
caus
transfusionrel
major
morbid
mortal
hydrostat
pulmonari
edema
key
major
risk
factor
includ
speed
volum
transfus
date
preclin
studi
investig
infus
speed
volum
pulmonari
capillari
pressur
aim
studi
develop
rat
model
taco
investig
influenc
risk
factor
studi
designmethod
twohit
rat
model
develop
use
lewi
rat
blood
harvest
donor
rat
use
make
red
blood
cell
unit
rbc
follow
nation
blood
bank
practic
gener
anesthesia
cardiac
leftventricular
pressur
transduc
place
isovolem
anemia
induc
replac
circul
volum
colloid
solut
larg
myocardi
infarct
induc
ligat
leftanterior
descend
coronari
arteri
firsthit
anim
random
per
group
receiv
unit
rbc
minut
secondhit
anim
followedup
posttransfus
primari
outcom
differ
leftventricular
enddiastol
pressur
dlvedp
gold
standard
measur
increas
pulmonari
pressur
hallmark
taco
secondari
outcom
includ
lung
wetdri
ratio
wdr
hemodynam
paramet
resultsfind
pretransfus
lvedp
mmhg
iqr
follow
transfus
signific
increas
dlvedp
seen
vs
vs
unit
resp
p
p
higher
transfus
speed
trend
toward
higher
pressur
significantli
differ
elev
lvedp
baselin
persist
hour
transfus
unit
group
ns
wdr
show
differ
unit
transfus
speed
conclus
first
anim
transfus
model
investig
effect
transfus
speed
pulmonari
hydrostat
pressur
key
featur
taco
strong
dosedepend
effect
transfus
volum
pulmonari
hydrostat
pressur
found
higher
transfus
speed
show
trend
toward
higher
pressur
signific
model
futur
experi
model
allow
test
intervent
therapeut
strategi
prevent
taco
backgroundcas
studi
cultur
residu
compon
detect
septic
transfus
reaction
str
accord
aabb
criteria
signssymptom
suggest
str
includ
fever
rise
plu
follow
rigor
hypotens
shock
tachycardia
dyspnea
andor
nauseavomit
isol
hypotens
limit
criteria
includ
hypotens
tachycardia
undefin
fever
may
occur
absenc
signssymptom
fever
may
occur
patient
premed
antipyret
goal
project
develop
improv
criteria
detect
str
cultur
residu
product
adult
patient
studi
designmethod
collect
retrospect
data
transfus
reaction
adult
year
result
cultur
residu
product
calendar
year
also
collect
data
reaction
posit
residu
product
cultur
result
enrich
dataset
posit
result
modifi
aabb
criteria
defin
hypotens
systol
blood
pressur
mmhg
andor
diastol
blood
pressur
mmhg
anddecreas
baselin
tachycardia
increas
baselin
also
modifi
recommend
cultur
fever
absenc
signssymptom
absenc
fever
patient
premed
antipyret
signssymptom
present
retrospect
determin
sensit
specif
backgroundcas
studi
septic
transfus
reaction
str
suspect
aabb
bulletin
recommend
test
return
product
bacteri
contamin
well
draw
blood
sampl
patient
cultur
grow
bacteri
speci
two
sourc
support
diagnosi
str
howev
patient
blood
cultur
neg
set
true
str
patient
antibiot
therapi
time
transfus
multicent
retrospect
intern
studi
describ
rate
patient
cultur
set
product
cultur
organ
detect
cultur
studi
designmethod
collect
data
transfus
reaction
residu
product
cultur
calendar
year
includ
recipi
demograph
data
type
product
implic
patient
andor
product
cultur
result
data
set
addit
enrich
case
product
cultur
posit
imput
clinic
signific
posit
product
cultur
defin
definit
str
patient
cultur
grew
organ
possibl
str
patient
cultur
cultur
neg
grew
differ
organ
product
resultsfind
transfus
reaction
product
cultur
institut
patient
concurr
cultur
eightyeight
product
cultur
grew
bacteri
organ
posit
product
cultur
concord
patient
cultur
definit
imput
organ
implic
either
member
skin
microbiota
staphylococcu
spp
gastrointestin
tract
escherichia
coli
case
patient
blood
cultur
grew
nonconcord
organ
tabl
case
patient
cultur
neg
possibl
imput
remain
case
patient
cultur
unabl
assess
imput
conclus
minor
patient
concurr
blood
cultur
obtain
residu
product
cultur
workup
str
imput
therefor
could
assign
posit
product
cultur
isol
bacteri
speci
patient
product
allow
assign
definit
imput
case
posit
product
cultur
transfus
reaction
sign
symptom
warrant
cultur
residu
product
patient
blood
cultur
collect
concurr
aid
interpret
product
cultur
result
report
rate
lower
plasma
compar
plt
rbc
p
differ
reaction
cultur
rate
compon
type
observ
tabl
survey
result
demonstr
mark
variat
institut
cultur
polici
major
center
use
publish
criteria
cultur
str
center
allow
cultur
residu
unit
without
medic
director
approv
formal
review
process
trigger
str
investig
center
report
histor
clinic
relev
str
overal
higher
reaction
cultur
rate
vs
p
suggest
recal
bia
may
driver
increas
cultur
conclus
mark
variat
institut
practic
surround
cultur
residu
compon
detect
str
histor
report
clinic
relev
str
appear
result
higher
cultur
rate
opportun
practic
standard
transfusionassoci
circulatori
overload
understand
pathogenesi
robert
klanderman
joachim
bosboom
marij
wijnberg
adri
maa
margreeth
vroom
nicol
jufferman
marku
hollmann
bart
geert
alexand
vlaar
depart
intens
care
medicin
academ
medic
center
laboratori
experiment
intens
care
anesthesiolog
academ
medic
center
depart
anesthesiolog
academ
medic
center
backgroundcas
studi
transfusionassoci
circulatori
overload
taco
one
lead
caus
transfusionrel
morbid
mortal
definit
taco
caus
hydrostat
pulmonari
edema
due
circulatori
overload
exact
pathophysiolog
howev
unclear
case
occur
transfus
unit
date
anim
model
abl
induc
taco
sinc
healthi
heart
abl
deal
larg
infus
volum
hypothes
underli
volum
incompli
eg
cardiac
dysfunct
subsequ
transfus
caus
taco
aim
induc
taco
anim
model
investig
pathophysiolog
studi
designmethod
twohit
taco
model
develop
use
lewi
rat
gener
anesthesia
leftventricl
catheter
use
colloid
circul
volum
replac
induc
isovolem
anemia
larg
myocardi
infarct
induc
ligat
leftanterior
descend
coronari
arteri
firsthit
rat
random
per
group
receiv
unit
rbc
prepar
donor
rat
similar
volum
lactat
ringer
lr
minut
secondhit
anim
follow
posttransfus
primari
outcom
leftventricular
enddiastol
pressur
lvedp
gold
standard
measur
increas
pulmonari
capillari
pressur
hallmark
taco
secondari
outcom
lung
watercont
resultsfind
baselin
hemodynam
similar
group
lvedp
mmhg
iqr
larg
increas
lvedp
tabl
seen
directli
infus
rbc
lr
p
posttransfus
lvedp
dissip
rapidli
fluid
infus
group
minut
p
signific
anymor
lung
watercont
differ
group
conclus
twohit
model
anem
rat
underli
cardiac
dysfunct
blood
fluid
infus
increas
pulmonari
capillari
pressur
taco
model
first
compar
fluid
blood
product
measur
direct
pulmonari
capillari
pressur
pulmonari
edema
blood
transfus
profoundli
differ
effect
capillari
pressur
lung
studi
current
underpow
detect
differ
pulmonari
edema
howev
inclus
ongo
data
suggest
taco
pathophysiolog
sole
fluid
overload
blood
center
pacificirwin
center
backgroundcas
studi
transfusionassoci
circulatori
overload
taco
common
often
sever
advers
reaction
blood
transfus
associ
increas
morbid
mortal
sought
develop
predict
algorithm
would
use
pretransfus
patient
characterist
identifi
patient
high
risk
develop
taco
transfus
studi
designmethod
case
control
studi
four
academ
hospit
util
activ
surveil
enrol
case
taco
well
match
transfus
control
without
pulmonari
edema
measur
cardiac
stress
ntermin
probrain
natriuret
peptid
ntprobnp
measur
case
taco
control
prior
follow
transfus
case
detect
algorithm
identifi
patient
highest
risk
taco
develop
use
classif
regress
tree
cart
analys
evalu
approxim
pretransfus
risk
factor
produc
rank
import
predictor
order
rel
import
predict
taco
algorithm
perform
evalu
use
crossvalid
misclassif
error
rate
averag
squar
error
ase
sensit
specif
receiv
oper
characterist
curv
analys
use
determin
accuraci
pretransfus
clinic
predictor
differenti
taco
control
resultsfind
inform
determin
case
taco
versu
control
statu
pretransfus
sf
ratio
ntprobnp
level
hospit
set
histori
hypertens
elev
systol
blood
pressur
respiratori
rate
pretransfus
hemoglobin
level
gdl
patient
pretransfus
sf
ratio
less
ntprobnp
level
greater
orpacu
emerg
depart
procedur
suit
set
highest
probabl
develop
taco
patient
pretransfus
sf
ratio
greater
respiratori
rate
less
lowest
probabl
develop
taco
algorithm
perform
excel
discrimin
taco
vs
control
area
curv
cart
analysi
achiev
misclassif
rate
ase
sensit
specif
conclus
cartbas
screen
algorithm
differenti
case
taco
transfus
control
use
pretransfus
clinic
data
casecontrol
set
classif
tree
algorithm
may
improv
identif
patient
risk
develop
taco
prospect
studi
need
assess
util
realtim
predict
algorithm
plu
clinic
intervent
prevent
taco
largescal
hospit
patient
cohort
backgroundcas
studi
massachusett
blood
bank
requir
massachusett
depart
public
health
mdph
submit
monthli
transfus
activ
advers
reaction
data
nation
healthcar
safeti
network
nhsn
hemovigil
modul
sinc
june
standard
statewid
data
collect
allow
comprehens
analys
includ
potenti
gener
local
benchmark
transfusionassoci
circulatori
overload
taco
current
interest
due
intern
discuss
propos
modif
current
surveil
case
definit
result
perceiv
local
increas
taco
incid
examin
data
submit
involv
taco
report
find
studi
designmethod
taco
reaction
meet
nhsn
case
definit
imput
criteria
possibl
probabl
definit
facil
includ
analyz
age
gender
product
receiv
transfus
indic
hospit
bed
size
select
clinic
criteria
use
sa
rate
calcul
per
unit
transfus
resultsfind
taco
reaction
report
mean
year
femal
age
age
year
notabl
two
age
facil
bed
report
taco
reaction
occur
bed
bed
rate
taco
per
unit
transfus
facil
bed
bed
bed
indic
transfus
document
medic
frequent
follow
malign
intern
bleed
hematolog
disord
surgeri
season
variat
observ
lowest
incid
taco
occur
june
juli
rate
taco
increas
unit
transfus
studi
period
threeyear
taco
rate
per
unit
transfus
product
type
plasma
platelet
highest
rbc
conclus
modest
increas
taco
observ
threeyear
period
well
bimod
age
distribut
among
case
season
variat
higher
rate
among
smaller
facil
provid
guidanc
target
awar
potenti
intervent
limit
includ
lack
extern
data
valid
possibl
inconsist
case
definit
interpret
applic
studi
demonstr
util
nhsn
trend
identif
select
reaction
analysi
target
transfus
safeti
effort
transfus
incorrect
blood
compon
ibct
report
norwegian
hemovigil
system
aurora
espinosa
flesland
christin
torsvik
norwegian
director
health
backgroundcas
studi
norwegian
hemovigil
system
implement
voluntari
report
system
becom
mandatori
seriou
advers
event
norwegian
hemovigil
system
ibct
report
transfus
complic
even
patient
experi
symptom
studi
designmethod
ibct
defin
transfus
blood
compon
intend
anoth
patient
transfus
blood
compon
compli
specifi
requir
clinic
reaction
sever
well
caus
error
regist
includ
error
order
blood
compon
select
issu
label
test
bedsid
patient
identif
resultsfind
period
norwegian
hemovigil
system
receiv
case
ibct
includ
case
blood
compon
transfus
wrong
patient
case
blood
compon
meet
specifi
requir
four
addit
case
blood
compon
fail
meet
expect
requir
transfus
wrong
patient
exampl
nonconform
regard
lack
specifi
requir
blood
compon
lack
irradi
requir
transfus
incompat
red
cell
presenc
previous
identifi
red
cell
antibodi
thirtyf
report
ibct
occur
patient
age
twenti
case
transfus
blood
compon
meet
specifi
requir
total
number
case
multipl
error
report
hemolyt
transfus
reaction
caus
ibct
twenti
abo
incompat
case
six
case
caus
incompat
blood
group
system
abo
even
antibodi
known
prior
transfus
nine
aboincompat
blood
transfus
less
sever
reaction
ten
seriou
lifethreaten
three
fatal
two
patient
known
antiiga
anaphylact
reaction
transfus
red
blood
cell
concentr
patient
receiv
incorrect
blood
compon
advers
reaction
error
frequent
relat
order
blood
compon
clinic
depart
select
issu
blood
compon
blood
bank
inadequ
bedsid
patient
identif
prior
transfus
one
assum
case
patient
receiv
blood
compon
intend
anoth
patient
bedsid
patient
ident
control
perform
accord
local
guidelin
conclus
error
occur
area
transfus
chain
high
number
case
multipl
error
made
case
blood
compon
transfus
wrong
patient
could
prevent
adequ
bedsid
patient
identif
perform
main
caus
lead
ibct
error
regard
order
blood
product
inadequ
bedsid
patient
identif
patient
age
twenti
main
caus
ibct
transfus
blood
compon
meet
specifi
requir
especi
irradi
norwegian
hemovigil
system
strongli
recommend
use
electron
patient
identif
transfus
reduc
number
transfus
blood
compon
intend
anoth
patient
hospit
norway
implement
system
backgroundcas
studi
transfus
entail
risk
acut
disturb
febril
f
allerg
andor
cardiorespiratori
c
present
although
overal
odd
transfus
reaction
tr
low
minor
respiratori
transfus
reaction
rtr
likeli
sever
lead
caus
transfusionrel
morbid
mortal
rtr
may
cardiogen
transfusionassoci
circulatori
overload
taco
andor
noncardiogen
latter
rang
direct
insult
transfusionrel
acut
lung
injuri
trali
allerg
bronchopulmonari
transfus
reaction
abtr
indirect
manifest
injuri
bacteri
contamin
acut
hemolyt
incompat
criteria
met
harm
underli
diseas
progress
play
role
diagnosi
exclus
transfus
associ
dyspnea
tad
tr
rtr
particular
challeng
investig
patient
complex
comorbid
work
environ
inform
gap
extent
tr
patient
present
multipl
disturb
extent
review
reach
conclus
certain
mere
possibl
interest
measur
tr
investig
especi
rtr
studi
designmethod
hemovigil
databas
academ
adult
healthcar
institut
compris
site
transfus
componentsyear
consecut
tr
retrospect
analyz
mode
present
fac
multipl
mode
present
count
measur
complex
final
conclus
respect
conclusionspecif
certaintyimput
underw
review
gaug
diagnost
confid
rtr
also
analyz
number
conclus
reach
per
case
frequenc
taco
trali
abtr
tad
conclus
respect
certainti
resultsfind
year
tr
investig
transfus
laboratori
team
fever
occur
case
rtr
note
referr
one
disturb
eg
fc
occur
case
referr
provision
diagnosi
tr
referr
ultim
certain
possibl
case
rtr
conclus
reach
valu
greater
number
referr
conclus
stratifi
low
confid
possibl
rule
versu
high
confid
probabl
definit
weight
low
confidenceskew
rtr
categori
taco
trali
tad
versu
abtr
respect
overal
ratio
low
confid
high
confid
rtr
conclus
tad
code
time
commonest
conclus
taco
conclus
overal
tr
present
one
disturb
referr
tr
reach
conclus
better
possibl
likeliest
provision
diagnosi
rtr
compar
problemat
conclus
reach
case
backgroundcas
studi
babesia
protozoan
parasit
infect
red
blood
cell
lead
infecti
caus
mortal
transfus
recipi
report
fda
babesia
usual
transmit
via
tick
may
transfus
transmit
ttb
mother
child
pregnanc
deliveri
prospect
test
blood
donat
endem
area
us
reveal
donor
posit
babesia
dna
antibodi
us
fda
current
requir
donor
screen
babesia
plan
issu
draft
guidanc
recommend
reduc
ttb
risk
includ
requir
screen
blood
donat
studi
designmethod
coba
babesia
use
coba
system
highlysensit
qualit
polymeras
chain
reaction
nucleic
acid
amplif
test
pcrnat
develop
detect
whole
blood
wb
year
screen
idnat
mpnat
screen
context
fifti
unit
state
district
columbia
individu
recipi
blood
compon
exposur
sampl
data
zikarel
advers
health
event
experienc
transfus
recipi
sexual
partner
infant
born
recipi
sexual
partner
captur
model
run
vari
zikv
rate
confirmedposit
unit
everi
blood
unit
collect
everi
million
estim
uncertainti
calcul
use
probabilist
sensit
analysi
assum
willingnesstopay
threshold
million
per
qualityadjust
life
year
gain
qali
resultsfind
estim
mpnat
costeffect
donor
popul
zikv
rate
exce
posit
unit
per
thousand
trigger
strategi
idnat
costeffect
popul
zikv
rate
exce
per
thousand
zikv
rate
per
million
estim
transfusiontransmiss
zikv
would
result
one
case
mild
febril
ill
everi
month
ci
month
one
case
guillainbarr
everi
year
ci
year
one
case
congenit
zika
syndrom
everi
year
ci
year
screen
estim
outcom
variou
zikv
rate
report
tabl
conclus
peak
zika
epidem
america
zikv
rate
among
donor
fifti
unit
state
approach
threshold
univers
mpnat
idnat
would
consid
costeffect
threshold
even
million
per
qali
exclus
screen
donor
group
higher
expect
zikv
rate
donor
recent
travel
resid
area
experienc
autochthon
zika
transmiss
may
costeffect
evid
analysi
consid
alongsid
risk
benefit
genet
variabl
zika
viru
isol
us
blood
donor
andriyan
grinev
felip
assi
evgeniya
volkova
emilia
sippert
rafael
faresgusmao
suzan
ok
bruno
rocha
caren
chancey
maria
rio
backgroundcas
studi
zika
viru
zikv
flaviviru
relat
spondweni
dengu
virus
spread
aed
mosquito
also
transmit
human
human
sexual
contact
mother
fetu
pregnanc
blood
transfus
zikv
infect
asymptomat
seriou
diseas
manifest
includ
neurolog
disord
birth
defect
microcephali
may
occur
zika
diseas
becam
threat
public
health
us
addit
travelrel
case
local
transmiss
report
continent
us
us
blood
suppli
screen
zikv
rna
sinc
use
investig
later
fdalicens
nucleic
acid
test
nat
mutat
viral
genom
may
potenti
neg
affect
zikv
blood
screen
caus
mismatch
viral
sequenc
primer
probe
detect
nat
therefor
studi
aim
analyz
genet
divers
human
zikv
isol
us
panama
studi
designmethod
anonym
plasma
sampl
obtain
variou
blood
collect
facil
isol
expand
cultur
vero
cell
viral
rna
purifi
cell
supernat
sequenc
use
sanger
method
complet
zikv
genom
isol
collect
epidem
puerto
rico
florida
sequenc
addit
analyz
clinic
isol
panama
zikv
sequenc
align
use
mega
softwar
zikv
genom
also
subject
bayesian
maximum
likelihood
phylogenet
analysi
resultsfind
viral
isol
blood
donor
collect
show
averag
nucleotid
diverg
compar
ancestor
micronesia
strain
genbank
usual
among
flavivirus
nucleotid
chang
silent
transit
c
g
number
nucleotid
mutat
rang
result
amino
acid
substitut
isol
geograph
locat
genet
similar
phylogenet
zikv
isol
florida
cluster
togeth
isol
hondura
nicaragua
isol
puerto
rico
panama
cluster
caribbean
clade
togeth
isol
puerto
rico
panama
colombia
conclus
level
zikv
genet
divers
observ
studi
warrant
monitor
zikv
among
human
popul
ensur
suitabl
current
licens
investig
blood
donor
screen
assay
determin
whether
zikv
divers
may
associ
function
chang
viral
gene
backgroundcas
studi
follicular
regulatori
tfr
cell
recent
identifi
special
subset
regulatori
treg
cell
locat
germin
center
gc
suppress
follicular
helper
tfh
cell
b
cell
antibodi
product
tfr
cell
play
import
regulatori
role
pathogenesi
autoimmun
diseas
like
sle
addit
baicalin
natur
compound
isol
chines
herb
report
promot
express
differenti
treg
cell
amelior
kidney
inflamm
lupuspron
mrllpr
mice
thu
specul
tfr
cell
plu
baicalin
might
promis
cellular
therapeut
approach
treatment
antibodymedi
autoimmun
diseas
studi
determin
baicalin
could
effect
induc
tfr
cell
treg
cell
baicalininduc
tfr
cell
also
could
reliev
lupu
nephriti
mous
model
studi
designmethod
vitro
naiv
cell
first
purifi
spleen
mice
stimul
baicalin
plu
ab
term
baicalininduc
tfr
cell
phenotyp
prolifer
seriou
cytokin
product
suppress
tfr
cell
assess
meanwhil
baicalininduc
tfr
cell
vehicleinduc
tfr
cell
transfer
iv
mrllpr
mice
week
last
week
control
mice
treat
pb
urin
protein
measur
everi
week
histopatholog
test
kidney
antidsdna
antibodi
titer
cytokin
serum
th
subset
spleen
analyz
mice
treat
tfr
cell
week
resultsfind
baicalin
induct
day
vitro
percent
tfr
cell
cell
increas
significantli
treg
cell
show
posit
express
high
level
key
marker
tfr
cell
baicalin
could
promot
tfr
cell
differenti
accompani
induc
product
baicalininduc
tfr
cell
could
effect
inhibit
tfh
cell
prolifer
suppress
secret
induc
tfh
cell
apoptosi
vitro
determin
suppress
function
baicalininduc
tfr
cell
vivo
sle
mous
model
use
treatment
remark
antiinflammatori
activ
improv
clinic
renal
score
histolog
endpoint
kidney
found
baicalininducedtfrtr
group
tfrtreat
group
treatment
baicalininduc
tfr
cell
could
significantli
decreas
antidsdna
antibodi
titer
serum
reduc
urin
protein
tfr
cell
treatment
moreov
transfus
baicalininduc
tfr
cell
result
obviou
decreas
percentag
tfh
cell
lower
level
conclus
result
indic
tfr
cell
induc
baicalin
show
effect
suppress
vitro
reduc
markedli
sever
progress
lupu
nephriti
tfr
cell
sle
mous
model
associ
modul
tfhthr
polar
secret
vivo
studi
highlight
baicalin
might
assist
stimul
tfr
cell
expans
baicalininduc
tfr
cell
show
potenti
therapeut
util
lupu
backgroundcas
studi
mesenchym
stromal
cell
msc
show
promis
treatment
trauma
although
mechan
action
fulli
understood
msc
possess
properti
may
limit
postinjuri
damag
promot
heal
antiinflammatoryimmun
modulatori
activ
msc
interact
affect
function
sever
immun
cell
type
studi
investig
interact
msc
innat
lymphoid
cell
ilc
ilc
import
rapid
respond
infect
like
also
import
respons
trauma
beyond
previous
identifi
cytotox
natur
killer
nk
cell
sever
noncytotox
subtyp
describ
differ
inflammatoryantiinflammatori
function
propos
subtyp
thu
subtyp
ratio
import
may
chang
injuri
treatment
light
interact
msc
immun
cell
propos
interact
ilc
interact
alter
function
cell
type
studi
designmethod
msc
commerci
sourc
use
earli
passag
human
peripher
blood
mononuclear
cell
pbmc
isol
deidentifi
human
whole
blood
collect
isr
research
blood
bank
approv
standard
oper
procedur
ilc
subtyp
identif
perform
flow
cytometri
ilc
enrich
whole
blood
use
easysep
human
panilc
magnet
enrich
kit
stemcel
technolog
cocultur
perform
rpmi
medium
supplement
fb
day
nonadher
cell
subject
flow
cytometri
identif
ilc
subtyp
resultsfind
ilc
subtyp
character
whole
blood
perform
individu
donor
high
degre
variat
donor
observ
magnet
enrich
pbmc
increas
number
ilc
total
event
compar
unenrich
pbmc
allow
accur
ilc
subtyp
character
human
pbmc
cultur
presenc
absenc
human
adiposederiv
msc
differ
subtyp
distribut
observ
day
pbmc
alon
compar
pbmc
cocultur
msc
conclus
base
current
studi
conclud
identifi
whole
human
blood
pbmc
flow
cytometri
variabl
subset
distribut
differ
donor
enrich
ilc
magnet
separ
allow
greater
accuraci
subtyp
identif
flow
cytometri
msc
influenc
ilc
subtyp
distribut
cocultur
sinc
differ
ilc
subset
differ
function
interplay
two
cell
type
could
meaning
effect
immunomodul
molecular
character
antiabo
blood
group
antibodi
khoa
nguyen
tho
pham
scott
boyd
stanford
univers
school
medicin
depart
patholog
stanford
univers
backgroundcas
studi
antibodi
respons
carbohydr
antigen
specif
abo
blood
group
system
import
foundat
aspect
transfus
transplant
medicin
seek
molecularli
defin
antibodi
involv
abo
carbohydr
blood
group
recognit
investig
antibodi
somat
hypermut
level
isotyp
makeup
clonal
antiabo
antibodi
healthi
human
also
assess
presenc
stereotyp
converg
antibodi
express
differ
individu
studi
designmethod
use
fluoresc
label
abo
antigen
perform
fac
identifi
bcell
healthi
human
peripher
blood
surfac
immunoglobulin
specif
blood
group
antigen
bulksort
perform
highthroughput
dna
sequenc
rearrang
immunoglobulin
heavi
chain
vdj
locu
character
abospecif
antibodi
sequenc
sequenc
pars
analyz
specif
antibodi
characterist
ighv
usag
sequenc
ighv
mutat
rate
resultsfind
discov
abospecif
bcell
compris
hundr
clone
express
isotyp
show
evid
ighv
gene
restrict
isotyp
makeup
antiabo
antibodi
compris
approxim
igm
igd
igg
iga
ige
among
gener
popul
antiabo
antibodi
respons
also
appear
polyclon
within
individu
exampl
averag
antia
antibodi
clone
per
group
person
interestingli
report
prior
literatur
also
found
exist
antiself
abo
antibodi
eg
antia
antibodi
group
individu
found
evid
ighv
gene
restrict
signific
differ
ighv
usag
among
abo
blood
group
antibodi
among
differ
individu
furthermor
found
bcell
reactiv
blood
group
exhibit
higher
mutat
rate
unsort
bcell
igm
vs
p
vs
p
antibodi
final
identifi
hundr
converg
antia
antibodi
cluster
appear
multipl
blood
group
individu
exhibit
significantli
higher
mutat
rate
compar
converg
antia
antibodi
found
individu
blood
group
p
blood
group
ab
p
individu
blood
group
b
p
conclus
data
provid
new
molecular
insight
anticarbohydr
antibodi
may
provid
new
avenu
studi
antibodi
across
divers
biomed
field
find
potenti
impact
transfus
transplant
medicin
direct
relev
clinic
signific
event
hemolyt
diseas
newborn
organ
transplant
reject
cooper
immunogen
mhc
alloantigen
murin
model
krystalyn
e
hudson
andrea
sl
wong
amanda
l
richard
linda
kapp
jame
c
zimr
bloodworksnw
research
institut
backgroundcas
studi
humor
alloimmun
hla
lead
refractori
state
patient
requir
platelet
transfus
problem
patient
subsequ
requir
transplant
also
lead
trali
caus
donat
product
contain
antihla
alloimmun
hla
requir
exposur
alloantigen
overal
degre
mhc
mismatch
affect
immunogen
individu
alloantigen
unclear
studi
designmethod
mice
b
mhc
haplotyp
expos
k
alloantigen
infus
leukocyt
differ
context
k
isol
cell
novel
mous
express
k
singl
mhc
alloantigen
background
context
multipl
mismatch
alloantigen
eg
whole
haplotyp
balbc
mice
congen
anim
alloimmun
assess
incub
serum
balbc
target
follow
floresc
antimous
ig
analysi
flow
cytometri
alloimmun
calcul
mean
floresc
intens
mfi
mice
precursor
frequenc
cell
specif
k
alloantigen
modifi
adopt
transfer
cell
cell
receptor
transgen
mice
specif
immunodomin
k
peptid
present
mhcii
cell
immun
immunodomin
peptid
k
resultsfind
compar
control
mice
detect
antik
alloantibodi
mfi
strong
antik
respons
observ
singl
exposur
leukocyt
mice
express
whole
haplotyp
mfi
mice
experi
p
contrast
signific
alloimmun
observ
respons
k
isol
alloantigen
despit
repeat
exposur
adopt
transfer
cell
preimmun
k
peptid
result
strong
alloimmun
respons
subsequ
infus
leukocyt
express
k
isol
alloantigen
equival
leukocyt
express
whole
locu
mfi
p
artifact
induct
antik
maneuv
increas
cell
number
neither
peptid
immun
induc
detect
antik
conclus
find
indic
immunogen
singl
alloantigen
affect
context
encount
isol
k
induc
signific
alloantibodi
respons
howev
strong
antik
respons
observ
multipl
mismatch
present
mechan
effect
involv
magnitud
cell
help
challeng
notion
mhci
alloantigen
intrins
strong
immunogen
indic
rather
cooper
effect
differ
mismatch
mhc
alloantigen
encount
togeth
backgroundcas
studi
despit
preval
clinic
signific
red
blood
cell
rbc
alloantibodi
known
laboratori
test
predict
patient
may
form
antibodi
transfus
also
known
fc
gamma
express
monocyt
marker
type
interferon
signatur
autoimmun
diseas
given
autoimmun
associ
rbc
alloimmun
type
interferon
shown
play
role
rbc
alloimmun
anim
model
hypothes
express
monocyt
may
correl
rbc
alloimmun
studi
designmethod
fortytwo
adult
sickl
cell
diseas
recruit
demograph
inform
red
blood
cell
alloantibodi
histori
extract
electron
medic
record
flow
cytometri
complet
peripher
blood
low
cell
classifi
classic
monocyt
high
cell
classifi
intermedi
monocyt
high
cell
classifi
nonclass
inflammatori
monocyt
mean
fluoresc
intens
mfi
monocyt
subset
calcul
resultsfind
nonalloimmun
patient
document
receiv
rbc
transfus
studi
institut
refer
nonrespond
fortysix
percent
nonrespond
femal
mean
age
year
rang
year
nonrespond
compar
alloimmun
respond
patient
alloimmun
patient
femal
mean
age
year
rang
year
patient
total
antibodi
identifi
primarili
e
k
antigen
statist
signific
differ
percentag
total
classic
intermedi
nonclass
monocyt
nonrespond
respond
nonrespond
show
trend
higher
express
total
monocyt
conclus
contrari
hypothesi
observ
lower
express
classic
intermedi
monocyt
alloimmun
patient
sickl
cell
diseas
compar
nonrespond
possibl
type
interferon
signal
impact
alloimmun
anim
model
way
respons
alter
express
one
potenti
mechan
previous
shown
vitro
may
involv
type
interferon
mitig
abil
interferon
gamma
upregul
oral
abstract
session
product
manufactur
contamin
pathogen
reduct
backgroundcas
studi
screen
platelet
concentr
pc
bacteri
contamin
perform
use
autom
cultur
system
sinc
august
pc
shelflif
extend
day
improv
bacteri
test
algorithm
delay
test
hour
post
collect
inocul
aerob
anaerob
cultur
bottl
screen
doubl
apheresi
pc
three
aerob
bottl
one
anaerob
bottl
postsampl
quarantin
hour
contamin
pc
neg
screen
result
found
qualiti
control
qc
test
outdat
pc
report
transfus
reaction
studi
designmethod
august
februari
buffi
coat
bc
pool
apheresi
unit
screen
routin
test
addit
outdat
pc
qctest
posit
result
classifi
confirm
posit
bacterium
isol
initi
confirmatori
cultur
implic
associ
compon
fals
posit
bacteria
isol
posit
screen
cultur
unconfirm
posit
initi
posit
cultur
result
could
confirm
fals
neg
unit
neg
screen
result
posit
qc
test
involv
septic
transfus
reaction
sinc
march
cocompon
associ
fals
posit
result
bc
pool
releas
inventori
resultsfind
thirtythre
three
cultur
result
categor
confirm
posit
routin
screen
bc
pool
apheresi
unit
respect
bacteria
isol
bc
pool
propionibacterium
acn
nine
confirm
posit
involv
initi
cultur
pc
pool
confirmatori
test
associ
rbc
contamin
p
acn
one
three
confirm
posit
apheresi
pc
also
identifi
p
backgroundcas
studi
chikungunya
chikv
dengu
denv
zika
zikv
arbovirus
transmit
aed
albopictu
speci
mosquito
vector
result
geograph
distribut
overlap
result
area
three
virus
circul
time
cocircul
increas
likelihood
patient
becom
coinfect
cocircul
virus
recent
report
sever
endem
countri
larg
number
asymptomat
arboviru
infect
rais
possibl
transfusiontransmit
infect
tti
risk
chikv
denv
zikv
tti
whether
alon
combin
reduc
use
photochem
intercept
blood
system
pathogen
reduct
pr
technolog
previous
demonstr
effect
multipl
arbovirus
includ
chikv
denv
zikv
report
treatment
amotosalenuva
inactiv
combin
chikv
denv
zikv
platelet
concentr
pc
plasma
studi
designmethod
plasma
pc
platelet
addit
solut
pa
unit
cocontamin
chikv
zikv
treat
amotosalen
uva
light
infecti
viral
titer
determin
plaqu
assay
inactiv
determin
compar
log
titer
treatment
resultsfind
follow
amotosalenuva
treatment
three
virus
simultan
inactiv
limit
detect
pc
plasma
see
tabl
result
log
chikv
log
log
zikv
inactiv
pc
log
chikv
log
log
zikv
inactiv
plasma
amr
renal
transplant
pt
gener
carri
excel
prognosi
amr
cardiac
transplant
pt
denot
poor
prognosi
treatment
option
less
well
understood
standard
studi
designmethod
review
record
heart
transplant
pt
refer
immunotherapi
treat
amr
median
age
pt
time
reject
year
year
old
pt
male
pt
present
symptom
congest
heart
failur
diastol
andor
systol
dysfunct
decreas
eject
fraction
ef
pt
endomyocardi
biopsi
result
consist
amr
pt
evid
circul
dsa
time
reject
includ
pt
evid
concurr
acut
cellular
reject
time
amr
pt
dsa
tcell
crossmatch
neg
time
cardiac
transplant
median
time
transplant
amr
bimod
yr
yr
pt
yr
yr
pt
pt
receiv
follow
immunotherapi
protocol
plasma
exchang
tpe
everi
day
treatment
tx
follow
intraven
immun
globulin
ivig
gramkgday
x
day
pt
receiv
high
dose
cs
serial
dsa
measur
obtain
pharmacolog
intervent
refractori
recurr
amr
pt
receiv
weekli
rituximab
dose
pt
receiv
twiceweekli
bortezomib
dose
resultsfind
pt
underw
cours
tpe
coursespt
follow
posttp
ivig
pt
moder
improv
allograft
function
pt
show
substanti
improv
systol
andor
diastol
dysfunct
ef
pt
signific
reduct
elimin
class
ii
dsa
resolut
amr
cours
tx
pt
requir
minimum
cours
tx
amr
pt
refractori
amr
requir
cours
tx
common
dsa
present
refractori
amr
includ
class
ii
pt
refractori
amr
receiv
monthli
ivig
intermitt
cours
tpe
bortezomib
mean
followup
yr
yr
time
amr
cardiac
transplant
amr
pt
lost
allograft
reject
wherea
mean
followup
yr
yr
renal
transplant
amr
pt
lost
allograft
p
group
treat
rel
similar
protocol
amr
conclus
plasma
exchang
ivig
rituximab
bortezomib
use
treatment
modal
cardiac
transplant
pt
amr
suppress
refractori
class
ii
dq
dr
dsa
may
critic
provid
durabl
allograft
rescu
develop
effect
protocol
treat
refractori
recurr
amr
cardiac
transplant
pt
need
backgroundcas
studi
autom
red
cell
exchang
rce
wellestablish
therapi
sickl
cell
diseas
scd
mainten
therapi
emerg
intervent
quantif
hemoglobin
speci
use
determin
goal
rce
achiev
howev
recent
public
includ
formula
estim
postrc
hemoglobin
hb
use
preand
postrc
platelet
count
correct
factor
xm
creat
deriv
fraction
platelet
remain
dfpr
close
approxim
fraction
cell
remain
fcr
keiser
et
al
est
posthb
dfpr
prehb
dfpr
postrc
platelet
platelet
count
certain
situat
could
use
lieu
tradit
labori
timeconsum
hb
determin
perform
extern
valid
formula
scd
patient
determin
generaliz
formula
studi
designmethod
irbapprov
retrospect
studi
queri
institut
apheresi
databas
identifi
rce
procedur
perform
scd
patient
preprocedur
hb
use
prerc
hb
preand
postrc
platelet
count
appli
formula
scd
popul
deriv
estim
posthb
procedur
wilcoxon
matchedpair
sign
rank
test
perform
compar
deriv
actual
postrc
hb
valu
statist
signific
defin
p
resultsfind
appli
formula
rce
procedur
perform
patient
procedur
deriv
postrc
hb
within
actual
postrc
hb
measur
high
perform
liquid
chromatographi
quantif
hemoglobin
speci
statist
differ
dfpr
fcr
prehb
deriv
postrc
hb
actual
postrc
hb
prehb
interpati
variat
note
patient
rce
procedur
account
half
deriv
postrc
hb
valu
discrep
actual
posthb
valu
rce
perform
emerg
versu
elect
mainten
therapi
bear
formula
accuraci
conclus
formula
accur
approxim
postrc
hb
use
preand
postrc
platelet
count
patient
prerc
hb
scd
patient
popul
instanc
tradit
postrc
hb
determin
may
take
consider
time
formula
may
use
instead
expedit
remov
temporari
vascular
access
time
discharg
addit
investig
necessari
better
character
formula
perform
less
well
small
proport
scd
patient
fivefold
increas
frequenc
mtp
activ
larg
academ
medic
center
lean
analysi
implement
mitig
strategi
jame
gorham
gay
wehrli
thoma
bradi
theresa
libbi
eric
p
shield
joseph
schoeni
jahan
chowdhuri
matthew
p
robertson
stephani
corbett
kathi
butler
stuart
lowson
jf
calland
univers
virginia
school
medicin
univers
virginia
health
system
backgroundcas
studi
mtp
rapidli
provid
recurr
issu
blood
product
specif
ratio
patient
risk
exsanguin
follow
initi
rollout
institut
larg
amc
level
trauma
center
design
mtp
usag
pattern
chang
dramat
mtp
activ
frequenc
maf
rose
steadili
concomit
increas
frequenc
trauma
patient
sinc
mtp
demand
signific
effort
larg
increas
maf
potenti
indic
seriou
misalloc
resourc
sought
understand
reason
maf
increas
identifi
effect
solut
studi
designmethod
extens
lean
process
undertaken
problem
statement
develop
follow
process
map
fishbon
diagram
priorit
grid
solut
propos
discuss
deploy
toward
end
assess
efficaci
data
collect
prev
outcom
maf
across
equival
pre
vs
post
time
period
outcom
includ
rbc
u
transfus
per
activ
rta
indic
bleed
sever
mtpspecif
product
wastag
usd
resultsfind
maf
rose
mo
rta
fell
vs
mean
sd
p
stdnt
ttest
indic
mtp
increasingli
activ
patient
lesser
bleed
sever
storm
cloud
reveal
probabl
caus
dramat
chang
maf
rta
sustain
educ
compon
decis
support
tool
low
clinician
confid
standard
blood
order
feedback
appropri
mtp
activ
solut
developeddeploy
comprehens
educ
campaign
use
orthogon
approach
literatureback
decis
support
tool
incorpor
patient
vital
sign
abc
score
creation
emrindepend
altern
pathway
rapidli
issu
small
number
rbcplasma
time
mtp
review
mechan
provid
feedback
compar
st
day
respect
maf
drop
vs
rta
trend
upward
vs
p
mtpspecif
product
wastag
fell
usd
conclus
comprehens
root
caus
analysi
involv
multipl
stakehold
identifi
underli
base
increas
misus
mtp
allow
us
develop
test
solut
address
like
caus
chang
mtp
usag
pattern
result
alter
usag
align
mtp
primari
purpos
provid
blood
rapidli
exsanguin
patient
transfusionassoci
hla
sensit
patient
bridg
heart
transplant
use
ventricular
assist
devic
jae
elkind
juliana
sobczyk
oscar
ostbergbraun
jorg
enciso
eric
adler
gerald
p
morri
depart
patholog
univers
california
san
diego
depart
medicin
univers
california
san
diego
backgroundcas
studi
heart
transplant
cur
therapi
endstag
heart
failur
limit
organ
avail
often
requir
use
ventricular
assist
devic
vad
bridg
patient
transplant
vad
allow
recipi
benefit
otherwis
unattain
transplant
associ
complic
increas
hla
sensit
rate
hla
sensit
associ
neg
clinic
outcom
posttransplant
includ
increas
reject
increas
mortal
vadassoci
hla
sensit
consequ
blood
product
transfus
associ
thorac
surgeri
though
factor
determin
incid
extent
alloantibodi
format
remain
undefin
examin
examin
vadassoci
transfus
effect
hlasensit
subsequ
transplant
studi
designmethod
perform
retrospect
cohort
studi
patient
receiv
vad
academicbas
hospit
januari
septemb
medic
record
data
includ
transfus
blood
product
antihla
antibodi
test
crossmatch
test
time
transplant
evalu
categor
data
analyz
fisher
exact
test
quantit
data
analyz
use
mannwhitney
test
multivari
analys
perform
use
stata
softwar
resultsfind
patient
receiv
averag
rang
rbc
rang
singl
donor
platelet
transfus
associ
vad
surgeri
increas
incid
hla
antibodi
vad
surgeri
approxim
higher
rate
describ
literatur
among
potenti
organ
transplant
recipi
receiv
transfus
multivari
analys
indic
develop
new
antihla
antibodi
directli
correl
volum
type
blood
product
exposur
relat
patient
prevad
hla
sensit
statu
rel
risk
new
antihla
antibodi
vad
recipi
prevad
alloantibodi
higher
patient
without
prior
alloantibodi
develop
new
antihla
antibodi
postvad
associ
increas
time
transplant
versu
conclus
find
concur
literatur
describ
vad
associ
increas
rate
hla
sensit
uniqu
studi
indic
presenc
antihla
antibodi
prevad
signific
risk
factor
develop
addit
antibodi
postvad
suggest
subset
patient
may
predispos
alloantibodi
format
increas
risk
develop
antihla
antibodi
identif
atrisk
patient
import
develop
strategi
minim
hla
sensit
prevent
potenti
avoid
barrier
subsequ
transplant
backgroundcas
studi
train
major
medic
traine
obtain
inform
consent
blood
transfus
literatur
demonstr
inform
consent
transfus
time
incomplet
poorli
understood
hurri
andor
inaccur
part
due
lack
educ
resourc
gold
standard
narr
would
help
ensur
true
patient
inform
consent
util
teach
traine
risk
benefit
transfus
studi
designmethod
modifi
delphi
approach
use
survey
purpos
select
intern
group
transfus
medicin
tm
expert
experi
consent
patient
transfus
critic
knowledg
regard
risk
benefit
transfus
case
scenario
woman
gastrointestin
bleed
present
particip
ask
draft
narr
script
obtain
inform
consent
patient
use
techniqu
qualit
descript
content
analysi
smaller
steer
committe
tm
expert
analyz
script
core
theme
topic
common
theme
categori
identifi
eg
risk
transfus
benefit
transfus
etc
specif
topicsitem
eg
possibl
allerg
reaction
possibl
hiv
infect
etc
affect
structur
content
also
captur
eg
manner
engag
second
survey
develop
base
collat
topic
theme
first
survey
redistribut
particip
first
survey
pilot
particip
particip
ask
rate
topic
point
scale
low
import
high
importanceessenti
content
valid
index
cvi
item
calcul
narr
develop
use
topic
score
cvi
higher
resultsfind
survey
complet
tm
expert
span
countri
pilot
particip
major
particip
year
experi
practic
tm
half
year
content
analysi
identifi
high
level
theme
specif
topic
narr
includ
second
round
delphi
second
survey
complet
particip
complet
first
survey
origin
pilot
particip
respons
rate
forti
topic
cvi
greater
incorpor
narr
develop
meet
flesch
kincaid
grade
level
topic
cvi
ask
patient
question
ask
directli
consent
blood
transfus
discuss
risk
transfus
discuss
risk
transfus
transmit
diseas
low
given
high
incid
transfus
associ
circulatori
overload
taco
high
mortal
associ
transfus
relat
acut
lung
injuri
trali
surpris
see
low
cvi
score
relat
topic
state
possibl
lung
injuri
state
possibl
fluid
overload
state
gener
possibl
short
breath
transfus
mean
cci
ci
success
rate
mean
cci
per
patient
ci
conclus
use
delphi
approach
gold
standard
narr
obtain
inform
consent
blood
transfus
develop
plan
valid
narr
healthcar
provid
patient
use
survey
focu
group
elucid
feedback
refin
narr
backgroundcas
studi
variant
creutzfeldtjakob
diseas
vcjd
rare
human
prion
diseas
caus
infect
bovin
prion
although
clinic
case
vcjd
evalu
prion
protein
gene
prnp
methionin
homozygot
codon
year
first
definit
heterozyg
vcjd
patient
methionin
valin
mv
genotyp
recent
describ
unit
kingdom
patient
met
diagnost
criteria
probabl
sporad
cjd
scjd
neuropatholog
molecular
analysi
prion
strain
type
autopsi
confirm
vcjd
recent
public
underlin
previou
concern
possibl
second
wave
vcjd
case
attribut
altern
genotyp
codon
secondari
transmiss
iatrogen
transmiss
vcjd
blood
transfus
alreadi
document
three
recipi
nonleucodeplet
red
blood
cell
concentr
donor
incub
diseas
one
addit
probabl
case
vcjd
transmiss
blood
transfus
reveal
autopsi
mv
patient
die
nonneurolog
disord
vcjd
prion
protein
detect
spleen
highli
sensit
specif
premortem
test
discrimin
mv
vcjd
scjd
urgent
need
rapidli
accur
diagnos
futur
mv
vcjd
patient
studi
designmethod
protein
misfold
cyclic
amplif
pmca
alreadi
demonstr
high
perform
detect
vcjd
prion
blood
clinic
patient
allow
detect
silent
carriag
prion
clinic
onset
two
blood
donor
later
develop
vcjd
ultrasensit
technolog
adapt
specif
detect
vcjd
cerebrospin
fluid
csfpmca
identifi
vcjd
infect
individu
includ
recent
mv
patient
resultsfind
among
csf
sampl
analys
blind
diagnosi
csfpmca
identifi
specif
vcjd
sampl
thu
achiev
diagnost
sensit
confid
interv
ci
importantli
assay
allow
discrimin
heterozyg
mv
vcjd
case
mv
neuropatholog
confirm
scjd
patient
test
csfpmca
also
show
analyt
specif
ci
none
potenti
crossreact
csf
specimen
patient
scjd
genet
cjd
alzheim
diseas
nonneurodegen
diseas
give
posit
result
conclus
result
indic
csfpmca
may
allow
identif
mv
vcjd
life
combin
test
csf
realtim
quakinginduc
convers
accur
discrimin
scjd
presenc
infect
blood
first
definit
mv
vcjd
patient
involv
studi
uncertain
requir
investig
cryopreserv
platelet
possess
classic
phenotyp
characterist
procoagul
platelet
lacey
johnson
lauren
water
ben
wood
denes
c
mark
research
develop
australian
red
cross
blood
servic
sydney
medic
school
backgroundcas
studi
platelet
cryopreserv
dmso
increas
shelflif
day
year
cryopreserv
platelet
result
signific
increas
expos
phosphatidylserin
releas
phosphatidylserineexpress
microparticl
mediat
procoagul
function
understand
procoagul
natur
platelet
defin
discret
phenotyp
popul
area
continu
interest
content
platelet
biolog
procoagul
platelet
refer
activ
coat
apoptot
necrot
thu
aim
studi
determin
whether
phenotyp
attribut
cryopreserv
platelet
align
current
definit
constitut
procoagul
platelet
studi
designmethod
buffi
coatderiv
platelet
frozen
dmso
final
concentr
cryopreserv
platelet
thaw
reconstitut
unit
thaw
plasma
vitro
test
pair
unit
carri
prior
freez
fresh
thaw
postthaw
use
flow
cytometri
western
blot
data
analys
use
pair
twosid
ttest
p
consid
statist
signific
resultsfind
phosphatidylserin
externalis
significantli
increas
cryopreserv
platelet
measur
lactadherin
annexinv
bind
mitochondri
damag
evid
cryopreserv
platelet
evidenc
reduct
tetramethylrhodamin
tmre
sequestr
cryopreserv
platelet
display
higher
intracellular
calcium
superoxid
anion
format
dihydroethidium
dhe
stain
fresh
platelet
use
western
blot
member
intrins
bak
bax
bclx
l
extrins
fadd
fa
apoptot
pathway
differenti
alter
cryopreserv
chang
clearli
indic
proapoptot
state
activ
fitclehdfmk
cleavag
greater
cryopreserv
platelet
howev
activ
execution
molecul
reddevdfmk
similar
cryopreserv
fresh
platelet
interestingli
cleavag
characterist
procoagul
platelet
observ
cryopreserv
platelet
conclus
cryopreserv
platelet
acquir
mani
classic
featur
use
defin
procoagul
platelet
mani
overlap
apoptot
necrot
pathway
work
requir
fulli
dissect
molecular
event
occur
cryopreserv
platelet
understand
chang
may
influenc
clinic
util
glutathion
gsh
inactiv
broad
spectrum
virus
bacteria
protozoa
tcell
transfus
depend
thalassemia
tdt
patient
requir
chronic
rbc
transfus
combin
iron
chelat
lifetim
exposur
increas
risk
transfusiontransmit
infect
studi
designmethod
aim
random
control
doubleblind
noninferior
studi
evalu
leukocytereduc
lr
rbc
comparison
control
lrrbc
method
tdt
patient
enrol
baselin
exclus
criteria
includ
natur
antibodi
rbc
dat
hypersplen
anticip
splenectomi
pregnanc
breast
feed
patient
underw
transfus
episod
rbc
control
rbc
twotreat
period
crossov
design
maintain
pretransfus
hb
threshold
hemoglobin
hb
gdl
primari
efficaci
endpoint
rbc
hb
consumpt
transfus
episod
treatment
period
total
hb
mass
transfus
adjust
bodi
weight
paramet
fresh
postthaw
annexinv
posit
tmre
mfi
dhe
mfi
fitclehdfmk
mfi
kg
durat
support
hb
gkg
day
non
inferior
defin
predetermin
margin
controlperiod
mean
hb
consumpt
primari
safeti
endpoint
treatmentemerg
antibodi
rbc
resultsfind
subject
enrol
transfus
two
site
itali
one
turkey
mean
age
year
rang
male
age
year
eleven
percent
patient
preexist
rbc
alloantibodi
intent
treat
itt
popul
mean
exposur
rbc
rang
rang
control
rbc
mean
transfus
interv
test
control
day
total
transfus
hb
onstudi
offstudi
rbc
test
period
gram
g
versu
g
hb
p
control
period
total
mean
hb
consumpt
efficaci
evalu
period
gkgday
rbc
gkgday
control
rbc
non
inferior
robustli
achiev
treatment
differ
gkgday
noninferior
margin
treatmentemerg
rbc
alloantibodi
rbcspecif
antibodi
detect
advers
event
balanc
test
control
period
death
grade
advers
event
event
certain
like
relat
rbc
transfus
conclus
noninferior
control
rbc
transfusiondepend
patient
thalassemia
base
hb
consumpt
safeti
profil
differ
control
rbc
antibodi
detect
rbc
resuscit
hemorrhag
shock
high
molecular
weight
polymer
hemoglobin
alexand
william
andr
palmer
pedro
cabral
univers
california
san
diego
ohio
state
univers
backgroundcas
studi
hemoglobin
hb
base
oxygen
carrier
hboc
propos
altern
red
blood
cell
rbc
transfus
medicin
decad
lack
mechanist
analysi
side
effect
earli
hboc
formul
lead
clinic
evalu
low
molecular
weight
mw
product
fail
due
myriad
hb
associ
toxic
seen
preclin
trial
increas
mw
hboc
decreas
side
effect
confin
hboc
vascular
space
increas
nitric
oxid
gener
via
vascular
mechanotransduct
hboc
advantag
blood
includ
nonimmunogen
properti
potenti
use
nonhuman
hb
sourc
among
other
studi
compar
efficaci
fresh
blood
store
blood
freshli
synthes
polymer
bovin
hb
polybhb
polybhb
store
year
restor
cardiac
function
hemorrhag
shock
studi
designmethod
polybhb
synthes
low
oxygen
affin
state
ratio
glutaraldehyd
bovin
hb
subject
cycl
diafiltr
result
polybhb
solut
contain
polymer
hb
molecul
um
polybhb
frozen
store
use
fresh
red
blood
cell
prepar
blood
remov
hemorrhag
centrifug
minut
remov
buffi
coat
remov
plasma
hematocrit
store
red
blood
cell
store
week
leukodeplet
hemorrhag
blood
volum
held
hypovolemia
minut
resuscit
recov
blood
pressur
prehemorrhag
fresh
autolog
blood
fresh
blood
blood
polybhb
gener
within
month
studi
polybhb
polybhb
gener
two
year
prior
studi
polybhb
resultsfind
shock
result
impair
oxygen
deliveri
cardiac
function
resuscit
fresh
blood
store
blood
polybhb
polybhb
restor
cardiac
function
system
vascular
resist
store
blood
requir
significantli
larger
volum
achiev
slightli
higher
volum
polybhb
infus
compar
fresh
blood
restor
prehemorrhag
map
fresh
blood
polybhb
fresh
store
impair
cardiac
contractil
caus
excess
vasoconstrict
rel
store
blood
conclus
studi
indic
polybhb
efficaci
fresh
blood
restor
cardiac
function
rat
hemorrhag
shock
addit
polybhb
safe
store
two
year
retain
efficaci
unlik
red
blood
cell
lose
efficaci
storag
impact
preprint
order
implement
prothrombin
complex
concentr
academ
tertiari
care
hospit
qualiti
assur
audit
krista
marcon
ko
ta
k
chen
xinyu
zhang
andrew
wy
shih
kristin
roland
tyler
smith
vancouv
coastal
health
univers
british
columbia
centr
blood
research
british
columbia
institut
technolog
backgroundcas
studi
sinc
approv
health
canada
order
prothrombin
complex
concentr
pcc
academ
tertiari
care
hospit
requir
approv
hematopathologist
hp
except
intracrani
hemorrhag
ich
due
high
acuiti
march
year
experi
preprint
order
ppo
implement
streamlin
hp
approv
process
urgent
warfarin
revers
scenario
simplifi
expedit
pcc
administr
goal
ppo
standard
pcc
vitamin
k
dose
decreas
turnaroundtim
tat
reduc
nonvaluead
call
hp
purpos
qualiti
assur
studi
review
pcc
usag
preand
postppo
implement
determin
impact
ppo
achiev
goal
studi
designmethod
retrospect
chart
review
pcc
usag
perform
two
year
preand
postppo
implement
march
march
relev
medic
inform
includ
pcc
indic
dose
use
vitamin
k
thrombosi
event
mortal
record
appropri
pcc
dosag
adjud
use
canadian
nation
advisori
committe
nac
pcc
guidelin
appropri
pcc
indic
adjud
base
chart
review
bleed
episod
verifi
review
clinic
note
endoscopi
report
imag
report
surgic
start
time
document
anesthet
record
urgent
surgeri
defin
less
hour
pcc
order
resultsfind
baselin
characterist
patient
receiv
pcc
preimplement
postimplement
similar
includ
sex
age
warfarin
use
inr
level
proport
patient
receiv
pcc
dose
within
iu
nac
guidelin
significantli
higher
postppo
period
vs
administr
least
intraven
vitamin
k
frequent
follow
ppo
introduct
vs
signific
differ
observ
tat
addit
dose
pcc
red
cell
transfus
inr
correct
thrombosi
mortal
introduct
ppo
call
volum
hp
pcc
approv
significantli
lower
vs
p
ppo
use
releas
pcc
inappropri
indic
time
case
patient
warfarin
urgent
surgeri
surgeri
hour
pcc
order
case
patient
warfarin
without
hp
consult
conclus
mani
goal
ppo
achiev
increas
appropri
pcc
dose
vitamin
k
usag
pcc
order
process
streamlin
reduct
call
volum
hp
prevent
unnecessari
delay
pcc
administr
although
ppo
use
inappropri
one
quarter
case
guid
refin
ppo
improv
appropri
pcc
util
backgroundcas
studi
mesenchym
stromal
cell
msc
show
tremend
promis
treatment
militari
civilian
trauma
base
abil
regul
inflamm
promot
wound
heal
studi
implement
assay
design
compar
angiogen
potenti
msc
cellular
therapi
product
investig
relationship
cellular
metabol
studi
designmethod
human
umbil
vein
endotheli
cell
huvec
human
msc
bmmsc
admsc
ucmsc
obtain
commerci
sourc
mrna
isol
earli
passag
huvec
transwel
cocultur
use
gener
cdna
huvec
express
gene
relat
angiogenesi
vegf
tissu
factor
tf
signal
metabol
evalu
qrtpcr
tube
format
assay
perform
huvec
plate
onto
geltrex
ldev
subconflu
densiti
presenc
condit
media
cocultur
msc
plate
transwel
insert
angiogenesi
determin
quantit
tube
format
use
imag
j
express
huvec
cellular
protein
transwel
cocultur
visual
western
blot
quantit
odyssey
scanner
bioenerget
analysi
via
extracellular
flux
measur
carri
confluent
cell
sea
hors
xfe
bioanalyz
resultsfind
huvec
respond
msc
increas
tf
protein
express
well
increas
express
angiogen
mrna
cocultur
bmmsc
admsc
hr
alter
bioenerget
profil
increas
oxygen
consumpt
ratio
ocr
spare
respiratori
capac
huvec
cell
cocultur
either
bmmsc
admsc
increas
tube
format
huvec
increas
respect
condit
medium
umbil
cordderiv
msc
less
potent
assay
conclus
use
tube
format
assay
qrtpcr
western
blot
bioenerget
analysi
evalu
angiogen
potenti
msc
cell
therapi
product
preliminari
result
suggest
potenc
differ
exist
msc
deriv
differ
tissu
sourc
direct
contact
huvec
msc
requir
stimul
angiogenesi
msc
suggest
paracrin
mechan
primarili
respons
evalu
bioenerget
profil
cocultur
sampl
allow
investig
relationship
angiogenesi
cellular
metabol
increas
angiogen
activ
accompani
increas
tf
express
potenti
increas
thrombot
risk
msc
therapi
studi
warrant
explor
interrelationship
metabol
activ
procoagul
proangiogen
gene
express
thejaswi
bikkani
nasha
elavia
matthew
hsieh
courtney
fitzhugh
john
tisdal
david
f
stroncek
sandhya
r
panch
nation
institut
health
nhlbi
backgroundcas
studi
allogen
transplant
cur
treatment
patient
sickl
cell
diseas
scd
howev
relat
donor
scd
patient
least
probabl
sickl
cell
trait
sct
mobil
peripher
blood
mononuclear
cell
pbmnc
sct
donor
graft
often
cryopreserv
collect
ensur
success
posttranspl
outcom
thaw
pbmnc
must
contain
adequ
quantiti
hematopoiet
progenitor
cell
hpc
studi
designmethod
data
mobil
pbmnc
graft
thaw
transplant
scd
patient
review
graft
donor
sct
sctd
compar
normal
healthi
donor
nhd
graft
data
stratifi
product
immedi
cryopreserv
ic
post
apheresi
held
overnight
delay
cryopreserv
dc
vs
hour
resultsfind
mean
postthaw
pt
total
nucleat
cell
tnc
viabil
vs
tnc
viabl
recoveri
vr
vs
pt
tcell
vr
vs
show
trend
toward
lower
sctd
compar
nhd
howev
differ
note
pt
cfugm
vs
pt
vr
vs
stratifi
data
tabl
show
significantli
lower
pt
tnc
viabil
tcell
vr
dc
compar
ic
sctd
pt
vr
pt
cfugm
similar
group
nhd
pt
tcell
vr
lower
dc
posttranspl
differ
seen
sctd
nhd
graft
ic
dc
graft
base
time
platelet
neutrophil
engraft
durat
cryopreserv
impact
pt
vr
either
sctd
nhd
graft
r
conclus
pt
tnc
viabil
pt
tcell
vr
sctd
graft
lower
nhd
graft
especi
graft
underw
dc
pt
hpc
recoveri
invitro
coloni
form
capabl
posttranspl
platelet
neutrophil
engraft
unaffect
like
due
inher
durabl
hpc
compar
tcell
eas
logist
dc
sctd
graft
may
feasibl
howev
caution
must
exercis
regard
product
holdov
given
definit
decreas
overal
viabil
donor
lymphocyt
infus
plan
cryopreservedthaw
pbmnc
dose
pt
viabl
count
may
use
backgroundcas
studi
umbil
cord
uc
blood
cryopreserv
long
term
storag
function
hematopoiet
progenitor
cell
recov
year
suitabl
use
sourc
materi
induc
pluripot
stem
cell
ipsc
gener
broxmey
et
al
advanc
ipsc
technolog
includ
develop
varieti
cgmp
compat
transgenefre
approach
reprogram
use
gener
ipsc
small
amount
peripher
uc
blood
zhou
et
al
translat
autom
platform
paull
et
al
uc
tissu
rich
msc
easili
expand
ex
vivo
without
compromis
attribut
consid
import
futur
clinic
applic
explor
util
uc
tissu
cryopreserv
composit
materi
newborn
stem
cell
bank
ipsc
reprogram
use
integrationfre
reprogram
method
translat
semiautom
platform
ipsc
coloni
isol
subsequ
cultur
studi
designmethod
uc
tissu
collect
consent
mother
cryopreserv
composit
materi
msc
isol
thaw
tissu
explant
outgrowth
describ
skile
et
al
cell
line
expand
reprogram
ipsc
use
nyscf
global
stem
cell
paull
et
al
footprint
free
modifi
mrna
encod
transcript
factor
nuclear
gfp
ngfp
reprogram
also
perform
parallel
use
cytotuneip
sendai
reprogram
kit
ipsc
expand
autom
qualiti
control
steril
mycoplasma
pluripot
karyotyp
ident
differenti
potenti
resultsfind
uc
cell
line
expand
autom
platform
pass
qualiti
control
test
prepar
reprogram
two
method
ipsc
reprogram
mrna
sendai
viru
valid
lead
gener
success
reprogram
ipsc
uc
cell
display
strong
abil
transfect
mrna
encod
ngfp
howev
success
mrna
reprogram
limit
high
toxic
observ
express
confirm
presenc
coloni
prior
enrich
cell
display
normal
marker
pluripot
differenti
capac
karyotyp
expect
conclus
uc
cell
isol
thaw
uc
tissu
util
gener
ipsc
amen
semi
fulli
autom
reprogram
method
donor
variabl
method
depend
reprogram
effici
highlight
import
method
optim
may
cell
popul
specif
effort
import
consider
greater
util
autom
highthroughput
technolog
reprogram
ipsc
line
propag
well
increas
interest
altern
noninvas
start
materi
neonat
tissu
resultsfind
cart
product
studi
clinic
protocol
antibcma
mean
cart
dose
cellskg
dg
result
signific
deplet
rbc
p
platelet
p
neutrophil
signific
enrich
monocyt
p
rel
lymphocyt
prior
cart
cultur
initi
result
similar
protocol
univari
analys
neutrophil
deplet
effici
follow
dg
posit
correl
final
cart
transduct
effici
te
lymphocyt
fraction
postdg
sampl
correl
higher
p
convers
greater
monocyt
proport
postdg
sampl
correl
higher
ratio
p
boxcox
transform
mix
effect
model
compris
postdg
rbc
platelet
neutrophil
monocyt
lymphocyt
count
rbc
count
platelet
count
strong
neg
posit
predictor
te
final
product
respect
pseudor
p
neutrophil
monocyt
minim
neg
impact
te
cell
composit
postdg
affect
cell
fe
conclus
dg
deplet
rbc
platelet
neutrophil
enrich
monocyt
significantli
lymphocyt
start
materi
cart
cultur
te
significantli
improv
neutrophil
deplet
effici
interestingli
higher
rbc
count
postdg
sampl
worsen
te
wherea
platelet
opposit
effect
regard
rbc
deplet
method
may
studi
monocyt
increas
ratio
possibl
impact
final
cart
product
characterist
analysi
overal
combin
effect
dg
final
cart
critic
characterist
underway
unit
use
set
singl
unit
transplant
becom
paramount
import
ucb
unit
typic
select
base
hla
match
nucleat
cell
dose
addit
test
perform
upon
thaw
prior
infus
includ
total
nucleat
cell
tnc
count
viabil
cell
enumer
steril
cfu
assay
cfu
assay
vitro
assay
assess
biolog
function
hpc
studi
document
influenc
postthaw
cfu
dose
engraft
ucb
transplant
studi
designmethod
attempt
investig
potenti
impact
postthaw
cfugm
count
qualiti
efficaci
ucb
retrospect
studi
transplant
outcom
patient
malign
nonmalign
diseas
receiv
singl
ucb
transplant
evalu
independ
effect
cell
count
use
fine
gray
regress
model
endpoint
platelet
neutrophil
engraft
also
correl
postthaw
cfugm
count
unit
prefreez
postthaw
graft
characterist
hope
optim
select
criteria
ucb
data
analysi
includ
total
nucleat
cell
viabil
cell
content
nucleat
red
blood
cell
postthaw
hematocrit
frozen
storag
time
ucb
bank
resultsfind
infus
cfugm
dose
high
kg
cumul
incid
neutrophil
platelet
engraft
patient
undergo
singl
ucb
unit
transplant
respect
demonstr
associ
postthaw
cfugm
dose
speed
neutrophil
platelet
engraft
myeloabl
malign
nonmalign
patient
postthaw
cell
dose
cfugm
dose
highli
correl
howev
observ
interact
cfugm
show
addit
benefit
top
patient
receiv
lowest
quartil
cell
dose
increas
risk
platelet
engraft
everi
one
unit
increas
cfugm
p
increas
risk
neutrophil
engraft
everi
one
unit
increas
cfugm
cell
dose
cfugm
dose
includ
model
control
hla
dispar
type
diseas
condit
intens
hla
dispar
advers
impact
either
platelet
neutrophil
engraft
p
evalu
ucb
unit
show
despit
potenti
standard
issu
ie
prefreez
test
bank
postthaw
test
transplant
center
postthaw
cfugmmillion
show
moder
correl
measur
prefreez
postthaw
paramet
show
weak
correl
post
thaw
cfugmmillion
postthaw
cfugm
influenc
storag
time
impact
ucb
bank
p
conclus
cfugm
measur
facil
time
unit
thaw
seem
provid
effect
measur
qualiti
efficaci
ucb
cell
count
low
analysi
suggest
prefreez
postthaw
cd
cell
enumer
reflect
unit
potenc
thu
cell
enumer
provid
bank
could
consid
addit
select
criterion
particularli
hla
match
nucleat
cell
dose
equival
among
avail
option
backgroundcas
studi
thrombocytopenia
qualit
platelet
disord
requir
lifesav
platelet
transfus
howev
platelet
transfus
limit
alloimmun
donordepend
suppli
cost
increas
effort
focus
stem
cell
deriv
vitro
platelet
product
fail
gener
platelet
scale
requir
platelet
transfus
henc
aim
understand
basic
molecular
aspect
megakaryopoiesi
thrombopoiesi
enabl
greater
yield
megakaryocyt
mk
platelet
vitro
studi
designmethod
hematopoiet
stem
cell
isol
human
umbil
cord
blood
grown
serum
free
stem
cell
media
supplement
stem
cell
factor
thrombopoietin
day
favor
mk
growth
subpopul
cultur
studi
mk
marker
apoptosi
signal
proplatelet
format
rna
sequenc
analysi
cultur
mk
identifi
encod
bclw
candid
apoptosi
regul
significantli
correl
platelet
count
healthi
individu
fdradjust
overexpress
cultur
mk
achiev
lentivir
transduct
vitro
platelet
product
studi
resultsfind
mk
cultur
three
distinct
cell
popul
name
observ
flow
cytometri
defin
forward
side
scatter
day
cell
show
increas
mk
marker
vs
vs
activ
respons
platelet
agonist
thrombin
collagen
relat
peptid
morpholog
characterist
similar
matur
mk
cell
show
featur
apoptosi
annexin
v
cell
show
similar
normal
human
platelet
overexpress
antiapoptot
cultur
mk
increas
function
mk
importantli
mk
proplatelet
format
increas
ultim
result
increas
platelet
vitro
platelet
function
demonstr
thrombininduc
activ
releas
overal
result
show
restrain
apoptosi
cultur
mk
promot
proplatelet
format
cultur
platelet
activ
associ
human
platelet
number
conclus
novel
target
improv
mk
platelet
yield
cultur
system
enforc
express
may
facilit
vitro
mk
platelet
product
backgroundcas
studi
low
birth
weight
vlbw
infant
highli
transfus
popul
estim
transfus
rate
remain
poorli
character
popul
rate
blood
product
util
may
inform
design
transfus
studi
provid
data
individu
discuss
parent
probabl
vlbw
infant
receiv
blood
transfus
studi
designmethod
secondari
analysi
prospect
multicent
observ
cohort
studi
infant
birth
weight
g
transfus
admiss
includ
follow
day
discharg
death
blood
product
transfus
includ
time
prospect
record
blood
product
util
rate
along
confid
interv
estim
transfus
red
blood
cell
rbc
fresh
frozen
plasma
ffp
platelet
plt
cryoprecipit
cryo
per
hospit
day
birth
weight
ga
specif
estim
calcul
rel
transfus
rate
compar
use
incid
rate
ratio
resultsfind
among
studi
cohort
vlbw
infant
blood
product
transfus
record
infant
day
followup
blood
transfus
occur
infant
rbc
rate
ci
plt
rate
ffp
cryo
among
birth
weight
strata
blood
transfus
occur
infant
g
rate
g
rate
infant
g
rate
rbc
transfus
rate
decreas
increas
ga
tabl
rate
wk
ga
fold
higher
ci
infant
wk
ga
observ
similar
trend
plt
ffp
cryo
conclus
among
vlbw
infant
blood
product
util
rbc
plt
ffp
cryo
decreas
increas
ga
gaspecif
transfus
rate
may
inform
discuss
famili
guid
need
earli
proactiv
consent
data
may
also
help
inform
design
futur
studi
examin
blood
product
transfus
vlbw
infant
backgroundcas
studi
septic
transfus
reaction
str
signific
risk
blood
product
transfus
pediatr
patient
heavili
transfus
suffer
higher
rate
acut
transfus
reaction
atr
compar
adult
patient
versu
per
transfus
respect
uniform
approach
detect
contamin
blood
product
use
product
cultur
follow
atr
pediatr
neonat
patient
goal
project
develop
improv
criteria
detect
str
cultur
residu
product
neonat
pediatr
patient
studi
designmethod
collect
retrospect
data
transfus
reaction
occur
neonat
pediatr
patient
year
age
result
cultur
residu
product
calendar
year
also
collect
data
reaction
posit
residu
product
cultur
result
enrich
dataset
posit
result
use
current
aabb
criteria
cultur
blood
compon
follow
atr
refer
point
clinic
paramet
cultur
result
compar
determin
modifi
criteria
includ
use
agespecif
object
definit
hypotens
tachycardia
would
increas
sensit
detect
posit
residu
product
cultur
tabl
resultsfind
institut
submit
complet
reaction
data
cultur
residu
compon
pediatr
neonat
patient
posit
cultur
result
platelet
rbc
product
two
consid
definit
str
patient
cultur
grew
organ
consid
possibl
str
patient
cultur
neg
discord
patient
cultur
sensit
aabb
criteria
detect
posit
cultur
definit
possibl
ci
specif
ci
backgroundcas
studi
noninfecti
advers
event
transfus
well
report
adult
recipi
howev
literatur
scarc
pediatr
recipi
primari
object
compar
rate
variou
advers
transfus
reaction
atr
report
quebec
hemovigil
system
qh
among
year
age
recipi
children
versu
adult
studi
designmethod
atr
investig
report
transfus
safeti
offic
locat
design
hospit
quebec
standard
definit
atr
use
data
valid
hospit
blood
bank
hematologist
provinci
tso
medic
epidemiologist
consult
hematologist
rate
comparison
made
use
data
four
pediatr
hospit
report
atr
among
children
actual
number
unit
transfus
hospit
use
rate
calcul
resultsfind
blood
compon
transfus
quebec
hospit
includ
transfus
children
total
atr
deem
possibl
probabl
definit
associ
transfus
report
occur
among
children
atr
infant
year
old
repres
atr
among
children
rate
atr
labil
product
unit
transfus
describ
tabl
pediatr
recipi
like
experienc
febril
allerg
acut
hemolyt
reaction
wherea
adult
recipi
like
present
circulatori
overload
incid
fatal
atr
similar
group
rate
atr
children
higher
apheresi
platelet
follow
red
blood
cell
conclus
atr
rate
twice
common
children
compar
adult
mostli
due
higher
occurr
allerg
febril
reaction
whether
due
physiolog
differ
better
report
remain
determin
backgroundcas
studi
despit
introduct
leukodeplet
blood
compon
shown
donor
leukocyt
engraft
microchimer
remain
longterm
consequ
red
blood
cell
rbc
transfus
patient
group
incid
transfusionassoci
microchimer
tam
may
affect
intern
differ
blood
process
method
transfus
practic
patient
type
australia
found
incid
transfusionassoci
microchimer
tam
trauma
patient
howev
incid
tam
extens
studi
outsid
trauma
set
studi
conduct
determin
incid
tam
australian
pediatr
recipi
rbc
unit
studi
designmethod
pediatr
patient
studi
defin
patient
year
age
time
admiss
patient
n
transfus
least
one
red
blood
cell
rbc
unit
approach
particip
studi
incid
tam
determin
use
pcr
analysi
panel
insertiondelet
indel
biallel
polymorph
resultsfind
sampl
return
potenti
particip
mostli
hematologyoncolog
patient
diagnos
bone
marrow
failur
usual
result
acut
lymphoblast
leukemia
seventeen
femal
fifteen
male
median
age
time
transfus
year
old
day
chlorid
shift
mm
day
atp
mmolg
hb
day
day
day
mmolg
hb
day
day
backgroundcas
studi
biolog
manufactur
variabl
recogn
key
factor
impact
red
blood
cell
storag
potenti
transfus
outcom
metabolom
approach
use
assess
impact
factor
phenotyp
store
pack
red
blood
cell
prbc
studi
designmethod
multi
center
rbcomic
studi
enrol
whole
blood
donor
four
differ
us
blood
center
base
endofstorag
day
rbc
hemolysi
measur
spontan
osmot
stress
oxid
stress
select
donor
end
hemolysi
spectrum
measur
recal
donat
second
unit
leukocytefilt
prbc
studi
sampl
drawn
prbc
unit
day
snap
frozen
later
process
ultrahigh
pressur
liquid
chromatographi
coupl
mass
spectrometri
vanquish
q
exact
thermo
fisher
featur
compound
assign
perform
via
compound
discover
thermo
fisher
basi
highresolut
accur
intact
mass
isotop
pattern
retent
time
hous
standard
librari
pure
chemic
compound
stabl
isotopelabel
intern
standard
includ
previous
establish
marker
metabol
age
prbc
msm
valid
transit
fingerprint
resultsfind
untarget
metabolom
analys
includ
sampl
donor
strong
impact
prbc
storag
durat
varianc
blood
center
collect
varianc
metabol
phenotyp
latter
differ
attribut
addit
solut
use
differ
site
vs
area
receiv
oper
characterist
curv
note
minimum
varianc
observ
across
blood
center
use
suggest
overal
consist
standard
blood
process
protocol
metabol
phenotyp
sampl
store
differ
differ
beyond
compon
addit
formul
eg
sampl
store
mannitolfreecitr
load
character
higher
level
highenergi
compound
increas
glycolyt
rate
higher
atp
dpg
total
glutathion
levelsal
factor
significantli
correl
rbc
propens
hemolyz
challeng
prooxid
agent
dihydrochlorid
increas
methionin
metabol
activ
transsulfur
pathway
note
sampl
process
site
use
conclus
studi
highlight
impact
storag
addit
metabol
heterogen
hemolyt
phenotyp
sampl
process
largest
multicent
rbc
metabolom
studi
conduct
date
observ
may
contribut
explain
differ
result
smallscal
singlecent
laboratori
studi
clinic
trial
age
blood
metric
associ
expans
platelet
pediatr
transfus
servic
hospit
system
alex
ryder
dawn
moreau
le
bonheur
children
hospit
backgroundcas
studi
due
short
shelflif
requir
bacteri
cultur
releas
test
platelet
present
signific
inventori
manag
challeng
recent
fda
clearanc
rapid
test
platform
bacteri
contamin
safeti
measur
hospit
transfus
servic
may
extend
platelet
shelflif
mani
circumst
pediatr
transfus
servic
recent
implement
test
platform
soon
thereaft
extend
test
includ
platelet
unit
two
adult
hospit
transfus
servic
within
hospit
network
describ
metric
associ
implement
studi
designmethod
preimplement
data
gather
period
platelet
receiv
inventori
pediatr
transfus
servic
well
two
affili
adult
transfus
servic
januari
septemb
descript
statist
regard
platelet
transfus
expir
compar
postimplement
period
octob
march
pediatr
transfus
servic
postimplement
period
januari
march
affili
adult
transfus
servic
platelet
product
consist
entir
singledonor
apheresi
unit
unit
consid
expir
reach
outdat
prior
transfus
use
aliquot
prepar
resultsfind
preimplement
period
pediatr
transfus
servic
receiv
apheresi
platelet
unit
expir
prior
use
preimplement
period
two
combin
adult
transfus
servic
receiv
apheresi
platelet
unit
expir
prior
use
postimplement
period
pediatr
transfus
servic
receiv
apheresi
platelet
unit
unit
expir
prior
use
postimplement
period
platelet
unit
pgd
test
unit
test
unit
test
twice
total
test
estim
spent
test
test
unit
use
transfus
repres
approxim
save
addit
outdat
pgdtest
unit
provid
addit
day
platelet
stock
estim
amount
addit
cost
avoid
replac
unit
purchas
period
test
extend
platelet
affili
adult
transfus
servic
unit
transfus
total
number
expir
unit
repres
signific
decreas
preimplement
period
save
transfus
extend
platelet
short
period
time
estim
conclus
describ
recent
implement
fdaclear
rapid
bacteri
test
platelet
safeti
measur
achiev
outdat
pediatr
transfus
servic
subsequ
extens
practic
posit
impact
inventori
manag
two
associ
adult
transfus
servic
continu
improv
logist
process
believ
test
continu
decreas
platelet
wastag
increas
platelet
avail
patient
safeti
storag
platelet
plasma
function
apheresi
instrument
storag
contain
stephen
wagner
cheryl
hapip
annett
turgeon
lenora
abel
nadin
kaelber
american
red
cross
holland
laboratori
fda
backgroundcas
studi
storag
properti
apheresi
platelet
suspend
experiment
addit
solut
plasma
may
affect
collect
instrument
storag
contain
studi
evalu
impact
amicu
trima
collect
platform
platelet
collect
donor
store
either
two
manufactur
contain
studi
designmethod
consent
donor
provid
platelet
concurr
plasma
target
yield
platelet
occas
plasma
follow
collect
platelet
rest
hour
centrifug
rpm
ace
plasma
express
resuspend
yield
unit
plasma
follow
hour
rest
platelet
place
agit
either
maintain
origin
storag
contain
transfer
manufactur
storag
contain
place
agit
day
unit
assay
vitro
test
includ
platelet
count
ph
blood
gase
mitochondri
membran
potenti
reactiv
oxygen
speci
extent
shape
chang
esc
hypoton
shock
respons
aggreg
adp
collagen
glucos
lactat
bicarbon
morpholog
annexin
v
bind
data
analyz
repeat
measur
anova
bonferroni
posttest
anova
p
valu
consid
signific
due
repeat
measur
resultsfind
averag
unit
volum
yield
percent
plasma
ml
respect
compar
collect
either
apheresi
instrument
store
either
manufactur
contain
day
platelet
activ
similar
either
collect
instrument
contain
except
ph
day
co
day
esc
day
everi
invitro
paramet
similar
apheresi
platform
manufactur
contain
day
valu
ph
co
esc
given
tabl
ph
valu
unit
day
storag
except
unit
collect
store
contain
ph
day
ph
day
conclus
base
vitro
measur
storag
platelet
suspend
plasma
feasibl
origin
manufactur
contain
day
base
co
level
contain
greater
ga
exchang
contain
util
thromboelastographi
teg
bleed
risk
assess
tool
prior
intervent
radiolog
procedur
christin
cahil
ashwani
sharma
neil
blumberg
ami
e
schmidt
maje
refaai
univers
rochest
transfus
medicin
univers
rochest
backgroundcas
studi
intern
normal
ratio
inr
commonli
use
bleed
risk
assess
prior
invas
procedur
practic
may
sub
optim
inr
develop
monitor
warfarin
therapi
primarili
affect
factor
vii
activ
sever
societi
guidelin
recommend
correct
inr
prior
procedur
mitig
bleed
risk
evid
base
plasma
transfus
prothrombin
complex
concentr
pcc
without
vitamin
k
administr
usual
use
purpos
teg
whole
blood
assay
measur
full
spectrum
primari
secondari
hemostasi
may
superior
tool
risk
assess
studi
designmethod
record
patient
undergo
intervent
radiolog
procedur
collect
period
retrospect
review
patient
teg
addit
tradit
laboratori
screen
assay
run
prior
procedur
patient
characterist
medic
condit
laboratori
result
advers
event
collect
analyz
tabl
resultsfind
averag
age
cohort
year
common
diagnosi
pulmonari
disord
coronari
arteri
diseas
andor
renal
failur
intervent
radiolog
procedur
perform
biopsi
central
line
cathet
placement
thoracentesi
drain
placement
preprocedur
renal
liver
chemistri
profil
show
mild
moder
liver
abnorm
renal
failur
nine
patient
warfarin
patient
direct
oral
anticoagul
apixiban
patient
aspirin
although
preprocedur
inr
averag
teg
result
larg
normal
suggest
low
risk
bleed
tabl
bleed
complic
blood
product
transfus
vitamin
k
administr
given
conclus
pilot
studi
teg
appear
superior
assay
assess
bleed
risk
patient
undergo
invas
intervent
radiolog
procedur
particularli
patient
receiv
oral
anticoagul
although
inr
higher
suggest
guidelin
patient
signific
bleed
complic
studi
use
larger
cohort
warrant
evalu
consist
trend
backgroundcas
studi
data
exist
guid
dose
platelet
plt
oncolog
outpati
center
special
coordin
assign
plt
oncolog
patient
recommend
either
one
two
singl
donor
apheresi
plt
transfus
base
pt
medic
transfus
histori
eg
abo
type
hla
antibodi
statu
splenomegali
bodi
mass
respons
previou
transfus
well
plt
attribut
abo
type
plt
yield
volum
studi
sought
determin
whether
transfus
one
versu
two
unit
apheresi
plt
effect
posttransfus
plt
count
time
next
transfus
plt
count
prior
next
plt
transfus
studi
designmethod
obtain
irb
approv
retrospect
studi
adult
oncolog
pt
receiv
outpati
transfus
collect
date
time
transfus
unit
number
date
time
preand
posttransfus
plt
count
resultsfind
total
pt
receiv
plt
transfus
cumul
studi
period
major
pt
variabl
transfus
plt
per
outpati
visit
minor
transfus
exclus
pltonli
pltonli
strategi
throughout
studi
period
vast
major
plt
given
patient
receiv
mixtur
transfus
studi
period
summar
tabl
preand
posttransfus
plt
count
interv
outpati
visit
medic
similar
although
statist
differ
regardless
transfus
strategi
addit
pt
receiv
plt
probe
blood
group
antigen
across
blood
group
gene
abo
gypa
gypb
gype
rhd
rhce
kel
darc
ach
ermap
bsg
captur
sampl
sequenc
use
illumina
nextseq
nineti
five
sampl
blood
donor
previous
test
licens
snp
assay
use
comparison
test
select
repres
divers
set
antigen
phenotyp
use
bloodtyp
autom
blood
group
type
softwar
platform
interpret
ng
data
lane
wj
et
al
lancet
haematolog
press
bloodtyp
enhanc
analyz
mip
base
ng
data
mip
base
ng
result
compar
serolog
snp
type
antigen
b
ermap
fail
qualiti
filter
repeatedli
care
review
reveal
captur
es
librari
serolog
valid
k
fy
fy
b
jk
jk
b
perform
rbc
sampl
particip
result
discrep
due
cleric
error
attribut
failur
antibodi
detect
express
weak
kidd
allel
ten
novel
frameshift
nonsens
variant
identifi
bcam
gene
predict
deleteri
enzymat
function
antigen
express
describ
opensourc
informat
tool
translat
ng
data
predict
extend
rbc
phenotyp
demonstr
applic
analysi
es
file
result
corrobor
rel
high
frequenc
weak
kidd
allel
caucasian
popul
cliacertifi
serolog
antigen
sampl
correl
ng
predict
latter
precis
detect
weak
kidd
express
one
percent
particip
carri
novel
blood
group
variant
predict
deleteri
nonsens
frameshift
mechan
current
investig
backgroundcas
studi
unravel
genet
base
blood
group
facilit
implement
novel
diagnost
tool
transfus
medicin
relat
field
system
except
one
resolv
allow
genotyp
antigen
predict
xg
antigen
report
pbdx
xg
identifi
underli
gene
howev
reason
men
women
lack
xg
remain
undefin
hypothet
regulatori
locu
xgr
propos
alreadi
govern
express
antigen
xg
system
xg
encod
xg
highfrequ
antigen
encod
neighbour
gene
xg
locat
pseudoautosom
region
sex
chromosom
disrupt
produc
protein
unknown
function
x
hypothes
xg
express
transcript
control
singlenucleotid
polymorph
snp
within
xg
region
studi
designmethod
calcul
xg
allel
frequenc
differ
popul
compil
literatur
comparison
made
multipl
xg
variant
genom
project
express
quantit
trait
loci
eqtl
region
analyz
http
gtexportalorg
transcript
factor
bind
analyz
http
jaspargeneregnet
blood
sampl
blood
donor
anonym
gender
phenotyp
xg
genotyp
flow
cytometr
type
xg
perform
subset
donor
mrna
level
quantifi
rtqpcr
electrophoret
mobil
shift
assay
emsa
luciferas
report
assay
assess
function
import
identifi
snp
resultsfind
among
investig
xg
variant
show
best
fit
xg
frequenc
histor
dataset
strikingli
snp
locat
kb
upstream
xg
transcript
start
site
also
eqtl
signific
impact
xgmrna
level
whole
blood
also
abolish
site
corrobor
clear
chip
seq
peak
dataset
erythropoiet
cell
genotyp
show
xg
donor
regardless
gender
carri
least
one
allel
one
femal
sampl
posit
flow
cytometri
xg
women
xg
men
homozyg
xg
men
c
accompani
g
presum
yderiv
oppos
xg
donor
xg
show
lowtoundetect
xgmrna
level
bind
oligonucleotid
probe
c
shown
emsa
confirm
mass
spectrometri
follow
proteinoligonucleotid
pulldown
experi
intact
motif
enhanc
transcript
luciferas
report
assay
final
express
rbc
also
correl
statu
gg
gc
cc
xg
phenotyp
depend
intact
site
upstream
xg
xg
due
impair
transcript
follow
backgroundcas
studi
caucasian
woman
metastat
ovarian
carcinoma
histori
pregnanc
transfus
type
serolog
weak
weakli
posit
gel
nonreact
tube
sampl
reflex
rhd
genotyp
reveal
patient
rhd
weak
type
thereaft
manag
recommend
aabbcap
workgroup
guidelin
individu
weak
type
consid
risk
product
clinic
signific
antid
receiv
rbc
day
chemotherapi
induc
anemia
unexplain
hemolysi
undergo
carboplatin
paclitaxel
therapi
four
week
last
transfus
present
worsen
anemia
antid
plasma
studi
designmethod
plasma
antid
investig
determin
alloor
autoantid
serolog
test
standard
method
rhag
rhd
rhce
cdna
amplif
sequenc
perform
determin
mutat
rh
protein
part
rh
membran
complex
combin
g
p
associ
weak
type
could
potenti
explain
alloimmun
resultsfind
pretransfus
rbc
phenotyp
antibodi
screen
dat
neg
four
week
transfus
unit
present
worsen
anemia
gdl
slight
increas
bilirubin
clinic
concern
hemolysi
dat
neg
antid
present
plasma
peg
iat
eluat
antibodi
carboplatin
paclitaxel
detect
refer
laboratori
test
suggest
alloantid
plasma
adsorb
rr
rbc
contain
antid
antilw
rule
antid
react
variant
rbc
diii
div
dv
dvi
dvii
r
har
react
weak
type
rbc
test
patient
rbc
alba
advanc
partial
type
kit
gave
pattern
reactiv
consist
weak
type
sampl
test
parallel
sequenc
rhd
rhce
rhag
found
addit
chang
sampl
obtain
month
later
show
antid
antid
antik
respect
lookback
indic
least
unit
also
k
sampl
test
month
last
transfus
unit
continu
show
antid
although
react
weaker
prior
contrast
reactiv
equival
shown
titrat
plasma
adsorb
autolog
rbc
conclus
report
robust
product
alloantid
patient
weak
type
weak
type
individu
consid
risk
alloantid
base
observ
studi
primarili
europ
rare
except
known
date
antid
associ
clinic
signific
rbc
destruct
patient
antid
may
contribut
exacerb
anemia
howev
confound
clinic
histori
abnorm
pretransfus
lab
valu
make
definit
assess
challeng
transfus
least
dk
unit
sensit
antigen
suggest
may
act
synergist
complement
alloimmun
backgroundcas
studi
human
immunoglobulin
g
higg
includ
igg
subtyp
contain
differ
isoallotyp
due
genet
variat
contain
isoallotyp
describ
previous
shown
fdaapprov
monoclon
antiigg
fail
recogn
antikel
k
isoallotyp
indirect
antiglobulin
test
iat
failur
detect
two
antik
antibodi
due
amino
acid
chang
isotyp
heavi
chain
antik
second
common
caus
hemolyt
diseas
fetu
newborn
observ
rais
concern
potenti
clinic
impact
two
isoallotyp
want
examin
whether
isoallotyp
differenti
effect
human
monocytemacrophag
receptormedi
phagocytosi
compar
phagocyt
activ
purifi
recombin
antik
isoallotyp
use
opsonizederythrocyt
monocyt
monolay
assay
mma
studi
designmethod
novel
monoclon
recombin
antik
antibodi
isol
use
creat
panel
isoallotyp
thu
monoclon
antibodi
ident
variabl
region
gene
recogn
k
antigen
epitop
differ
heavi
chain
region
antik
antibodi
preincub
kposit
kk
kk
red
blood
cell
rbc
opson
rbc
examin
use
iat
tube
gel
flow
cytometri
use
antilambda
chain
antibodi
avoid
variat
fc
heavi
chain
region
mma
resultsfind
dosag
effect
seen
mani
isoallotyp
kk
iat
result
lower
kk
particularli
opsonis
kk
rbc
optim
determin
flow
cytometri
analysi
differenti
effect
isoallotyp
induct
phagocytosi
compar
phagocyt
index
show
reduc
capac
induc
phagocytosi
pi
respect
howev
show
significantli
enhanc
abil
induc
phagocytosi
induc
clinic
signific
phagocytosi
requir
increas
concentr
achiev
pi
suggest
clinic
signific
conclus
certain
amino
acid
variat
fc
region
antibodi
may
lead
enhanc
reduc
capac
abil
induc
phagocytosi
result
indic
antik
isoallotyp
clinic
signific
measur
mma
thu
antiglobulin
reagent
fail
detect
could
present
problem
oral
abstract
session
blood
group
new
antigen
new
allel
character
novel
highpreval
antigen
lutheran
blood
group
system
vrignaud
ramelet
denis
amiranoff
laur
bourguignat
guy
mpoy
sylvi
poupel
joell
nataf
thierri
peyrard
laboratoir
dexcel
grex
inserm
institut
nation
de
la
transfus
sanguin
ef
ile
de
franc
simon
veil
backgroundcas
studi
lutheran
blood
group
system
consist
antigen
locat
basalcel
adhes
glycoprotein
call
bcam
highpreval
equilibr
one
lowpreval
antigen
report
date
protein
strongli
involv
interact
red
blood
cell
rbc
extracellular
matrix
aim
present
work
describ
novel
highpreval
antigen
lutheran
system
investig
two
sister
produc
correspond
antilu
antibodi
studi
designmethod
blood
sampl
pregnant
woman
firstli
refer
laboratori
investig
panagglutin
antibodi
antibodi
identif
geltest
iat
biorad
perform
nativ
papaintr
diagast
trypsintr
sigma
rbc
genom
dna
extract
peripher
blood
cell
fulli
autom
method
amplifi
lu
exonspecif
primer
sequenc
resultsfind
proband
group
r
r
k
yo
femal
patient
turkish
origin
first
pregnanc
serum
reactiv
nativ
rbc
nonreact
trypsintr
rbc
lu
null
sampl
autolog
control
neg
lu
phenotyp
unambigu
lu
underli
alloantibodi
common
specif
rule
antibodi
final
conclud
socal
paralu
antibodi
ie
antibodi
probabl
highpreval
lu
antigen
unknown
specif
proband
anoth
child
two
year
later
without
complic
despit
stronger
reactiv
antibodi
blood
sampl
sibl
requir
compat
test
rbc
antibodi
screen
elder
sister
turn
compat
howev
investig
perform
time
paralu
antibodi
also
detect
proband
elder
sister
pregnanc
genom
dna
sequenc
reveal
presenc
sister
two
nucleotid
chang
homozyg
state
lubcam
gene
lu
allel
basi
first
one
synonym
chang
exon
known
present
gener
popul
second
one
found
exon
respons
amino
acid
chang
mutat
report
frequenc
less
exom
aggreg
consortium
exac
databas
conclus
serolog
molecular
studi
allow
us
provid
evid
novel
highpreval
antigen
lutheran
blood
group
system
importantli
identifi
specif
patient
antibodi
recommend
optim
transfus
polici
suggest
provision
assign
name
luya
proband
name
antigen
accord
structur
model
parson
et
al
blood
luya
express
predict
fourth
igsf
domain
bcam
antigen
sumi
novel
low
incid
antigen
mn
blood
group
antigen
shoichi
ito
sayaka
kaito
toru
miyazaki
naoko
watanabeokochi
yumi
suzuki
hatsu
tsuneyama
ryuichi
yabe
kazumi
isa
kenichi
ogasawara
makoto
uchikawa
nelsonhirokazu
tsuno
kazunori
nakajima
tohoku
block
blood
center
japanes
red
cross
kanto
koshinetsu
block
blood
center
japanes
red
cross
hokkaido
block
blood
center
japanes
red
cross
central
blood
institut
japanes
red
cross
backgroundcas
studi
case
posit
reaction
major
crossmatch
consult
blood
center
antibodi
screen
patient
plasma
neg
appli
variou
antibodi
crossmatchposit
relev
blood
product
could
identifi
antigen
name
sumi
first
proband
whose
rbc
carri
antigen
sumi
antigen
recogn
unidentifi
lowincid
antigen
report
sumi
antigen
present
glycophorin
gpa
studi
designmethod
serolog
test
perform
standard
tube
method
autom
blood
group
machin
standard
method
also
appli
rbc
treatment
proteolyt
enzym
antisumi
monoclon
antibodyproduc
cell
line
obtain
lymphocyt
antisumi
posit
individu
hybridoma
method
immunecomplex
captur
fluoresc
analysi
icfa
use
luminex
use
analyz
sumi
antigen
genom
dna
extract
peripher
white
blood
cell
sumiposit
individu
nucleotid
sequenc
gypa
examin
direct
sequenc
ta
clone
resultsfind
nine
sumi
posit
found
screen
japanes
blood
donor
human
monoclon
igm
antibodi
sumi
sensit
red
cell
treatment
trypsin
ficin
pronas
sialidas
dtt
antisumi
higher
found
among
normal
sera
salin
tube
method
room
temperatur
strongest
antibodi
titer
hand
case
umbil
cord
blood
plasma
show
neg
reaction
sumiposit
rbc
icfa
assay
murin
monoclon
antibodi
intracellular
potion
gpa
show
sumi
antigen
locat
gpa
gypa
gene
analysi
show
mutat
c
p
thr
pro
mutat
recogn
sumi
sumi
show
antigen
posit
conclus
sumi
antigen
novel
low
frequenc
antigen
mn
blood
group
system
repres
substitut
gpa
frequenc
sumi
antigen
among
japanes
donor
famili
analysi
confirm
sumi
antigen
dominantli
inherit
antisumi
detect
healthi
donor
consid
natur
occur
antibodi
igm
class
new
york
blood
center
backgroundcas
studi
algorithm
donor
antigen
type
dna
analysi
inhous
polici
serolog
confirm
dna
test
order
lead
discoveri
multipl
rhce
discord
investig
six
sampl
conflict
result
e
donor
c
donor
ob
patient
studi
designmethod
autom
manual
tube
method
use
rbc
type
genom
dna
isol
wbc
rna
rbc
hea
precisetyp
rhce
beadchip
rhce
gene
sequenc
inhous
assay
done
rhcespecif
cdna
analysi
perform
two
sampl
resultsfind
three
caucasian
donor
type
clone
reflex
hea
test
extend
rbc
profil
predict
rbc
e
tube
test
rbc
w
immucor
biorad
anti
rhce
beadchip
indic
e
phenotyp
review
genotyp
result
show
sampl
heterozyg
g
gene
sequenc
snpspecif
primer
confirm
presenc
rhce
ce
caucasian
hispan
donor
c
clone
predict
hea
tube
test
sampl
immucor
gammaclon
ortho
bioclon
biorad
seraclon
antic
multiplex
pcr
rhce
beadchip
sampl
lack
insert
intron
characterist
rh
c
rhce
exon
sequenc
howev
consist
rh
c
rhcdna
analysi
found
convent
rhce
transcript
indic
novel
allel
encod
c
phenotyp
lack
insert
hispan
ob
patient
anti
patern
sampl
refer
rhce
genotyp
evalu
risk
hdfn
patern
sampl
genotyp
consist
serolog
children
predict
e
patient
rbc
predict
hea
serolog
confirm
rbc
c
w
immucor
gammaclon
ortho
bioclon
singl
donor
sourc
antic
albaclon
biorad
seraclon
singl
donor
sourc
antic
rhce
beadchip
indic
phenotyp
genotyp
indic
heterozygos
rhcdna
analysi
show
chang
rhce
ce
indic
express
c
antigen
novel
allel
rhce
conclus
report
three
new
rhce
allel
rhce
associ
variabl
e
antigen
type
rhce
ce
lack
classic
intron
insert
associ
c
antigen
rhce
encod
variabl
c
antigen
express
report
two
rhce
allel
addit
chang
rhce
rhce
variabl
e
express
interestingli
rhce
found
three
midwest
caucasian
donor
continu
discoveri
rh
variant
knowledg
serolog
preval
allel
potenti
clinic
impact
import
design
futur
genotyp
assay
novel
rhce
allel
express
rhd
epitop
respons
falseposit
type
posttransfus
antid
alloimmun
patient
western
european
descent
vrignaud
ramelet
dominiqu
gien
ine
molini
creppi
thierri
peyrard
laboratoir
dexcel
grex
inserm
institut
nation
de
la
transfus
sanguin
ef
alp
backgroundcas
studi
rh
current
compris
antigen
encod
two
highli
homolog
gene
rhd
rhce
rhd
protein
express
antigen
wherea
rhce
protein
carri
cc
ee
antigen
howev
rhd
variant
may
paradox
code
rhce
reactiv
rhd
diiiac
rhd
respons
c
reactiv
clone
convers
rhce
allel
rhce
cehar
rhce
cecf
rhce
cert
rhce
cesl
may
express
rhd
epitop
less
detect
antid
reagent
depend
clone
use
describ
serolog
molecular
investig
dposit
patient
western
european
descent
antid
alloimmun
studi
designmethod
rhd
type
carri
standard
hemagglutin
techniqu
polyclon
monoclon
antibodi
adsorptionelut
test
perform
polyclon
antid
acid
elut
method
genom
dna
amplifi
rhd
rhcespecif
primer
sequenc
rhd
gene
also
investig
wrhd
dnabeadchip
devic
immucorbioarray
resultsfind
blood
sampl
group
w
cece
k
yo
male
patient
spanish
origin
refer
march
refer
laboratori
explor
antid
neg
dat
autocontrol
patient
conclud
carri
weak
phenotyp
refer
laboratori
like
consid
european
ancestri
antid
observ
month
first
transfus
rbc
unit
june
patient
regularli
transfus
platelet
drbc
unit
year
weak
express
found
routin
techniqu
ortho
biovu
clone
reactiv
biorad
idsystem
polyclon
use
panel
monoclon
antid
show
posit
reaction
clone
reactiv
clone
rhd
analysi
show
exon
amplif
new
blood
sampl
sent
anoth
transfus
episod
rhd
gene
found
patient
specul
reactiv
could
origin
rhce
variant
allel
confirm
presenc
heterozyg
g
nontempl
mutat
exon
besid
adsorptionelut
studi
polyclon
antid
found
neg
conclus
describ
novel
rhce
allel
rhce
genbank
number
express
epitop
detect
sever
commonli
use
monoclon
antid
reagent
may
caus
falseposit
type
especi
clone
reactiv
risk
antid
alloimmun
seemingli
patient
especi
matter
concern
type
women
childbear
age
accord
rh
protein
structur
model
flegel
wa
curr
opin
hematol
locat
extracellular
domain
rhce
protein
within
socal
rh
protein
vestibul
data
new
allel
seem
confirm
import
vestibul
area
term
rhd
epitop
express
propos
call
new
variant
rhce
cerg
rg
arg
gli
similarli
name
procedur
follow
rhce
cesl
rhce
cert
serolog
molecular
character
three
new
rhd
allel
judith
aeschlimann
sunitha
vege
christin
lomasfr
amanda
kinsingerstickel
jay
p
hudgin
ira
shulman
conni
westhoff
immunohematolog
genom
laboratori
new
york
blood
center
new
york
blood
center
univers
virginia
health
system
keck
school
medicin
usc
lacusc
medic
center
backgroundcas
studi
serolog
molecular
divers
rhd
antigen
without
question
list
rhd
variant
allel
continu
grow
investig
sampl
femal
refer
weaker
expect
type
rh
genotyp
studi
designmethod
genom
dna
isol
wbc
rhd
beadchip
assay
rhd
sequenc
perform
rhdspecif
cdna
analysi
done
two
sampl
serolog
test
standard
method
multipl
antid
albaclon
advanc
partial
rhd
type
kit
two
sampl
resultsfind
sampl
pregnant
woman
ethnic
unknown
whose
rbc
type
w
rbc
also
react
immedi
spin
iat
antid
ortho
bioclon
immucor
gammaclon
seri
seri
quotient
antid
blend
alpha
delta
rbc
also
type
vv
monoclonalpolyclon
antig
three
clone
alba
partial
kit
nonreact
rbc
pattern
match
indic
partial
rhd
beadchip
show
low
signal
exon
marker
suggest
hybrid
allel
rhd
exon
sequenc
rhdcdna
analysi
confirm
hemizyg
rhdce
hybrid
g
associ
c
antigen
silent
chang
exon
rhce
beadchip
detect
rhce
sampl
rbc
woman
unknown
ethnic
sent
rhd
genotyp
react
iat
biorad
seraclon
immucor
gammaclon
orthobioclon
rhd
beadchip
detect
chang
exon
sequenc
identifi
heterozyg
chang
c
associ
partial
rhd
dvii
rhdcdna
analysi
confirm
rhd
dvii
identifi
rhdce
hybrid
addit
chang
g
exon
sampl
africanamerican
pregnant
woman
refer
variabl
type
rbc
react
iat
ortho
bioclon
immucor
gammaclon
seri
seri
biorad
seraclon
seraclon
blend
type
go
rbc
type
react
five
clone
alba
partial
kit
div
pattern
rhd
beadchip
detect
c
rhd
gene
sequenc
confirm
new
allel
conclus
report
new
rhd
allel
two
variabl
type
evid
encod
partial
phenotyp
one
silent
rh
hybrid
tran
dvii
sampl
found
new
rhdce
hybrid
g
exon
chang
characterist
rhce
suggest
allel
aros
gene
convers
event
rhdce
hybrid
report
without
g
chang
found
sampl
lastli
describ
new
allel
rhd
rbc
reactiv
pattern
div
alba
partial
kit
go
lack
alloimmun
antigen
neg
orthotop
liver
transplant
recipi
receiv
posit
rbc
periop
lindsey
wlosinski
jaber
elbashir
zaher
k
otrock
henri
ford
hospit
backgroundcas
studi
neg
patient
pt
routin
transfus
drbc
due
increas
immunogen
antigen
rate
alloimmun
antigen
follow
transfus
high
howev
immunosuppress
pt
may
less
like
becom
alloimmun
dpt
undergo
liver
transplant
may
requir
larg
number
rbc
unit
risk
inventori
drbc
consid
rel
rare
donor
unit
compar
posit
rbc
blood
bank
may
forc
suppli
pt
rbc
due
inventori
constraint
though
process
provid
rbc
dtransplant
recipi
accept
blood
bank
practic
incid
alloimmun
dantigen
dliver
transplant
pt
well
defin
activ
liver
transplant
program
institut
studi
preval
antid
format
dliver
transplant
pt
receiv
rbc
periop
assist
success
patient
blood
manag
studi
designmethod
retrospect
studi
perform
singl
larg
academ
medic
center
studi
approv
institut
review
board
electron
medic
record
blood
bank
file
pt
underw
orthotop
liver
transplant
henri
ford
hospit
detroit
michigan
august
decemb
review
resultsfind
twelv
dpt
receiv
blood
periop
tabl
summar
characterist
pt
median
age
year
rang
year
male
median
number
rbc
unit
transfus
unit
rang
unit
evid
alloimmun
patient
median
follow
month
rang
month
one
patient
die
surgeri
dpt
dliver
transplant
recipi
present
alloimmun
transplant
none
pt
transfus
blood
institut
conclus
studi
show
risk
alloimmun
antigen
dorthotop
liver
transplant
recipi
receiv
rbc
periop
complement
stabil
thaw
plasma
inventori
plasmapheresi
implic
laura
stephen
linacel
g
cadden
samuel
pepkowitz
cedarssinai
medic
center
backgroundcas
studi
donor
plasma
select
albumin
therapeut
plasmapheresi
replac
fluid
nononcot
function
compon
clot
factor
need
replet
plasma
also
contain
complement
protein
benefici
function
immun
inflamm
may
diseaseaccentu
role
condit
transplant
reject
complementmedi
glomerular
diseas
postprocedur
complement
level
concern
select
patient
coagul
protein
fibrinogen
known
preserv
thaw
plasma
tp
stabil
report
multipl
refer
laboratori
stabil
comment
suggest
serum
complement
level
drop
three
day
storag
accordingli
studi
assay
refriger
tp
patient
serum
day
storag
studi
designmethod
measur
fdaapprov
nephelometr
method
four
unit
donor
plasma
time
thaw
day
storag
also
measur
three
random
patient
sampl
store
condit
resultsfind
donor
tp
unit
level
averag
chang
valu
rang
day
thaw
tabl
patient
serum
sampl
initi
level
mgdl
refer
rang
mgdl
level
mgdl
refer
rang
mgdl
serum
level
chang
averag
respect
day
refriger
conclus
level
maintain
shelflif
tp
plasmapheresi
case
mainten
complement
level
postprocedur
indic
would
advantag
use
immedi
thaw
plasma
prepar
store
tp
patient
lower
complement
concentr
desir
albumin
replac
prefer
clinic
accept
store
tp
would
provid
benefit
immedi
thaw
plasma
prepar
serum
level
also
appear
stabl
refriger
day
investig
allow
tertiari
caretrauma
center
confid
maintain
roll
inventori
tp
support
immedi
avail
emergencymass
transfus
need
addit
routin
use
tp
plasmapheresi
fluid
replac
curtail
expir
tp
product
inventori
disord
eg
hemophilia
today
primarili
use
replac
fg
trauma
acquir
coagulopathi
cryo
guidelin
requir
use
within
hr
thaw
may
overli
restrict
cryo
use
fg
replac
assess
hemostat
qualiti
thaw
pool
cryo
store
refriger
room
temperatur
rt
day
studi
designmethod
cryo
pool
type
thaw
distribut
ml
aliquot
storag
cold
rt
cryo
dilut
pb
analyz
fg
fviii
hematolog
analyz
vwf
activ
quantifi
ristocetin
cofactor
assay
coagul
cryo
dilut
cryopoor
plasma
cpp
origin
ratio
measur
rotem
thrombin
gener
cryocpp
mixtur
quantifi
thrombogram
pack
red
cell
platelet
concentr
frozen
plasma
cryo
combin
simul
massiv
transfus
analyz
rotem
vwf
function
also
measur
shearinduc
adhes
platelet
collagenco
surfac
flow
recent
year
therefor
compli
current
month
deferr
polici
selfdef
dhq
donat
blood
last
year
declar
plan
current
month
deferr
polici
although
sexual
intercours
anoth
man
last
year
rais
rate
blood
donor
among
msm
popul
particip
studi
respond
support
support
suggest
new
fpqp
introduc
would
consid
donat
blood
rais
rate
blood
donor
among
respond
addit
msm
donat
blood
last
year
state
agre
reveal
sexual
orient
dhq
order
includ
program
compar
current
month
deferr
polici
conclus
introduct
new
approach
need
increas
complianc
lgbt
commun
enabl
take
part
life
save
blood
donat
without
compromis
blood
recipi
safeti
suggest
plasma
quarantin
polici
bring
probabl
msm
donat
blood
truli
state
sexual
practic
retest
donor
futur
donat
significantli
increas
blood
safeti
compar
current
practic
accept
suggest
chang
polici
accompani
adequ
educ
campaign
blood
donor
recipi
hypothes
unlik
modifi
human
rbc
multipl
background
human
gene
product
mous
rbc
would
serv
blank
canva
without
human
rbc
alloantigen
could
engin
express
individu
human
alloantigen
studi
designmethod
transgen
mice
rbc
express
either
k
k
jk
b
alloantigen
subject
extend
phenotyp
antibodi
common
human
rbc
alloantigen
transgen
wildtyp
mous
rbc
also
test
plasma
two
human
patient
known
identifi
alloantibodi
human
plasma
incub
wildtyp
mous
rbc
bound
antibodi
elut
test
carbohydr
bind
glycan
array
contain
differ
carbohydr
known
chemistri
resultsfind
mous
rbc
type
neg
rhd
rhc
rhc
rhe
rhe
fy
fy
b
k
k
jk
b
antigen
reactiv
antijk
natur
occur
alloantibodi
mous
rbc
igm
igg
detect
multipl
sampl
human
plasma
eluat
mous
wildtyp
rbc
incub
human
plasma
observ
strong
igg
signal
singl
carbohydr
structur
reactiv
seen
carbohydr
similar
structur
eg
polynacetyllactosamin
human
antimous
antibodi
easili
absorb
use
wildtyp
rbc
result
plasma
free
activ
wildtyp
rbc
test
absorb
plasma
transgen
mous
rbc
wildtyp
k
k
jk
b
correctli
identifi
antik
antijk
b
two
separ
patient
specimen
flow
cytometri
wettub
test
immunohematolog
lab
conclus
studi
report
novel
approach
isol
individu
human
blood
group
antigen
one
time
mous
rbc
use
rbc
nonhuman
origin
provid
sever
advantag
includ
blank
canva
without
human
alloantigen
rbc
use
exist
immunohematolog
platform
stabl
sourc
rbc
wellcharacter
anim
problem
includ
assess
basi
reactiv
antijk
mous
rbc
elimin
human
antimous
rbc
antibodi
although
absorpt
work
well
identifi
target
elimin
would
prefer
genet
modif
andor
enzymat
treatment
ongo
work
includ
expand
panel
transgen
line
understand
background
reactiv
rais
concern
may
miss
clinic
signific
alloantibodi
patient
whose
genom
encod
andor
variant
studi
designmethod
sequenc
analysi
known
human
variant
igg
subtyp
carri
monoclon
antibodi
express
recombinantli
differ
variant
panel
use
target
assess
abil
bind
kk
target
incub
express
variant
follow
analyz
flow
cytometri
addit
mice
immun
human
igg
splenocyt
fuse
myeloma
partner
novel
monoclon
antiahg
antibodi
clone
character
use
assay
resultsfind
amino
acid
residu
identifi
within
variant
analyz
common
canon
miss
variant
singl
amino
acid
e
posit
also
found
variant
recogn
q
express
variant
mutat
natur
e
posit
q
caus
gain
reactiv
moreov
q
instead
e
posit
amino
acid
differ
nonreact
reactiv
addit
new
monoclon
antibodi
isol
recogn
express
variant
variant
new
monoclon
ahg
map
posit
r
express
variant
q
variant
analyz
report
find
identifi
epitop
recogn
contain
amino
acid
polymorph
respons
unintend
lack
recognit
well
use
nonreact
report
new
monoclon
maintain
virtu
remedi
defect
combin
new
monoclon
would
gener
ahg
mixtur
nonreact
unlik
lose
reactiv
due
yet
undescrib
polymorph
backgroundcas
studi
number
blood
program
recogn
opportun
blood
donat
provid
identifi
ostens
healthi
individu
might
unawar
risk
health
program
includ
along
mandat
serolog
test
assay
nonfast
total
cholesterol
tc
hemoglobin
also
taken
step
notifi
individu
whose
result
suggest
risk
cardiovascular
diseas
diabet
sinc
program
long
histori
provid
donor
inform
tc
decid
find
individu
elev
tc
met
criteria
famili
hypercholesterolemia
fh
fh
preval
gener
popul
common
frequent
underdiagnos
genet
diseas
diseas
mark
sever
elev
cholesterol
evid
coronari
arteri
diseas
earli
age
untreat
earli
death
due
myocardi
infarct
resultsfind
storag
time
platelet
recoveri
declin
significantli
compar
fresh
p
day
day
platelet
surviv
decreas
significantli
fresh
day
day
day
p
intrins
apoptot
event
measur
mitochondri
membran
integr
decreas
nonsignificantli
storag
time
similarli
apoptosi
measur
activ
effector
caspas
increas
nonsignificantli
fresh
day
phosphatidyl
serin
exposur
measur
annexin
v
bind
increas
significantli
day
day
marker
platelet
activ
specif
microparticl
pselectin
increas
significantli
day
respect
note
platelet
respons
collagen
stimul
reveal
function
insideout
signal
integrin
activ
compar
nonsignificantli
differ
fresh
platelet
day
storag
best
predictor
day
platelet
recoveri
surviv
collagenstimul
integrin
activ
respect
conclus
perform
first
studi
extend
storag
cold
plasmastor
apheresi
platelet
day
fresh
compar
show
continu
loss
recoveri
day
storag
overal
continu
platelet
activ
hallmark
coldstor
platelet
marker
caspas
activ
mitochondri
membran
integr
show
delay
apoptosi
coldstorag
platelet
function
test
show
preserv
integrin
activ
compar
fresh
day
storag
best
predictor
day
platelet
recoveri
surviv
collagenstimul
integrin
activ
taken
togeth
storag
day
cold
appear
yield
accept
vitro
vivo
result
pathogen
reduct
platelet
rich
plasma
abrog
cell
allorespons
mice
johnson
q
tran
rachael
p
jackman
blood
system
research
institut
backgroundcas
studi
alloimmun
follow
platelet
transfus
lead
reject
subsequ
transfus
transplant
recipi
cell
key
mediat
alloimmun
respons
recogn
allogen
mhc
via
either
direct
bind
donor
cell
indirectli
donor
antigen
present
recipi
antigen
present
cell
prior
work
shown
pathogen
reduct
riboflavin
uv
light
uvr
allogen
platelet
rich
plasma
prp
prevent
alloimmun
mice
provid
partial
antigenspecif
toler
subsequ
transfus
vitro
work
demonstr
mechan
uvr
treatment
prevent
alloimmun
associ
downregul
donor
cell
surfac
adhes
molecul
prevent
direct
recognit
allogen
cell
howev
role
cell
may
complex
vivo
involv
either
indirect
recognit
weak
direct
signal
better
understand
uvr
treatment
regul
alloimun
studi
provid
comprehens
evalu
cell
respons
allogen
prp
transfus
mice
studi
designmethod
white
blood
cell
wbc
rich
prp
isol
donor
balbc
mice
left
untreat
treat
uvr
transfus
mice
evalu
impact
secondari
exposur
given
second
transfus
untreat
wbcrich
prp
two
week
later
cell
respons
measur
spleen
blood
recipi
mice
time
flow
cytometri
cell
activ
delet
anergi
examin
resultsfind
expect
signific
upregul
activ
marker
cell
blood
spleen
follow
transfus
untreat
allogen
prp
includ
ico
peak
day
p
contrast
mice
receiv
singl
uv
r
transfus
show
cell
respons
blood
spleen
although
small
signific
enrich
ico
cell
observ
blood
seventh
day
challeng
p
mice
given
uvr
prp
follow
untreat
prp
display
earli
weaker
transient
respons
peak
around
day
p
evid
delet
anergi
observ
cell
compart
conclus
allogen
cell
respons
significantli
diminish
pathogen
reduct
uvr
treatment
howev
cell
allorecognit
vivo
complet
absent
small
signific
induct
activ
cell
observ
blood
failur
cell
allorespons
uvr
treatment
like
due
cell
delet
anergi
possibl
associ
activ
cell
toler
immun
avoid
anupam
prakash
jelena
medv
juan
salazar
andria
li
chanc
j
luckey
univers
virginia
univers
virginia
medic
center
backgroundcas
studi
antibodi
gener
nonabo
red
blood
cell
rbc
antigen
respons
transfus
major
caus
morbid
mortal
chronic
transfus
patient
despit
clinic
signific
molecular
mechan
regul
immun
respons
transfus
rbc
remain
poorli
understood
previou
work
lab
arneja
et
al
demonstr
defici
mice
mount
significantli
lower
antibodi
respons
rbc
antigen
howev
alloantibodi
product
still
occur
absenc
suggest
altern
pathway
capabl
drive
rbc
alloimmun
sinc
observ
increas
skew
cytokin
respons
transfus
defici
mice
hypothes
key
cytokin
downstream
transcript
factor
also
drive
rbc
alloimmun
studi
designmethod
use
previous
establish
rbc
alloimmun
mous
model
contain
fusion
protein
hen
egg
lysozym
hel
ovalbumin
human
duffi
antigen
hod
rbc
model
rbc
alloimmun
wild
type
defici
defici
mice
transfus
store
hod
blood
sera
collect
mice
variou
time
point
week
post
transfus
total
antihel
igg
titer
measur
use
elisa
resultsfind
wild
type
mice
elicit
robust
igg
respons
hel
respons
defici
mice
lower
week
post
transfus
similarli
antibodi
respons
defici
mice
lower
week
post
transfus
interestingli
week
post
transfus
igg
titer
defici
mice
lower
p
compar
wild
type
demonstr
also
play
role
antibodi
evanesc
statist
done
use
student
test
use
holmsidak
correct
conclus
first
data
suggest
role
rbc
alloimmun
ongo
studi
lab
focus
uncov
specif
cell
type
activ
respons
transfus
rbc
pathway
interact
pathway
control
rbc
alloimmun
backgroundcas
studi
polyunsatur
fatti
acid
pufa
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
import
membran
fluiditi
cellular
signal
dietari
supplement
epa
dha
associ
improv
red
blood
cell
rbc
deform
hydrat
membran
fluiditi
along
reduc
irrevers
sickl
pain
episod
patient
sickl
cell
diseas
howev
pufa
complet
benign
highli
suscept
peroxid
oxid
environ
potenti
damag
rbc
structur
age
cold
storag
therefor
import
evalu
whether
diet
enrich
pufa
affect
rbc
lifespan
posttransfus
recoveri
ptr
studi
designmethod
mice
strain
known
good
poor
fvb
refriger
rbc
storag
fed
diet
enrich
safflow
fish
oil
micegroup
week
rbc
biotinyl
vivo
lifespan
measur
track
biotinyl
rbc
day
leukoreduc
blood
also
prepar
rbc
deform
lorca
microsphiltr
ptr
evalu
day
refriger
storag
metabolom
studi
fresh
store
blood
perform
resultsfind
rbc
lifespan
fvb
mice
safflow
diet
significantli
greater
strain
fish
oil
diet
fvb
p
safflow
oil
diet
baselin
rbc
deform
significantli
higher
compar
fvb
mice
furthermor
rbc
deform
significantli
decreas
strain
fish
oil
diet
rbc
transfus
storag
ptr
significantli
lower
fish
oil
group
strain
fvb
p
p
respect
also
strong
correl
ptr
deform
lorca
r
microsphiltr
r
metabolom
studi
plasma
rbc
reveal
markedli
lower
level
free
esterifi
carnitin
fish
oil
group
storag
conclus
data
suggest
diet
contain
high
level
dha
epa
fish
oil
kcal
associ
decreas
membran
deform
vivo
lifespan
ptr
cold
storag
carnitin
modul
rbc
fluiditi
due
role
phospholipid
repair
stabil
spectrinactin
complex
sodiumpotassium
atpas
activ
strong
correl
decreas
carnitin
level
deform
rbc
lifespan
ptr
suggest
potenti
mechan
underli
effect
identifi
possibl
intervent
improv
rbc
qualiti
backgroundcas
studi
understand
megakaryocyt
mk
biolog
critic
understand
treat
diseas
affect
platelet
product
function
howev
procur
adequ
number
rare
myeloid
popul
remain
ratelimit
vitro
studi
reli
mk
differenti
hematopoiet
stem
cell
hsc
remain
lack
consensu
optim
method
present
optim
protocol
gener
matur
mk
peripher
blood
pb
cell
increas
platelet
product
studi
designmethod
assess
featur
function
mk
differenti
twophas
cultur
system
use
set
gold
standard
metric
includ
morphologyultrastructur
bright
field
electron
microscopi
em
cell
surfac
marker
express
ploidi
cell
size
flow
cytometri
cytoskelet
organ
granul
content
confoc
microscopi
protein
content
luminex
assay
also
quantifi
releas
static
cultur
bioreactor
set
character
result
platelet
rest
upon
activ
resultsfind
consist
megakaryopoiesi
decreas
cell
increas
cours
differenti
size
ploidi
differenti
cell
consist
valu
mk
cord
bloodderiv
mk
mk
contain
factin
cytoskelet
element
characterist
matur
mk
well
marker
alphagranul
vwf
dens
granul
thrombospondin
serotonin
differenti
cell
express
growth
factor
includ
egf
vegf
pdgf
level
similar
found
human
platelet
lysat
addit
differenti
mk
produc
proplatelet
function
platelet
day
static
cultur
increas
adultlik
platelet
produc
use
novel
bioreactor
conclus
differenti
protocol
rapidli
consist
gener
matur
mk
pb
hsc
despit
resembl
cord
blood
mk
size
ploidi
cell
produc
larger
number
proplatelet
previous
report
earli
day
differenti
backgroundcas
studi
pathomechan
complic
due
blood
transfus
fulli
understood
elev
level
heme
deriv
store
rbc
thought
associ
transfus
reaction
especi
inflammatori
respons
recent
proinflammatori
effect
heme
wide
studi
howev
still
unknown
whether
heme
influenc
resolut
inflamm
key
step
inflammatori
respons
result
aggrav
inflamm
studi
designmethod
murin
model
selflimit
periton
initi
zymosan
use
effect
hemin
resolut
assess
resolut
indic
western
blot
qrtpcr
flow
cytometri
chemotaxi
assay
enzymelink
immunosorb
assay
luciferas
report
assay
lentiviru
infect
use
investig
possibl
mediat
mechan
neutrophil
differenti
cell
resultsfind
administr
hemin
significantli
increas
leukocyt
infiltr
entir
time
cours
h
enhanc
express
periton
lavag
murin
serum
prolong
resolut
interv
h
mous
periton
vitro
hemin
significantli
downregul
formyl
peptid
receptor
protein
level
p
key
resolut
receptor
lead
suppress
proresolut
respons
trigger
proresolut
ligand
resolvin
subsequ
four
predict
mirna
like
bind
identifi
two
predict
databas
among
significantli
upregul
hemin
p
inhibit
attenu
inhibitori
effect
hemin
protein
express
p
luciferas
report
assay
confirm
directli
bound
overexpress
significantli
downregul
protein
level
wherea
inhibit
led
signific
increas
p
conclus
result
suggest
hemin
prolong
resolut
selflimit
inflamm
action
associ
downregul
mediat
hemininduc
find
demonstr
novel
mechan
hemin
deriv
store
rbc
inflammatori
respons
cold
backgroundcas
studi
sodium
citrat
becom
prefer
anticoagul
use
apheresi
collect
platform
includ
platelet
addit
solut
sinc
pasii
suggest
sodium
citrat
includ
pa
prevent
spontan
aggreg
research
cancer
cell
line
demonstr
concentr
sodium
citrat
present
current
pa
formul
caus
apoptosi
light
data
evalu
whether
remov
sodium
citrat
pasiii
could
posit
impact
platelet
storag
studi
designmethod
hyper
concentr
apheresi
platelet
unit
collect
amicu
normal
consent
donor
pasiii
without
sodium
citrat
ad
ml
hyper
concentr
platelet
achiev
plateletplasma
pa
ratio
rest
unit
split
polyolefin
bag
seal
half
ad
bag
increas
concentr
sodium
citrat
ad
obtain
final
concentr
platelet
qualiti
function
assess
day
platelet
count
ph
glucos
lactat
blood
gase
measur
quantit
surfac
marker
evalu
flow
cytometri
includ
annexin
v
bind
reactiv
oxygen
speci
measur
use
platelet
function
assess
aggregometri
collagen
resultsfind
platelet
count
ph
accept
compar
throughout
day
storag
regardless
pasiii
condit
platelet
store
day
pasiii
without
sodium
citrat
cit
significantli
increas
glucos
level
cit
mm
cit
mm
significantli
decreas
lactat
level
cit
mm
cit
mm
ro
level
cit
mm
cit
mm
annexin
v
posit
cit
cit
pselectin
express
cit
cit
compar
store
citrat
trend
toward
better
preserv
gpib
surfac
platelet
store
without
sodium
citrat
platelet
store
without
citrat
also
show
trend
toward
greater
extent
aggreg
compar
contain
citrat
collagen
aggreg
cit
cit
trap
aggreg
cit
cit
conclus
remov
sodium
citrat
pasiii
result
spontan
platelet
aggreg
clot
could
lead
decreas
platelet
count
day
storag
absenc
sodium
citrat
improv
nearli
measur
paramet
demonstr
sodium
citrat
contribut
platelet
storag
lesion
remov
result
improv
cell
qualiti
function
backgroundcas
studi
alloimmun
common
follow
transfus
platelet
rich
plasma
prp
caus
complic
platelet
refractori
transplant
reject
previous
shown
pathogen
reduct
prp
riboflavin
uv
light
uvr
protect
alloimmun
mice
induc
partial
toler
subsequ
transfus
studi
evalu
rel
contribut
major
histocompat
antigen
mhc
minor
antigen
allorespons
prp
transfus
toler
induc
uvr
treatment
studi
designmethod
mice
transfus
prp
syngen
balbc
allogen
mhc
minor
antigen
allogen
mhc
uvr
uvr
follow
untreat
week
later
balbc
mice
transfus
prp
allogen
mhc
minor
antigen
allogen
minor
antigen
uvr
uvr
follow
untreat
week
later
two
week
final
transfus
blood
screen
antibodi
differ
donor
type
cell
splenocyt
challeng
ex
vivo
differ
donor
type
cell
cultur
cytokin
measur
evalu
prime
vivo
group
compar
use
anova
tukey
posttest
resultsfind
total
mhc
specif
antibodi
respons
highest
mhc
minor
antigen
mismatch
lower
antibodi
respons
observ
mhc
mismatch
alon
p
weak
signific
p
alloantibodi
respons
minor
antigen
uvr
treatment
protect
major
minor
antigen
alloimmun
allogen
mhc
minor
antigen
prime
enhanc
cytokin
respons
ex
vivo
though
weaker
minor
antigen
respons
block
uvr
treatment
reduc
cytokin
respons
observ
mice
given
uvr
treat
prp
follow
untreat
prp
allogen
mhc
balbc
mice
given
uvr
treat
prp
follow
untreat
prp
allogen
minor
antigen
conclus
allogen
mhc
suffici
drive
alloantibodi
product
model
respons
bulk
alloantibodi
respons
minor
alloantigen
induc
small
antibodi
respons
also
enhanc
antimhc
respons
minor
alloantigen
induc
weak
cytokin
respons
allogen
mhc
necessari
suffici
induc
toler
use
pathogen
reduct
technolog
transfus
mice
effici
gener
germin
center
produc
poor
plasma
cell
jelena
medv
chanc
j
luckey
univers
virginia
univers
virginia
medic
center
backgroundcas
studi
welldescrib
complic
transfus
nonabo
red
blood
cell
rbc
alloimmun
despit
univers
prescreen
alloantibodi
patient
transfus
complic
still
rel
common
occurr
delay
hemolyt
transfus
reaction
remain
third
lead
caus
transfusionrel
fatal
usa
major
caus
morbid
mortal
remark
high
rate
evanesc
patient
alloantibodi
drop
level
detect
within
year
initi
product
molecular
cellular
control
high
rate
antirbc
evanesc
complet
unknown
herein
studi
antirbc
alloantibodi
evanesc
experiment
tractabl
mous
model
alloimmun
contrast
antibodi
respons
transfus
rbc
gener
respons
standard
vaccin
studi
designmethod
wild
type
mice
transfus
store
mous
rbc
express
hod
hen
egg
lysozym
ovalbumin
human
duffi
b
antigen
vaccin
npova
precipit
aluminum
hydroxid
antigenspecif
total
igg
measur
sera
collect
week
postimmun
elisa
presenc
antigenspecif
shortand
longliv
plasma
cell
slpc
llpc
examin
elispot
day
week
immun
germin
center
gc
differenti
assess
percentag
igd
lo
pna
hi
hi
gc
b
hi
hi
hi
follicular
helper
tfh
cell
examin
flow
cytometri
day
immun
resultsfind
antigenspecif
antibodi
evanesc
transfus
mice
compar
vaccin
antirbc
alloantibodi
decreas
week
transfus
antinp
antibodi
decreas
p
vaccin
transfus
mice
gener
similar
gc
b
respect
p
tfh
cell
p
vaccin
mice
effici
produc
slpc
splenic
slpc
per
million
seed
slpc
product
transfus
mice
slpc
p
compar
unimmun
control
slpc
p
signific
differ
also
found
number
llpc
bone
marrow
vaccin
transfus
mice
week
immun
llpc
respect
p
conclus
studi
indic
hod
mous
model
blood
transfus
recapitul
high
rate
alloantibodi
evanesc
seen
patient
furthermor
higher
rate
antirbc
evanesc
like
due
decreas
gener
slpc
llpc
rel
vaccin
given
transfus
vaccin
gener
similar
earli
gc
product
transfus
may
induc
select
defect
extrafollicular
plasma
cell
product
backgroundcas
studi
immun
thrombocytopenia
itp
autoimmun
disord
character
low
platelet
count
increas
risk
bleed
patient
format
pathogen
antiplatelet
antibodi
like
caus
acceler
platelet
destruct
decreas
platelet
product
antid
rhig
effect
firstlin
treatment
itp
pool
donorderiv
product
come
certain
limit
addit
antid
also
carri
fdaissu
black
box
warn
seriou
complic
may
occur
patient
itp
address
potenti
side
effect
antirbc
antibodi
separ
therapeut
activ
murin
model
passiv
itp
util
two
differ
antirbc
antibodi
two
major
advers
event
evalu
anemia
defin
signific
decreas
rbc
count
mice
inflammatori
activ
defin
signific
chang
core
bodi
temperatur
studi
designmethod
monoclon
antibodi
recogn
differ
murin
erythrocyt
antigen
evalu
abil
amelior
itp
two
well
character
inbr
mous
strain
balbc
outbr
strain
mice
erythrocyt
number
evalu
day
compar
baselin
count
day
bodi
temperatur
mice
measur
rectal
minut
post
antirbc
antibodi
inject
resultsfind
abl
amelior
itp
balbc
mice
caus
signific
anemia
nadir
day
three
mous
strain
caus
anemia
balbc
mice
dramat
reduct
core
bodi
temperatur
seen
post
inject
balbc
mice
signific
chang
temperatur
observ
mice
either
antibodi
conclus
abl
amelior
itp
three
strain
mice
anemia
observ
balbc
mice
therefor
conclud
anemia
strictli
requir
itp
amelior
antirbc
antibodi
murin
passiv
itp
addit
chang
bodi
temperatur
major
advers
event
mice
observ
balbc
mice
mice
therefor
also
conclud
inflammatori
activ
assess
bodi
temperatur
requir
itp
amelior
murin
passiv
itp
base
conclus
may
possibl
develop
monoclon
antirbc
antibodi
amelior
itp
without
caus
sever
advers
event
plasmin
eight
lncrna
four
mrna
chosen
valid
rtpcr
bioinformat
method
appli
construct
lncrna
mrna
coexpress
profil
go
kegg
pathway
analys
predict
lncrna
function
cisregul
analysi
reveal
potenti
molecular
mechan
lncrna
target
gene
express
resultsfind
lncrna
express
level
shift
th
storag
day
compar
nd
day
upregul
downregul
lncrna
express
level
shift
th
storag
day
compar
nd
day
respect
lncrna
differenti
express
increas
decreas
day
addit
number
lncrna
increas
express
level
much
greater
increas
express
level
result
rtpcr
consist
microarray
express
level
increas
reduc
four
target
mrna
downregul
platelet
storag
go
kegg
pathway
analys
reveal
mani
lncrna
coexpress
mrna
relat
platelet
aggreg
platelet
activ
endocytosi
addit
lncrna
might
cisregul
express
gene
implic
platelet
physiolog
function
conclus
first
studi
analyz
stabil
lncrna
bank
platelet
mani
lncrna
alter
express
level
storag
moreov
shift
lncrna
like
role
regul
platelet
physiolog
function
backgroundcas
studi
blood
unit
store
pack
red
blood
cell
prbc
presum
minim
storageinduc
cell
lesion
howev
water
compact
pack
undergo
abnorm
structur
process
among
breakag
hydrogen
bond
affect
water
interact
neighbor
molecul
impli
routin
coldstorag
prbc
subject
repeat
temperatur
fluctuat
critic
temperatur
respect
volumedens
variat
anomali
expect
induc
acceler
prbc
lesion
studi
present
aim
test
hypothesi
studi
designmethod
six
prbc
unit
leukofiltr
store
sagm
employ
sampl
prbc
collect
unit
store
small
storag
bag
divid
two
group
unit
group
ga
store
routin
blood
bank
refriger
temperatur
fluctuat
unit
group
b
gb
store
assur
temperatur
go
prbc
lesion
monitor
chang
cell
deform
determin
immedi
process
prbc
day
day
storag
use
cell
flow
properti
analyz
cfa
cell
shapechang
express
chang
cell
elong
ratio
er
calcul
cell
er
ab
b
major
minor
cell
axe
respect
cfa
imag
analysi
provid
er
distribut
larg
rbc
popul
fraction
low
deform
cell
ldfc
prbc
popul
deriv
resultsfind
accord
previous
obtain
result
deform
prbc
ga
decreas
consider
deform
prbc
gb
remain
unchang
entir
storag
period
tabl
particular
tabl
show
portion
rel
rigid
rbc
ldfc
ga
prbc
consider
higher
gb
conclus
present
studi
show
store
prbc
condit
expos
temperatur
fluctuat
around
ga
induc
consider
elev
rbc
rigid
wherea
exposur
condit
avoid
gb
rbc
deform
unchang
storag
although
limit
scope
studi
demonstr
prbc
qualiti
express
cell
deform
maintain
better
prbc
expos
repeat
temperatur
fluctuat
critic
temperatur
cell
subject
water
anomali
backgroundcas
studi
despit
almost
univers
use
leukodeplet
blood
compon
shown
donor
leukocyt
engraft
microchimer
remain
longterm
consequ
red
blood
cell
rbc
transfus
patient
group
clinic
consequ
remain
cell
mechan
surviv
follow
blood
transfus
unclear
furthermor
incid
transfusionassoci
microchimer
tam
may
affect
intern
differ
blood
process
method
transfus
practic
australia
trauma
patient
found
tam
despit
introduct
univers
leukodeplet
rbc
unit
sinc
octob
incid
tam
extens
studi
outsid
trauma
set
studi
aim
analyz
incid
tam
patient
major
thermal
injuri
follow
rbc
transfus
backgroundcas
studi
grow
concern
risk
transfus
pack
red
blood
cell
prbc
follow
numer
studi
report
neg
transfus
outcom
includ
reduc
blood
perfus
rbc
uniqu
flowaffect
properti
particularli
deform
adher
vascular
endotheli
cell
defin
rbc
hemodynam
function
hf
name
capac
affect
blood
flow
search
mechan
behind
neg
transfus
outcom
explor
effect
prbc
hf
transfus
outcom
tm
patient
routin
treat
frequent
lifelong
transfus
elder
blood
recipi
nonhemolyt
anemia
studi
designmethod
effect
prbc
hf
examin
transfusioninduc
chang
recipi
skin
blood
flow
hematocrit
timeinterv
transfus
tibt
sbf
determin
use
laserdopplerimag
prbc
deform
adher
determin
use
cell
flowproperti
analyz
cfa
resultsfind
group
patient
increas
increas
hf
transfus
prbc
highli
signific
correl
invers
proport
recipi
sbf
transfus
transfus
outcom
also
depend
hf
recipi
rbc
trrbc
prbc
hf
higher
trrbc
recipi
sbf
increas
invers
prbc
hf
lower
trrbc
sbf
decreas
tm
patient
time
interv
consecut
transfus
increas
increas
prbc
hf
exhibit
highli
signific
depend
conclus
studi
provid
first
time
human
direct
evid
hf
transfus
prbc
potent
effector
transfus
outcom
determin
prbc
hf
vs
recipi
rbc
condit
transfus
use
select
patientspecif
blood
unit
current
prbc
test
exclus
immunolog
compat
suppli
primarili
firstinfirstout
fifo
criteria
function
hf
particular
complet
ignor
addit
test
rbc
hf
transfus
recipi
rbc
introduc
new
paradigm
technolog
bloodbank
would
contribut
substanti
improv
transfus
therapi
enabl
person
transfus
medicin
backgroundcas
studi
wnt
signal
play
crucial
role
mammalian
cell
regul
aspect
cell
fate
migrat
polar
platelet
poss
mani
protein
signal
pathway
howev
role
platelet
function
poorli
understood
one
studi
shown
inhibit
platelet
adhes
shape
chang
aggreg
studi
investig
role
signal
protein
synthesi
use
agonist
solubl
frizzledrel
protein
wash
store
platelet
studi
designmethod
level
determin
immunoblot
analys
respect
protein
plasma
platelet
plt
prepar
whole
blood
collect
citrat
anticoagul
wash
citrateglucosesalin
buffer
incub
kept
untreat
control
presenc
puromycin
pm
follow
activ
adp
storag
experi
aliquot
apheresi
pc
store
small
inhous
prepar
bag
mimic
storag
featur
common
plt
bag
two
set
aliquot
spike
pm
store
day
respect
plt
vitro
qualiti
assess
use
platelet
activ
bind
respons
presenc
adp
assay
phosphatidylserin
exposur
annexinv
bind
metabol
activ
protein
synthesi
monitor
lysat
prepar
triton
buffer
immunoblot
analys
pm
determin
band
intens
use
odyssey
softwar
lycor
imagin
system
resultsfind
wash
activ
plt
show
strong
band
pattern
synthes
protein
affect
presenc
combin
reduc
presenc
alon
storag
studi
confirm
abund
amount
plasma
howev
level
low
detect
day
day
storag
show
concentr
depend
increas
pm
incorpor
respect
compar
untreat
control
trend
mirror
increas
glucos
consumpt
lactat
product
well
platelet
activ
backgroundcas
studi
donat
blood
process
blood
bank
storag
pack
red
blood
cell
prbc
process
pack
cell
prepar
pcp
blood
often
subject
remov
white
cell
leukofiltr
reduc
risk
advers
reaction
procedur
rbc
expos
high
level
shear
stress
induc
alter
cell
deform
present
studi
examin
effect
pack
cell
prepar
process
rbc
deform
studi
designmethod
blood
sampl
collect
healthi
volunt
donor
correspond
unit
follow
process
prbc
pcp
includ
leukofiltr
rbc
deform
determin
use
cell
flowproperti
analyz
cfa
cell
shapechang
directli
visual
narrowgap
flowchamb
control
flowinduc
shear
stress
cell
deform
express
chang
cell
elong
ratio
er
calcul
cell
er
b
b
major
minor
cell
axe
respect
cfa
imag
analysi
provid
er
distribut
larg
rbc
popul
sever
deform
paramet
deriv
includ
fraction
rigid
undeform
cell
rbc
popul
udfc
er
portion
undeform
cell
deriv
rbc
sampl
pcp
udfc
b
udfc
respect
chang
calcul
udfc
udfc
udfc
b
resultsfind
effect
pcp
level
undefrom
cell
depend
initi
level
freshlycollect
blood
sampl
udfc
b
higher
pcp
reduc
fraction
rigid
cell
contrast
initi
fraction
rigid
cell
lower
pcp
increas
udfc
b
udfc
sampl
exhibit
clear
linear
correl
udfc
b
r
signific
p
conclus
note
procedur
pack
cell
prepar
rbc
subject
high
shear
stress
probabl
provok
opposit
phenomena
removaldestruct
rigid
cell
therebi
reduc
level
one
side
b
mechan
damag
cell
membran
subsequ
reduct
cell
deform
therebi
increas
level
udfc
result
studi
support
exist
phenomenon
backgroundcas
studi
blood
group
b
antigen
abo
system
antigen
forssman
system
for
well
structur
relat
glycan
isoglobotriaosylceramid
synthes
action
evolutionarili
relat
nac
transferas
distinct
glycosyltransferas
activ
substrat
specif
blood
group
b
transferas
bt
forssman
glycolipid
synthas
fs
globotriaosylceramid
synthas
gt
respect
previous
shown
amino
acid
codon
human
atbt
crucial
defin
distinct
sugar
specif
elucid
molecular
genet
basi
abo
glycosyl
polymorph
clinic
import
transfus
transplant
medicin
studi
designmethod
better
understand
structur
basi
nac
transferas
diversif
prepar
eukaryot
express
construct
enzym
possess
atspecif
alaglygli
leuglygli
btspecif
metglyala
fsspecif
glyglyala
gtspecif
hisalaala
tripeptid
codon
correspond
human
atbt
perform
dna
transfect
use
appropri
recipi
cell
exist
newli
creat
immunolog
examin
appear
cell
surfac
oligosaccharid
antigen
resultsfind
immunocytochemistri
result
use
monoclon
antiglycan
antibodi
dna
transfect
express
construct
reveal
sever
tripeptid
origin
also
bestow
transferas
activ
surprisingli
howev
repertoir
function
amino
acid
vari
among
transferas
quantif
fac
immunocytometri
confirm
differenti
effect
substrat
specif
nac
transferas
interestingli
also
observ
transferas
activ
correspond
enzym
name
fs
activ
human
at
alaglygli
glyglyala
conclus
tripeptid
codon
correspond
human
atbt
also
affect
acceptor
substrat
specif
addit
known
function
determin
donor
nucleotidesugar
specif
may
contribut
gener
divers
famili
nac
transferas
exclud
primat
leuglygli
predomin
alaglygli
tripeptid
frequent
present
at
mani
vertebr
speci
therefor
possibl
at
may
also
exhibit
fs
activ
certain
condit
appropri
acceptor
substrat
present
case
two
genet
loci
abo
rather
alon
may
specifi
express
speci
backgroundcas
studi
vitro
product
blood
platelet
import
goal
transfus
present
context
sustain
demand
control
product
free
infecti
immun
inflammatori
risk
current
possibl
produc
platelet
vitro
howev
cultur
platelet
consid
real
altern
transfus
paramount
import
demonstr
platelet
free
contamin
nucleat
cell
nonplatelet
cellular
fragment
studi
designmethod
aim
studi
evalu
effect
acousticbas
fraction
devic
separ
newli
releas
platelet
residu
megakaryocyt
mk
cytoplasm
debri
cd
platelet
produc
vitro
peripher
bloodderiv
progenitor
follow
protocol
describ
strassel
et
al
blood
platelet
releas
cell
suspens
follow
success
pipet
platelet
recoveri
puriti
compar
follow
standard
centrifug
fraction
use
acoustophoresisbas
devic
allow
separ
two
object
differ
acoust
properti
resultsfind
fraction
use
combin
two
acoust
devic
led
signific
reduct
number
residu
mk
cd
mv
obtain
celland
debrisdeplet
prbc
supernat
differenti
centrifug
count
highsensit
flow
cytometri
concomitantli
rbc
deform
determin
use
cell
flowproperti
analyz
rbc
shapechang
directli
visual
arrowgap
flowchamb
monitor
function
shear
stress
cell
deform
express
cell
elong
ratio
er
er
ab
b
long
short
axe
cell
respect
calcul
appli
cell
provid
er
distribut
larg
rbc
popul
enabl
deriv
sever
deform
measur
median
er
mer
percent
low
deform
cell
popul
ldfc
resultsfind
shown
tabl
mv
level
prbc
supernat
invers
correl
rbc
deform
mer
posit
correl
fraction
rel
rigid
cell
ldfc
measur
show
highli
signific
logarithm
depend
mv
level
conclus
format
mv
known
lead
decreas
content
rbc
membran
protein
eg
stomatin
flotillin
flotillin
accord
previous
report
rbc
becom
progress
rigid
stomatin
deplet
cell
membran
togeth
present
studi
show
clear
associ
mv
format
declin
rbc
deform
store
prbc
unit
propos
mv
format
signific
factor
account
increas
rbc
rigid
occur
storag
blood
unit
order
save
live
time
manner
method
transfus
frozen
platelet
use
emerg
situat
meet
need
purpos
studi
compar
therapeut
effect
infus
leukocytedeplet
frozen
platelet
leukocytedeplet
fresh
platelet
studi
designmethod
patient
thrombocytopenia
select
includ
male
femal
age
year
given
first
blood
transfus
exclud
immun
factor
affect
platelet
transfus
efficaci
due
multipl
transfus
randomli
divid
two
group
patient
infus
leukocytedeplet
frozen
platelet
patient
infus
leukocytedeplet
fresh
platelet
infus
platelet
complet
within
minut
rate
patient
could
toler
patient
test
bleed
time
infus
hour
infus
elev
platelet
count
peripher
blood
hour
infus
data
statist
process
measur
data
check
test
enumer
data
analyz
chisquar
test
resultsfind
signific
differ
gener
data
two
group
p
statist
signific
differ
bleed
time
min
vs
min
infus
leukocytedeplet
fresh
platelet
leukocytedeplet
frozen
platelet
p
platelet
count
l
vs
l
transfus
leukocytedeplet
fresh
platelet
leukocytedeplet
frozen
platelet
statist
signific
p
conclus
statist
signific
differ
bleed
time
infus
equival
amount
leukocytedeplet
frozen
platelet
leukocytedeplet
fresh
platelet
suggest
hemostat
function
two
exogen
platelet
patient
close
differ
platelet
count
statist
signific
platelet
count
increas
significantli
patient
receiv
leukocytedeplet
fresh
platelet
bind
capac
cryopreserv
platelet
membran
surfac
adhes
receptor
significantli
enhanc
procoagul
activ
significantli
increas
therefor
infus
leukocytedeplet
frozen
platelet
emerg
achiev
effect
rapid
hemostasi
backgroundcas
studi
human
platelet
lysat
hpl
contain
abund
growth
factor
cytokin
boost
vitro
cell
prolifer
grow
number
institut
use
hpl
altern
anim
sera
manufactur
cellbas
medicin
product
addit
porcin
heparin
default
prevent
hplsupplement
media
clot
achiev
anim
componentfre
cultur
system
protocol
mechan
deplet
fibrinogen
coagul
factor
recent
introduc
studi
designmethod
studi
investig
far
unclear
influenc
heparin
gene
express
stromal
cell
deriv
umbil
cord
uc
white
adipos
tissu
wat
bone
marrow
bm
stromal
cell
isol
propag
use
hpl
plu
heparin
vs
fibrinogendeplet
hpl
plusminu
heparin
whole
genom
microarray
analyz
use
rbioconductor
follow
confirm
qrtpcr
immunophenotyp
vitro
differenti
prolifer
clonogen
immunomodulatori
potenc
investig
cell
uptak
heparin
analyz
fluoresc
microscopi
flow
cytometri
backgroundcas
studi
accur
precis
red
blood
cell
rbc
quantif
hematopoiet
stem
cell
transplant
sct
product
import
process
clinic
aspect
stem
cell
transplant
abo
antigenantibodi
mismatch
rbc
caus
deleteri
effect
sct
recipi
product
ml
may
subject
rbc
reduct
accept
level
infus
rbc
quantif
context
vari
total
product
volum
rbc
amount
perform
regularli
littl
report
specif
perform
characterist
rbc
quantif
hsct
product
differ
sourc
differ
quantiti
vari
rbc
amount
potenti
effect
sct
process
studi
designmethod
sct
product
sampl
hospitalbas
cellular
therapi
laboratori
undergo
parallel
determin
rbc
content
base
hematocrit
hct
measur
manual
autom
method
manual
hematocrit
mhct
perform
centrifug
direct
observ
autom
hematocrit
ahct
perform
sysmex
autom
hematolog
analyz
dilut
rbc
volum
determin
multipli
hct
product
volum
ml
sampl
group
sct
sourc
apheresi
hpca
bone
marrow
harvest
hpcm
hpca
product
subgroup
apheresi
instrument
use
spectra
optia
terumo
bct
amicu
freseniu
kabi
retrospect
analysi
mhct
ahct
perform
determin
statist
signific
differ
measur
exist
pair
twotail
student
test
result
cross
threshold
ml
rbc
volum
resultsfind
sct
product
analyz
hpca
product
hpcm
product
hpca
sampl
collect
spectra
optia
amicu
apheresi
instrument
respect
hpca
product
cross
threshold
ml
rbc
volum
hpca
sct
product
ml
rbc
mhct
fell
threshold
ahct
hpca
sct
product
ml
rbc
mhct
cross
threshold
ahct
affect
product
collect
amicu
hpcm
sct
product
rbc
either
method
conclus
hct
measur
method
result
hpca
sct
product
rbc
volum
differ
could
potenti
chang
need
process
case
mismatch
sct
product
cross
ml
rbc
volum
threshold
rbc
reduct
chang
need
addit
process
hpcm
sct
product
note
addit
sampl
need
analyz
hct
differ
hpca
product
collect
amicu
addit
studi
warrant
determin
impact
cellular
therapi
laboratori
workflow
patient
outcom
backgroundcas
studi
genom
edit
engin
nucleas
rnaguid
nucleas
allow
target
genet
manipul
hold
great
promis
treatment
inherit
acquir
disord
howev
effici
genom
edit
limit
factor
larg
enough
quantiti
correctli
edit
cell
requir
recent
devis
robust
coselect
strategi
gener
domin
cellular
resist
ouabain
highli
potent
plantderiv
inhibitor
ubiquit
essenti
sodiumpotassium
pump
encod
gene
use
crispr
technolog
gener
ouabainresist
allel
coselect
correct
edit
event
second
locu
interest
faith
vitro
model
erythropoiesi
studi
specif
genet
variant
would
use
tool
investig
gene
function
help
guid
manag
complex
clinic
case
field
transfus
medicin
studi
designmethod
work
exploit
crisprbas
gene
edit
ouabain
coselect
strategi
combin
hscerythroid
differenti
protocol
develop
cellular
model
showcas
desir
genet
variant
use
threestep
cultur
method
effici
produc
cultur
red
blood
cell
crbc
hematopoiet
stem
progenitor
cell
hspc
resultsfind
erythroiddifferenti
procedur
yield
averag
expans
enucl
day
use
mobil
peripher
blood
hspc
cell
sourc
genemodif
strategi
purifi
hspc
incub
erythroid
expans
medium
h
upon
thaw
electropor
ribonucleoprotein
rnp
complex
contain
betaglobin
hbb
guid
rna
along
ssodn
aim
insert
sickl
cell
anemiacaus
mutat
hb
ouabainresist
allel
three
day
follow
transfect
ouabain
treatment
ad
differenti
protocol
continu
day
day
cultur
precis
gene
modif
obtain
hbb
locu
backgroundcas
studi
hematopoiet
progenitor
cell
typic
cryopreserv
use
control
rate
freezer
crf
recent
lab
observ
increas
unaccept
freez
curv
ie
meet
expect
freez
curv
paramet
cryopreserv
bag
manufactur
origen
recommend
maximum
fill
volum
rang
suggest
optim
minimum
volum
theoriz
lower
optim
freez
volum
could
produc
unaccept
freez
curv
determin
minimum
volum
one
could
lessen
rate
unsatisfactori
freez
curv
studi
designmethod
retrospect
document
review
perform
clinic
cell
therapi
product
freez
curv
timefram
freez
curv
gener
suboptim
nearli
unaccept
curv
demonstr
addit
temperatur
spike
prior
heat
fusion
mani
variabl
examin
potenti
caus
includ
cell
type
cell
concentr
crf
calibr
date
prevent
mainten
perform
product
volum
product
unaccept
freez
curv
sampl
viabil
acridin
orang
propidium
iodid
use
frozen
tube
segment
explor
impact
product
volum
canist
measur
calip
obtain
depth
variou
volum
water
ad
origen
freez
bag
bag
fill
water
bag
fill
water
bag
place
press
depth
measur
record
variou
fill
volum
compar
depth
canist
resultsfind
common
factor
unaccept
freez
curv
low
product
volum
compar
recommend
maximum
fill
volum
viabil
thaw
segment
found
accept
conclus
fill
volum
play
critic
role
abil
sampl
probe
make
continu
contact
product
bag
fill
volum
low
bag
may
contain
suffici
weight
ensur
continu
contact
sampl
probe
undergo
appear
undergo
prematur
temperatur
spike
initi
cool
phase
crf
compar
fill
volum
depth
canist
determin
minimum
depth
bag
water
minimum
depth
bag
water
base
data
establish
minimum
volum
bag
bag
sinc
institut
minimum
fill
volum
frequenc
suboptim
freez
curv
decreas
backgroundcas
studi
optim
cell
concentr
cryopreserv
autolog
hpc
apheresi
product
publish
literatur
less
nucleat
cell
nc
per
ml
howev
product
higher
cell
concentr
pragmat
cell
process
facil
may
potenti
reduc
patient
complic
relat
total
volum
product
reinfus
studi
designmethod
perform
retrospect
analysi
postthaw
viabil
neutrophil
recoveri
platelet
recoveri
compar
product
clinic
outcom
patient
receiv
lower
concentr
nc
per
ml
higher
concentr
nc
per
ml
product
autolog
hpc
apheresi
product
collect
consecut
mobil
patient
process
fix
final
product
volum
variabl
cell
concentr
cryopreserv
vv
dimethyl
sulfoxid
dmso
use
control
rate
freezer
held
vapor
phase
liquid
nitrogen
monitor
storag
resultsfind
cryopreserv
hpc
apheresi
product
multipl
myeloma
patient
lymphoma
patient
includ
product
outcom
analysi
see
tabl
median
cell
concentr
nc
per
ml
lower
concentr
group
compar
nc
per
ml
higher
concentr
group
betweengroup
differ
median
postthaw
viabil
vs
patient
includ
clinic
outcom
analysi
receiv
least
total
cell
per
kilogram
see
tabl
exclus
betweengroup
differ
total
cell
per
kilogram
reinfus
vs
use
cibmtr
definit
recoveri
median
day
neutrophil
recoveri
vs
platelet
recoveri
vs
differ
conclus
postthaw
viabil
neutrophil
recoveri
platelet
recoveri
differ
patient
receiv
lower
concentr
nc
per
ml
higher
concentr
nc
per
ml
product
addit
greater
simplic
cell
process
step
higher
cell
concentr
cryopreserv
product
offer
potenti
backgroundcas
studi
long
term
storag
cellular
therapi
product
requir
vapor
phase
liquid
nitrogen
storag
tank
due
indefinit
retent
cryopreserv
product
footprint
larg
liquid
nitrogen
freezer
adequ
connect
suppli
space
requir
challeng
meet
storag
demand
offsit
storag
facil
commiss
largescal
transport
cellular
therapi
product
previous
describ
studi
designmethod
case
studi
resultsfind
primari
risk
involv
transport
product
damag
frozen
product
tank
transport
small
number
product
increas
likelihood
warm
event
well
need
handl
product
overal
time
reloc
would
prohibit
increas
therefor
move
fill
tank
select
trial
move
freezer
perform
assess
effect
measur
taken
run
map
smooth
road
absenc
pothol
railroad
track
etc
custom
pallet
air
dampen
cushion
hard
rubber
surfac
made
would
offer
shock
absorpt
support
weight
full
tank
precis
jack
lift
use
rais
lower
tank
full
control
masonit
sheet
laid
tile
hallway
smoother
transport
move
truck
air
suspens
system
use
transport
fulli
valid
function
tank
fill
frozen
product
either
mock
deceas
patient
product
tank
slowli
place
onto
pallet
use
jack
secur
strap
put
back
move
truck
pallet
secur
place
truck
ensur
nt
move
tank
also
strap
side
truck
extra
assur
would
nt
tip
move
occur
offhour
earli
polic
escort
transport
mph
use
move
tank
offsit
locat
tank
reloc
product
thaw
evalu
sign
breakag
transport
product
remain
intact
subsequ
tank
move
patient
product
without
incid
prior
move
actual
product
empti
valid
backup
tank
preposit
offsit
locat
precaut
repres
sampl
product
examin
tank
ensur
integr
conclus
precaut
taken
plan
prove
safe
effect
way
transport
full
tank
cryopreserv
product
success
transfer
full
tank
offsit
storag
facil
allow
laboratori
continu
meet
patient
need
store
product
indefinit
backgroundcas
studi
autolog
hematopoiet
progenitor
cell
hpc
transplant
requir
mobil
hpc
peripher
blood
mobil
perform
administr
gcsf
alon
g
associ
chemotherapi
gct
hpc
product
obtain
two
method
present
differ
cell
content
could
result
differ
clinic
outcom
hematolog
recoveri
advers
reaction
ar
product
infus
retrospect
studi
aim
evalu
rate
ar
product
infus
accord
type
cell
mobil
gcsf
alon
associ
chemotherapi
studi
designmethod
total
patient
lymphoma
multipl
myeloma
mm
underw
mobil
harvest
hpc
autolog
transplant
last
year
g
gct
underw
transplant
institut
apheresi
procedur
result
bag
ml
cryopreserv
dmso
kept
liquid
nitrogen
contain
thaw
infus
evalu
ar
nauseavomit
diarrhea
arrhythmia
dyspnea
neurolog
abnorm
cephalea
encephalopathi
possibl
ar
patient
cell
infus
complet
resultsfind
median
rang
age
year
group
g
gct
respect
p
peak
g
gct
group
respect
p
g
product
contain
higher
number
granulocyt
x
vs
p
platelet
x
vs
p
g
group
receiv
higher
dose
dmso
gkg
vs
p
inferior
dose
cell
x
kg
vs
p
hematolog
recoveri
neutrophil
occur
day
g
gct
group
respect
p
ar
occur
patient
group
g
gct
respect
p
howev
number
reaction
possibl
possibl
g
gct
group
respect
p
patient
receiv
bag
hpc
similar
dose
dmso
observ
higher
number
ar
g
group
vs
p
femal
gender
associ
higher
rate
nauseavomit
vs
p
conclus
mobil
hpc
gcsf
alon
mani
advantag
although
result
higher
number
unwant
cell
granulocyt
platelet
less
cell
final
product
explain
least
part
higher
rate
advers
reaction
cell
infus
observ
final
mobil
gcsf
alon
result
fewer
cell
transplant
protract
hematolog
recoveri
addit
plerixafor
poorli
mobil
allogen
hematopoiet
stem
cell
donor
lefan
zhuang
pudpong
boriboonnangkul
shirong
wang
yuan
backgroundcas
studi
peripher
blood
stem
cell
pbsc
becom
predomin
graft
sourc
adult
allogen
hematopoiet
stem
cell
transplant
hsct
recent
year
granulocyt
coloni
stimul
factor
gcsf
standard
agent
pbsc
mobil
poorli
mobil
autolog
donor
plerixafor
often
ad
improv
collect
outcom
allogen
donor
mobil
poorli
gcsf
studi
review
experi
use
plerixafor
rescu
agent
poorli
mobil
allogen
donor
studi
designmethod
retrospect
examin
allogen
pbsc
collect
januari
march
center
donor
receiv
gcsf
mcgkg
daili
four
day
undergo
apheresi
collect
day
collect
perform
mnc
protocol
cobe
spectra
optia
amicu
apheresi
instrument
liter
blood
process
hour
goal
collect
cellskg
recipi
weight
plerixafor
ad
base
poor
cell
collect
yield
first
second
collect
day
resultsfind
allogen
donor
receiv
one
dose
plerixafor
addit
gcsf
first
second
day
collect
due
poor
collect
yield
plerixafor
well
toler
donor
without
signific
advers
reaction
cell
yield
backgroundcas
studi
minimum
dose
cell
desir
autolog
hematopoiet
stem
cell
hpc
transplant
treat
hematopoiet
malign
yield
cell
obtain
apheresi
collect
larg
predict
peripher
blood
concentr
therefor
common
standard
proceed
apheresi
determin
flow
cytometri
flow
criteria
autolog
hpc
transplant
candid
may
disqualifi
basi
poor
anticip
collect
yield
goal
studi
determin
altern
treatment
option
avail
low
report
patient
still
proceed
apheresi
collect
transplant
name
minimum
dose
cell
obtain
mani
collect
requir
addit
numer
number
collect
neg
impact
engraft
studi
designmethod
patient
low
accur
report
flow
initi
cutoff
chang
use
intern
societi
hematotherapi
graft
engin
protocol
includ
studi
retrospect
review
apheresi
laboratori
electron
medic
record
perform
collect
data
includ
diagnosi
number
patient
proceed
transplant
mobil
regimen
number
collect
attempt
number
apheresi
procedur
apheresi
method
dose
collect
infus
neutrophil
platelet
engraft
resultsfind
patient
diagnosi
includ
nonhodgkin
lymphoma
diffus
larg
bcell
lymphoma
multipl
myeloma
hodgkin
lymphoma
amyloidosi
mantl
cell
lymphoma
plasma
cell
leukemia
burkitt
lymphoma
peripher
tcell
lymphoma
primit
neuroectoderm
tumor
germ
cell
tumor
almost
patient
mobil
neupogen
plerixafor
np
spectra
optia
use
collect
process
blood
volum
patient
patient
proceed
transplant
transplant
minimum
dose
cell
could
collect
patient
mobil
np
attempt
collect
rest
made
case
patient
underw
mean
apheresi
procedur
rang
collect
mean
kg
cell
rang
patient
proceed
transplant
requir
collect
attempt
mean
apheresi
procedur
rang
requir
collect
cell
mean
dose
collect
rang
mean
dose
infus
rang
incid
delay
neutrophil
engraft
day
one
patient
demonstr
delay
platelet
engraft
day
one
patient
fail
engraft
platelet
conclus
despit
low
report
flow
patient
abl
collect
cell
mean
apheresi
collect
proceed
transplant
case
delay
neutrophil
engraft
infrequ
case
delay
fail
platelet
engraft
therefor
disqualifi
patient
treatment
option
hpc
transplant
base
low
alon
may
deni
patient
life
prolong
lifesav
therapi
elizabeth
godbey
stephani
dormesi
bruce
sachai
patricia
shi
new
york
blood
center
backgroundcas
studi
mani
transplant
center
still
process
fix
number
liter
total
blood
volum
hematopoiet
progenitor
cell
collect
predict
algorithm
achiev
target
dose
valid
primarili
autolog
donor
wide
adopt
perhap
due
eas
use
thu
valid
allogen
donor
simpl
predict
algorithm
base
centerspecif
th
percentil
collect
effici
ce
directli
calcul
number
liter
achiev
target
ce
report
lower
allogen
versu
autolog
donor
also
test
whether
use
cobe
spectra
cfr
tool
base
preapheresi
mnc
count
result
higher
ce
compar
histor
control
collect
standard
mlmin
studi
designmethod
retrospect
singlecent
analysi
analyz
allogen
donor
nmdp
relat
collect
cobe
spectra
mnc
spectra
optia
cmnc
procedur
jan
feb
peripher
blood
count
drawn
hr
preapheresi
use
calcul
roundedup
liter
process
follow
total
target
product
per
ul
actualpredict
liter
process
vari
median
mean
actual
dose
collect
adjust
follow
actual
total
product
actual
volum
processedpredict
volum
process
ce
use
mncguid
cobe
cfr
tool
compar
nmdp
histor
control
collect
cobe
spectra
mnc
procedur
fix
cfr
mlmin
resultsfind
adjust
dose
achiev
target
goal
patient
process
median
donor
tbv
rang
adjust
dose
median
rang
mean
sd
time
predict
dose
correl
adjust
target
total
due
variat
ce
evid
correl
ce
adjustedtarget
ratio
tabl
show
cfrrelev
data
weak
correl
cfr
product
granulocyt
platelet
seen
mean
similar
previous
report
allogen
donor
mean
tbv
process
cancela
ja
transfus
conclus
easi
use
predict
algorithm
use
conserv
ce
volum
process
may
achiev
higher
percent
collect
reach
target
dose
compar
predict
algorithm
base
regress
analysi
leberfing
transfus
use
mncguid
rather
fix
cfr
may
increas
ce
studi
popul
backgroundcas
studi
continu
mononuclear
cell
collect
cnmc
fdaapprov
method
peripher
blood
stem
cell
pbsc
collect
use
spectra
optia
terumo
bct
shown
result
compar
slightli
improv
collect
effici
ce
smaller
product
volum
compar
mnc
collect
method
optia
adult
popul
howev
cmnc
method
well
studi
smaller
pediatr
patient
studi
aim
review
institut
pbsc
collect
experi
pediatr
patient
use
cmnc
method
studi
designmethod
retrospect
review
data
autolog
collect
procedur
perform
patient
pediatr
hospit
april
march
use
cmnc
protocol
examin
patient
demograph
data
mobil
characterist
preand
postprocedur
laboratori
valu
procedur
detail
pbsc
product
characterist
procedurerel
advers
reaction
hypocalcemia
access
complic
hypotensionhypertens
transfus
reaction
includ
review
resultsfind
twentyfour
autolog
collect
perform
patient
mean
weight
rang
kg
neuroblastoma
nbl
central
nervou
system
cn
neoplasm
nbl
cn
patient
mobil
daili
mcgkg
gscf
follow
chemotherapi
plerixafor
administ
hour
prior
collect
procedur
preand
postprocedur
lab
valu
mean
prehematocrit
hct
rang
posthct
rang
mean
preplatelet
count
rang
postplatelet
count
rang
mean
prewbc
rang
postwbc
rang
eighteen
patient
receiv
red
blood
cell
prime
mean
ac
infus
rate
collect
mlmintbv
rang
mean
inlet
rate
mlmin
rang
whole
blood
wb
ac
ratio
mean
collect
flow
rate
mlmin
rang
mean
procedur
length
min
rang
blood
volum
process
rang
four
patient
nbl
cn
requir
collect
day
mean
rang
rang
respect
three
procedur
collect
flow
rate
mlmin
procedur
associ
miss
gcsf
dose
day
prior
collect
mean
final
product
count
rang
hct
rang
volum
ml
rang
target
dose
achiev
patient
procedur
toler
report
asymptomat
hypocalcemia
resolv
titrat
iv
calcium
cvl
access
complic
conclus
cmnc
method
effici
safe
method
pbsc
collect
pediatr
popul
kg
new
flow
cytometri
approach
assess
cord
blood
unit
potenc
carl
simard
dian
fournier
sonia
medic
affair
innov
cord
blood
bank
backgroundcas
studi
regen
potenti
cord
blood
unit
cbu
must
determin
repres
sampl
cryopreserv
product
releas
transplant
center
cord
blood
bank
measur
potenc
use
colonyform
unit
cultur
method
cfu
delay
releas
cbu
day
acceler
distribut
process
cbu
develop
rapid
method
base
measur
respons
cell
test
base
flow
cytometri
measur
phosphoryl
within
cell
test
compar
cfu
method
current
consid
gold
standard
well
aldehyd
dehydrogenas
aldh
enzymebas
assay
studi
designmethod
ten
cryopreserv
cbu
aliquot
tube
thaw
follow
standard
oper
procedur
sop
analyz
content
viabl
cell
use
ishag
protocol
eclon
ratio
cbu
number
prefreez
cell
number
proport
aldhbright
cell
respons
cell
test
determin
cbu
use
sampl
store
hour
room
temperatur
rt
postthaw
simul
extrem
warm
case
scenario
well
milder
warm
event
store
sampl
day
thaw
also
compar
potenc
segment
tube
bag
five
cbu
use
cfu
test
resultsfind
test
accur
analyz
sampl
handl
follow
sop
subject
rt
warm
event
tabl
base
result
establish
accept
threshold
cell
test
sensit
identifi
cbu
subject
warm
event
identifi
seven
ten
sampl
store
sampl
subject
rt
storag
intraassay
perform
reproduc
cv
segment
tube
show
mean
differ
respect
respect
bag
differ
deem
signific
inferior
intraassay
precis
conclus
new
method
determin
cbu
potenc
rapid
unbias
robust
clone
test
perform
better
aldh
viabil
test
identifi
sampl
subject
warm
event
test
sensit
accur
moreov
eas
gate
cell
respons
asset
routin
qualif
cbu
test
describ
herein
fulfil
requir
valid
intend
implement
method
cord
blood
bank
facil
studi
designmethod
public
cord
blood
bank
cbb
clinic
inventori
current
cbu
distribut
clinic
graft
transplant
worldwid
addit
cbb
provid
research
cbu
academ
institut
research
laboratori
industri
case
research
cbu
provid
without
identifi
mother
irbapprov
consent
exchang
scientif
technic
logist
inform
investig
cbb
manag
predominantli
via
email
howev
approach
timeconsum
parti
may
associ
unnecessari
delay
improv
commun
expedit
acquisit
cbu
specif
characterist
requir
variou
laboratori
studi
cbb
establish
effici
webbas
applic
webresearch
support
distribut
research
cbu
resultsfind
cbb
webresearch
facilit
transact
order
research
cbu
provid
automat
real
time
email
confirm
notif
upload
ship
document
check
order
statu
track
ship
inform
allow
user
search
previou
order
use
variou
field
printupload
report
order
etc
bidirect
flow
commun
cbu
provid
research
fresh
unprocess
nonclin
grade
unit
within
hour
collect
limit
inform
infecti
diseas
test
b
frozen
cbu
undergon
volumereduct
cryopreserv
storag
liquid
nitrogen
meet
criteria
clinic
use
array
data
may
avail
blood
count
flow
cytometri
data
bacteriolog
result
hemoglobin
phenotyp
hla
type
matern
infecti
diseas
marker
blood
group
type
backgroundcas
studi
frontier
transfus
medicin
transplant
field
cellular
therapi
ct
emerg
novel
ct
product
produc
investig
clear
standard
across
cell
process
center
across
institut
manufactur
protocol
may
vari
depend
type
ct
product
purpos
studi
uncov
variat
manufactur
practic
similar
ct
product
across
differ
cellular
process
laboratori
institut
worldwid
studi
designmethod
exploratori
survey
identifi
variat
manufactur
practic
novel
ct
product
design
sent
cellular
process
laboratori
director
worldwid
questionnair
focus
first
process
method
use
regard
type
ct
process
also
five
stage
process
event
collect
purif
vitro
expans
freez
storag
thaw
wash
secondli
questionnair
focus
level
environment
monitor
em
use
ct
product
resultsfind
respond
survey
cellular
process
laboratori
thirtyon
process
product
investig
label
either
phase
iii
phase
iii
clinic
trial
hpc
product
peripher
blood
pb
bone
marrow
bm
cord
blood
cb
commonli
process
respond
lymphocyt
l
commonli
nonhpc
product
handl
five
process
stage
ie
facil
similarli
facil
handl
dendrit
cell
dc
natur
killer
nk
cell
andor
mesenchym
stromal
cell
msc
process
product
five
process
stage
minor
center
process
pancreat
islet
cell
neural
cell
ipsc
purif
method
vari
type
product
institut
n
tabl
em
use
ct
product
shown
tabl
conclus
exploratori
survey
show
wide
variat
ct
manufactur
practic
across
differ
cellular
process
laboratori
better
understand
effect
variat
qualiti
ct
product
import
novel
ct
develop
effect
temperatur
time
hematopoiet
stem
cell
postthaw
viabil
elizabeth
godbey
shawn
desinc
nita
patel
shanlong
jiang
yvett
c
tanhehco
columbia
univers
irv
medic
center
new
yorkpresbyterian
hospit
backgroundcas
studi
determin
effect
temperatur
time
total
cell
viabil
hematopoiet
stem
cell
hsc
product
cryopreserv
dmso
thaw
studi
designmethod
hsc
product
qualiti
control
qc
vial
deceas
autolog
donor
whose
hsc
product
cryopreserv
dmso
obtain
thaw
demograph
inform
includ
age
donat
gender
diagnosi
prefreez
viabil
length
cryopreserv
collect
one
vial
donor
store
room
temperatur
rt
hour
thaw
total
cell
viabil
measur
use
trypan
blue
dye
exclus
assay
hour
thaw
repeat
measur
anova
bonferroni
posttest
perform
use
graphpad
prism
determin
effect
temperatur
time
postthaw
viabil
hsc
resultsfind
mean
age
hsc
collect
year
donor
femal
mean
product
cryopreserv
durat
year
eighteen
vial
donor
vialsdonor
thaw
pair
viabil
measur
rt
hour
postthaw
interact
temperatur
time
statist
signific
indic
time
effect
total
cell
viabil
temperatur
time
p
temperatur
found
significantli
affect
total
cell
viabil
postthaw
mean
postthaw
viabil
cell
store
rt
declin
time
tabl
match
effect
statist
signific
p
statist
signific
differ
found
mean
viabil
cell
time
point
mean
immedi
hour
postthaw
cell
viabil
rt
vs
p
met
accept
criteria
postthaw
viabil
cell
store
hour
retain
viabil
greater
accept
criteria
cell
store
rt
hour
viabil
conclus
total
cell
viabil
hsc
product
decreas
time
thaw
store
rt
rapid
declin
backgroundcas
studi
one
major
challeng
laboratori
medicin
address
evolv
need
patient
serv
need
increasingli
met
limit
resourc
hematopoiet
progenitor
stem
cell
transplant
patient
hpsct
popul
mobil
regimen
drug
increas
avail
stem
cell
apheresi
evolv
subject
felt
use
new
mobil
regimen
result
increas
requir
number
collect
per
patient
result
increas
technologist
effort
increas
usag
flow
cytometri
specif
donor
preapheresi
apheresi
product
quantif
increas
process
reagent
requir
purpos
studi
provid
object
data
regard
impact
evolv
mobil
regimen
blood
transfus
servic
resourc
studi
designmethod
review
patient
medic
record
blood
transfus
servic
record
includ
apheresi
process
flow
cytometri
record
document
mobil
regimen
requir
number
collect
total
cell
per
collect
total
cell
per
kilogram
bodi
weight
concentr
diseas
aid
unrespons
convent
therapi
treatment
aim
ablat
autoreact
clone
b
cell
allow
regener
new
toler
immun
system
mobil
harvest
hpc
peripher
blood
essenti
part
therapi
hpc
mobil
includ
administr
granulocyt
colonystimul
factor
gcsf
alon
combin
chemotherapi
aim
harvest
least
cellskg
retrospect
studi
purpos
analyz
mobil
characterist
accord
specif
aid
studi
designmethod
total
patient
enrol
multipl
sclerosi
ms
system
sclerosi
ssc
system
lupu
erythematosu
sle
cell
mobil
cyclophosphamid
cy
g
associ
median
rang
gcsf
dose
day
initi
day
follow
cy
administr
continu
daili
cell
harvest
autoimmun
diseas
group
differ
gcsf
dose
harvest
initi
peripher
blood
cell
count
reach
minimum
one
patient
sle
fail
mobil
apheres
perform
use
cell
separ
cobe
spectra
caridian
lakewood
co
usa
collect
hpc
product
cryopreserv
solut
dimethyl
sulphoxid
cell
bag
place
metal
rack
insert
freezer
kept
thaw
infus
one
three
month
later
neutrophil
recoveri
took
place
day
ms
ssc
sle
respect
p
ms
vs
ssc
ms
vs
sle
hpc
harvest
day
mobil
ms
ssc
sle
respect
p
ms
vs
sle
ssc
vs
sle
blood
volum
process
differ
aid
group
patient
underw
singl
session
apheresi
howev
sle
ms
ssc
patient
requir
day
ms
vs
sle
p
ssc
vs
sle
p
conclus
patient
aid
effici
hpc
mobil
gcsf
plu
cyclophosphamid
regimen
patient
sle
yield
lower
number
mobil
hpc
thu
lower
number
collect
cell
ms
ssc
despit
higher
day
apheresi
evalu
impact
retriev
cord
blood
unit
clinic
applic
adjac
unit
remain
cryopreserv
aleisha
k
chamberlain
kate
brown
jennif
l
wheeler
buenger
heather
l
brown
cbr
system
inc
backgroundcas
studi
exposur
potenti
transient
warm
event
cryogen
storag
cord
blood
unit
cbu
minim
avoid
advers
impact
postthaw
unit
qualiti
retriev
cbu
manual
liquid
nitrogen
dewar
shipment
cell
therapi
center
involv
exposur
neighbor
unit
rack
ambient
air
temperatur
sought
investig
impact
remov
cbu
storag
neighbor
unit
evalu
postthaw
unit
viabil
ptuv
cbu
releas
dewar
rack
differ
length
storag
studi
designmethod
retrospect
analysi
conduct
use
data
cbu
releas
privat
cord
blood
bank
control
varieti
method
determin
viabil
cbu
avail
ptuv
data
obtain
trypan
blue
includ
cbu
classifi
either
first
subsequ
releas
dewar
rack
group
respect
randomli
select
cbu
releas
dewar
group
differ
rack
cbu
select
random
differ
dewar
serv
control
group
respect
wilcoxon
rank
sum
test
use
examin
differ
pvalu
consid
signific
data
analys
perform
use
stata
softwar
stata
corp
lp
resultsfind
unit
releas
ptuv
base
trypan
blue
stain
cbu
group
includ
final
analysi
unit
repres
pair
releas
dewar
rack
signific
differ
precryopreserv
unit
viabil
group
group
respect
signific
differ
ptuv
primari
secondari
cbu
releas
dewar
rack
ptuv
group
group
similarli
compar
conclus
studi
base
actual
use
scenario
limit
small
sampl
size
pair
unit
releas
dewar
rack
howev
result
consist
previou
studi
suggest
remov
cord
blood
unit
convent
dewar
control
valid
procedur
affect
postthaw
viabil
neighbor
unit
convent
dewar
procedur
manual
retriev
consist
regulatori
guidelin
standard
establish
prevent
loss
product
qualiti
normal
lifecycl
cryopreserv
product
valid
bmp
platform
spectra
pediatr
institut
theresa
bilodeau
kent
soik
karen
sommer
deborah
holman
ralph
quinon
ami
keat
children
hospit
colorado
univers
colorado
school
medicin
backgroundcas
studi
abo
incompat
bone
marrow
product
often
requir
manipul
reduc
red
blood
cell
volum
infus
addit
pediatr
popul
often
necessari
reduc
overal
product
volum
patient
low
bodi
weight
spectra
optia
bmp
platform
provid
reliabl
method
bone
marrow
process
yield
safe
infus
product
studi
designmethod
concurr
valid
perform
product
infus
patient
undergo
allogen
bone
marrow
transplant
abo
incompat
donor
product
process
spectra
optia
per
manufactur
recommend
evalu
tnc
mnc
recoveri
residu
red
cell
volum
second
phase
valid
perform
goal
improv
mnc
recoveri
institut
specif
accept
paramet
mnc
recoveri
tnc
recoveri
incompat
rbc
volum
mlkg
recipi
bodi
weight
resultsfind
valid
result
summar
tabl
phase
product
mnc
recoveri
phase
ii
mnc
recoveri
exceed
desir
paramet
sampl
accept
tnc
recoveri
product
red
cell
reduct
overal
volum
reduct
approxim
final
incompat
rbc
volum
infus
product
within
institut
specif
guidelin
patient
exhibit
advers
event
infus
patient
report
hypertens
exhibit
fever
within
hour
infus
conclus
spectra
optia
bmp
platform
provid
safe
effect
consist
method
process
abo
incompat
bone
marrow
product
autom
interfac
manag
aim
system
allow
less
oper
variabl
ensur
optim
cell
recoveri
pediatr
popul
method
result
product
manag
volum
infus
incompat
rbc
volum
well
allow
excel
cell
recoveri
patient
toler
infus
advers
event
smaller
infus
volum
easili
manag
nurs
staff
backgroundcas
studi
patient
undergo
hematopoiet
stem
cell
transplant
hsct
major
abo
incompat
increas
risk
delay
red
blood
cell
rbc
engraft
prolong
rbc
transfus
depend
patient
evalu
report
serolog
abo
discrep
forward
type
ft
revers
type
rt
may
clarifi
statu
rbc
engraft
goal
studi
compar
abo
ft
rt
discrep
patient
major
abo
incompat
hsct
use
two
differ
serolog
techniqu
correl
transfus
rate
studi
designmethod
review
compar
ft
rt
abo
serolog
type
result
rbc
transfus
need
blood
sampl
drawn
patient
major
abo
incompat
hsct
either
day
day
posttranspl
use
either
autom
gel
gt
versu
manual
tube
mt
method
rt
perform
use
mt
immedi
spin
addit
min
room
temperatur
incub
data
evalu
includ
hsct
donor
abo
ft
rt
strength
reaction
grade
w
number
rbc
unit
transfus
within
week
prior
abo
type
differ
ft
rt
grade
determin
gt
grade
minu
mt
grade
group
compar
use
student
ttest
resultsfind
sampl
drawn
day
day
day
day
post
transplant
day
posttranspl
signific
differ
observ
reactiv
hsct
donor
abo
ft
use
gel
compar
mt
method
differ
observ
reactiv
rt
either
anti
anti
b
hsct
donor
sampl
stronger
reaction
use
mt
method
p
furthermor
signific
increas
detect
either
w
anti
hsct
donor
abo
sampl
test
mt
method
minut
incub
compar
reactiv
detect
gel
method
day
transfus
rate
mean
abstract
cellular
therapi
develop
patient
cell
allogen
cellular
therapi
may
also
option
patient
allogen
cellular
therapi
requir
healthi
donor
will
abl
provid
start
materi
order
produc
final
cellular
therapi
consist
donor
experi
collect
critic
cellular
therapi
manufactur
donor
util
extens
experi
cell
sourc
donor
manag
cell
collect
donor
volunt
registri
contact
consent
provid
start
materi
research
clinic
andor
commerci
use
strong
emphasi
provid
posit
donat
experi
volunt
donor
studi
designmethod
sinc
volunt
donor
contact
consent
donat
mononuclear
cell
product
collect
apheresi
mnc
therapi
allogen
hematopoiet
stem
cell
transplant
effort
result
mnc
collect
thu
far
order
donat
mnc
product
consent
donor
ask
complet
multipl
phone
call
well
inperson
appoint
prior
collect
order
assess
medic
fit
donat
well
determin
elig
statu
purpos
mandatori
donor
meet
elig
requir
domest
regulatori
agenc
certain
intern
regulatori
agenc
donor
proceed
collect
week
follow
donat
donor
sent
electron
satisfact
survey
complet
donor
ask
rate
satisfact
donat
process
thirteen
key
metric
area
rang
flexibl
schedul
educ
materi
explan
risk
feel
appreci
care
resultsfind
nearli
donor
donat
mnc
octob
decemb
complet
postdon
survey
respons
perform
goal
met
exceed
time
area
scale
averag
overal
donor
satisfact
experi
rate
conclus
whole
donor
report
donat
experi
posit
suggest
rich
histori
process
support
donor
stem
cell
donat
translat
favor
donor
experi
donat
type
start
materi
cellular
therapi
market
xueyu
jiang
shanghai
blood
center
backgroundcas
studi
clinic
blood
recipi
often
accompani
inflamm
mainli
caus
infect
sepsi
immun
statu
recipi
may
influenc
effect
blood
transfus
guidelin
blood
transfus
condit
discuss
lot
fact
clinician
china
give
blood
transfus
patient
bodi
temperatur
mainli
caus
inflamm
except
urgent
situat
research
demonstr
viral
mimic
polyinosin
polycytidyl
acid
poli
c
synthet
doublestrand
rna
molecul
induc
robust
antibodi
product
mous
model
blood
transfus
report
viral
disord
demonstr
trend
toward
increas
risk
rbc
alloimmun
human
studi
investig
transfus
mice
simul
bacteri
infect
could
boost
stronger
immun
respons
underli
mechan
studi
designmethod
inject
mice
gramposit
bacteria
mimic
lipoteicho
acid
lta
gramneg
bacteria
mimic
lipopolysaccharid
lp
transfus
mice
human
red
blood
cell
induc
antibodi
simul
experiment
system
studi
effect
infect
rbc
immun
mice
divid
normal
control
group
human
rbc
transfus
posit
control
group
receiv
human
rbc
intraven
experiment
group
receiv
lp
four
hour
human
rbc
transfus
experiment
group
receiv
lta
four
hour
human
rbc
transfus
assess
rbc
immun
perform
measur
serum
immunoglobulin
g
igg
immunoglobulin
igm
human
rbc
weekli
two
week
lymphocyt
chang
spleen
also
monitor
flow
cytometri
backgroundcas
studi
success
hematopoiet
stem
cell
transplant
relat
hla
match
unrel
donorrecipi
transplant
present
genotyp
includ
routin
test
donor
select
studi
shown
mismatch
increas
risk
gvhd
match
reduc
overal
risk
hematopoiet
stem
cell
transplant
studi
retrospect
analyz
associ
match
short
tandem
repeat
str
result
unrel
hematopoiet
stem
cell
transplant
studi
designmethod
individu
pair
unrel
donorrecipi
underw
unrel
allogen
hsct
hla
allel
match
donor
zhejiang
provinc
collect
retrospect
analysi
genotyp
sampl
perform
pcrsbt
method
accord
previou
report
correl
match
short
tandem
repeat
str
result
sampl
pair
unrel
donorrecipi
transplant
analyz
str
loci
sexual
locu
detect
everi
donor
recipi
genescan
method
commerci
powerplex
fusion
system
result
str
collect
three
time
includ
one
month
three
month
six
month
transplant
resultsfind
donorrecipi
pair
studi
str
result
recipi
show
success
hematopoiet
stem
cell
implant
without
relaps
remain
recipi
show
chimer
statu
studi
associ
match
str
result
implement
group
chimer
group
divid
three
subgroup
accord
result
genotyp
shown
tabl
match
effect
statu
hematopoiet
stem
cell
implant
accord
result
chisquar
test
p
conclus
match
relat
result
short
tandem
repeat
str
unrel
hematopoiet
stem
cell
transplant
citrat
phosphat
dextros
much
good
thing
matthew
wilgo
angela
dexter
brad
blaney
cassandra
kirwan
jawad
husein
troy
wang
rebecca
gagnon
damari
nazario
grace
centola
new
england
cord
blood
bank
inc
backgroundcas
studi
one
threat
viabil
cord
blood
product
clot
coagul
normal
physiolog
process
bodi
prevent
blood
loss
initi
vascular
repair
anticoagul
match
includ
complet
match
partial
match
complet
mismatch
routin
use
collect
cord
blood
prevent
clot
citrat
phosphat
dextros
cpd
common
studi
directli
look
ratio
cpd
cb
volum
effect
viabil
cord
blood
collect
volum
vari
greatli
studi
aim
address
effect
ratio
studi
designmethod
umbil
cord
blood
unit
obtain
consent
irb
approv
cb
unit
mix
aliquot
conic
tube
contain
fix
amount
cpd
final
volum
condit
viabil
total
nucleat
cell
count
tnc
determin
time
hour
hour
hour
unit
kept
gentl
agit
room
temperatur
viabil
determin
flow
cytometri
util
run
beckman
coulter
ishag
analysi
protocol
tnc
obtain
autom
cell
counter
use
acridin
orang
percent
loss
viabil
time
calcul
obtain
differ
origin
viabil
day
viabil
subsequ
day
day
day
day
statist
analys
anova
ttest
carri
graphpad
prism
excel
resultsfind
loss
viabil
time
directli
affect
concentr
cpd
p
larger
ratio
cpd
cb
show
increas
loss
viabil
compar
lower
dilut
p
regard
loss
tnc
statist
signific
differ
dilut
group
p
signific
differ
time
point
within
group
p
tabl
show
progress
loss
viabil
time
conclus
previou
data
review
investig
suggest
low
cb
volum
lose
viabil
faster
data
suggest
cpd
may
play
signific
role
loss
viabil
time
regard
high
volum
cpd
relat
small
volum
cord
blood
higher
volum
cb
cpd
appear
show
indic
abnorm
viabil
loss
conclus
everi
cord
blood
bank
continu
strive
maxim
volum
cord
blood
collect
process
within
short
time
frame
possibl
ensur
highest
qualiti
cell
product
possibl
institut
andor
client
backgroundcas
studi
hematopoiet
stem
cell
transplant
complex
procedur
requir
optim
coordin
clinic
transplant
servic
apheresi
process
team
infus
cryopreserv
product
necessit
optim
qualiti
control
ensur
stabl
engraft
cryopreserv
stem
cell
mobil
vari
consider
among
patient
especi
patient
underli
hematolog
diseas
extens
prior
therapi
current
paradigm
posit
cell
per
kilogram
recipi
weight
ensur
engraft
ablat
marrow
repres
calcul
surplu
pluripot
stem
cell
home
marrow
mani
variabl
may
impact
collect
qualiti
final
product
empir
observ
postul
invers
correl
yield
cell
subsequ
postthaw
viabil
cell
cryopreserv
product
studi
designmethod
order
evalu
possibl
invers
correl
data
gather
autolog
stem
cell
collect
paramet
collect
tabul
data
pars
ensur
standard
apheresi
protocol
respect
techniqu
collect
paramet
evalu
relationship
postthaw
viabil
cd
cell
yield
collect
procedur
linear
regress
trendlin
analysi
resultsfind
data
sequenti
hpc
collect
incorpor
yield
autolog
stem
cell
transplant
candid
tabul
cd
cell
yield
rang
cell
per
patient
kg
weight
statist
mean
cd
cell
yield
collect
cell
per
patient
kg
weight
postthaw
viabil
collect
rang
statist
mean
postthaw
viabil
compris
one
four
apheresi
collect
per
patient
patient
receiv
product
infus
engraft
graphic
scatter
plot
analysi
demonstr
mark
variabl
respect
cell
yield
vs
postthaw
viabil
regress
trendlin
analysi
relationship
cd
cell
yield
function
postthaw
viabil
demonstr
consist
neg
slope
conclus
base
preliminari
analysi
postthaw
viabil
autolog
stem
cell
collect
product
show
appar
invers
relationship
procedur
yield
cell
howev
mani
variabl
deserv
focus
analysi
improv
qualiti
mobil
peripher
hematopoiet
stem
cell
yield
backgroundcas
studi
acut
traumat
coagulopathi
atc
lead
high
morbid
mortal
trauma
manifest
prolong
prothrombin
time
pt
decreas
platelet
function
clot
firm
increas
fibrinolyt
activ
myxoma
viru
protein
member
serin
proteas
inhibitor
superfamili
shown
inhibit
fibrinolyt
serum
proteas
includ
plasmin
tissueor
urokinas
plasminogen
activ
tpa
upa
well
exert
antiinflammatori
activ
variou
anim
model
studi
administ
preclin
atcmodel
use
rat
polytrauma
hemorrhag
shock
hypothes
improv
outcom
atc
studi
designmethod
isofluran
anesthet
spraguedawley
rat
underw
polytrauma
within
minut
follow
hemorrhag
rat
resuscit
shed
volum
fresh
whole
blood
fwb
anesthet
donor
rat
trauma
vehicl
given
intraven
prior
trauma
pt
measur
baselin
trauma
lung
wetdri
weight
measur
end
experi
addit
whole
blood
healthi
human
donor
treat
determin
direct
effect
hemostasi
rotat
thromboelastogram
platelet
function
imped
aggregomet
use
adenosin
diphosph
proteaseactiv
collagen
resultsfind
prior
trauma
modestli
delay
rise
pt
immedi
trauma
trauma
compar
vehicl
percent
chang
pt
baselin
trauma
vehicl
limit
resuscit
fwb
led
signific
rise
wetdri
weight
ratio
lung
significantli
attenu
treatment
vs
vehicl
p
invitro
significantli
decreas
clot
time
vs
vehicl
p
increas
maximum
clot
firm
vs
vehicl
p
effect
platelet
aggreg
stimul
agonist
conclus
directli
potenti
clot
format
measur
invitro
assess
administr
rat
atc
delay
develop
atc
temporarili
attenu
pt
elev
immedi
trauma
may
also
reduc
acut
lung
injuri
trauma
antiinflammatori
activ
attenu
vascular
permeabl
addit
attenu
trauma
induc
coagulopathi
preliminari
studi
suggest
potenti
benefit
use
sever
trauma
investig
optim
dose
time
strategi
indic
survey
impact
thromboelastometri
hospit
blood
bank
elizabeth
p
crow
robert
desimon
ruchika
goel
thorsten
haa
melissa
cush
weill
cornel
medicin
depart
pediatr
new
york
presbyterian
hospit
weill
cornel
medicin
zurich
univers
children
hospit
backgroundcas
studi
viscoelast
test
rotat
thromboelastometri
vt
implement
hospit
blood
bank
guid
transfus
manag
bleed
patient
obtain
order
privileg
vt
clinic
provid
must
complet
initi
train
cours
pass
initi
compet
assess
aim
studi
determin
user
perceiv
vt
result
practic
chang
assess
ongo
user
knowledg
compet
vt
studi
designmethod
brief
onlin
questionnair
includ
annual
compet
assess
mandatori
multiplechoic
question
educ
administ
week
compet
question
basic
level
valid
vt
expert
provid
requir
complet
survey
pass
compet
assess
score
maintain
vt
order
privileg
addit
educ
offer
fail
provid
incomplet
survey
analyz
result
compar
clinicallaboratori
data
collect
blood
bank
vt
qualiti
inform
databas
qidb
resultsfind
respons
rate
respond
demograph
order
practic
report
tabl
common
userreport
indic
vt
order
includ
trauma
cardiovascular
cv
gastrointestin
gi
hemorrhag
howev
common
indic
qidb
cv
gi
postpartum
hemorrhag
half
respond
order
interpret
vt
report
order
least
investig
possibl
hyperfibrinolysi
minor
respond
report
order
vt
nonbleed
patient
commonli
preprocedur
baselin
coagulopath
patient
decid
treat
bleed
patient
vt
order
respond
wait
result
vt
treat
base
recent
standard
lab
avail
use
vt
confirm
decis
remaind
base
treatment
decis
clinic
stabil
sever
bleed
qidb
vt
repeat
ensur
defect
improv
intervent
wherea
respond
report
almost
alway
order
repeat
vt
mean
compet
assess
question
respond
perform
best
low
fibrinogen
hyperfibrinolysi
case
scenario
provid
repeatedli
order
vt
clinic
practic
like
pass
compet
assess
backgroundcas
studi
coagulopath
bleed
seriou
complic
cardiac
surgeri
key
contributor
acquir
hypofibrinogenaemia
plasma
fibrinogen
gl
standard
treatment
cryoprecipit
purifi
fibrinogen
concentr
also
use
compar
data
exist
randomis
trial
need
primari
object
fibrinogen
replenish
surgeri
fibr
studi
demonstr
new
fibrinogen
concentr
octafibrinfibryga
octapharma
noninferior
cryoprecipit
studi
designmethod
pragmat
multicentr
activecontrol
randomis
singleblind
noninferior
phase
trial
adult
cardiac
surgic
patient
clinic
signific
bleed
due
acquir
hypofibrinogenaemia
patient
undergo
cardiopulmonari
bypass
cpb
fibrinogen
supplement
order
within
hour
randomis
receiv
g
fibrinogen
concentr
unit
cryoprecipit
dose
equival
research
personnel
obtain
outcom
assess
blind
treatment
alloc
randomis
patient
receiv
fibrinogen
supplement
accord
clinic
need
patient
consent
randomis
waiv
written
inform
consent
obtain
soon
possibl
theraft
primari
outcom
combin
red
cell
platelet
plasma
transfus
within
hour
cpb
secondari
outcom
includ
blood
product
use
within
day
major
bleed
within
hour
fibrinogen
level
advers
event
enrol
patient
provid
power
demonstr
noninferior
base
noninferior
margin
patientsgroup
dropout
rate
safeti
review
dsmb
perform
everi
patient
interim
analysi
perform
patient
prespecifi
stop
rule
futil
overwhelm
efficaci
pragmat
design
treatment
algorithm
align
standard
practic
aid
adher
generaliz
resultsfind
largest
randomis
studi
fibrinogen
concentr
versu
cryoprecipit
adult
cardiac
surgic
patient
conduct
canadian
center
expect
complet
late
result
avail
earli
fourhundr
patient
random
april
safeti
issu
far
assess
dsmb
conclus
noninferior
new
fibrinogen
concentr
compar
cryoprecipit
would
support
use
cardiac
surgic
patient
experienc
signific
bleed
due
hypofibrinogenaemia
understudi
yet
highrisk
bleed
popul
rbc
unit
thought
increas
recipi
hemoglobin
hgb
gdl
smaller
increment
may
occur
set
better
understand
recipi
factor
affect
hgb
increment
could
help
provid
better
manag
patient
studi
designmethod
data
collect
part
red
cell
outpati
transfus
outcom
retro
studi
prospect
observ
studi
outpati
rbc
tx
inclus
criteria
age
ambulatori
least
prior
rbc
tx
within
month
subject
report
activ
bleed
time
tx
exclud
hgb
measur
pretx
minut
tx
posttx
multivari
linear
regress
chang
hemoglobin
minut
week
perform
use
backward
elimin
identifi
signific
clinic
variabl
resultsfind
total
subject
complet
studi
includ
analysi
mean
age
sd
year
patient
receiv
rbc
unit
transfus
episod
baselin
oneweek
hgb
measur
subject
receiv
addit
rbc
unit
part
patient
care
subject
includ
week
increment
assess
mean
chang
hgb
gdlunit
sd
minut
gdlunit
sd
one
week
hgb
increment
minut
decreas
larger
patient
blood
volum
nadler
higher
patient
baselin
hgb
increas
rbc
compon
volum
transfus
hgb
chang
one
week
increas
chang
hgb
minut
decreas
subject
blood
volum
nadler
lower
patient
hospit
hgb
measur
subject
age
gender
nonrbc
volum
transfus
total
rbc
dose
week
analysi
chemotherapi
use
week
studi
transfus
elimin
backward
elimin
conclus
cohort
patient
hgb
increment
less
gdlunit
tx
two
recipientspecif
factor
influenc
hgb
increment
minut
patient
diseas
statu
associ
hgb
respons
one
week
donoror
unitspecif
factor
captur
studi
may
also
impact
hgb
increment
data
suggest
pretx
recipi
factor
help
predict
hgbrespons
posttx
provid
account
recipi
circul
blood
volum
pretransfus
hgb
addit
expect
increment
per
rbc
unit
achiev
tx
goal
backgroundcas
studi
platelet
morpholog
activ
believ
import
success
prophylact
platelet
transfus
thrombocytopen
patient
develop
kunicki
morpholog
score
km
evalu
qualiti
platelet
undergo
morpholog
transform
due
condit
storag
temperatur
age
higher
percentag
nondiscoid
platelet
believ
predict
poor
platelet
recoveri
surviv
transfus
recent
year
flow
cytometri
emerg
prefer
tool
quantif
platelet
activ
surfac
markerprotein
express
pselectin
put
platelet
activ
marker
studi
attempt
find
correl
km
pselectin
express
store
platelet
explor
possibl
use
km
costeffect
altern
flow
cytometri
platelet
activ
quantif
studi
designmethod
apheresi
platelet
ap
collect
donor
ml
mini
platelet
storag
bag
either
agit
rt
without
agit
sampl
assess
day
storag
km
use
phase
contrast
microscopi
one
hundr
free
float
nonadher
platelet
assign
arbitrari
grade
base
morpholog
km
calcul
sum
grade
superior
morpholog
disc
equal
assess
surfac
pselectin
express
ap
stain
antibodi
analyz
fac
canto
data
report
mean
km
pselectin
express
data
analyz
pearson
correl
coeffici
r
use
twoway
anova
signific
set
p
resultsfind
high
km
observ
day
platelet
platelet
morpholog
highli
preserv
rt
storag
condit
similar
kmss
subsequ
day
day
day
platelet
store
increas
amoeboid
morpholog
decreas
kmss
day
day
rt
sampl
show
margin
increas
pselect
express
day
day
day
wherea
signific
increas
observ
sampl
day
day
km
pselectin
express
strong
neg
correl
r
p
expect
percentag
nondiscoid
morpholog
display
strong
posit
correl
pselectin
express
r
p
result
studi
suggest
km
compar
pselect
express
measur
via
flow
cytometri
good
indic
platelet
activ
phenotyp
store
sampl
therefor
kunicki
morpholog
score
quick
econom
altern
flow
cytometri
platelet
assess
backgroundcas
studi
approv
fourfactor
prothrombin
complex
concentr
kcentra
revers
vitamin
k
antagonistassoci
bleed
us
becom
rel
common
practic
use
offlabel
fashion
correct
coagulopathi
caus
direct
oral
anticoagul
doac
antixa
inhibitor
howev
efficaci
safeti
wellstudi
scenario
studi
designmethod
perform
retrospect
observ
studi
offlabel
use
revers
doacassoci
bleed
level
one
trauma
center
novemb
februari
follow
data
collect
patient
age
gender
weight
indic
dosag
inr
hemoglobin
hgb
prior
post
administr
clinic
outcom
acut
chronic
thromboembol
event
within
hour
day
administr
respect
addit
thromboembol
event
document
primari
team
post
infus
subsequ
evalu
author
determin
potenti
contribut
notabl
five
patient
die
within
one
week
administr
four
due
irrevers
brain
damag
associ
initi
intracrani
bleed
one
due
inoper
gi
bleed
find
thromboembol
event
within
hour
administr
howev
four
patient
thromboembol
event
day
receiv
includ
stroke
myocardi
infarct
atrial
thrombi
nonocclus
ij
tube
thrombi
conclus
data
show
rel
effici
aid
revers
doac
patient
sever
hemorrhag
notic
patient
experienc
form
thromboembol
event
daystoweek
administr
although
imput
process
versu
underli
diseas
difficult
pars
addit
prospect
studi
would
warrant
evalu
safeti
offlabel
indic
backgroundcas
studi
supratherapeut
inr
major
bleed
secondari
warfarin
therapi
occur
approxim
patient
chronic
anticoagul
atrial
fibril
avail
treatment
option
revers
anticoagul
includ
withhold
warfarin
administ
oral
intraven
vitamin
k
fresh
frozen
plasma
ffp
prothrombin
complex
concentr
pcc
use
pcc
recommend
sever
bleed
sever
organ
respect
consensu
guidelin
includ
accp
transfus
servic
laboratori
bed
health
system
recent
recogn
warfarin
revers
transfus
indic
plasma
transfus
occur
furthermor
plasma
order
unit
recommend
dose
plasma
unit
adult
retrospect
analysi
plasma
transfus
indic
order
deem
appropri
warfarin
revers
account
inappropri
order
multidisciplinari
team
assembl
address
inappropri
use
plasma
within
health
system
studi
designmethod
team
evalu
current
practic
examin
avail
literatur
review
standard
transfus
guidelin
indic
relat
polici
well
provid
educ
key
stakehold
group
intern
anticoagul
revers
guidelin
updat
recommend
use
ppc
emerg
revers
warfarin
recommend
use
vitamin
k
patient
warfarin
revers
remov
transfus
indic
order
plasma
addit
weightbas
clinic
decis
tool
creat
incorpor
electron
medic
record
calcul
recommend
quantiti
plasma
base
predefin
algorithm
six
month
period
follow
intervent
individu
provid
receiv
time
feedback
regard
inappropri
use
plasma
resultsfind
six
month
immedi
follow
educ
effort
percentag
plasma
order
deem
appropri
due
warfarin
revers
decreas
number
unit
plasma
order
decreas
review
also
indic
mani
provid
modifi
number
plasma
unit
recommend
clinic
decis
support
tool
suggest
need
intervent
conclus
intern
review
plasma
util
bed
health
system
identifi
concern
order
indic
well
dose
provid
educ
time
feedback
appear
posit
impact
appropri
use
plasma
transfus
provid
educ
like
need
reinforc
messag
influenc
plasma
dose
practic
floor
moenen
yvonn
hensken
patti
neleman
paul
verhezen
rick
wetzel
harri
schouten
erik
becker
mumc
univers
maastricht
backgroundcas
studi
prophylact
platelet
transfus
wide
use
chemotherapi
induc
thrombocytopenia
cit
howev
platelet
count
alon
poor
predictor
bleedingfor
adequ
hemostasi
format
sustain
stabl
clot
essenti
bleed
event
cit
patient
similar
platelet
count
might
influenc
chang
clot
lysi
potenti
patient
hypothes
bleed
risk
cit
similar
platelet
count
might
influenc
chang
clot
lysi
potenti
investig
clot
strength
suscept
tpa
induc
clot
lysi
measur
tparotem
inhous
design
whole
blood
rotat
thromboelastometri
assay
design
assess
clot
firm
stabil
studi
designmethod
tparotem
result
cit
compar
result
healthi
individu
tparotem
paramet
wereclot
time
ct
clot
format
time
cft
maximum
clot
firm
mcf
lot
lt
delta
ls
multivari
linear
regress
use
identifi
independ
determin
tparotem
outcom
variabl
includ
fibrinogen
fii
fvii
fxiii
plasminogen
tpa
tafi
hemoglobin
platelet
leucocyt
count
also
tparotem
result
cit
hour
hour
postplatelet
transfus
compar
resultsfind
consecut
cit
patient
healthi
individu
includ
patient
hour
posttransfus
hour
posttransfus
result
cit
patient
low
tafi
level
express
high
fviii
fibrinogen
ddimer
vwf
activ
compar
healthi
individu
ct
cft
significantli
longer
mcf
significantli
lower
cit
lot
lt
shorter
cit
patient
delta
ls
min
significantli
differ
combin
lotlt
result
show
hyperfibrinolysi
platelet
transfus
patient
delta
lysi
speed
normal
patient
multivari
analysi
higher
plasminogen
level
significantli
associ
shorter
lotlt
higher
leukocyt
fxiii
fii
significantli
associ
prolong
lotlt
higher
fibrinogen
associ
decreas
lysi
speed
patient
receiv
platelet
hour
posttransfus
cft
significantli
shorter
mcf
significantli
higher
compar
pretransfus
valu
although
signific
increas
cft
decreas
mcf
notic
hour
outcom
still
improv
compar
pretransfus
lotlt
significantli
prolong
hour
hour
posttransfus
lotlt
result
postplatelet
transfus
indic
reduct
number
patient
hyperfibrinolysi
conclus
tparotem
outcom
determin
agreement
expect
chang
associ
hyperfibrinolysi
cit
patient
slower
clot
format
form
weaker
clot
less
resist
fibrinolysi
signific
proport
cit
patient
hyperfibrinolysi
accord
lotlt
valu
platelet
transfus
significantli
improv
resist
fibrinolysi
especi
hour
postplatelet
transfus
patient
tpa
rotem
chang
hyperfibrinolyt
profil
less
hyperfibrinolyt
normal
profil
platelet
transfus
qiushi
wang
zhun
xing
xinxin
hao
guanghui
tong
haixia
bai
qiaoni
yang
shengj
hospit
china
medic
univers
backgroundcas
studi
neonat
coagul
differ
adult
first
sever
day
life
due
incomplet
liver
develop
result
clot
factor
level
less
adult
applic
adult
coagul
standard
may
affect
abnorm
clot
assess
neonat
patient
premis
manag
clot
newborn
understand
normal
clot
interv
newborn
accur
determin
coagul
anomali
conduc
effici
treatment
compar
adult
teg
report
less
frequent
pediatr
especi
neonatolog
even
less
patholog
neonat
establish
teg
paramet
interv
healthi
peopl
differ
age
conduc
expans
teg
applic
studi
designmethod
test
rang
normal
neonat
thromboelastographi
teg
valu
chines
popul
evalu
coagul
statu
newborn
patholog
pregnanc
total
neonat
enrol
studi
follow
healthi
neonat
neonat
gravida
gestat
hypertens
neonat
anem
gravida
neonat
diabet
gravida
preterm
newborn
test
compar
analys
base
cord
blood
teg
blood
coagul
blood
function
test
resultsfind
normal
neonat
teg
particip
differ
adult
clot
reaction
time
r
valu
min
lower
adult
clot
kinet
k
valu
min
adult
angl
valu
similar
adult
maximum
amplitud
valu
mm
equival
lower
limit
adult
coagul
index
ci
valu
compar
adult
neonat
teg
paramet
pregnancyinduc
hypertens
pregnancyinduc
anemia
significantli
differ
normal
neonat
statist
teg
differ
r
k
angl
valu
newborn
diabet
gravida
newborn
healthi
gravida
statist
teg
differ
r
angl
valu
prematur
neonat
neonat
teg
paramet
differ
interv
adult
analysi
result
also
differ
tradit
coagul
test
need
reinvestig
backgroundcas
studi
coagulopathi
trauma
extens
studi
last
decad
valu
viscoelastometri
guid
manag
patient
well
document
notabl
studi
coagulopathi
burn
patient
scarc
sever
studi
shown
burn
patient
hypercoagu
howev
studi
done
use
sampl
collect
patient
resuscit
upon
admiss
icu
addit
although
burn
patient
typic
normal
slightli
elev
platelet
platelet
function
question
sever
studi
studi
designmethod
conduct
prospect
observ
studi
burn
patient
year
present
level
trauma
center
teg
order
burn
team
variou
patient
done
part
studi
citrat
sampl
collect
patient
present
whole
blood
aggreg
studi
perform
immedi
remain
sampl
process
immedi
plasma
kept
frozen
c
test
addit
sampl
collect
day
sampl
studi
microparticl
number
ident
microrna
cytokinechemokin
concentr
coagul
factor
fviii
fix
fx
fv
fvii
ps
pc
von
willebrand
factor
antigen
activ
valu
resultsfind
date
patient
enrol
studi
still
ongo
major
patient
thermal
burn
caus
flame
exposur
mean
sd
age
patient
rang
year
male
mean
total
bodi
surfac
area
burn
tbsa
rang
mean
number
rbc
transfus
rang
unit
patient
receiv
plasma
platelet
transfus
none
die
teg
trace
normal
shorten
r
time
mean
platelet
count
within
refer
rang
time
point
figur
patient
abnorm
whole
blood
aggreg
respons
adp
collagen
arachidon
acid
obviou
even
patient
littl
tbsa
burn
patient
abnorm
platelet
activ
platelet
inhibitor
therapi
conclus
reason
decreas
platelet
activ
unclear
studi
ongo
one
theori
platelet
may
degranul
respons
acut
phase
reaction
may
produc
higher
percentag
platelet
microparticl
contribut
hypercoagu
state
observ
other
teg
studi
backgroundcas
studi
rigor
donor
screen
blood
product
test
reduc
transmiss
rate
infecti
organ
blood
transfus
risk
transmiss
emerg
pathogen
persist
pathogen
reduct
method
steril
blood
product
result
decreas
pathogen
load
previou
studi
demonstr
alter
coagul
factor
level
pathogen
reduc
cryoprecipit
prcryo
assess
procoagul
microparticl
mp
activ
pathogen
reduct
scarc
cryoprecipit
purpos
studi
compar
mp
prothrombinas
activ
sampl
wholeblood
wb
apheresisderiv
aph
cryoprecipit
without
pathogen
reduct
studi
designmethod
irbexempt
studi
donor
plasma
group
donor
pool
split
produc
six
ident
aph
six
ident
wb
cryoprecipit
unit
pr
treatment
perform
three
aph
three
wb
unit
accord
manufactur
recommend
amotosalen
uva
light
remain
three
aph
three
wb
unit
serv
nonprcryo
control
procoagul
mp
activ
assess
use
function
prothrombinas
assay
accord
manufactur
instruct
level
thrombin
report
phosphatidylserin
ps
equival
comparison
pr
nonprcryo
group
perform
use
independ
sampl
ttest
signific
result
declar
p
resultsfind
signific
decreas
prothrombinas
activ
note
wb
prcryo
compar
wb
nonprcryo
signific
differ
measur
aph
pr
nonprcryo
tabl
conclus
find
small
studi
suggest
pathogen
reduct
may
decreas
prothrombinas
activ
cryoprecipit
could
potenti
explain
sequestr
mp
amotosalen
adsorpt
devic
pathogen
reduct
quantit
thrombin
gener
assay
function
assess
thromboelastometri
evalu
hemostat
equival
prcryo
warrant
transfus
hemosiderosi
could
first
step
twohit
model
transfus
associ
circulatori
overload
taco
philipp
renaudi
francois
bertrand
ann
damai
nathali
de
rekeneir
ann
schuhmach
styliani
bartziali
heinrici
nicola
malvaux
thierri
peyrard
jeanclaud
faber
centr
de
transfus
sanguin
croix
roug
luxembourgeois
universitair
de
strasbourg
jacqu
monod
direct
de
la
ctscrl
institut
nation
de
la
transfus
sanguin
associ
luxembourgeois
de
backgroundcas
studi
taco
cardiogen
pulmonari
edema
trigger
transfus
patient
chronic
heart
failur
high
risk
taco
systol
heart
failur
wellestablish
risk
factor
diastol
failur
might
import
lieberman
l
et
al
tmr
studi
designmethod
herein
report
two
case
taco
diastol
heart
failur
relat
transfus
iron
overload
could
first
hit
resultsfind
case
year
old
sickl
cell
patient
die
hour
liver
transplant
indic
haemochromatosi
hepat
cirrhosi
child
pugh
diabet
cardiac
involv
major
iron
overload
sign
ventricular
hypertrophi
ekg
systol
eject
fraction
major
relax
disord
associ
diseas
deferroxamin
deferasirox
introduc
sever
time
stop
side
effect
deferripron
well
toler
introduc
late
patient
die
postsurgeri
intract
hemorrhag
cardiogen
shock
vascular
fill
previous
grade
taco
grade
risk
factor
diastol
heart
failur
relat
hemosiderosi
case
year
old
chronic
transfus
myelodysplasia
patient
receiv
pack
red
cell
prc
year
refer
hospit
impair
gener
condit
fever
upon
arriv
hb
g
dl
ctscan
show
hepatosplenomegali
two
prc
transfus
slowli
seven
hour
complet
experienc
dyspnea
arteri
desatur
hypertens
bilater
crackl
increas
bnp
pgml
iv
furosemid
isosorbid
dinitr
immedi
administ
patient
die
congest
heart
multipl
organ
failur
discrep
sever
heart
failur
known
cardiac
histori
serum
ferritin
assay
retrospect
perform
show
level
ngml
conclus
cardiac
hemochromatosi
character
diastol
dysfunct
arrhythmia
late
stage
dilat
cardiomyopathi
retrospect
studi
among
consecut
taco
case
eject
fraction
wherea
show
evid
diastol
dysfunct
lieberman
l
et
al
analog
transfus
relat
acut
lung
injuri
propos
twohit
model
red
blood
cell
transfus
could
respons
first
step
caus
heart
iron
overload
consequ
diastol
dysfunct
second
step
transfus
fluid
volum
remain
intravascular
hypothesi
could
result
consid
iron
chelat
prevent
measur
prevent
taco
chronic
transfus
patient
backgroundcas
studi
wide
accept
point
care
whole
blood
coagul
test
devic
use
detect
coagulopathi
real
time
manner
massiv
bleed
situat
major
cardiac
surgeri
howev
implement
still
limit
japan
cost
lack
public
insur
support
studi
designmethod
fifti
consecut
case
elect
cardiac
surgeri
cardiopulmonari
bypass
analyz
studi
blood
sampl
collect
three
point
ie
surgeri
termin
cardiopulmonari
bypass
protamin
administr
surgeri
respect
laboratori
data
measur
two
point
care
devic
sonoclot
routin
coagul
blood
count
test
collect
blood
sampl
case
data
obtain
point
care
devic
provid
clinician
consequ
use
determin
transfus
indic
case
first
evalu
linear
correl
laboratori
examin
data
pearson
test
next
theoret
total
blood
loss
calcul
hemoglobin
content
total
amount
periop
rbc
transfus
also
record
thorough
clinic
data
collect
patient
electron
record
final
tri
establish
multivari
linear
regress
model
predict
periop
bleed
rbc
transfus
amount
measur
laboratori
data
collect
clinic
paramet
resultsfind
case
includ
studi
case
receiv
type
transfus
ie
case
rbc
transfus
case
plasma
transfus
case
platelet
transfus
respect
averag
amount
rbc
transfus
japanes
unit
abstract
approxim
us
unit
measur
paramet
routin
laboratori
platelet
count
fibrinogen
valu
strongli
correl
contrari
act
valu
routin
coagul
test
correl
sonoclot
paramet
multivari
regress
analysi
fail
establish
ration
comprehens
linear
regress
model
although
oper
time
act
valu
termin
cardiopulmonari
bypass
strongli
associ
periop
bleed
amount
rbc
transfus
extract
explanatori
variabl
paradox
exhibit
invers
correl
bleed
tendenc
plateletcoagul
function
suggest
hidden
confound
factor
studi
popul
limit
studi
design
signific
point
care
test
explanatori
variabl
sonoclot
pf
valu
termin
cardiopulmonari
bypass
correl
platelet
transfus
volum
well
oper
time
preoper
platelet
count
conclus
act
valu
termin
cardiopulmonari
bypass
use
predictor
periop
bleed
major
cardiac
surgeri
although
measur
paramet
may
use
independ
paramet
convent
act
test
intervent
studi
requir
determin
use
major
cardiac
surgeri
japanes
popul
elimin
transfus
indic
statist
reduc
number
patient
transfus
jessica
l
jacobson
lilli
sorkin
bellevu
hospitalnyulmc
brearley
school
backgroundcas
studi
histor
rbc
order
place
use
transfus
indic
blood
bank
perform
prospect
audit
order
contain
lab
valu
part
indic
although
mani
instanc
patient
satisfi
specif
approv
transfus
indic
order
provid
select
bypass
prospect
audit
process
remov
indic
cpoe
system
physician
need
place
order
outsid
approv
criteria
hesh
would
need
call
blood
bank
explain
rbc
transfus
requir
document
reason
patient
emr
remov
indic
made
process
order
potenti
medic
unnecessari
rbc
harder
sought
determin
impact
chang
total
number
blood
product
patient
transfus
studi
designmethod
quarterli
transfus
statist
includ
number
rbc
sdp
plasma
patient
transfus
preelimin
compar
post
data
test
statist
signific
use
major
unit
transfus
attribut
surgic
subspecialti
emerg
medicin
posttransfus
inr
avail
transfus
event
demonstr
signific
chang
pretransfus
baselin
final
common
indic
transfus
could
discern
includ
hypovolemia
bleed
ie
plasma
transfus
red
blood
cell
conclus
daili
audit
plasma
transfus
reveal
singleunit
transfus
event
rel
common
includ
transfus
patient
normal
coagul
valu
surgic
subspecialti
emerg
medicin
account
major
transfus
like
repres
inappropri
transfus
opportun
improv
practic
institut
though
singleunit
red
cell
platelet
transfus
repres
desir
practic
singleunit
plasma
transfus
undesir
qualiti
improv
metric
chisa
yamada
meghan
delaney
angela
c
lee
maureen
edelson
univers
michigan
children
nation
health
system
backgroundcas
studi
hyperkalemia
rare
lifethreaten
complic
rbc
transfus
store
rbc
leak
intracellular
potassium
k
due
inhibit
membran
atp
pump
gamma
irradi
potenti
k
leak
rbc
transfus
administ
slowli
shown
littl
effect
serum
k
concentr
howev
massiv
rapid
transfus
may
caus
tempor
hyperkalemia
especi
patient
total
blood
volum
small
serum
k
transfus
product
high
mani
case
report
occurr
transfus
associ
hyperkalemia
tah
characterist
patient
implic
blood
product
studi
systemat
multiinstitut
studi
tah
conduct
aabb
pediatr
subcommitte
data
two
facil
report
studi
designmethod
studi
period
medic
record
patient
age
year
old
k
level
refer
rang
within
hour
rbc
transfus
review
patient
demograph
medic
histori
comorbid
symptom
treatment
hyperkalemia
well
age
volum
modif
transfus
rbc
unit
resultsfind
total
patient
receiv
total
rbc
transfus
hyperkalemia
within
hour
rbc
transfus
found
patient
receiv
rbc
transfus
irradi
median
k
increas
previou
k
level
hyperkalemia
mmoll
patient
median
age
weight
time
transfus
year
old
kg
respect
patient
seriou
comorbid
includ
prematur
patient
cardiac
dysfunct
renal
diseas
sepsi
brain
lesion
patient
high
volum
rbc
use
extracorpor
membran
oxygen
ecmo
patient
associ
mortal
mortal
occur
patient
within
day
hyperkalemia
occurr
among
patient
decreas
followup
k
hyperkalemia
occurr
treat
hyperkalemia
patient
die
soon
hyperkalemia
note
transfus
patient
transfus
patient
estim
total
blood
volum
irradi
rbc
within
hour
hyperkalemia
occurr
overal
patient
receiv
median
estim
total
blood
volum
within
hour
hyperkalemia
occurr
median
age
rbc
unit
transfus
day
old
conclus
fourteen
patient
experienc
hyperkalemia
within
hour
rbc
transfus
patient
hyperkalemia
time
death
possibl
attribut
rbc
transfus
patient
median
age
weight
time
hyperkalemia
transfus
year
old
kg
respect
cardiac
dysfunct
common
risk
factor
possibl
tah
prematur
renal
dysfunct
ecmo
associ
massiv
rbc
transfus
also
associ
higher
risk
tah
addit
data
facil
pend
periop
backgroundcas
studi
tranexam
acid
txa
inexpens
wide
avail
antifibrinolyt
agent
known
reduc
red
blood
cell
rbc
transfus
cardiac
surgeri
select
orthoped
surgeri
use
cardiac
surgeri
routin
use
effect
noncardiac
surgeri
compar
rate
bleed
transfus
uncertain
object
studi
evalu
txa
util
pattern
noncardiac
surgeri
high
risk
transfus
studi
designmethod
accur
character
txa
use
noncardiac
surgeri
high
risk
periop
rbc
transfus
complet
retrospect
cohort
studi
evalu
patient
year
age
undergo
noncardiac
surgeri
five
hospit
two
citi
januari
decemb
identifi
noncardiac
procedur
high
risk
transfus
use
standard
canadian
classif
health
intervent
cci
procedur
code
contain
within
hospit
discharg
abstract
databas
dad
link
dad
transfus
databas
laboratori
databas
obtain
supplementari
transfus
laboratori
data
evalu
contemporari
txa
util
pattern
identifi
cohort
highrisk
procedur
perform
chart
review
chart
databas
queri
describ
proport
patient
receiv
intraop
txa
also
describ
detail
txa
dose
resultsfind
citi
identifi
noncardiac
open
surgeri
associ
transfus
rate
cohort
tranexam
acid
use
surgeri
rang
txa
usag
highest
orthoped
spine
surgeri
includ
total
hip
arthroplasti
femur
osteotomi
pelvic
osteoplastyosteotomi
vertebrectomi
vertebr
fusion
exclud
orthoped
spine
surgeri
txa
use
limit
open
surgeri
mean
time
oper
start
time
txa
administr
minut
minut
txa
administ
bolu
infus
mean
txa
dose
mg
mg
conclus
tranexam
acid
routin
use
cardiac
orthoped
spine
surgeri
yet
util
surgic
domain
high
risk
periop
red
blood
cell
transfus
remain
low
year
greater
death
injuri
attribut
firearm
unit
state
howev
transfus
requir
patient
well
understood
studi
sought
determin
blood
util
mortal
differ
victim
gun
violenc
versu
victim
nongun
relat
trauma
patient
requir
transfus
trauma
center
urban
set
also
assess
cost
transfus
patient
studi
designmethod
state
trauma
registri
review
trauma
patient
present
tertiari
care
facil
januari
june
studi
popul
limit
patient
receiv
blood
product
hospit
cours
patient
categor
base
mechan
injuri
gunshot
wound
gsw
trauma
nongsw
number
type
blood
product
assess
primari
outcom
mortal
blood
util
cost
transfusionwith
cost
assess
two
method
blood
acquisit
cost
activitybas
cost
total
cost
transfus
includ
overhead
resultsfind
data
shown
tabl
gsw
patient
younger
like
male
higher
injuri
sever
score
among
trauma
patient
requir
blood
product
administr
victim
gun
violenc
mortal
emerg
depart
ed
time
higher
overal
mortal
time
higher
gsw
cohort
compar
nongsw
cohort
gsw
patient
requir
transfus
demonstr
approxim
ed
mortal
overal
mortal
gsw
patient
receiv
averag
time
amount
blood
product
per
patient
compar
nongsw
patient
includ
prbc
ffp
platelet
cryoprecipit
transfus
gsw
patient
million
went
activitybas
transfus
cost
averag
transfus
cost
per
patient
time
higher
gsw
victim
versu
nongsw
trauma
patient
conclus
compar
traumat
injuri
gunshotassoci
injuri
associ
substanti
greater
mortal
well
greater
blood
util
cost
transfus
gsw
patient
select
highrisk
group
sinc
previou
report
institut
includ
gsw
victim
transfus
report
onehalf
mortal
rate
report
abstract
transfus
studi
designmethod
prospect
retrospect
crosssect
studi
investig
nonpediatr
micu
patient
transfus
transfus
januari
june
studi
util
facil
laboratori
inform
system
electron
medic
record
system
identifi
patient
demograph
diagnosi
anemia
statu
preadmiss
specifi
undetermin
hemoglobin
hgb
track
admiss
transfus
trigger
laboratori
phlebotomi
perform
number
rbc
unit
transfus
chi
squar
ttest
use
analyz
data
resultsfind
studi
popul
investig
undetermin
anemia
statu
identifi
major
transfus
untransfus
patient
mean
total
phlebotomi
blood
loss
transfus
patient
ml
phlebotomi
blood
loss
untransfus
patient
ml
p
transfus
patient
receiv
unit
rbc
admiss
chang
hgb
admiss
discharg
interpret
confid
determin
hgb
valu
chang
gdl
group
overal
chang
hgb
signific
group
transfus
trigger
initi
clinician
mean
hgb
valu
gdl
median
hgb
gdl
conclus
evid
suggest
iatrogen
anemia
caus
transfus
micu
popul
facil
though
transfus
popul
admit
lower
hgb
level
discharg
hgb
level
lower
studi
control
group
higher
hgb
level
control
group
possibl
mitig
need
transfus
intervent
also
undetermin
anemia
classif
identifi
highest
frequenc
studi
popul
data
may
relat
diagnost
phlebotomi
iatrogen
anemia
within
transfus
popul
mani
patient
receiv
unit
rbc
averag
volum
ml
admiss
correspond
averag
total
blood
loss
base
transfus
trigger
data
guidelin
facil
clinician
unnecessarili
transfus
patient
micu
patient
popul
total
stabl
nonrefractori
hematooncolog
patient
enrol
studi
fulfil
inclus
criteria
studi
approv
institut
ethic
committe
patient
receiv
apheresi
platelet
low
dose
platelet
unit
medium
dose
plateletsunit
high
dose
plateletsunit
differ
time
point
sequenc
standard
low
high
dose
request
receiv
base
hisher
pre
transfus
platelet
count
clinic
profil
post
transfus
count
assess
hour
transfus
post
transfus
respons
indic
calcul
term
platelet
increment
correct
count
increment
cci
percent
platelet
recoveri
ppr
transfus
free
interv
bleed
event
also
record
differ
dose
resultsfind
post
transfus
respons
indic
cci
ppr
compar
standard
dose
low
dose
post
transfus
increment
compar
standard
high
dose
howev
cci
ppr
better
standard
dose
statist
signific
higher
post
transfus
increment
observ
high
dose
compar
low
dose
howev
cci
ppr
better
low
dose
statist
signific
transfus
free
interv
standard
dose
low
dose
high
dose
day
day
day
respect
howev
differ
statist
signific
donor
exposur
patient
significantli
reduc
owe
split
platelet
product
form
custom
dose
transfus
conclus
standard
dose
apheresi
platelet
best
choic
adequ
post
transfus
respons
hematooncolog
patient
howev
possibl
low
dose
altern
standard
consid
stabl
thrombocytopen
patient
owe
compar
post
transfus
respons
indic
cci
ppr
two
group
backgroundcas
studi
target
base
transfus
strategi
aim
provid
enough
blood
achiev
select
target
hgbhct
due
signific
variabl
respons
transfus
transfus
depend
patient
blood
usual
order
empir
rather
achiev
specif
goal
hgb
transfus
schedul
patient
dose
red
cell
transfus
degre
red
cell
product
influenc
long
given
transfus
may
keep
specif
patient
desir
target
hgb
individu
model
guid
transfus
could
improv
precis
order
reduc
unnecessari
visit
well
unit
transfus
base
develop
comput
algorithm
decis
support
capabl
individu
transfus
recommend
transfus
depend
patient
studi
designmethod
hematolog
blood
util
calcul
heme
buc
predict
individu
patient
respons
transfus
base
data
past
transfus
calcul
pull
inform
electron
medic
record
calcul
transfus
halfliv
prior
transfus
halfliv
use
predict
respons
futur
transfus
given
patient
current
hgb
weight
option
present
order
provid
select
transfus
dose
unit
determin
followup
time
patient
expect
stay
select
target
hgb
perform
prospect
pilot
heme
buc
patient
transfus
depend
anemia
primari
outcom
percentag
patient
return
schedul
hgb
within
select
target
intent
treat
fashion
resultsfind
nine
month
transfus
order
use
heme
buc
complet
data
analysi
target
hgb
select
case
fortyf
percent
transfus
singl
unit
two
unit
repres
signific
increas
singl
unit
transfus
histor
order
mean
predict
time
return
transfus
day
patient
followup
within
day
select
buc
return
time
overal
transfus
patient
return
hgb
target
conclus
hemebuc
provid
flexibl
individu
transfus
recommend
transfus
depend
patient
use
adapt
mathemat
algorithm
learn
patient
person
experi
rbc
transfus
within
option
present
hembuc
patient
remain
target
hemoglobin
select
order
provid
studi
expand
role
adaptivelearn
decis
support
technolog
ongo
efficaci
intraven
iron
administr
women
heavi
uterin
bleedinga
retrospect
studi
soraia
catarina
jacinto
correia
ana
oliveira
carla
pereira
chln
hospit
de
santa
maria
backgroundcas
studi
heavi
uterin
bleed
hub
report
caus
iron
defici
anemia
onefifth
twothird
affect
women
hub
carri
import
clinic
problem
also
emot
social
issu
limit
normal
activ
affect
significantli
qualiti
life
anemia
due
hub
potenti
treat
iron
therapi
object
evalu
efficaci
intraven
administr
ferric
carboxymaltos
correct
iron
defici
anemia
due
heavi
uterin
bleed
use
real
life
data
terciari
centerhospit
daycar
hospit
dedic
patient
blood
manag
pbm
studi
designmethod
retrospect
studi
select
women
refer
immunohemotherapi
daycar
hospit
gynecologyobstetr
depart
medic
appoint
januari
april
diagnos
irondefici
anemia
secondari
hub
due
nononcolog
caus
collect
laboratori
data
includ
hemoglobin
concentr
ferritin
level
transferrin
satur
previou
administr
intraven
ferric
carboxymaltos
compar
valu
week
therapi
observ
effect
iron
therapi
anemia
bodi
iron
store
subset
anem
patient
resultsfind
medium
age
women
refer
gynecolog
appoint
diagnos
irondefici
anemia
followup
manag
immunohemotherapi
daycar
hospit
select
studi
year
previou
therapi
medium
hemoglobin
concentr
gdl
ferritin
medium
valu
ngml
medium
transferrin
satur
laboratori
reevalu
intraven
iron
therapi
rise
hemoglobin
concentr
medium
gdl
increas
gdl
also
ferritin
increas
ngml
medium
ngml
improv
transferrin
satur
increas
obtain
medium
valu
women
treat
first
visit
nt
need
addit
intraven
iron
therapi
reevalu
also
report
improv
clinic
symptom
qualiti
life
conclus
women
hub
commonli
iron
defici
anemia
therefor
import
assess
iron
bodi
store
patient
appropri
initi
adequ
treatment
also
import
establish
good
interdepart
commun
differ
medic
specialti
provid
assess
followup
treatment
particular
subset
populationa
wellestablish
protocol
gynecologyobstetr
depart
immunohemotherapi
daycar
hospit
essenti
better
manag
anemia
patient
facilit
referr
procedur
reduc
time
proper
treatment
intraven
iron
safe
effect
therapi
quick
replenish
bodi
iron
store
correct
anemia
administr
therefor
therapeut
choic
particular
clinic
entiti
pbm
program
facilit
interdisciplinari
manag
anemia
reduc
blood
transfus
whether
medic
set
well
periop
set
continu
implement
backgroundcas
studi
patient
blood
manag
pbm
principl
highli
applic
surgic
practic
ideal
pbm
approach
multifacet
multimod
multidisciplinari
design
implement
execut
goal
investig
assess
chang
transfus
behavior
implement
robust
pbm
program
larg
tertiari
care
surgic
center
studi
designmethod
singl
center
observ
studi
pbm
implement
larg
divers
surgic
practic
formal
multidisciplinari
pbm
effort
initi
earli
consist
multipl
simultan
intervent
includ
educ
present
onlin
train
modul
standard
transfus
guidelin
electron
clinic
decis
support
cd
rule
transfus
order
advanc
transfus
analyt
provid
specif
transfus
report
transfus
data
deriv
use
baselin
inform
major
pbm
effort
initi
earli
subsequ
year
compris
postimplement
cohort
outcom
includ
annual
blood
product
transfus
total
percentag
surgic
patient
receiv
least
one
unit
allogen
rbc
frequenc
percentag
patient
discharg
hospit
hemoglobin
valu
gdl
also
assess
resultsfind
total
surgic
patient
admiss
includ
annual
surgic
volum
increas
p
percentag
surgic
patient
transfus
one
unit
allogen
rbc
decreas
studi
period
p
percentag
patient
receiv
plasma
decreas
p
rel
stabil
platelet
cryoprecipit
util
patient
receiv
rbc
number
patient
discharg
hemoglobin
valu
gdl
decreas
p
conclus
pbm
implement
effort
larg
surgic
practic
associ
substanti
reduct
rbc
plasma
transfus
minim
effect
util
platelet
cryoprecipit
addit
patient
receiv
rbc
like
discharg
hemoglobin
valu
gdl
suggest
increas
toler
postop
anemia
effort
underway
assess
relationship
chang
transfus
pattern
patient
center
outcom
backgroundcas
studi
transfus
red
blood
cell
rbc
essenti
hematopoiet
stem
cell
transplant
hct
risk
transfus
reaction
tr
cost
blood
led
effort
reduc
blood
use
patient
blood
manag
pbm
recommend
includ
transfus
rather
unit
rbc
need
chang
inpati
practic
transfus
instead
unit
red
blood
cell
rbc
hct
patient
hemoglobin
hypothesi
would
reduc
rbc
util
describ
impact
chang
rbc
util
preval
transfus
reaction
nurs
staff
workflow
studi
designmethod
includ
patient
year
receiv
allogen
hct
chang
practic
transfus
instead
unit
red
blood
cell
rbc
hemoglobin
compar
rbc
util
patient
receiv
allogen
hct
month
control
arm
implement
new
practic
intervent
arm
use
regress
model
estim
independ
effect
transfus
practic
vs
unitsepisod
length
hospit
condit
regimen
donor
type
patient
receiv
least
rbc
unit
outcom
variabl
total
number
inpati
transfus
addit
survey
assess
impact
resultsfind
patient
includ
analysi
control
group
intervent
arm
cohort
match
age
primari
diagnosi
graft
sourc
condit
regimen
median
number
rbc
unit
transfusedpati
ident
arm
interquartil
rang
unitspati
mean
number
rbc
transfus
vs
howev
differ
attribut
highli
transfus
patient
use
regress
model
length
stay
rel
increas
unitsday
ci
independ
predictor
number
rbc
unit
patient
receiv
data
patient
day
control
arm
receiv
unit
vs
intervent
arm
receiv
unit
result
reduct
unit
trpatient
standard
deviat
sd
control
arm
vs
reactionspati
sd
intervent
arm
survey
rn
show
felt
posit
affect
workflow
neutral
rn
felt
advers
impact
conclus
found
signific
differ
median
number
rbc
unit
transfus
number
transfus
reaction
per
patient
compar
histor
control
modest
reduct
rbc
util
base
unit
addit
posit
impact
rn
workflow
kinnera
chada
joyc
obidi
joann
gruber
graca
dore
emili
storch
alan
william
juan
banda
saurabh
gombar
deepa
balraj
ross
hayden
daniel
hood
thoma
falcon
karthik
natarajan
eldar
allakhverdiiev
sara
dempster
christian
reich
nerissa
william
azadeh
shoaibi
center
biolog
evalu
research
cber
food
drug
administr
stanford
univers
observ
health
data
scienc
informat
regenstrief
institut
columbia
univers
odysseu
data
servic
inc
iqvia
backgroundcas
studi
assess
whole
blood
blood
compon
util
compris
vital
piec
inform
promot
optim
safe
blood
suppli
manag
clinic
guidelin
develop
blood
compon
use
past
decad
practic
impact
guidelin
uncertain
aim
studi
assess
preval
whole
blood
blood
compon
transfus
biolog
effect
safeti
best
initi
studi
designmethod
use
electron
health
record
health
claim
databas
best
initi
center
biolog
evalu
research
cber
sentinel
program
compon
three
data
partner
particip
provid
record
approxim
million
patient
transfus
event
captur
use
medic
bill
reimburs
data
includ
intern
classif
diseas
clinic
modif
ninth
tenth
revis
current
procedur
terminolog
cpt
healthcar
common
procedur
code
system
hcpc
code
code
categor
identifi
transfus
event
whole
blood
red
blood
cell
rbc
platelet
plasma
event
defin
occurr
compon
specif
code
per
person
regardless
number
unit
transfus
resultsfind
tabl
show
transfus
whole
blood
blood
compon
total
transfus
event
period
rbc
compris
transfus
compon
platelet
plasma
whole
blood
account
respect
period
overal
transfus
event
whole
blood
decreas
transfus
plasma
platelet
slightli
fluctuat
wherea
rbc
transfus
slight
increas
show
declin
conclus
studi
demonstr
medic
bill
reimburs
data
medic
record
captur
blood
transfus
provid
addit
capabl
cber
hemovigil
system
observ
overal
declin
whole
blood
rbc
transfus
sentinel
best
initi
hemovigil
activ
includ
whole
blood
blood
compon
util
trend
inform
encourag
implement
transfus
guidelin
manag
blood
resourc
unit
state
appropri
red
blood
cell
transfus
follow
computer
provid
order
entri
alert
jacob
c
snyder
moham
osman
anna
w
rain
christoph
clark
univers
tennesse
graduat
school
medicin
univeristi
tennesse
medic
center
backgroundcas
studi
computer
provid
order
entri
alert
cpoe
clinic
decis
support
reduc
inappropri
transfus
goal
determin
alert
truli
decreas
inappropri
transfus
delay
red
blood
cell
rbc
transfus
goal
determin
effect
cpoe
alert
system
lower
rbc
transfus
rate
determin
patient
popul
receiv
addit
rbc
unit
alert
studi
designmethod
retrospect
data
cpoe
alert
aim
restrict
strategi
promot
transfus
order
practic
rbc
transfus
collect
june
novemb
alert
fire
base
specif
criteria
effort
avoid
alert
fatigu
provid
transfus
review
appropri
base
upon
aabb
rbc
transfus
guidelin
patient
popul
consist
inpati
exclud
intraop
transfus
massiv
transfus
outpati
transfus
patient
receiv
addit
unit
within
hour
alert
review
appropri
hemoglobin
level
preand
posttransfus
demograph
list
indic
transfus
clinic
scenario
resultsfind
initi
order
alert
fire
time
initi
order
cancel
time
chang
time
continu
time
patient
receiv
unit
patient
receiv
addit
rbc
unit
patient
receiv
addit
rbc
unit
within
hour
initi
alert
cpoe
alert
rbc
unit
save
period
result
product
acquisit
cost
save
nearli
alert
result
reduct
number
rbc
unit
transfus
popul
clinic
set
addit
unit
popul
includ
gastrointestin
gi
bleed
sepsi
surgic
patient
oncolog
diagnosi
nongi
activ
bleed
trauma
final
initi
order
met
aabb
guidelin
addit
unit
meet
criteria
averag
age
patient
receiv
addit
unit
yearsold
male
femal
ratio
conclus
cpoe
alert
system
clinic
decis
support
effect
reduc
inappropri
rbc
transfus
common
set
addit
transfus
gi
bleed
continu
blood
loss
vast
major
patient
receiv
rbc
unit
follow
alert
clinic
situat
meet
guidelin
therefor
alert
effect
promot
restrict
transfus
strategi
rbc
order
without
delay
transfus
need
backgroundcas
studi
plasma
routin
transfus
nonevidencebas
indic
expos
patient
risk
includ
transfusionassoci
circulatori
overload
alloimmun
hemolyt
transfus
reaction
clinic
order
plasma
transfus
academ
medic
institut
occur
comput
provid
order
entri
system
cpoe
filter
patient
recent
lab
evid
base
institutionchosen
transfus
guidelin
order
meet
guidelin
trigger
request
inform
provid
choos
indic
prepopul
pulldown
menu
eg
dic
inr
andor
add
comment
laboratori
data
select
indic
comment
collect
retrospect
review
studi
designmethod
plasma
overrid
order
januari
decemb
review
determin
prefix
indic
recent
inr
freetext
comment
attend
servicedepart
order
assign
one
follow
code
iindic
ninot
indic
base
institut
aabb
guidelin
nmine
inform
pprotocol
nicnon
indic
comment
freetext
comment
assign
code
tabul
analyz
common
word
free
text
indic
includ
bleed
bleed
hemorrhag
time
inr
time
transplant
time
backgroundcas
studi
anemia
defici
total
amount
red
blood
cell
rbc
hemoglobin
hgb
concentr
affect
oxygen
carri
capac
preval
hospit
patient
appropri
treatment
vari
base
etiolog
iron
defici
common
caus
anemia
independ
risk
factor
hospit
readmiss
prolong
length
stay
diminish
qualiti
life
increas
risk
morbid
mortal
newli
develop
laboratori
anemia
panel
provid
effici
assess
anemia
screen
one
simplifi
order
algorithm
studi
designmethod
reflex
algorithm
anemia
panel
establish
lab
june
medic
record
adult
patient
screen
anemia
use
reflex
panel
retrospect
review
month
period
patient
characterist
treatment
modal
collect
along
clinic
laboratori
data
includ
iron
studi
resultsfind
total
patient
found
anem
common
diagnosi
iron
defici
anemia
signific
improv
post
treatment
hgb
observ
compar
screen
hgb
vs
p
similar
improv
also
detect
mcv
rdw
indic
improv
rbc
hgb
product
tabl
averag
treatment
durat
day
oral
iron
replac
therapi
common
intervent
two
patient
treat
iv
iron
one
patient
treat
folic
acid
signific
reaction
complic
report
conclus
newli
develop
reflex
algorithm
anemia
screen
panel
provid
time
diagnosi
earlier
initi
manag
util
laboratori
resourc
effici
patient
studi
cohort
show
signific
increas
hgb
indic
success
manag
follow
anemia
backgroundcas
studi
despit
acknowledg
benefit
patient
blood
manag
pbm
implement
effect
program
remain
challeng
especi
multihospit
healthcar
system
serv
multipl
state
larg
healthcar
system
hospit
state
total
electron
medic
record
platform
initi
systemwid
blood
acquisit
expenditur
blood
spend
annual
form
interdisciplinari
partnership
expedit
comprehens
pbm
program
less
year
studi
designmethod
implement
plan
develop
support
first
year
goal
establish
pbm
infrastructur
develop
state
scienc
transfus
guidelin
order
set
dissemin
educ
provid
system
provid
level
data
team
develop
priorit
matrix
formula
consist
hospit
size
data
avail
transfus
volum
guid
effici
workflow
strong
emphasi
place
phase
maxim
behavior
modif
effect
system
level
pbm
steer
committe
form
individu
pbm
task
forc
throughout
hospit
carri
strateg
plan
inscop
hospit
implement
guidelin
cpoe
blood
order
set
committe
launch
awar
campaign
across
hospit
deliv
cme
ce
educ
program
largest
hospit
transfus
data
report
develop
hospit
util
one
system
largest
inform
technolog
platform
site
key
perform
indic
see
form
basi
evalu
program
resultsfind
period
processdriven
aggress
oversight
rbc
util
declin
system
overal
despit
patient
volum
increas
decreas
transfus
volum
site
data
report
implement
overal
rbc
transfus
hemoglobin
hgb
declin
rbc
transfus
hgb
increas
singl
unit
order
increas
first
month
healthcar
organ
blood
acquisit
cost
declin
averag
patient
day
fell
vs
baselin
year
conclus
creat
comprehens
pbm
program
expans
healthcar
structur
requir
innov
strategi
success
scale
key
programmat
compon
direct
regular
access
key
decis
maker
along
streamlin
decisionmak
process
provid
educ
cpoe
data
analyt
key
driver
success
find
show
signific
reduct
red
blood
cell
util
possibl
across
larg
system
oneyear
time
frame
backgroundcas
studi
allerg
transfus
reaction
common
advers
reaction
blood
product
wide
rang
sever
reaction
usual
mild
occur
within
hour
transfus
present
cutan
manifest
local
urticari
lesion
pruritu
presum
mechan
mast
cell
degranul
histamin
releas
diphenhydramin
invers
agonist
histamin
receptor
commonli
use
medic
allevi
symptom
proven
prevent
allerg
reaction
although
recommend
premed
patient
histori
allergi
blood
transfus
studi
designmethod
conduct
retrospect
analysi
blood
bank
softwar
transfus
mediwar
lenexa
ks
find
case
access
reaction
workup
narrow
allerg
reaction
june
august
review
pathologist
interpret
report
reaction
outcom
categor
accord
implic
blood
product
volum
transfus
partialincomplet
complet
premed
postmed
attempt
repeat
transfus
within
hour
report
reaction
sever
sever
nonseveremild
analysi
purpos
total
number
round
mild
allerg
reaction
report
case
sever
reaction
seen
major
mild
reaction
associ
rbc
major
sever
reaction
associ
platelet
premed
mild
reaction
postmed
case
incomplet
transfus
seen
case
associ
red
blood
cell
thirti
three
percent
patient
mild
reaction
incompleteparti
transfus
transfus
within
hour
reaction
repres
allerg
reaction
conclus
incomplet
transfus
occur
mani
mild
allerg
transfus
reaction
major
reaction
resolv
treatment
could
theori
complet
henc
repres
signific
wast
blood
product
result
present
opportun
qualiti
improv
regard
manag
mild
allerg
transfus
reaction
make
patient
safeti
first
prioriti
opportun
minim
avoid
blood
product
wastag
mani
reaction
backgroundcas
studi
alloimmun
human
red
cell
antigen
play
import
role
manag
patient
sickl
cell
diseas
scd
pediatr
center
support
larg
popul
scd
patient
includ
mani
chronic
transfus
protocol
order
reduc
risk
alloimmun
sinc
select
red
cell
donor
match
rh
c
e
kell
k
phenotyp
recipi
purpos
studi
evalu
state
alloimmun
patient
popul
assess
benefit
approach
studi
designmethod
chronic
transfus
patient
everi
donor
unit
transfus
trace
back
patient
electron
record
compar
donor
antigen
profil
record
blood
collect
facil
use
method
develop
independ
data
analysi
group
review
patient
transfus
histori
compris
median
rang
month
transfus
data
determin
often
mismatch
result
format
alloantibodi
compar
alloimmun
state
patient
refer
popul
studi
prior
adopt
c
e
k
match
gener
alloantigen
distribut
popul
resultsfind
program
achiev
signific
reduct
incid
alloimmun
c
e
k
popul
limit
prolifer
antibodi
often
observ
chronic
transfus
patient
thu
alloantibodi
distribut
popul
studi
castro
colleagu
extend
mani
antibodi
per
patient
limit
nevertheless
patient
receiv
dozen
transfus
made
least
one
alloantibodi
includ
antibodi
js
fy
v
kp
e
along
c
e
interestingli
observ
instanc
includ
antifi
antibodi
form
repeat
exposur
fy
red
cell
conclus
data
obtain
patient
cohort
consist
predict
castro
colleagu
conclus
subsequ
studi
eg
http
name
overal
reduct
sensit
possibl
care
select
donor
whose
antigen
profil
match
recipi
implement
novel
algorithm
select
donor
unit
larg
set
antigen
quantit
consider
immunogen
individu
antigen
determin
believ
achiev
improv
prevent
alloimmun
backgroundcas
studi
maximum
surgic
blood
order
schedul
msbo
first
describ
provid
guidanc
surgeon
much
blood
order
preop
phase
goal
cut
unnecessari
type
cross
order
make
sure
appropri
quantiti
blood
avail
surgeri
like
requir
transfus
concept
recent
emphasi
patient
blood
manag
newer
surgic
techniqu
contribut
decreas
util
blood
product
unnecessari
crossmatch
one
unintend
consequ
polici
might
underutil
type
screen
oper
requir
blood
transfus
routin
yet
unexpect
complic
aris
oper
lack
type
screen
neg
consequ
emerg
releas
blood
need
studi
designmethod
evalu
schedul
oper
institut
week
period
procedur
identifi
patient
type
screen
file
within
day
oper
within
day
cardiac
procedur
result
compar
publish
msbo
guidelin
recommend
procedur
type
screen
resultsfind
total
schedul
procedur
identifi
type
screen
file
averag
procedur
day
type
screen
order
urolog
cardiovascular
gastrointestin
surgeri
type
screen
recommend
publish
msbo
type
screen
rate
institut
procedur
recommend
type
screen
vari
rate
complianc
includ
open
hysterectomi
ovarian
surgeri
spinal
fusion
laminectomi
hip
replac
knee
replac
open
shoulder
neck
dissect
inconsist
amongst
differ
surgeon
frequenc
order
type
screen
procedur
also
inconsist
surgeon
differ
day
conclus
mani
surgeon
abl
complet
oper
minim
blood
loss
littl
need
transfus
mani
procedur
also
perform
without
type
screen
file
procedur
need
blood
orthoped
gynecolog
ent
surgeri
potenti
high
blood
loss
due
unexpect
complic
unusu
anatomi
patient
alreadi
alloantibodi
unidentifi
emerg
releas
neg
blood
could
lead
hemolyt
transfus
reaction
intersurgeon
intrasurgeon
variabl
across
hospit
demonstr
lack
unifi
approach
util
type
screen
show
push
decreas
overutil
blood
product
possibl
swung
pendulum
toward
underutil
nurs
studi
designmethod
studi
adopt
qualit
research
approach
employ
direct
applic
knowledg
chang
understand
influenc
think
behavior
nurs
toward
transfus
purpos
sampl
nurs
select
base
inclus
criteria
nurs
previou
knowledg
pbm
work
clinic
area
blood
product
administ
data
collect
via
facetofac
interview
followup
question
via
email
need
resultsfind
theme
gener
data
analysi
reveal
increas
knowledg
relat
associ
risk
factor
advers
reaction
blood
transfus
compet
convey
perform
expertli
act
independ
confid
voic
becom
inquisit
make
decis
educ
colleagu
motiv
spread
knowledg
educ
nurs
provid
particip
initi
action
plan
share
knowledg
spread
awar
provid
support
clinic
unit
exploit
present
learn
modul
inservic
creat
refer
page
pbm
feel
empower
mutual
among
particip
enthusiast
inform
other
risk
associ
transfus
ensur
safe
appropri
use
blood
product
encourag
patient
make
educ
decis
transfus
particip
report
empow
extent
challeng
inappropri
order
blood
product
backgroundcas
studi
therapeut
plasma
exchang
tpe
procedur
use
remov
patholog
substanc
plasma
howev
procedur
also
deplet
plasma
coagul
factor
lead
major
bleed
goal
studi
evalu
perform
mathemat
model
predict
postprocedur
coagul
factor
level
cohort
hospit
patient
smartphon
app
base
model
creat
determin
much
plasma
replac
need
achiev
target
posttp
factor
level
studi
designmethod
model
util
patient
weight
pretp
hematocrit
pretp
coagul
factor
level
well
volum
plasma
process
plasma
replac
model
accuraci
assess
compar
predict
versu
measur
posttp
fibrinogen
antithrombin
level
inpati
tpe
procedur
occur
larg
academ
medic
center
upon
model
valid
smartphon
app
develop
io
android
devic
resultsfind
minor
advers
event
occur
patient
resolv
spontan
manag
bleed
thrombot
complic
occur
mean
differ
predict
measur
posttp
fibrinogen
concentr
mgdl
sd
rang
percent
differ
measur
predict
fibrinogen
concentr
sd
rang
mean
differ
predict
measur
posttp
antithrombin
concentr
activ
sd
rang
mean
percent
differ
predict
measur
antithrombin
percent
activ
sd
rang
conclus
model
reliabl
predict
posttp
fibrinogen
antithrombin
concentr
within
measur
valu
mainten
critic
factor
level
essenti
clinician
consid
target
coagul
factor
higher
project
app
plexfactor
greatli
simplifi
calcul
plasma
replac
need
achiev
target
posttp
factor
level
avail
free
io
android
treat
pediatr
patient
crossrefer
actual
apheresi
procedur
perform
data
studi
designmethod
descript
pilot
investig
consist
survey
retrospect
analysi
member
asfa
pediatr
subcommitte
list
diseas
indic
believ
import
condit
apheresi
perform
children
list
base
particip
medic
judgmentsexperi
restrict
sourc
materi
member
collect
pediatr
apheresi
procedur
data
respect
center
calendar
year
keep
analys
consist
asfa
guidelin
use
current
version
avail
studi
period
resultsfind
top
condit
respond
felt
apheresi
therapi
perform
children
humor
reject
variou
solid
organ
transplant
thrombot
thrombocytopen
purpura
acut
sickl
cell
diseas
crisi
graft
versu
host
diseas
sickl
cell
diseas
mainten
therapi
myasthenia
gravi
guillainbarr
syndrom
focal
segment
glomerulosclerosi
recurr
abo
incompat
liver
transplant
desensit
acut
dissemin
encephalomyel
famili
hypercholesterolemia
rapidli
progress
glomerulonephr
neuromyel
optica
antinmethyldaspar
receptor
enceph
multiorgan
failuresepsi
fulmin
wilson
diseas
retrospect
procedur
analysi
children
treat
apheresi
diagnos
top
condit
treat
patient
treat
condit
top
includ
leukapheresi
acut
leukemia
cold
agglutinin
diseas
meconium
aspir
hemolysi
atyp
hemolyt
urem
syndrom
patient
diffus
alveolar
hemorrhag
system
lupu
erythematosi
brochiol
obliteran
syndrom
malaria
hypereosinophilia
major
abo
incompat
stem
cell
transplant
condit
except
antinmethyldaspar
receptor
enceph
meconium
aspir
hemolysi
hypereosinophilia
list
asfa
guidelin
conclus
heterogen
consid
import
condit
treat
pediatr
patient
apheresi
profession
uncommon
condit
neither
list
import
asfa
guidelin
treat
apheresi
find
provid
asfa
pediatr
subcommitte
justif
perform
multicent
analysi
help
clarifi
issu
follow
without
pe
treatment
group
patient
underw
singl
volum
therapeut
pe
patient
two
fold
increas
least
two
antiheart
antibodi
aha
level
cardiac
nuclear
antigen
endotheli
cardiomyocyt
conduct
smooth
muscl
cell
antigen
underw
endomyocardi
biopsi
emb
cardiac
ct
mri
myocardi
perfus
scan
coronari
angiographi
diagnos
myocard
patient
treat
either
immunosuppress
drug
without
echocardiograph
paramet
aha
level
detect
assess
baselin
two
followup
fu
visit
month
group
also
evalu
walk
test
classifi
respond
vs
respond
control
group
respond
studi
group
character
initi
higher
systol
pap
vs
p
six
treatment
group
patient
control
group
patient
got
methylprednisolon
p
mean
dose
mg
per
day
respect
p
conclus
pe
improv
cardiac
function
daili
activ
patient
idcm
studi
group
respond
systol
pap
mmhg
higher
good
outcom
predictor
pe
effici
pe
help
avoid
use
immunosuppress
medic
reduc
high
dose
transfus
manag
erythropoiet
protoporphyria
postorthotop
liver
transplant
patient
brian
adkin
garrett
booth
vanderbilt
univers
medic
center
backgroundcas
studi
erythropoiet
protoporphyria
epp
disord
heme
synthesi
caus
abnorm
termin
enzym
ferrochelatas
protoporphyirin
ppix
accumul
within
red
cell
deposit
skin
liver
manifest
photosensit
less
commonli
liver
diseas
hematopoiet
stem
cell
transplant
hsct
correct
enzymat
abnorm
patient
may
also
requir
orthotop
liver
transplant
olt
postolt
period
multipl
therapi
employ
reduc
plasma
ppix
level
simpl
transfus
hemin
infus
reduc
ppix
product
therapeut
plasma
exchang
tpe
red
blood
cell
exchang
rbcx
shown
transient
improv
laboratori
valu
histolog
find
fail
prevent
progress
liver
diseas
edit
american
societi
apheresi
guidelin
categor
epp
categori
iii
indic
apheresi
herein
present
pediatr
patient
epp
underw
olt
bridg
sct
manag
simpl
transfus
tpe
rbcx
studi
designmethod
present
male
epp
recurr
hepat
porphyria
crise
patient
present
right
upper
quadrant
pain
transamin
anemia
hemoglobin
mgdl
hematocrit
start
hemin
panhematin
recordati
rare
diseas
inc
lebanon
brunswick
new
jersey
daili
tpe
undergo
evalu
olt
olt
start
rbcx
everi
week
underw
total
rbcx
procedur
tpe
gradual
wean
daili
week
total
tpe
procedur
perform
addit
patient
hemoglobin
threshold
rais
mgdl
suppress
erythropoiesi
resultsfind
month
follow
olt
patient
mean
hemoglobin
hematocrit
mgdl
patient
continu
elev
ppix
normal
total
plasma
porphyrin
normal
associ
diffus
axon
polyneuropathi
addit
continu
elev
liver
enzym
posttranspl
liver
biopsi
show
increas
iron
deposit
mix
inflamm
increas
fibrosi
patient
also
develop
hypogammaglobulinemia
associ
chronic
tpe
patient
ultim
transfer
due
high
acuiti
care
prepar
hsct
conclus
tpe
rbcx
often
employ
manag
epp
patient
despit
asfa
categori
iii
indic
experi
ppix
total
porphyrin
remain
elev
patient
continu
liver
injuri
chronic
red
cell
transfus
maintain
hematocrit
shown
improv
symptom
patient
congenit
erythropoiet
porphyria
suppress
erythropoiesi
howev
patient
transfus
level
interest
wane
hypertransfus
patient
success
manag
hemin
infus
lower
iron
burden
though
treatment
also
inadequ
patient
stand
apheresi
remain
insuffici
impact
longterm
effect
epp
hypertransfus
remain
incomplet
explor
earli
plasma
exchang
effect
antithymocyt
globulinassoci
serum
sick
sarita
joshi
kristin
ricci
section
transfus
medicin
cleveland
clinic
cleveland
clinic
section
apheresi
backgroundcas
studi
antithymocyt
globulin
atg
potent
antireject
agent
kidney
allograft
recipi
serum
sick
ss
immun
complex
mediat
condit
occur
kidney
transplant
patient
receiv
rabbit
atg
ratg
prior
rabbit
exposur
consid
risk
factor
ss
develop
patient
classic
manifest
high
fever
polyarthr
arthralgia
rash
lymphadenopathi
renal
failur
rare
rapidli
progress
paralysi
treatment
includ
corticosteroid
antihistamin
symptomat
therapi
case
seri
suggest
effect
therapeut
plasma
exchang
tpe
procedur
manag
rapidli
evolv
serum
sick
report
case
ratgassoci
ss
renal
transplant
patient
improv
singl
plasma
exchang
treatment
studi
designmethod
case
report
literatur
review
resultsfind
year
old
femal
end
stage
renal
diseas
secondari
antigbm
antibodi
goodpastur
diseas
present
ten
day
deceas
donor
kidney
transplant
debilit
polyarticular
arthralgia
pleomorph
rash
sever
allodynia
rapidli
progress
upper
limb
weak
receiv
total
mg
ratg
induct
therapi
transplant
present
sever
joint
tender
upper
lower
extrem
swell
proxim
bilater
upper
extrem
paresi
ambul
normal
even
prior
admiss
imag
brain
spinal
cord
unremark
hypercoagul
caus
neuropathi
rule
complement
level
low
patient
undergon
cours
tpe
earli
posttranspl
cours
suspect
antibodymedi
reject
later
exclud
prior
exposur
rabbit
howev
past
medic
histori
signific
exposur
ratg
prior
renal
transplant
past
histori
serum
sick
due
sever
symptom
lack
respons
corticosteroid
plasma
exchang
use
albumin
replac
initi
follow
procedur
patient
notic
impress
reduct
pain
next
day
rash
wane
swell
subsid
regain
upper
extrem
function
abl
ambul
walker
point
discharg
week
later
addit
apheresi
treatment
perform
conclus
earli
plasma
exchang
highli
effect
revers
symptom
serum
sick
especi
patient
rapidli
progress
neuropathi
weak
sever
pain
refractori
corticosteroid
current
apheresi
guidelin
list
ss
indic
tpe
report
review
literatur
support
inclus
tpe
serum
sick
categori
iii
indic
grade
level
evid
futur
practic
guidelin
yearold
femal
histori
uncompl
term
pregnanc
appropri
receiv
rh
immun
globulin
spite
antibodi
screen
becam
posit
antidc
pattern
rd
pregnanc
unfortun
end
intrauterin
fetal
demis
week
present
institut
prenat
care
th
pregnanc
week
day
gestat
husband
homozyg
dd
studi
designmethod
refer
lab
test
reveal
presenc
antid
antig
anti
antibodi
neg
antic
antidg
titer
anti
titer
initi
see
tabl
week
day
patient
underw
three
day
cours
plasmapheresi
third
day
plasmapheresi
also
ivig
administr
weekli
antibodi
titer
follow
clinic
patient
manag
weekli
ivig
administr
intrauterin
transfus
iut
possibl
week
day
gestat
patient
underw
iut
middl
cerebr
arteri
peak
systol
veloc
greater
mom
doppler
ultrasonographi
total
iut
everi
week
deliveri
supplement
seriou
side
effect
anaphylaxi
rare
case
unfraction
heparin
ufh
serv
anticoagul
apheresi
howev
guidelin
standalon
ufh
dose
apheresi
avail
report
patient
develop
anaphylaxi
acda
plasmapheresi
success
use
ufh
standalon
anticoagul
studi
designmethod
man
chronic
kidney
diseas
caus
focal
segment
glomerulosclerosi
present
nephrolog
clinic
third
kidney
transplant
first
second
transplant
perform
age
year
avail
kidney
donor
wife
bloodgroup
incompat
patient
blood
type
wife
b
admiss
plasmapheresi
commenc
deplet
antiabo
antibodi
precondit
protocol
plasma
exchang
featur
acda
anticoagul
spectra
optia
terumo
bct
lakewood
co
usa
plan
everi
day
replac
fluid
ab
fresh
frozen
plasma
ffp
first
plasmapheresi
session
patient
develop
gener
itch
min
commenc
second
session
develop
urticaria
follow
dyspnea
hypotens
loss
conscious
plasmapheresi
stop
immedi
intraven
dexamethason
chlorpheniramin
maleat
administ
symptom
disappear
h
thereaft
skin
prick
intraderm
citrat
test
yield
strongli
posit
result
thu
use
ufh
standalon
anticoagul
plasmapheresi
elimin
acda
replac
fluid
chang
ffp
albumin
ffp
contain
citrat
ufh
infus
continu
plasmapheresi
whole
blood
ufh
ratio
held
plasma
exchang
perform
everi
plasmapheresi
session
resultsfind
success
perform
five
plasmapheresi
session
use
ufh
sole
anticoagul
two
session
schedul
preoper
deplet
antiabo
antibodi
three
postop
remov
class
ii
antihla
donorspecif
antibodi
patient
underw
success
kidney
transplant
maintain
good
graft
function
month
followup
conclus
patient
develop
allerg
reaction
citrat
plasmapheresi
ufh
use
safe
standalon
anticoagul
backgroundcas
studi
therapeut
phlebotomi
tp
standard
treatment
patient
blood
disord
result
excess
red
cell
product
doubl
red
blood
cell
drbc
procedur
offer
altern
therapeut
phlebotomi
option
potenti
effici
mean
deplet
excess
red
cell
tp
sixtyeightyearold
male
present
hospit
emerg
room
alter
mental
statu
strokelik
symptom
patient
past
medic
histori
notabl
hypertens
hypothyroid
possibl
hemochromatosi
physic
examin
confus
tachycard
plethor
initi
laboratori
result
show
elev
hemoglobin
hgb
hematocrit
hct
gdl
respect
laboratori
result
white
blood
cell
platelet
count
within
normal
rang
studi
designmethod
perform
emerg
backtoback
drbc
procedur
patient
given
rapid
clinic
deterior
monitor
patient
cbc
cours
drbc
procedur
tabl
resultsfind
complet
two
consecut
drbc
procedur
patient
total
hgb
hct
level
decreas
respect
first
drbc
collect
minut
durat
remov
ml
red
blood
cell
rbc
second
drbc
collect
minut
addit
remov
ml
rbc
albumin
administ
procedur
replac
fluid
instead
isoton
salin
maintain
appropri
intravascular
oncot
pressur
advers
event
note
procedur
patient
toler
without
difficulti
conclus
util
autom
doubl
red
cell
collect
allow
donor
apheresi
instrument
use
therapeut
treat
backgroundcas
studi
patient
undergo
seri
therapeut
plasma
exchang
tpe
often
receiv
steroid
part
treatment
underli
disord
use
albumin
replac
fluid
fibrinogen
often
follow
assess
need
fresh
frozen
plasma
ffp
part
replac
fluid
steroid
affect
mani
laboratori
paramet
hypothes
use
steroid
may
affect
fibrinogen
level
tpe
seri
studi
evalu
whether
steroid
use
seri
tpe
predict
need
use
ffp
part
replac
fluid
due
hypofibrinogenemia
studi
designmethod
retrospect
review
consecut
patient
academ
medic
center
underw
tpe
seri
albumin
initi
replac
fluid
patient
diagnos
ffp
indic
replac
fluid
exclud
indic
tpe
concurr
use
oral
intraven
steroid
trend
fibrinogen
whether
ffp
ever
use
replac
fluid
due
hypofibrinogenemia
note
statist
analysi
perform
use
backgroundcas
studi
bacteri
contamin
recov
tissu
allograft
pose
seriou
threat
transplant
recipi
antibiot
disinfect
standard
practic
util
cardiac
valv
cv
allograft
treatment
effort
reduc
risk
bacteri
contamin
howev
composit
antibiot
cocktail
well
incub
condit
vari
wide
depend
tissu
bank
chang
antibiot
avail
recent
revis
canadian
health
standard
result
requir
quantit
valid
tissu
allograft
bioburden
reduct
purpos
studi
investig
efficaci
revis
antibiot
cocktail
intent
contamin
cv
allograft
order
quantit
bioburden
reduct
defin
optim
incub
temperatur
disinfect
process
studi
designmethod
disinfect
solut
compos
vancomycin
tobramycin
cefoxitin
rpmi
inocul
cfuml
five
challeng
organ
consid
medic
signific
tissu
bank
follow
hour
incub
remain
cfu
count
log
reduct
calcul
evalu
appropri
disinfect
incub
rang
hour
hour
four
cv
bisect
inocul
cfu
challeng
organ
place
disinfect
solut
time
point
one
half
allograft
remov
wash
lactat
ringer
solut
recov
remain
bacteria
steril
salin
sonic
mechan
shake
final
recoveri
solut
filter
quantifi
bacteri
growth
resultsfind
recoveri
effici
sonic
cv
allograft
higher
aerob
vs
anaerob
cultur
microorgan
vs
maxim
inhibitori
dilut
mid
updat
antibiot
cocktail
util
throughout
valid
studi
demonstr
work
concentr
antibiot
suffici
inhibit
growth
five
challeng
microorgan
sensit
organ
staphylococcu
aureu
streptococcu
pyogen
inhibit
dilut
follow
escherichia
coli
clostridium
sporogen
pseudomona
aeruginosa
absenc
antibiot
challeng
organ
growth
remain
rel
stationari
aerob
anaerob
cultur
respect
incub
antibiot
temperatur
result
reduct
growth
aerob
anaerob
incub
temperatur
increas
greater
increas
bacteri
growth
hour
aerob
anaerob
bioburden
reduct
increas
incub
temperatur
aerob
anaerob
conclus
studi
demonstr
cardiac
valv
optim
decontamin
propos
disinfect
solut
cocktail
incub
temperatur
increas
disinfect
protocol
shown
reduc
bacteri
bioburden
greater
aerob
anaerob
challeng
organ
backgroundcas
studi
mma
test
use
predict
clinic
signific
alloantibodi
often
use
assess
antibodi
direct
high
preval
antigen
howev
may
also
use
assess
common
antibodi
specif
find
blood
patient
difficulttofind
antigen
requir
mma
result
greater
reactiv
result
transfus
recommend
antigen
neg
blood
neg
refer
rang
mma
laboratori
studi
designmethod
mma
data
present
review
data
updat
previou
data
incorpor
use
result
assay
perform
previous
describ
transfus
test
perform
fresh
complement
c
without
fresh
complement
nc
ad
test
system
resultsfind
follow
tabl
contain
mma
result
serum
sampl
test
antibodi
report
vari
degre
signific
other
test
insuffici
blood
product
avail
support
transfus
need
conclus
antiyt
continu
test
specif
sampl
yield
posit
result
common
specif
test
one
exampl
anti
demonstr
reactiv
cutoff
exampl
antim
yield
posit
result
emphas
import
test
without
c
sera
posit
fresh
c
ad
posit
c
present
mma
result
indic
continu
need
evalu
red
cell
transfus
patient
antibodi
specif
alon
resultsfind
prior
follow
transfus
ntprobnp
level
significantli
elev
patient
taco
possibl
trali
compar
trali
tacotrali
control
p
overal
comparison
preand
posttransfus
ntprobnp
significantli
higher
possibl
trali
case
compar
taco
case
pvalu
neither
differ
delta
ratio
postand
pretransfus
ntprobnp
differ
case
taco
compar
possibl
trali
howev
ratio
pre
posttransfus
ntprobnp
significantli
differ
taco
trali
case
pretransfus
ntprobnp
level
higher
case
taco
iqr
compar
control
subject
without
histori
congest
heart
failur
kidney
diseas
p
ntprobnp
level
correl
sever
pulmonari
edema
measur
degre
hypoxemia
p
hospit
mortal
p
blood
bank
polici
fdaapprov
concern
remain
relat
hemostat
efficaci
product
sinc
posttransfus
platelet
recoveri
shown
lower
seen
conv
platelet
assess
use
efficaci
product
analyz
platelet
red
cell
util
transit
period
studi
designmethod
transfus
adult
age
year
older
assess
platelet
use
receiv
pr
conv
platelet
indic
hemostat
efficaci
also
assess
red
blood
cell
rbc
util
patient
period
follow
platelet
transfus
number
shown
signific
p
backgroundcas
studi
preoper
autolog
blood
donat
pabd
declin
use
may
consid
patient
undergo
elect
surgeri
signific
blood
loss
likelihood
transfus
exce
howev
pabd
rare
clear
indic
known
increas
risk
periop
anemia
compensatori
erythropoiesi
requir
least
three
week
associ
gender
report
periop
anemia
data
gender
differ
compensatori
erythropoiesi
transfus
associ
pabd
program
institut
studi
designmethod
retrospect
studi
pabd
program
institut
twoyear
period
januari
decemb
follow
data
collect
patient
medic
record
patient
characterist
hemoglobin
valu
date
autolog
blood
donat
transfus
blood
product
hemoglobin
decreas
femal
male
calcul
compar
statist
analysi
perform
use
stata
statacorp
lp
texa
usa
resultsfind
patient
underw
pabd
donat
total
autolog
rbc
unit
femal
mean
age
rang
donat
one
unit
wherea
rest
donat
unit
review
transfus
medicin
physician
show
none
autolog
unit
indic
mean
number
day
pabd
date
surgeri
day
baselin
hemoglobin
hgb
prior
autolog
blood
donat
patient
gdl
g
dl
femal
gdl
male
p
hgb
level
measur
autolog
donat
prior
surgeri
gdl
gdl
femal
gdl
male
p
mean
hgb
decreas
donat
gdl
gdl
femal
gdl
gdl
femal
patient
receiv
autolog
transfus
compar
male
patient
differ
reach
statist
signific
unit
wast
patient
patient
transfus
autolog
unit
patient
receiv
allogen
blood
product
addit
autolog
unit
patient
postop
hgb
gdl
conclus
indic
pabd
clear
contrast
male
femal
patient
becam
anem
show
compensatori
erythropoiesi
interv
donat
surgeri
addit
femal
patient
transfus
compar
male
although
differ
reach
statist
signific
may
reflect
genderassoci
physiolog
differ
transfus
autolog
unit
also
justifi
patient
postop
hgb
valu
major
patient
subset
backgroundcas
studi
earli
balanc
administr
platelet
benefici
bleed
patient
rapid
infus
system
fluid
warmer
commonli
use
periop
massiv
transfus
order
keep
pace
bleed
prevent
hypothermia
unit
state
devic
approv
platelet
administr
due
lack
data
mani
physician
reluct
use
avoid
devic
lead
delay
reduc
platelet
transfus
associ
mortal
bleed
patient
sought
determin
effect
clinic
rapid
infus
system
fluid
warmer
invitro
function
store
apheresi
platelet
studi
designmethod
studi
approv
univers
wisconsin
institut
review
board
unit
apheresi
platelet
less
hour
past
clinic
expiri
date
suppli
hospit
blood
bank
mix
sampl
steril
obtain
unit
remain
volum
run
commerci
avail
rapid
infus
system
belmont
rapid
infus
belmont
instrument
corpor
billerica
rate
mlmin
warm
entir
unit
infus
second
sampl
drawn
proxim
port
outflow
line
platelet
count
maximum
amplitud
thromboelastogram
haemonet
braintre
measur
sampl
estim
test
unit
would
give
us
greater
power
detect
differ
preand
postinfus
mm
use
pair
ttest
pvalu
consid
signific
studi
repeat
parallel
sampl
protocol
use
platelet
aliquot
incub
minut
fluid
warmer
corp
minneapoli
mn
resultsfind
unit
reach
goal
infus
rate
mlmin
infus
circuit
malfunct
clot
observ
averag
postinfus
temperatur
rang
statist
signific
chang
postinfus
mean
mm
ci
p
minimum
maximum
differ
postpr
mm
respect
statist
signific
increas
postinfus
platelet
count
mean
cell
ci
p
equival
chang
baselin
platelet
count
similar
result
seen
fluid
warmer
tabl
conclus
wellpow
studi
unabl
detect
signific
effect
highspe
rapid
infus
warm
invitro
function
store
apheresi
platelet
statist
signific
increas
postinfus
platelet
count
probabl
result
disaggreg
small
platelet
aggreg
lead
higher
number
autom
cell
counter
result
strongli
suggest
rapid
infus
warm
apheresi
platelet
safe
avail
guidelin
recommend
transfus
donor
recipi
plasma
compat
platelet
howev
platelet
suspend
addit
solut
due
lower
plasma
content
respect
cell
abo
compat
seem
reason
approach
order
optim
post
transfus
platelet
count
object
compar
two
differ
strategi
platelet
select
abo
incompat
hsct
studi
designmethod
review
data
two
differ
platelet
transfus
protocol
use
patient
undergo
abo
incompat
hsct
hospit
protocol
platelet
transfus
plasma
compat
donor
recipi
abo
donor
group
major
incompat
abo
recipi
group
minor
incompat
protocol
b
platelet
transfus
abo
group
red
blood
cell
concentr
abo
recipi
group
major
incompat
abo
donor
group
minor
incompat
protocol
follow
specif
abo
platelet
avail
pack
rbc
rbcc
transfus
hemoglobin
level
patient
gdl
prophylact
pool
plt
transfus
plt
count
l
plt
transfus
independ
defin
last
plt
transfus
plt
transfus
follow
day
rbc
transfus
independ
defin
last
transfus
rbc
transfus
follow
day
record
transfus
requir
day
hsct
spss
softwar
v
use
perform
statist
analys
decreas
transfus
consist
trend
report
elsewher
increas
ar
may
due
increas
incid
increas
user
familiar
hm
within
bed
size
group
facil
outli
ar
rate
clear
limit
includ
lack
data
valid
possibl
inconsist
case
definit
interpret
applic
could
lead
underor
overreport
ar
mdph
collabor
cdc
improv
hm
includ
clarifi
report
discard
product
test
autom
case
definit
analys
allow
detect
trend
usag
ar
incid
provid
action
data
futur
work
assess
impact
surveil
attempt
detect
anomal
rate
associ
specif
product
wider
use
hm
allow
repres
surveil
ultim
safer
transfus
medicin
practic
five
relat
ahtr
includ
two
abo
incompat
ibct
two
trali
one
case
bacteri
infect
taco
conclus
studi
period
despit
signific
declin
use
blood
product
number
report
ae
remain
steadi
reflect
increas
knowledg
hemovigil
despit
high
qualiti
blood
product
seriou
advers
event
occur
human
error
account
mani
exampl
case
sever
dyspnea
especi
taco
doctor
unabl
recogn
caus
possibl
prevent
likewis
yet
see
improv
number
ahtr
result
blood
compon
intend
anoth
person
reflect
seriou
deviat
sop
patient
identif
futur
need
focu
improv
unsaf
practic
throughout
entir
blood
chain
especi
bed
side
procedur
checklist
ensur
patient
identif
risk
assess
taco
revis
report
criteria
joint
aabbisbtihn
taco
task
forc
welcom
backgroundcas
studi
append
common
caus
acut
abdomin
pain
typic
manag
either
antibiot
alon
combin
surgic
intervent
hematolog
malign
treatment
caus
pancytopenia
increas
risk
surgeri
postsurg
complic
neutropen
patient
howev
may
suffici
immun
respons
clear
local
infect
even
appropri
antibiot
granulocyt
transfus
previous
evalu
treatment
neutropen
patient
refractori
bacteri
fungal
infect
extens
report
medic
manag
acut
append
studi
designmethod
case
seri
adult
patient
hematolog
malign
undergo
chemotherapi
develop
acut
append
manag
medic
antibiot
granulocyt
transfus
granulocyt
obtain
via
granulocyt
colonystimul
factor
dexamethason
stimul
volunt
donor
apheresi
hydroxyethyl
starch
goal
dose
granulocyt
per
transfus
absolut
neutrophil
count
determin
prior
within
hour
administr
granulocyt
vital
sign
oxygen
satur
measur
transfus
resultsfind
time
granulocyt
infus
patient
initi
sever
neutropen
undetect
neutrophil
count
deem
surgic
candid
granulocyt
transfus
gener
well
toler
one
patient
two
report
episod
fever
chill
patient
receiv
granulocyt
transfus
rang
day
evid
clinic
radiolog
improv
patient
show
immedi
increas
measur
absolut
neutrophil
count
increas
highli
variabl
mean
increas
rang
thousand
neutrophil
per
microlit
tabl
one
day
follow
granulocyt
transfus
patient
frequent
develop
either
fever
increas
abdomin
pain
like
relat
increas
appendic
inflamm
respons
granulocyt
imag
studi
case
gradual
improv
show
resolut
inflammatori
find
reduct
appendic
distent
conclus
three
adult
neutropen
patient
hematolog
malign
radiolog
confirm
acut
append
manag
granulocyt
transfus
antibiot
resolut
acut
append
investig
necessari
determin
granulocyt
infus
provid
therapeut
benefit
treatment
local
infect
neutropen
patient
backgroundcas
studi
platelet
transfus
standard
approach
prevent
treat
bleed
thrombocytopen
patient
due
implement
improv
donor
histori
questionnair
donor
test
protocol
risk
plateletassoci
transfus
transmit
infect
decreas
year
sepsi
bacteri
contamin
platelet
howev
still
remain
concern
mitig
risk
institut
migrat
platelet
inventori
conv
platelet
fda
licens
pr
platelet
product
patient
suppli
constraint
transit
howev
necessit
mainten
dual
inventori
conv
pr
platelet
analyz
incid
transfus
reaction
consid
conv
platelet
analyz
bacteri
detect
assay
safeti
measur
pr
platelet
repres
standard
care
institut
accordingli
platelet
request
either
product
dispens
blood
bank
per
usual
blood
bank
inventori
manag
polici
studi
analyz
type
platelet
transfus
categori
transfus
reaction
patient
demograph
patient
receiv
pr
conv
platelet
reaction
ascrib
appropri
product
base
time
reaction
proxim
transfus
natur
reaction
use
nation
hemovigil
network
guidelin
resultsfind
total
transfus
reaction
identifi
follow
platelet
transfus
episod
atr
report
allerg
nonsever
patient
atr
identifi
underw
one
transfus
patient
found
shortest
interv
notif
atr
anoth
one
month
patient
type
atr
notifi
interv
month
transfus
two
differ
institut
report
allergi
meet
degre
probabl
definit
addit
case
lifethreaten
taco
trali
one
caus
death
taco
conclus
although
haemovigil
program
focu
mainli
notif
sever
atr
individu
monitor
patient
report
consid
relev
safeti
identifi
transfus
histori
order
mitig
appear
new
atr
also
collect
data
reaction
posit
residu
cultur
result
enrich
dataset
posit
result
limit
analysi
reaction
singl
plt
rbc
implic
reaction
involv
plasma
cryoprecipit
multipl
product
includ
analyz
aabb
cultur
criteria
assess
sensit
specif
detect
posit
residu
product
cultur
plt
compar
rbc
definit
str
defin
reaction
concord
bacteri
speci
isol
implic
unit
affect
patient
possibl
str
unit
cultur
posit
patient
cultur
either
neg
discord
patient
cultur
visual
inspect
plasma
neg
hemolysi
antibodi
screen
repeat
found
neg
direct
antiglobulin
test
dat
posit
antia
identifi
eluat
antia
titer
pp
platelet
unit
blood
supplier
notifi
test
reveal
donor
antia
titer
immedi
spin
fifth
antia
titer
salineigg
tabl
conclus
transfus
medicin
servic
blood
supplier
agre
patient
experienc
ahtr
due
high
titer
antia
donor
pp
platelet
unit
fortun
patient
recov
less
hour
discharg
week
later
may
tempt
think
pp
platelet
unit
dilut
high
titer
antibodi
case
serv
remind
group
transfus
platelet
pool
otherwis
potenti
caus
ahtr
bottl
remain
neg
five
day
incub
call
neg
discard
resultsfind
accord
packag
insert
verax
test
limit
detect
paeruginosa
aureu
cfuml
platelet
fall
right
middl
rang
test
spike
specimen
limit
detect
cultur
method
reach
studi
indic
sensit
less
lowest
dilut
test
cfuml
aureu
p
aeruginosa
bottl
spike
lowest
concentr
nearli
fold
concentr
requir
give
posit
verax
result
still
went
posit
less
day
screen
test
usual
identifi
mild
defici
mgdl
howev
secondari
test
necessari
identifi
true
defici
iga
mgdl
demonstr
presenc
antibodi
iga
present
data
hospitalbas
surveil
program
sigad
effort
identifi
patient
risk
possibl
sever
transfus
reaction
studi
designmethod
autom
weekli
report
low
iga
result
base
data
result
immunolog
depart
analyz
transfus
medicin
servic
retrospect
review
electron
medic
record
emr
assess
patient
sigad
develop
algorithm
approach
identifi
patient
presumpt
discuss
patient
clinic
team
make
addit
test
recommend
true
iga
defici
document
concern
possibl
transfus
reaction
delay
blood
product
emr
goal
categor
patient
sigad
least
low
iga
true
iga
defici
assess
iga
antibodi
resultsfind
low
iga
test
result
patient
new
diagnosi
sigad
made
patient
five
unexpect
base
clinic
impress
time
test
nine
patient
known
diagnosi
sigad
also
identifi
diagnosi
histori
alreadi
note
emr
case
three
patient
true
iga
defici
antiiga
antibodi
test
perform
one
new
two
known
case
three
patient
low
iga
igm
remain
patient
least
one
number
diagnos
explain
low
iga
result
new
diagnosi
sigad
order
physician
contact
fax
email
page
phone
recommend
addit
test
includ
high
sensit
iga
level
antiiga
elisa
document
possibl
issu
relat
transfus
ivig
administr
emr
identifi
case
sever
allerg
transfus
reaction
low
iga
defici
patient
conclus
retrospect
chart
review
identifi
new
case
sigad
patient
popul
includ
five
patient
sigad
immunodefici
iga
unexpect
find
review
allow
us
make
test
recommend
work
discuss
case
provid
new
case
one
patient
identifi
true
iga
defici
antiiga
antibodi
test
nine
patient
complet
studi
highlight
import
commun
transfus
medicin
servic
clinic
colleagu
interdisciplinari
effort
need
help
avoid
possibl
patient
harm
tabl
none
death
associ
transfus
complic
unexplain
drop
hemoglobin
hgb
level
gdl
averag
day
follow
ert
experienc
surviv
patient
associ
chang
hgb
level
amount
incompat
plasma
volum
transfus
establish
higher
mortal
rate
present
patient
receiv
blood
volum
replac
incompat
plasma
compar
lesser
percentag
tabl
conclus
incompat
abo
plasma
transfus
ert
safe
lifesav
strategi
associ
increas
transfus
relat
advers
event
incompat
plasma
transfus
account
blood
volum
associ
increas
mortal
compar
lesser
percentag
howev
overal
sever
injuri
rule
confound
factor
lead
increas
mortal
high
risk
group
backgroundcas
studi
massiv
transfus
event
time
requir
issu
larg
quantiti
blood
product
transport
patient
problemat
clinician
often
stockpil
blood
product
bedsid
better
avail
prompt
move
new
build
blood
bank
far
oper
room
implement
use
hemoroam
mobil
blood
storag
refriger
mbr
roemer
industri
sante
ca
univers
health
system
includ
hospit
level
trauma
center
obstetr
servic
liver
transplant
servic
inpati
bed
transfus
volum
red
cell
unit
annual
new
massiv
transfus
protocol
mtp
util
rotat
mbr
keep
blood
product
continu
avail
bedsid
studi
designmethod
approv
fund
obtain
hospit
administr
mbr
purchas
valid
new
standard
oper
procedur
sop
mbr
implement
blood
issu
sop
updat
previous
issu
process
involv
courier
read
product
inform
technologist
new
process
one
technologist
issu
product
comput
system
second
technologist
check
product
mbr
print
report
first
mbr
stock
unit
red
cell
plasma
roomtemperatur
drawer
contain
apheresi
platelet
order
cryoprecipit
first
mbr
issu
second
prepar
second
mbr
issu
third
prepar
third
mbr
issu
upon
return
first
cycl
continu
long
mtp
activ
mbr
pilot
liver
transplant
program
usag
subsequ
expand
entir
health
system
includ
mtp
highvolum
transfus
event
upon
request
issu
time
usag
trend
evalu
backgroundcas
studi
order
receiv
transfus
unit
platelet
plt
year
old
neutropen
patient
acut
lymphoblast
leukemia
outpati
set
two
apheresi
plt
alloc
issu
transfus
within
next
hour
sign
transfus
reaction
note
immedi
transfus
approxim
minut
complet
outpati
visit
patient
return
emerg
depart
ed
fever
chill
blood
cultur
collect
patient
admit
hospit
initi
thought
patient
central
line
port
contamin
follow
even
septic
symptom
link
transfus
transfus
reaction
report
transfus
servic
ts
studi
designmethod
blood
supplier
notifi
transfus
reaction
origin
plt
contain
longer
avail
cultur
st
unit
transfus
concurr
plasma
avail
second
plt
contain
collect
transfus
patient
anoth
hospit
facil
without
report
advers
reaction
nd
unit
transfus
part
tripl
collect
nd
contain
return
blood
supplier
due
presenc
clot
th
day
collect
rd
plt
contain
nd
unit
transfus
transfus
postbon
marrow
transplant
patient
day
transfus
contain
sign
symptom
transfus
reaction
cultur
concurr
plasma
st
unit
transfus
neg
cultur
clot
plt
nd
unit
transfus
posit
identifi
methicillinsuscept
staphylococcu
aureu
blood
cultur
septic
patient
also
grew
methicillinsuscept
staphylococcu
aureu
resultsfind
initi
cultur
perform
parent
plt
product
blood
center
sampl
hour
collect
neg
day
incub
bactalert
instrument
addit
initi
sampl
subsequ
plate
notif
transfus
reaction
found
neg
plt
contain
suspect
collect
test
hospit
use
point
issu
bacteri
test
verax
platelet
test
midnight
day
day
found
neg
presenc
bacteria
aureu
patient
blood
cultur
posit
plt
contain
sent
genotyp
found
ident
indic
patient
septic
reaction
caus
transfus
plt
product
conclus
although
point
issu
bacteri
screen
perform
appear
level
bacteria
limit
detect
may
result
fals
neg
result
clinic
side
even
symptom
reaction
present
initi
assumpt
patient
central
lineassoci
blood
stream
infect
clabsi
discuss
clinic
staff
show
current
clabsi
investig
process
includ
check
see
blood
product
recent
given
may
caus
patient
septic
lesson
learn
ts
realiz
clot
found
one
contain
might
indic
presenc
bacteria
cocompon
remov
inventori
backgroundcas
studi
identif
septic
transfus
reaction
str
reli
recognit
sign
symptom
prompt
report
suspect
transfus
reaction
clinic
sign
symptom
associ
possibl
str
includ
fever
hypotens
tachycardia
current
aabb
criteria
defin
fever
rise
howev
hypotens
tachycardia
undefin
goal
studi
compar
subject
report
symptom
object
record
vital
sign
analyz
larg
databas
transfus
reaction
report
adult
year
studi
designsmethod
collect
retrospect
data
transfus
reaction
result
cultur
residu
product
calendar
year
also
collect
data
reaction
posit
residu
product
cultur
result
enrich
dataset
posit
result
vital
sign
chang
defin
follow
fever
increas
hypotens
systol
blood
pressur
sbp
mmhg
andor
diastol
blood
pressur
dbp
mmhg
decreas
baselin
tachycardia
hr
increas
baselin
report
subject
observ
object
vital
sign
compar
precis
accuraci
report
resultsfind
reaction
vital
sign
data
adult
transfus
reaction
report
analyz
fever
report
reaction
meet
aabb
criteria
wherea
reaction
fever
report
fever
meet
aabb
criteria
hypotens
report
reaction
meet
definit
hypotens
wherea
reaction
hypotens
report
hypotens
tachycardia
report
reaction
meet
definit
tachycardia
wherea
reaction
tachycardia
report
tachycardia
comparison
precis
accuraci
subject
report
compar
defin
criteria
shown
tabl
conclus
studi
result
indic
accuraci
report
fever
hypotens
tachycardia
blood
transfus
adult
patient
high
greater
could
improv
inde
subject
report
associ
high
fals
posit
rate
greater
despit
high
neg
predict
valu
greater
mean
transfus
associ
vital
sign
chang
tend
overreport
improv
pairwis
kinship
analysi
use
massiv
parallel
sequenc
ran
li
hongyu
sun
sun
yatsen
univers
backgroundcas
studi
present
relationship
test
usual
perform
detect
str
loci
use
capillari
electrophoresi
technolog
power
discrimin
obtain
parentchild
relationship
may
confid
enough
determin
distant
relationship
genet
marker
need
distant
relationship
massiv
parallel
sequenc
mp
also
known
next
gener
sequenc
ng
offer
possibl
analyz
multipl
type
marker
singl
reaction
studi
evalu
perform
signatur
system
novel
type
system
base
ng
platform
pairwis
kinship
analysi
studi
designmethod
individu
two
famili
analyz
explor
efficaci
signatur
system
pairwis
kinship
analysi
amelogenin
autosom
str
ystr
xstr
ident
inform
snp
analyz
simutan
one
reaction
type
pairwis
relationship
includ
parentoffspr
full
sibl
grandparentgrandchild
uncleauntnephew
niec
first
cousin
select
two
famili
correspond
likelihood
ratio
lr
calcul
use
either
sequenc
length
genotyp
data
ie
lr
sequenc
lr
length
addit
system
power
str
snp
panel
also
estim
simul
resultsfind
addit
allel
observ
base
sequenc
autosom
str
ystr
xstr
respect
compar
base
length
novel
allel
identifi
mutat
found
str
mutat
observ
snp
autosom
str
loci
lr
increas
log
lr
length
log
lr
sequenc
patern
index
pi
full
sibl
index
fsi
grandparentgrandchild
index
gi
uncleauntnephewniec
index
uni
first
cousin
index
fci
respect
pi
valu
snp
separ
str
two
individu
nonparentoffspr
rel
simul
studi
effect
parentoffspr
relationship
threshold
full
sibl
threshold
low
error
rate
seconddegre
rel
pair
could
determin
threshold
effect
firstcousin
rel
high
error
rate
conclus
str
type
accord
sequenc
inform
polymorph
increas
discrimin
power
kinship
test
compar
str
marker
snp
marker
panel
advantag
patern
test
especi
mutat
str
involv
rel
alleg
parent
panel
power
enough
resolv
patern
test
full
sibl
test
second
degre
relationship
test
low
error
rate
marker
still
need
firstcousin
test
conclus
data
support
continu
reject
sampl
meet
local
patient
phlebotomist
identif
criteria
furthermor
data
support
perform
abo
rhd
type
sampl
collect
verifi
fidel
initi
abo
rhd
type
patient
without
histor
abo
rhd
type
file
backgroundcas
studi
cardiovascular
surgeri
cv
infant
month
age
expos
larg
volum
transfus
evid
support
use
rbc
larg
volum
transfus
well
establish
blood
bank
institut
perform
volum
reduct
rbc
infant
month
age
undergo
cv
labor
intens
process
decis
made
switch
wash
rbc
use
catsmart
cell
saver
freseniu
kabi
purpos
studi
establish
chang
process
volum
reduct
wash
rbc
catsmart
cell
saver
prior
place
patient
cardiopulmonari
bypass
provid
safe
consist
result
studi
designmethod
first
analyz
laboratori
characterist
rbc
unit
pre
post
volum
reduct
pre
post
cellwash
use
catsmart
cell
saver
tabl
includ
abstract
second
sampl
obtain
four
time
point
includ
sampl
unmanipul
red
cell
pre
cellsav
sampl
post
cellsav
wash
sampl
pump
bypass
prime
sampl
collect
minut
patient
bypass
blood
sampl
analyz
analyt
consid
clinic
signific
outsid
normal
rang
blood
sampl
collect
seven
case
time
cv
infant
month
age
test
perform
gem
blood
ga
analyz
osmol
perform
advanc
instrument
microosmomet
particular
test
part
standard
electrolyt
panel
test
time
surgeri
thu
omit
last
bypass
time
point
resultsfind
pre
post
red
cell
wash
conclus
potassium
glucos
concentr
high
rbc
unit
prior
manipul
concentr
significantli
decreas
wash
increas
stay
volum
reduct
plasma
free
hemoglobin
slightli
elev
prior
manipul
increas
manipul
rbc
unit
volum
reduct
wash
osmol
mildli
elev
prior
manipul
volum
reduct
decreas
wash
lactic
acid
elev
rbc
unit
prior
wash
significantli
decreas
wash
summari
wash
red
cell
use
catsmart
cell
saver
freseniu
kabi
prior
major
cv
infant
month
age
safe
shown
studi
wash
might
somewhat
better
volum
reduct
provid
final
red
cell
product
electrolyt
concentr
close
normal
physiolog
valu
retrospect
chart
review
influenc
adjud
often
bleed
patient
tabl
transfus
upcom
procedur
gener
appropri
singl
unit
order
hemoglobin
level
gdl
conclus
criteria
prospect
screen
larg
consid
suitabl
even
detail
gather
retrospect
review
potenti
except
bleed
patient
propos
prospect
screen
rbc
transfus
like
otherwis
appropri
medic
surgic
ward
may
initi
target
intervent
backgroundcas
studi
hemolyt
diseas
fetu
newborn
hdfn
caus
certain
matern
igg
antibodi
infant
red
blood
cell
rbc
antigen
well
recogn
typic
manag
effect
phototherapi
ivig
transfus
andor
exchang
transfus
report
case
prolong
hdn
possibl
inhibit
hematopoiesi
despit
intens
phototherapi
ivig
multipl
transfus
infant
eventu
respond
erythropoietin
treatment
studi
designmethod
test
perform
routin
tube
method
use
peg
liss
salin
use
igg
gel
card
acid
elut
edtaglycin
acid
treatment
ega
rbc
also
perform
identif
antid
antic
andor
antig
matern
plasmawer
perform
differenti
adsorptionelut
use
papaintr
r
r
adsorb
cell
titrat
antid
andor
antig
mother
infant
plasma
perform
use
r
r
indic
cell
rhd
genotyp
newborn
perform
use
pcrrflp
pcrssp
target
exon
intron
rhd
pseudogen
rhesu
box
ident
region
initi
evalu
sanger
sequenc
rhd
rhce
exon
also
done
determin
underli
rh
genotyp
resultsfind
mother
histori
hepat
drug
use
middl
cerebr
arteri
peak
systol
veloc
antibodi
titer
perform
throughout
pregnanc
indic
hdfn
fetal
hydrop
blood
type
neg
antid
antig
transfus
vol
supplement
abstract
identifi
differenti
adsorptionelut
method
last
antibodi
titer
perform
day
prior
deliveri
use
cell
plasma
reactiv
dilut
titer
use
r
r
cell
full
term
male
infant
visibl
jaundic
hydrop
total
bili
mgdl
direct
bili
mgdl
hct
elev
retic
count
birth
peripher
blood
smear
show
mark
polychromasia
increas
nucleat
rbc
breast
fed
right
birth
poor
feed
mani
day
infant
blood
type
posit
antigen
type
predict
genom
test
due
serolog
block
antigen
cord
cell
dat
antiigg
genet
sequenc
rhd
gene
reveal
nucleotid
substitut
associ
rhd
allel
acid
eluat
prepar
infant
rbc
demonstr
antig
antid
note
whole
blood
exchang
perform
due
venou
access
care
issu
fact
bilirubin
mildli
elev
newborn
anemia
prolong
almost
week
birth
sever
decreas
reticulocyt
count
observ
week
birth
interest
note
mild
initi
present
hdfn
prolong
clinic
cours
well
drastic
decreas
retic
count
rapid
respons
erythropoietin
treatment
conclus
report
clinic
present
prolong
hdfn
due
antid
andor
antig
low
retic
count
posit
dat
reticulocyt
possibl
inhibit
hematopoiesi
passiv
transfer
matern
antibodi
suspect
sever
low
reticulocyt
count
observ
week
birth
therefor
also
hypothes
coat
antig
may
protect
sever
hemolysi
inhibit
hematopoiesi
antid
birth
backgroundcas
studi
birth
conjoin
twin
constitut
rare
congenit
malform
estim
incid
birth
conjoin
twin
usual
present
complex
anatom
conjunct
multipl
congenit
anomali
vari
degre
conjoin
circul
pose
multipl
challeng
transfus
anesthet
manag
case
seri
aim
summar
experi
transfus
manag
three
set
conjoin
twin
undergo
separ
surgeri
singl
institut
studi
designmethod
medic
record
conjoin
twin
admit
hospit
surgic
separ
retrospect
review
three
set
conjoin
twin
underw
surgic
separ
gener
anesthesia
preoper
evalu
perform
determin
extent
anatom
conjunct
associ
anomali
anesthesia
simultan
induc
conjoin
twin
blood
usag
track
anesthesia
record
transfus
servic
laboratori
inform
system
resultsfind
set
femal
twin
identifi
set
twin
thoracoompalopagu
set
twin
thoracoomphaloischiopagu
multidisciplinari
approach
use
oper
plan
involv
anesthesia
pediatr
surgeri
plastic
surgeri
radiolog
transfus
medicin
oper
room
staff
biomed
engin
nurs
staff
clinic
care
unit
intradepartment
anesthesiatransfus
plan
meet
involv
director
transfus
servic
senior
junior
transfus
medicin
attend
physician
fellow
resid
laboratori
manag
staff
supervisor
base
transfusionanesthesia
meet
special
need
blood
compon
typic
pediatr
transfus
modif
base
hemodynam
consider
potenti
massiv
transfus
ie
leukoreduc
fresh
etc
conjoin
twin
success
separ
estim
blood
loss
rang
ml
ml
separ
reconstruct
red
blood
cell
transfus
rang
mlkg
mlkg
nonspecif
autoantibodi
determin
antilea
coldantibodi
anti
tabl
frequent
reason
agposit
rbc
transfus
neg
indirect
antiglobulin
test
iat
follow
detect
nonspecif
autoantibodi
lack
time
prepar
agneg
rbc
tabl
clinic
appar
hemolysi
observ
case
two
posit
antijra
one
antieantidib
anti
ninetynin
case
without
advers
effect
clinic
signific
antibodi
anti
antilea
antijka
conclus
first
multicent
collabor
studi
background
reaction
outcom
agposit
rbc
transfus
data
help
patient
irregular
antibodi
rbc
antigen
increas
total
number
product
use
reduc
pack
size
rather
slightli
differ
distribut
pattern
usag
time
see
tabl
major
still
use
pack
less
addit
reduc
tat
uncrossmatch
statu
first
round
led
product
discuss
lab
technologist
resid
physician
physician
prefer
wait
rather
take
uncrossmatch
allow
time
discuss
suitabl
protocol
conclus
conclus
review
process
put
place
level
trauma
center
allow
propos
monitor
two
effect
mtp
protocol
chang
main
effect
backup
pack
implement
rbc
inventori
lab
tat
product
discuss
number
mtp
use
pack
reduct
pack
size
overal
pictur
differ
greater
half
mtp
use
initi
pack
whether
pack
larg
small
studi
designmethod
assess
current
blood
suppli
chain
reveal
complex
process
anywher
step
get
blood
blood
bank
patient
suit
sever
area
handoff
failur
typic
transport
time
minut
long
minut
instanc
blood
unit
receiv
need
immedi
transfus
store
unlock
refriger
core
unit
multipl
patient
store
refrigeratorinclud
unit
patient
longer
orwith
mechan
barrier
place
prevent
remov
wrong
unit
addit
effect
way
control
access
refriger
monitor
temperatur
maintain
traceabl
resultsfind
went
live
juli
bloodtrack
ondemand
use
haemobank
devic
postanesthesia
care
unit
pacu
cardiovascular
recoveri
room
cvrr
tabl
summar
result
suppli
chain
complex
reduc
elimin
step
blood
avail
procedur
room
minutesan
faster
deliveri
time
without
requir
staff
leav
inner
core
blood
wastag
previous
unit
issu
decreas
save
approxim
annual
effici
enabl
blood
bank
reposit
staff
elimin
blood
bank
workload
relat
prepar
packag
transport
blood
productsand
track
miss
delay
unitsha
significantli
reduc
second
haemobank
instal
new
cvrricu
unit
addit
averag
number
unit
dispens
control
remot
dispens
devic
increas
total
red
cell
usag
lastli
importantli
patient
safeti
bloodtrack
electron
captur
record
blood
product
movement
verifi
right
blood
remov
right
patient
conclus
implement
bloodtrack
ondemand
haemobank
devic
manag
blood
product
alloc
hospit
pacu
cvrr
significantli
streamlin
hospit
process
elimin
handoff
risk
improv
avail
reduc
cost
effect
riboflavin
ultraviolet
light
pathogen
reduct
treatment
blood
type
test
use
gel
column
agglutin
method
suzann
doan
susan
yonemura
ozu
lohani
susann
marschner
terumo
bct
backgroundcas
studi
pathogen
reduct
devic
use
riboflavin
ultraviolet
light
ruv
reduc
potenti
infecti
pathogen
load
inactiv
white
blood
cell
wbc
whole
blood
wb
product
intend
transfus
develop
sever
substanc
shown
interfer
abo
blood
group
test
due
patient
sera
reactiv
nonblood
group
agglutinin
acriflavin
dye
use
antib
type
serum
neomycin
antibiot
monoclon
antibodi
daratumumab
use
immunotherapi
name
one
step
develop
process
ruv
leukoreduc
red
blood
cell
r
uv
lrrbc
ensur
riboflavin
element
treatment
process
would
alter
otherwis
interfer
blood
type
antigen
test
variou
manual
autom
blood
group
type
method
employ
us
one
common
method
autom
manual
gel
column
agglutin
gca
method
studi
evalu
use
gca
test
blood
type
rh
factor
rbc
untreat
wb
ruv
treat
wb
ruv
wb
ruv
lrrbc
studi
designmethod
ten
group
card
sampl
test
blood
type
addit
unit
character
via
cell
qualiti
measur
resultsfind
day
process
unit
blood
type
rh
factor
match
record
collect
blood
center
chang
observ
ruv
light
treatment
ruv
lrrbc
cell
qualiti
paramet
expect
rang
ruvlighttr
wb
base
histor
data
key
paramet
ph
well
hemolysi
well
requir
valu
respect
conclus
pathogen
reduct
use
ruv
light
interfer
b
ab
blood
type
rh
factor
rbc
treat
wb
ruv
lrrbc
test
common
gca
test
system
faisal
huqronni
beth
dy
p
dayand
borg
thoma
jefferson
univers
hospit
american
red
cross
backgroundcas
studi
septic
transfus
reaction
occur
patient
transfus
contamin
blood
product
howev
patient
expos
contamin
unit
exhibit
sign
reaction
other
reaction
sever
overal
clinic
circumst
patient
expos
contamin
unit
may
affect
likelihood
reaction
studi
assess
incid
patient
diagnos
presenc
neutropenia
septic
transfus
reaction
case
studi
designmethod
review
highli
probablydefinit
septic
transfus
reaction
report
american
red
cross
januari
decemb
clinic
diagnos
patient
record
patient
categor
follow
hematolog
malign
includ
transplant
aplast
anemiapancytopenia
includ
transplant
solid
organ
transplant
hematolog
condit
nonhematolog
cancer
cardiaccardiovascular
condit
infect
obstetricgynecolog
condit
accidenttrauma
renal
failur
patient
neutrophil
count
status
record
definit
like
specif
record
like
given
clinic
factor
patient
historyrecord
possibl
base
clinic
diagnosi
resultsfind
case
report
occur
patient
hematolog
malign
case
aplast
anemia
case
neutropenia
present
definit
like
possibl
case
respect
percent
incid
definitelik
neutropenia
definitelikelyposs
neutropenia
case
respect
case
definit
neutropenia
hematolog
malign
aplast
anemia
combin
categori
combin
categori
case
patient
neutropenia
combin
group
definitelik
neutropenia
present
case
definitelikelyposs
neutropenia
present
case
conclus
among
report
septic
transfus
reaction
case
patient
hematolog
malign
aplast
anemia
common
diagnos
neutropenia
risk
neutropenia
also
common
group
septic
transfus
reaction
find
may
due
frequenc
blood
product
transfus
group
caus
may
present
clinic
assess
warrant
backgroundcas
studi
emerg
neonat
transfus
fraught
challeng
blood
bank
bb
neonatolog
servic
must
provid
blood
time
manner
simultan
adher
proper
blood
bank
standard
navig
hospit
process
inform
system
occur
outsid
control
set
neonat
icu
neonat
transfus
immedi
follow
birth
pose
uniqu
challeng
describ
institut
experi
develop
protocol
particularli
difficult
scenario
studi
designmethod
need
interdepartment
protocol
address
immediatepostnat
red
blood
cell
rbc
transfus
recogn
specif
set
deliveri
room
oper
room
emerg
depart
key
stakehold
includ
bb
neonatolog
nurs
emerg
hospit
admissionregistr
laboratori
inform
system
inform
technolog
servic
challeng
address
involv
uniqu
identif
unborn
patient
document
transfus
said
patient
immedi
postnat
period
effici
commun
bb
rapid
provis
unmodifi
noncrossmatch
rbc
unit
adher
regul
standard
set
forth
fda
accredit
agenc
multipl
meet
protocol
draft
defin
respect
role
bb
neonatolog
servic
resultsfind
sever
revis
protocol
outlin
follow
neonatolog
creat
pend
neonat
admiss
profil
electron
medic
record
two
uniqu
identifi
assign
immedi
transfus
deem
necessari
neonatolog
telephon
blood
bank
code
babi
blood
unambigu
prompt
emerg
situat
bb
given
neonat
uniqu
identifi
request
rbc
emerg
releas
read
back
confirm
bb
issu
one
whole
unit
addit
solut
pack
rbc
group
rhneg
leukoreduc
hemoglobin
neg
nonirradi
freshest
avail
yet
perform
bb
perform
matern
type
screena
posit
screen
prompt
immedi
followup
test
issu
unit
two
time
simul
conduct
identifi
area
improv
first
complet
minut
second
minut
conclus
thought
protocol
immediatepostnat
neonat
transfus
help
streamlin
effort
decreas
confus
among
caregiv
situat
experi
reflect
one
possibl
approach
within
physic
logist
limit
institut
futur
effort
dissemin
knowledg
protocol
potentiallyinvolv
caregiv
within
hospit
backgroundcas
studi
select
compat
red
blood
cell
rbc
unit
includ
match
donor
sex
systemat
review
metaanalysi
aim
summar
evid
examin
impact
sexmismatch
rbc
transfus
recipi
mortal
studi
designmethod
ovid
medlin
ovid
embas
cinahl
pubm
web
scienc
cochran
databas
systemat
review
search
januari
identifi
random
control
trial
rct
observ
studi
examin
impact
donor
sex
recipi
outcom
metaanalysi
conduct
elig
studi
gener
pool
hazard
ratio
hr
use
randomeffect
model
threelevel
metaanalyt
model
appli
emphas
unknown
depend
among
effect
size
prespecifi
analysi
done
subgroup
cardiac
surgeri
patient
studi
qualiti
duplic
use
robin
tool
certainti
evid
outcom
assess
use
grade
figur
subgroup
cardiovascular
surgeri
n
signific
increas
mortal
sexmismatch
transfus
pool
hr
ci
data
prone
confound
select
bia
report
bia
certainti
evid
low
conclus
sexmismatch
rbc
transfus
associ
increas
risk
death
pool
analysi
howev
certainti
evid
low
observ
studi
press
need
studi
impact
donor
sex
potenti
widespread
impact
backgroundcas
studi
role
immatur
platelet
transfus
increment
elucid
immatur
platelet
singl
donor
platelet
sdp
greater
longev
biolog
activ
matur
counterpart
use
diagnost
marker
thrombocytopen
patient
studi
look
absolut
immatur
platelet
count
sdp
unit
given
neonat
patient
receiv
multipl
transfus
determin
affect
platelet
recoveryincr
studi
designmethod
sdp
unit
neonat
patient
identifi
time
aliquot
prepar
total
sdp
transfus
patient
sdppatient
identifi
onemonth
period
ml
sampl
aipc
measur
collect
unit
time
aliquot
prepar
sampl
analyz
use
autom
hematolog
analyz
complet
blood
count
cbc
percent
immatur
platelet
fraction
ipf
aipc
obtain
multipli
platelet
count
time
ipf
percent
platelet
recoveri
ppr
obtain
formula
posttransfus
platelet
countpretransfus
platelet
count
unit
platelet
count
splenic
factor
total
blood
volum
tbv
splenic
factor
tbv
bodi
weight
time
mlkg
week
estim
gestat
age
ega
mlkg
week
posttransfus
cbc
obtain
within
hour
resultsfind
sdp
transfus
patient
sdp
platelet
count
l
ipf
aipc
l
ppr
shown
tabl
ipf
appear
correl
platelet
increment
instead
aipc
indic
aipc
l
lead
approxim
improv
platelet
count
higher
aipc
appear
provid
addit
benefit
could
secondari
reduct
physiolog
capac
higher
number
immatur
platelet
irradi
backgroundcas
studi
electron
issu
ei
shown
improv
effici
hospit
blood
bank
provid
abil
blood
bank
respond
quickli
urgent
request
patient
known
blood
group
recent
neg
antibodi
screen
studi
evalu
extens
ei
allow
releas
blood
way
away
blood
bank
close
patient
util
electron
remot
blood
issu
erbi
network
electron
remot
blood
releas
system
blood
bank
staff
issu
blood
use
erbi
process
blood
refriger
blood
bank
studi
designmethod
studi
site
uk
usa
site
perform
erbi
blood
refriger
remot
blood
bank
blood
refriger
blood
bank
retrospect
data
collect
erbi
softwar
databas
blood
bank
laboratori
inform
system
li
prospect
time
motion
studi
data
collect
method
use
determin
blood
bank
clinic
staff
time
step
blood
issu
process
unit
red
blood
cell
resultsfind
erbi
remot
blood
refriger
tabl
time
taken
blood
unit
reach
clinic
area
reduc
hospit
use
erbi
remot
blood
refriger
blood
bank
staff
time
increas
erbi
blood
blood
bank
effici
improv
issu
transfus
ratio
lower
blood
unit
obtain
erbi
refriger
compar
ei
blood
bank
staff
cost
perform
erbi
reduc
compar
nonerbi
site
median
reduct
rang
per
unit
erbi
blood
refriger
blood
bank
tabl
time
taken
clinic
staff
obtain
blood
reduc
erbi
blood
refriger
blood
bank
blood
bank
staff
time
perform
erbi
reduc
compar
ei
perform
blood
bank
median
rang
secondsunit
mean
increas
cost
per
blood
unit
erbi
clinic
staff
refriger
rang
per
blood
unit
conclus
erbi
remot
refriger
improv
effici
transfus
reduc
time
taken
blood
unit
reach
patient
clinic
blood
bank
staff
time
cost
benefit
realiz
erbi
blood
refriger
blood
bank
except
time
involv
shift
blood
bank
clinic
staff
collect
blood
backgroundcas
studi
major
hemorrhag
protocol
mhp
provid
time
coordin
deliveri
blood
product
bleed
patient
evid
militari
civilian
trauma
studi
advoc
ratio
base
transfus
protocol
approach
wide
adopt
hospit
treat
patient
divers
bleed
etiolog
studi
investig
success
mhp
tertiari
univers
hospit
achiev
aim
includ
blood
product
wastag
sole
plasma
product
frozen
solvent
deterg
sd
plasma
studi
designmethod
retrospect
analysi
mhp
activ
year
perform
data
collect
use
hospit
laboratori
inform
system
electron
patient
record
databas
determin
number
locat
clinic
indic
mhp
activ
evid
blood
product
wastag
resultsfind
one
hundr
forti
one
mhp
activ
male
occur
seventi
two
occur
emerg
room
er
oper
room
intens
care
trauma
account
activ
gastrointestin
common
follow
vascular
surgic
bleed
event
case
emerg
group
rhd
neg
red
cell
use
prior
mhp
activ
mhp
activ
prespecifi
blood
pack
request
rather
individu
compon
offprotocol
case
median
red
cell
plasma
ratio
transfus
post
activ
deliveri
time
product
vari
product
type
red
cell
plasma
median
deliveri
time
minut
respect
blood
product
wastag
significantli
higher
plasma
compar
red
cell
mhp
activ
analysi
reveal
plasma
wastag
activ
major
occur
er
plasma
wastag
also
major
mhp
activ
wastag
case
death
occur
prior
transfus
unit
red
cell
transfus
plasma
wast
case
conclus
studi
demonstr
trauma
common
caus
mhp
tertiari
center
activ
rel
high
red
cell
plasma
ratio
achiev
plasma
wastag
high
reflect
limit
post
thaw
shelf
life
non
protocol
mhp
activ
plasma
wastag
occur
low
red
cell
transfus
event
indic
need
continu
educ
staff
involv
mhp
activ
futur
effort
reduc
plasma
wastag
would
necessit
increas
post
thaw
shelf
life
would
requir
chang
licensur
manufactur
altern
plasma
product
region
heather
toeppner
jerri
squir
michel
sharp
medic
univers
south
carolina
musc
health
backgroundcas
studi
accord
colleg
american
pathologist
cap
approxim
advers
event
occur
us
hospit
annual
due
specimen
identif
error
id
error
result
label
error
mislabel
specimen
associ
almost
actual
nearmiss
patient
safeti
event
pose
seriou
concern
blood
bank
bb
cord
blood
specimen
label
error
identifi
either
mislabel
unlabel
organ
implement
second
independ
sampl
requir
abo
blood
group
verif
collect
process
improv
outcom
type
screen
specimen
cord
blood
specimen
collect
labor
deliveri
l
unit
continu
demonstr
inconsist
label
practic
perform
improv
initi
identifi
bb
transfus
stewardship
offic
studi
designmethod
standard
practic
obstetr
unit
cord
blood
sampl
collect
newborn
deliveri
group
andor
rh
neg
mother
l
uniqu
environ
pregnant
patient
deliv
newborn
patient
present
one
hospit
room
increas
risk
specimen
label
error
attempt
improv
collect
label
process
cord
blood
collect
kit
pilot
june
prepar
collect
kit
kept
patient
room
contain
clear
storag
bag
specimen
tube
neon
green
advisori
label
cord
blood
use
red
biohazard
bag
deliveri
resultsfind
cord
blood
collect
kit
pilot
day
june
inpati
room
l
trial
result
decreas
cord
blood
specimen
label
error
base
outcom
l
leadership
agre
offici
adopt
prepar
collect
kit
best
practic
purpos
period
demonstr
almost
reduct
cord
blood
specimen
label
error
conclus
prior
implement
prepar
collect
kit
cord
blood
specimen
collect
label
practic
within
l
inconsist
noncompli
evidenc
incid
report
month
prepar
collect
kit
usag
l
leadership
recogn
mark
decreas
specimen
collect
error
eas
use
prepar
kit
low
cost
intervent
element
togeth
contribut
ongo
success
within
depart
improv
cord
reticulocyt
count
peripher
blood
smear
reveal
schistocyt
polychromasia
spherocytosi
hemoglobin
concentr
remain
essenti
unchang
throughout
rest
stay
patient
discharg
patient
readmit
one
week
later
hemoglobin
without
activ
bleed
hemolysi
addit
unit
rbc
result
increas
gdl
gdl
patient
type
fya
neg
account
rh
neg
rr
neg
unit
transfus
order
serial
monitor
allogen
cell
demonstr
shorten
surviv
rhd
neg
cell
partial
splenectomi
perform
use
embol
splenic
arteri
result
stabil
hemoglobin
around
base
appar
stabil
hemoglobin
splenic
arteri
embol
surgic
splenectomi
perform
result
hemoglobin
increas
gdl
patient
remain
transfus
free
day
postsplenectomi
conclus
sever
refractori
rbc
transfus
rare
event
although
spleen
like
culprit
organ
report
outcom
splenectomi
frequent
reluct
perform
splenectomi
patient
case
illustr
splenic
arteri
embol
may
use
initi
approach
potenti
predictor
util
subsequ
surgic
splenectomi
hemoglobin
arriv
gdl
decreas
gdl
hospit
admiss
day
given
patient
long
histori
transfus
multipl
known
antibodi
antic
anti
antijk
b
antik
warm
alloantibodi
recent
identifi
cold
react
antin
previou
delay
hemolyt
transfus
reaction
unidentifi
alloantibodi
red
blood
cell
transfus
avoid
due
continu
downtrend
hemoglobin
given
one
compat
unit
c
e
jk
b
k
n
pack
red
blood
cell
studi
designmethod
transfus
reaction
workup
request
clinic
team
due
progress
decreas
hemoglobin
gdl
gdl
follow
rbc
transfus
c
e
jk
b
k
n
given
n
antibodi
typic
igm
cold
react
transfus
unit
n
direct
polyclon
coomb
dat
perform
pretransfus
posttransfus
sampl
base
posit
post
transfus
dat
neg
pretransfus
dat
antibodi
screen
test
perform
resultsfind
patient
pretransfus
dat
neg
howev
posttransfus
polyclon
igg
dat
posit
neg
complement
antibodi
screen
posttransfus
also
panposit
gel
liss
screen
subsequ
red
cell
panel
initi
elut
also
panposit
adsorpt
perform
rr
cell
result
eluat
consist
igg
antin
red
cell
genotyp
show
patient
n
c
e
k
jk
b
antibodi
identif
show
antin
reactiv
ahg
igg
nonreact
previou
unidentifi
antibodi
found
patient
subsequ
transfus
crossmatch
compat
unitssh
good
respons
increas
repeat
hemolyt
reaction
patient
recov
treatment
reactiv
warm
autoimmun
hemolyt
anemia
medic
support
hemopur
patient
ultim
discharg
home
conclus
antin
usual
natur
occur
igmigg
coldreact
nonrbc
stimul
antibodi
act
agglutinin
test
perform
temperatur
howev
case
warm
react
antin
describ
presenc
warm
react
antin
eluat
combin
patient
sever
anemia
day
follow
n
red
cell
transfus
result
delay
hemolyt
transfus
reaction
secondari
warm
alloantibodi
antin
conclus
presenc
new
onset
antin
patient
recurr
red
cell
transfus
may
merit
administr
n
red
cell
identifi
onemonth
period
ml
sampl
aipc
collect
unit
time
aliquot
prepar
patient
transfus
sampl
analyz
use
autom
hematolog
analyz
complet
blood
count
cbc
percent
immatur
platelet
fraction
ipf
aipc
obtain
multipli
platelet
count
time
ipf
sampl
separ
group
depend
time
elaps
aliquot
issu
sampl
run
time
hour
hour
hour
sampl
analyz
hour
result
report
mean
standard
deviat
sd
unless
otherwis
indic
resultsfind
aliquot
identifi
uniqu
unit
uniqu
patient
unit
platelet
count
l
rang
ipf
rang
aipc
l
see
tabl
statist
differ
mean
platelet
count
ipf
aipc
separ
hour
hour
hour
backgroundcas
studi
acut
traumat
coagulopathi
associ
increas
mortal
studi
shown
prompt
administr
plasma
product
high
plasma
red
cell
ratio
trauma
set
improv
outcom
prior
april
transfus
medicin
tm
suppli
thaw
plasma
tp
trauma
patient
initi
massiv
transfus
protocol
mtp
type
ab
tp
typic
prethaw
weekday
type
ab
typic
prethaw
weekend
first
round
mtp
consist
tp
often
plasma
thaw
fulfil
first
round
delay
product
minimum
minut
respons
request
trauma
servic
effort
improv
plasma
suppli
time
tm
start
suppli
liquid
plasma
lp
april
first
round
mtp
plasma
product
requir
thaw
tm
label
dispens
practic
also
modifi
attempt
decreas
time
suppli
plasma
product
studi
perform
determin
switch
lp
modif
tm
labelingdispens
procedur
result
signific
decreas
time
provid
plasma
first
round
mtp
studi
designmethod
nonexperiment
retrospect
studi
time
initi
mtp
dispens
time
plasma
first
round
gather
determin
dispens
time
tm
provis
lp
label
dispens
procedur
modif
respect
mean
dispens
time
calcul
time
period
twosampl
test
perform
evalu
two
period
mean
differ
signific
resultsfind
total
record
retriev
record
exclud
plasma
product
transfus
thu
unabl
determin
dispens
time
mean
prelp
procedur
modif
time
dispens
minut
n
sd
mean
postlp
procedur
modif
minut
n
sd
differ
mean
signific
p
differenti
shift
also
show
reduct
mean
dispens
time
follow
result
day
shift
minut
n
sd
minut
n
sd
even
shift
minut
n
sd
minut
n
sd
late
night
shift
minut
n
sd
minut
n
sd
result
signific
even
shift
p
late
night
shift
p
day
shift
p
conclus
switch
lp
tp
first
round
mtp
modifi
label
dispens
procedur
tm
abl
significantli
reduc
time
requir
suppli
plasma
mtp
jenna
khan
jennif
hoek
nabiha
h
saife
univers
washington
medic
center
seattl
children
hospit
bloodwork
nw
backgroundcas
studi
studi
transfus
recipi
weak
type
shown
antirhd
alloimmun
thu
rhdposit
blood
product
may
safe
administ
allow
better
manag
limit
rhdneg
inventori
serolog
type
rhd
variabl
result
depend
specif
reagent
methodolog
use
easili
distinguish
weak
partial
rhd
variant
studi
aim
evalu
impact
rhd
genotyp
inventori
rhd
neg
blood
product
singl
tertiari
care
pediatr
hospit
studi
designmethod
transfus
histori
march
march
initi
aborhd
type
review
pediatr
patient
less
year
age
time
recent
aborhd
type
document
serolog
weak
posit
test
initi
aborhd
type
institut
includ
gel
column
technolog
orthoclin
diagnost
raritan
nj
preload
antid
tube
test
use
monoclon
igm
antid
blend
polyclon
igg
antid
bioclon
ortho
serolog
weak
test
perform
antid
result
weak
discrep
eg
antid
reagent
gel
show
tube
neg
weak
incid
antirhd
alloimmun
blood
product
exposur
gender
evalu
number
rhd
neg
unit
could
replac
rhd
posit
unit
rhd
genotyp
perform
determin
base
estim
preval
weak
type
ethnic
mix
us
popul
local
transfus
practic
give
rhd
posit
blood
product
male
weak
rhd
phenotyp
rhd
neg
blood
product
femal
weak
rhd
phenotyp
resultsfind
patient
less
year
old
abo
type
fortyeight
femal
male
identifi
serolog
weak
rbc
platelet
transfus
weak
patient
rbc
platelet
femal
rbc
platelet
male
weak
patient
receiv
rbc
platelet
transfus
transfus
go
five
patient
antirhd
alloimmun
detect
estim
rbc
platelet
transfus
could
replac
rhd
posit
product
year
time
period
rhd
genotyp
perform
conclus
given
variabl
rate
transfus
weak
patient
decis
perform
rhd
genotyp
take
consider
likelihood
transfus
although
report
rhdalloimmun
popul
predominantli
caucasian
limit
number
transfus
limit
followup
remain
particularli
import
prevent
alloimmun
pediatr
popul
greater
lifetim
risk
associ
morbid
maxim
benefit
rhd
genotyp
better
mechan
need
develop
inform
access
across
institut
optim
care
prevent
repeat
test
stephani
labib
shauna
l
backgroundcas
studi
hemorrhag
remain
major
caus
potenti
prevent
death
rapid
effect
respons
vital
success
outcom
major
blood
loss
institut
transfus
servic
respond
massiv
hemorrhag
follow
previous
develop
massiv
transfus
protocol
mtp
howev
time
took
issu
blood
product
long
clinic
feedback
unsatisfactori
recent
multipl
chang
made
mtp
improv
effici
transfus
servic
respond
clinic
set
studi
designmethod
base
root
caus
analysi
clinic
issu
follow
chang
made
redesign
paperwork
safeti
check
logist
preassembl
mtp
pack
optimizedcentr
equip
arrang
blood
bank
work
space
mtprelat
staff
train
evalu
effect
chang
length
time
blood
bank
notif
ie
activ
mtp
protocol
issuanc
blood
product
record
compar
previou
case
pair
ttest
use
statist
analysi
resultsfind
averag
time
spent
receipt
call
issuanc
product
implement
chang
minut
chang
time
spent
dramat
reduc
nearli
tenfold
minut
p
safetyrel
incid
report
studi
demonstr
work
effici
blood
bank
emerg
condit
significantli
improv
strateg
rearrang
order
work
flow
eg
preassembl
blood
product
instead
assembl
blood
product
activ
mtp
extrem
time
sensit
task
optim
equip
spatial
arrang
reduc
staff
walk
distanc
redesign
set
simplifi
goalorient
paperwork
relev
personnel
train
contribut
improv
transfus
servic
effici
without
compromis
patient
safeti
order
audit
report
pediatr
pt
perform
pt
met
follow
inclus
criteria
inpati
age
year
minimum
plt
order
admiss
neonat
intens
care
unit
pt
exclud
paramet
total
number
plt
order
indic
clinic
servic
order
plt
plt
transfus
order
indic
procedur
associ
plt
order
plt
count
within
hour
order
minimummaximum
plt
order
per
pt
analyz
descript
statist
use
summar
result
resultsfind
nineti
three
pt
includ
fourteen
clinic
servic
place
plt
order
total
accompani
indic
mean
plt
count
median
see
tabl
servic
frequent
order
plt
bone
marrow
transplant
follow
hematolog
oncolog
order
associ
procedur
invas
procedur
indic
select
mean
plt
count
pt
whose
indic
prophylaxi
spontan
hemorrhag
sixti
six
percent
n
pt
multipl
plt
order
mean
median
rang
pt
multipl
plt
order
order
associ
one
indic
wherea
pt
order
one
indic
conclus
plt
transfus
order
common
among
pediatr
patient
institut
major
pt
receiv
one
order
studi
requir
character
order
pattern
indic
pediatr
plt
transfus
backgroundcas
studi
g
antigen
rh
antigen
found
red
blood
cell
also
express
either
c
antigen
antig
difficult
distinguish
antibodi
panel
may
confus
antid
plu
antic
sinc
antig
commonli
found
alloantibodi
mixtur
antid
andor
antic
contribut
solitari
antig
alloantibodi
caus
hemolyt
diseas
fetu
newborn
hdfn
unclear
two
prior
case
report
isol
antig
pregnanc
demonstr
evid
hemolyt
diseas
one
cinfant
moder
hemolyt
diseas
requir
prolong
phototherapi
second
dc
infant
studi
designmethod
neg
woman
refer
maternalfet
medicin
servic
week
gestat
hypertens
alloimmun
antid
antic
alloantibodi
alloantibodi
first
identifi
year
ago
ectop
pregnanc
time
receiv
prophylact
rhig
transfus
neg
red
blood
cell
current
pregnanc
follow
serial
antibodi
titer
middl
cerebr
arteri
mca
doppler
ultrasound
refer
hospit
although
antid
antic
titer
elev
threshold
mca
doppler
show
evid
fetal
anemia
receiv
prophylact
rhig
pregnanc
due
previou
diagnosi
antid
alloantibodi
upon
arriv
hospit
g
differenti
test
perform
reveal
presenc
antig
plu
antic
antid
alloantibodi
resultsfind
posit
infant
deliv
week
due
matern
hypertens
neonat
dat
posit
eluat
react
c
cell
consist
antig
neonat
rbc
dc
first
day
life
infant
develop
elev
bilirubin
level
requir
day
phototherapi
treatment
hdfn
hematocrit
remain
stabl
transfus
given
conclus
presenc
antig
absenc
antid
establish
rhig
prophylaxi
administ
mother
postpartum
antig
suspect
pregnant
woman
antid
antic
appear
simultan
antibodi
panel
prophylact
rhig
administ
antid
present
g
differenti
studi
case
matern
alloantibodi
antig
antic
infant
neg
c
antigen
case
demonstr
develop
mild
hdfn
attribut
isol
antig
alloantibodi
backgroundcas
studi
massiv
transfus
greater
unit
rbc
hour
well
describ
increasingli
uncommon
event
previou
report
massiv
transfus
protocol
mtp
activ
met
old
unit
criteria
understand
episod
high
rateofbloodus
review
year
blood
use
high
acuiti
hospit
nonmtpactiv
episod
met
critic
administr
definit
three
blood
compon
administ
one
hour
studi
designmethod
year
worth
blood
use
bed
urban
counti
hospit
review
episod
occur
outsid
mtp
descript
statist
patient
episod
assembl
tabl
graph
use
microcomput
spreadsheet
softwar
resultsfind
hospit
admit
patient
administ
blood
compon
mtp
activ
trauma
nonmtp
episod
episod
occur
secondari
surgeri
trauma
patient
episod
bleed
nontrauma
relat
surgeri
patient
sever
gi
bleed
inhospitalmort
low
surgic
bleed
situat
higher
gi
bleed
conclus
apart
convent
massiv
transfus
situat
smaller
episod
highrateofblood
use
occur
frequent
acut
care
hospit
rapid
correct
low
mortal
transfus
servic
need
abl
support
situat
rapid
respons
hemostat
product
emerg
room
neurolog
intens
care
unit
consid
depart
manag
major
ich
patient
undergo
standard
protocol
request
blood
product
standard
protocol
platelet
requir
initi
review
clinician
order
lab
personnel
verifi
patient
confirm
blood
type
current
platelet
count
within
hr
number
previou
platelet
transfus
within
order
two
adult
dose
platelet
unit
platelet
countrel
concern
requir
audit
blood
bank
patholog
resid
fellow
count
exceed
cellsmcl
nonemerg
unit
cell
mcl
activ
bleed
patient
requir
followup
determin
clinic
need
suspect
brain
bleed
clinic
goal
maintain
platelet
count
cellsmcl
thu
major
platelet
request
patient
undergo
standard
protocol
basi
platelet
count
alon
addit
absenc
confirm
blood
type
may
present
delay
requir
blood
draw
test
prior
releas
platelet
transfus
three
tat
defin
time
admiss
symptom
present
transfus
time
platelet
request
issu
blood
bankdepend
time
platelet
issu
transfus
departmentdepend
resultsfind
initi
yield
signific
result
reduc
tat
ed
none
neuroicu
patient
blood
bank
depend
tat
also
reduc
tat
patient
group
data
pertain
departmentdepend
tat
show
overal
reduct
without
signific
tabl
preliminari
data
clinic
outcom
indic
hematoma
reduct
follow
tier
platelet
implement
tabl
conclus
tier
platelet
tat
reduct
limit
blood
bank
practic
investig
requir
determin
factor
affect
transfus
start
time
product
receiv
respect
hospit
unit
effect
tier
platelet
trauma
protocol
anoth
area
investig
trauma
protocol
also
bypass
product
audit
measur
clinic
outcom
limit
notat
ct
scan
enter
electron
medic
record
within
hour
period
postich
standard
measur
clinic
benefit
use
combin
ct
scan
lab
follow
platelet
transfus
would
provid
clearer
insight
number
rate
advers
reaction
pad
transfus
wherea
allogen
blood
transfus
respect
latter
signific
p
among
advers
reaction
pad
transfus
common
febril
nonhemolyt
transfus
reaction
fnhtr
follow
allerg
reaction
sever
advers
reaction
pad
transfus
grade
nonsever
case
regard
blood
compon
type
advers
reaction
involv
case
whole
blood
pad
frozen
pad
autolog
freshfrozen
plasma
advers
reaction
caus
autolog
blood
conserv
observ
periop
autolog
cell
salvag
acut
normovolem
hemodilut
studi
conclus
nonsever
advers
reaction
observ
pad
transfus
rate
institut
backgroundcas
studi
booklet
continu
educ
pediatr
apheresi
seri
third
instal
tackl
issu
surround
hematopoiet
stem
cell
collect
apheresi
hematopoiet
stem
cell
transplant
hsct
occur
annual
unit
state
patient
age
twenti
twenti
percent
transplant
util
apheresisderiv
autolog
allogen
product
increas
recent
year
invas
medic
procedur
hematopoiet
stem
cell
collect
apheresi
psycholog
upset
pediatr
popul
caus
fear
pain
feel
helpless
feel
manifest
anger
aggress
anxieti
lead
increas
procedur
time
treatment
delay
long
term
psycholog
trauma
studi
show
educ
pediatr
patient
famili
expect
well
hospit
staff
expect
reduc
feel
anxieti
help
patient
feel
empow
reduc
emot
trauma
previou
project
reveal
lack
age
appropri
literatur
apheresi
procedur
gener
includ
topic
cover
first
two
booklet
seri
therapeut
plasma
exchang
red
blood
cell
exchang
studi
designmethod
agespecif
storyboard
develop
collabor
pediatr
hematologistoncologist
apheresi
physician
accompani
artwork
produc
conjunct
medic
illustr
enhanc
stori
pediatr
audienc
resultsfind
stori
discuss
apheresi
stem
cell
collect
perform
detail
step
lead
procedur
review
occur
day
collect
includ
strategi
cope
well
brief
mention
expect
futur
child
return
transplant
storyboard
directli
address
procedur
standpoint
autolog
donat
booklet
may
also
help
allogen
pediatr
donor
prepar
collect
booklet
made
avail
hospit
websit
patient
use
conclus
instal
pediatr
apheresi
seri
provid
educ
materi
age
appropri
level
help
prepar
reduc
stress
experienc
children
caregiv
stem
cell
collect
materi
serv
anticipatori
guidanc
vulner
sensit
popul
ultim
design
promot
wellb
cope
strategi
empower
reduc
fear
unknown
smallest
patient
prepar
complex
invas
procedur
backgroundcas
studi
purpos
studi
gain
evid
effect
microlearn
video
donor
collect
oper
video
favor
accept
individu
organ
hypothesi
peopl
drawn
respond
video
much
inform
transmit
brain
visual
visual
aid
found
improv
learn
video
learn
advantag
engag
visual
auditori
channel
brain
assert
microlearn
video
help
knowledg
retent
video
spread
cognit
load
learner
auditori
visual
learn
channel
ten
microlearn
video
creat
one
year
learner
abl
access
video
demand
organ
intern
websit
banner
creat
homepag
organ
intern
websit
team
member
would
easili
abl
click
banner
access
quick
tip
video
librari
studi
designmethod
video
develop
partnership
market
commun
depart
train
depart
video
film
organ
orlando
locat
multimedia
studio
video
also
film
organ
simul
lab
script
develop
train
depart
review
approv
director
process
improv
repres
qualiti
assur
attend
film
ensur
video
accur
repres
current
step
sop
topic
follow
video
creat
studi
efficaci
microlearn
video
physician
base
knowledg
regard
standard
blood
transfus
guidelin
applic
practic
patient
care
present
studi
aim
assess
basic
knowledg
clinic
resid
institut
regard
blood
transfus
guidelin
bedsid
transfus
practic
set
accordingli
intervent
strategi
plan
execut
postintervent
assess
perform
understand
impact
intervent
studi
designmethod
studi
divid
three
phase
preintervent
phase
blood
transfus
practic
assess
predecid
clinic
area
observ
transfus
episod
step
occur
patient
bedsid
assess
includ
inform
consent
physician
order
blood
requisit
bedsid
check
start
transfus
monitor
document
use
predesign
proforma
assess
knowledg
clinic
resid
subject
questionnair
base
institut
blood
transfus
guidelin
fill
gap
knowledg
practic
clinic
resid
regard
blood
transfus
practic
educ
strategi
includ
audiovisu
interact
seminar
clinic
specialti
regular
messag
email
alert
regularli
sensit
intervent
phase
implement
postintervent
phase
clinic
area
assess
blood
transfus
practic
resultsfind
averag
score
knowledg
regard
bedsid
transfus
practic
studi
found
gain
resid
word
mouth
senior
colleagu
clinic
experi
stay
hospit
first
year
resid
correct
respons
rate
questionnair
increas
year
howev
actual
good
bedsid
transfus
practic
follow
less
observ
improp
bedsid
storag
blood
compon
major
concern
lead
deterior
qualiti
blood
compon
best
sampl
label
practic
follow
less
observ
inform
consent
record
found
less
observ
despit
fact
knowledg
regard
knowledg
assess
educ
intervent
slight
improv
practic
like
blood
transfus
consent
physician
order
document
patient
ident
check
file
improp
storag
compon
ward
refriger
improv
statist
signific
multitask
patient
bedsid
without
help
nurs
staff
blood
transfusionrel
activ
major
reason
noncompli
conclus
present
studi
gave
us
insight
lot
scope
improv
bedsid
transfus
practic
hospit
achiev
continu
educ
effort
follow
effect
assess
gap
analysi
object
project
improv
current
transfus
practic
train
medic
staff
hv
establish
system
monitor
evalu
safeti
blood
transfus
compar
acut
transfusionrel
advers
reaction
trar
patient
receiv
transfus
whole
blood
wb
treat
use
mirasol
pathogen
reduct
technolog
prt
system
patient
receiv
convent
wb
transfus
korl
bu
teach
hospit
accra
komfo
anoky
teach
hospit
kumasi
select
site
studi
designmethod
hv
train
plan
design
aabb
consult
servic
aabbc
assess
exist
practic
nbsg
aim
develop
practic
train
materi
creat
hv
awar
increas
transfus
medicin
knowledg
among
traine
hospit
nbsg
staff
train
program
incorpor
lectur
practic
session
ward
develop
use
ghanaian
aabb
expertis
aabbc
engag
dovel
technolog
llc
develop
hv
infrastructurea
cloudbas
data
repositori
portal
electron
data
captur
manag
analysi
transfus
trar
hv
train
includ
follow
topic
qualiti
system
defin
africa
societi
blood
transfus
standard
trar
base
isbt
definit
noninfecti
transfus
reaction
near
miss
follow
hv
form
complet
report
write
databas
develop
use
cloudbas
portal
analysi
tbct
provid
train
oper
process
includ
manufactur
issu
mirasol
nonmirasol
administr
blood
product
resultsfind
nbsg
current
monitor
project
collabor
lead
two
hospit
sinc
launch
project
earli
june
transfus
record
report
cloudbas
portal
midmarch
audit
conduct
five
month
posttrain
demonstr
increas
level
knowledg
enthusiasm
hv
better
complianc
oper
process
addit
principl
behind
train
train
trainer
realiz
hv
knowledg
mirasol
experi
share
amongst
staff
conclus
establish
effect
hv
infrastructur
multistakehold
undertak
hv
train
strengthen
qualiti
requir
transfus
practic
better
monitor
report
transfus
trar
lesson
learn
assist
expans
similar
train
program
hv
infrastructur
site
goal
establish
nation
hv
system
ghana
backgroundcas
studi
requir
individu
must
achiev
elig
donat
blood
student
may
find
difficult
learn
requir
lectur
present
topic
may
dri
typic
unengag
blood
bank
professor
medic
laboratori
scienc
program
northeast
want
find
new
method
teach
subject
matter
program
gener
senior
level
student
instruct
senior
year
design
block
student
spend
certain
number
day
content
area
immunohematolog
section
consist
day
includ
lectur
laboratori
experi
compress
schedul
one
day
dedic
donat
process
effort
creat
interact
learn
experi
fit
schedul
provid
student
qualiti
content
workshop
develop
role
play
aid
student
learn
requir
studi
designmethod
pilot
workshop
design
student
role
play
donor
interview
process
aid
learn
variou
reason
deferr
lectur
present
prior
workshop
introduc
student
interview
process
donor
elig
student
work
pair
given
instructordesign
donor
binder
serv
guid
workshop
binder
contain
inform
regard
medic
deferr
travel
restrict
two
predetermin
scenario
contain
donor
inform
use
inform
one
student
complet
interview
questionnair
student
interview
given
inform
regard
hemoglobin
hematocrit
weight
donor
platelet
count
applic
mini
physic
interview
review
questionnair
well
mini
physic
card
ask
follow
question
applic
interview
complet
worksheet
answer
question
whether
donor
elig
reason
inelig
role
switch
student
opportun
play
role
resultsfind
workshop
execut
januari
shown
initi
success
student
describ
workshop
help
engag
process
averag
exam
score
donor
elig
exam
averag
anecdot
evid
show
increas
understand
content
conclus
although
elig
criteria
donor
complex
ever
chang
inform
present
way
maxim
learner
engag
understand
potenti
workshop
adapt
train
healthcar
profession
donat
facil
compet
assess
tool
keep
mind
time
constraint
facil
autom
titrat
studi
consist
time
leigh
frost
jenni
petkova
michael
heali
michael
lankiewicz
backgroundcas
studi
august
fda
approv
ortho
blood
bank
analyz
employ
column
agglutin
gel
technolog
june
two
transfus
servic
within
bed
commun
hospit
system
implement
routin
use
ortho
test
menu
fulli
evalu
includ
antibodi
titrat
valid
studi
clearli
demonstr
increas
sensit
autom
antibodi
titrat
result
twofold
increas
titer
averag
tradit
tube
techniqu
titer
result
howev
unknown
whether
age
reagent
red
blood
cell
factor
sensit
autom
assay
studi
designmethod
retrospect
analysi
conduct
compar
autom
titrat
result
time
minimum
three
separ
patient
sera
contain
antibodi
follow
blood
group
system
studi
rh
kell
duffi
kidd
sampl
frozen
multipl
aliquot
facilit
studi
time
autom
antibodi
titrat
perform
upon
receipt
fresh
lot
ortho
panel
b
titrat
studi
repeat
week
use
exact
reagent
red
cell
reagent
expir
panel
one
addit
titrat
studi
perform
sampl
use
next
fresh
lot
ortho
panel
cell
differ
reagent
red
cell
donor
attempt
fulli
evalu
autom
titrat
consist
time
resultsfind
total
sera
evalu
studi
result
titer
result
onefold
differ
throughout
entir
studi
period
includ
across
lot
number
ortho
panel
two
outlier
one
antik
antifi
b
antik
sampl
demonstr
twofold
increas
titer
upon
test
fresh
reagent
red
cell
differ
lot
antifi
b
sampl
demonstr
twofold
increas
titer
upon
test
fresh
reagent
red
cell
differ
lot
note
serolog
phenotyp
target
antigenallel
reagent
red
cell
select
titrat
studi
ident
across
lot
number
provid
standard
methodolog
conduct
titrat
studi
high
degre
reproduc
autom
titer
result
vari
onefold
differ
time
upon
use
consist
reagent
red
cell
antigen
sourc
even
antigen
sourc
inconsist
titer
result
chang
twofold
origin
result
data
suggest
age
indat
reagent
red
cell
signific
impact
autom
titrat
result
howev
random
differ
individu
reagent
red
cell
may
affect
titer
result
twofold
differ
oper
evalu
hybridizationbas
rbc
genotyp
system
within
hospit
environ
chelsea
hay
ellen
b
klapper
jina
seo
ghislain
noumsi
backgroundcas
studi
hospit
transfus
servic
use
us
fda
approv
dna
genotyp
system
predict
extend
rbc
phenotyp
donor
patient
aim
studi
evalu
oper
characterist
research
use
genotyp
platform
idcor
xt
grifol
diagnost
solut
inc
ca
studi
designmethod
dna
extract
edta
whole
blood
sampl
test
use
idcor
xt
current
system
turnaround
time
tat
dna
extract
final
result
receipt
technologist
handson
time
compar
differ
batch
size
end
studi
questionnair
administ
oper
evalu
eas
perform
key
procedur
step
system
use
scale
easiest
resultsfind
total
sampl
test
system
tat
method
comparison
associ
oper
survey
result
present
tabl
idcor
xt
show
reduct
mean
tat
handson
time
respect
compar
current
system
oper
perform
mean
idcor
xt
run
mean
overal
oper
rate
idcor
xt
current
system
key
featur
respect
backgroundcas
studi
purpos
studi
prospect
evalu
perform
highthroughput
gelbas
analyz
autom
blood
group
biorad
laboratori
inc
hercul
ca
academ
hospit
transfus
servic
perform
approxim
type
screen
test
annual
analyz
evalu
concord
highthroughput
solidphas
platform
immucor
inc
norcross
ga
current
use
well
tube
test
blood
supplier
label
studi
designmethod
test
aborh
forward
revers
antibodi
screen
ab
aborh
donor
unit
confirm
crossmatch
compat
igg
perform
use
ihsystem
gel
card
compar
control
method
use
edta
sampl
edta
cord
blood
sampl
test
ihnewborn
card
compar
addit
sampl
test
antiigg
antiigg
correl
tube
test
dat
antigen
type
c
c
e
e
k
compar
tube
test
use
commerci
reagent
blood
supplier
label
concord
rate
calcul
togeth
compar
control
method
use
assay
resultsfind
concord
control
abo
group
assay
abo
rh
donor
confirm
rh
kell
antigen
type
assay
well
antiigg
crossmatch
newborn
test
card
tabl
regard
dat
concord
increas
sensit
reflect
gel
methodolog
tube
test
conclus
highthroughput
autom
immunohematolog
system
essenti
support
test
volum
larg
hospit
transfus
servic
environ
perform
type
screen
aborh
unit
confirm
rh
kell
antigen
type
antibodi
identif
studi
demonstr
analyz
ihsystem
gel
card
equival
immunohematolog
analyz
tube
test
use
sampl
concord
rare
methoddepend
exampl
antijk
identifi
system
accept
lower
concord
comparison
dat
tube
test
attribut
known
increas
sensit
gel
base
antiglobulin
test
evalu
autom
instrument
blood
bank
implement
gwen
howel
melissa
r
georg
nanci
hinkl
sue
kale
laura
duke
penn
state
health
milton
hershey
medic
center
backgroundcas
studi
autom
blood
bank
test
platform
allow
staff
multitask
reduc
turnaround
time
improv
antibodi
detect
autom
instrument
meet
perform
expect
histor
state
util
immucor
galileo
instrument
perform
type
screen
test
antibodi
identif
solid
phase
methodolog
staff
encount
increas
posit
antibodi
reactiv
appear
nonspecif
nonrepeat
gold
standard
method
peg
led
increas
turnaround
time
critic
patient
temporari
elimin
autom
antibodi
panel
test
workflow
studi
designmethod
addit
autom
instrument
platform
immucor
echo
immucor
assess
compar
current
instrument
eas
use
turnaround
time
method
comparison
focus
nonrepeat
antibodi
posit
rate
staff
train
use
new
instrument
compar
day
day
oper
exist
instrument
eas
use
workflow
capabl
turnaround
time
compar
instrument
type
screen
sampl
run
specimen
well
concurr
load
sampl
size
run
method
comparison
perform
twenti
sampl
one
month
period
three
instrument
sampl
util
test
antibodi
screen
posit
exist
neg
peg
antibodi
screen
repeat
echo
assess
reactiv
resultsfind
staff
determin
echo
instrument
similar
use
compar
exist
instrument
would
difficult
implement
lab
compar
turnaround
time
instrument
type
screen
test
determin
shorter
turnaround
time
sampl
run
shorter
turnaround
time
larger
concurr
run
turnaround
time
reduc
minut
reduct
increas
run
size
becam
larger
abl
provid
aborh
result
minut
faster
sampl
initi
test
antibodi
screen
posit
galileo
sampl
repeat
neg
echo
sampl
repeat
neg
overal
nonrepeat
antibodi
posit
rate
found
nonrepeat
antibodi
posit
rate
found
echo
conclus
complet
instrument
assess
determin
immucor
echo
immucor
would
accept
instrument
altern
exist
instrument
factor
lead
conclus
includ
reduct
turnaround
time
type
screen
aborh
test
eas
use
echo
staff
reduct
nonrepeat
antibodi
posit
rate
echo
instrument
reduct
could
lead
decreas
manual
test
requir
abil
use
autom
antibodi
panel
test
complet
complex
workup
without
neg
affect
workflow
creat
unnecessari
reagent
util
backgroundcas
studi
blood
product
intend
inventori
must
maintain
temperatur
defin
feder
regul
evalu
tempcheck
tc
thermomet
digitrax
lincolnshir
il
possibl
enhanc
exist
blood
product
return
process
tc
similar
scale
appear
take
temperatur
blood
product
read
outsid
bag
sit
devic
temperatur
report
integ
unsur
measur
outsid
bag
would
compar
gold
standard
use
previou
temperatur
valid
temperatur
probe
insert
center
unit
accord
manufactur
materi
tc
sold
calibr
certif
state
accur
within
one
degre
celsiu
error
rang
standard
deviat
confid
interv
provid
latter
particular
concern
establish
cutoff
product
return
accept
studi
designmethod
two
rbc
two
plasma
unit
remov
refriger
allow
warm
toward
room
temperatur
multipl
pair
temperatur
read
perform
tc
devic
establish
gold
standard
institut
logtag
record
logtag
record
auckland
new
zealand
total
sixti
pair
read
taken
total
data
point
use
linear
regress
softwar
packag
r
r
foundat
statist
comput
found
mean
measur
error
variabl
independ
true
temperatur
error
approxim
normal
distribut
around
true
temperatur
inform
establish
possibl
estim
rang
possibl
true
temperatur
normal
bellshap
distribut
mean
equal
observ
temperatur
minu
expect
error
standard
deviat
sd
equal
measur
error
sd
resultsfind
estim
measur
error
mean
sd
rel
true
temperatur
thu
tc
detect
downward
bia
within
manufactur
state
accuraci
rang
observ
distribut
calcul
probabl
gold
standard
true
temperatur
given
tc
read
see
tabl
conclus
probabl
read
tc
actual
less
cutoff
unaccept
institut
chose
read
tc
reason
certain
indic
unit
true
temperatur
less
conclus
advertis
accuraci
tempcheck
devic
found
true
averag
error
around
read
upper
limit
need
establish
order
reason
confid
unit
accept
return
inventori
vitro
manufactur
platelet
overcom
issu
suppli
provid
readi
sourc
independ
avail
donor
closedloop
bioreactor
system
design
recreat
key
vivo
characterist
nativ
hematopoiet
stem
cell
hsc
nich
modifi
cellular
environ
cgmp
grade
reagent
procedur
util
throughout
entir
process
eventu
clinic
grade
manufactur
mind
studi
designmethod
closedloop
bioreactor
system
consist
peristalt
pump
cell
cultur
bioreactor
fresh
media
reservoir
wast
media
contain
platelet
collect
vessel
tube
strateg
placement
valv
connect
compon
creat
closedloop
system
compon
exclud
pump
design
onetimeus
dispos
move
process
toward
cgmp
bioreactor
consist
multichamb
unit
separ
porou
membran
capabl
allow
sizespecif
cellular
product
move
chamber
cord
blood
mononuclear
cellderiv
hsc
seed
bioreactor
differenti
matur
megakaryocyt
mk
serumfre
media
platelet
plateletlik
particl
harvest
matur
mk
extend
proplatelet
proplt
chambersepar
porou
membran
increas
shear
rate
celladjac
chamber
within
bioreactor
chamber
hsc
differenti
matur
mk
rate
n
extend
proplt
respons
flow
platelet
shed
respons
shear
forc
analyz
flow
cytometri
use
hematolog
analyz
matur
mk
count
analyz
flow
cytometri
propltproduc
mk
assess
count
cell
seed
fibrinogenco
plate
conclus
use
novel
bioreactor
system
design
recapitul
bone
marrow
microenviron
physiolog
relev
shear
forc
improv
mk
differenti
platelet
product
vitro
deriv
mk
repres
signific
step
road
produc
vitroderiv
transfus
platelet
unit
rbc
yet
suffici
address
promis
new
avenu
cell
stabil
includ
biomimet
approach
base
intracellular
condit
found
anim
abil
maintain
viabl
cell
tissu
frozen
desicc
state
cryptobiosi
approach
address
storag
limit
lyophil
human
rbc
powder
could
theoret
store
sever
year
rehydr
need
transfus
process
involv
nonreduc
sugar
trehalos
compound
wellestablish
cytoprotect
properti
cryptobiot
anim
howev
trehalos
imperm
mammalian
cell
hamper
progress
use
promis
biomolecul
rbc
preserv
approach
util
sonopor
sugar
load
rbc
sonopor
process
transient
pore
induc
cell
membran
ultrasoundmedi
oscil
ga
microbubbl
object
studi
verifi
efficaci
trehalos
load
longterm
stabil
function
preserv
blood
unit
studi
designmethod
human
red
blood
cell
obtain
inform
consent
donor
rbc
resuspend
dilut
load
buffer
contain
trehalos
immedi
prior
treatment
lipidco
microbubbl
ad
sampl
bmode
ultrasound
puls
appli
use
ultrasound
imag
system
trehalos
uptak
rbc
confirm
enzymat
rbc
cool
rate
follow
freezedri
dri
rbc
store
ambient
temperatur
resuspend
deioniz
water
cell
recoveri
measur
use
autom
cell
count
cell
viabil
assess
stain
calceinam
resultsfind
sonoporationmedi
trehalos
load
minim
toxic
rbc
recov
treatment
trehaloseload
rbc
show
recoveri
viabil
storag
wherea
significantli
reduc
recoveri
observ
without
treatment
n
p
recoveri
lyophil
rbc
rehydr
cell
viabil
cell
popul
n
without
trehalos
load
viabl
rbc
recov
freezedri
rehydr
conclus
result
demonstr
sonopor
enhanc
deliveri
trehalos
rbc
dramat
increas
recoveri
intact
rbc
follow
freezingthaw
dryingrehydr
although
test
need
evalu
rbc
function
vivo
dri
preserv
approach
offer
signific
potenti
help
stabil
clinic
blood
suppli
increas
access
blood
transfus
futur
studi
designmethod
aliquot
plasma
suspend
pc
store
small
inhous
prepar
bag
mimic
storag
featur
common
plt
bag
six
bag
fill
day
product
five
place
storag
continu
agit
per
current
practic
one
place
storag
without
agit
follow
five
day
one
rt
store
bag
move
cold
storag
aliquot
analyz
metabol
activ
ph
glucos
lactat
plt
activ
respons
adp
bind
phosphatidylserin
exposur
annexinv
bind
supernat
microvesicl
count
stain
clot
format
evalu
use
rotat
thromboelastometri
rotem
resultsfind
increas
delay
transfer
storag
ph
drop
trend
mirror
increas
glucos
consumpt
increas
lactat
product
plt
activ
chang
first
three
cold
storag
delay
time
thereaft
increas
plt
effect
also
reflect
alter
respons
adp
decreas
high
two
shortest
cold
storag
delay
time
almost
respons
longer
delay
time
annexinv
bind
increas
releas
microvesicl
increas
two
shortest
cold
storag
delay
time
longer
delay
time
therapeut
dose
thaw
transfus
patient
pc
frozen
vladimir
region
blood
bank
februari
april
cpc
dose
thaw
transfus
patient
pc
frozen
tyumen
region
blood
bank
august
april
cpc
dose
thaw
transfus
patient
freezethaw
recoveri
platelet
origin
popul
blood
bank
defrost
cpc
show
platelet
cellsdos
moscow
sklifosovski
institut
emerg
medicin
cellsdos
vladimir
region
blood
bank
cell
dose
tyumen
region
blood
bank
surgic
postcardiac
surgeri
patient
neurosurg
patient
patient
organ
transplant
moscow
sklifosovski
institut
emerg
medicin
oncolog
haematolog
patient
neurosurg
patient
surgic
patient
vladimir
region
blood
bank
haematolog
patient
surgic
patient
postcardiac
surgeri
patient
tyumen
region
blood
bank
receiv
therapeut
cpc
transfus
hemorrhag
stop
subject
given
cpc
transfus
complic
seen
medic
center
posttransfus
cci
respect
moscow
sklifosovski
institut
emerg
medicin
respect
vladimir
region
blood
bank
posttransfus
cci
tyumen
region
blood
bank
cci
high
h
would
suggest
donor
platelet
still
circul
recipi
blood
within
hour
complet
transfus
conclus
cpc
demonstr
highli
effect
blood
bank
mark
clinic
effect
due
high
perform
cpc
michael
gannett
richard
gammon
oneblood
inc
orlando
immunohematolog
refer
laboratori
oneblood
inc
backgroundcas
studi
previous
pathway
volum
reduc
sourc
antibodi
interest
use
expens
andor
labori
tradit
method
eg
ultrafiltr
membran
dialysi
fraction
precipit
mani
antibodi
specif
avail
commerci
must
obtain
plasma
donor
patient
sourc
found
typic
contain
addit
antibodi
sinc
routin
screen
detect
antibodi
low
preval
antigen
antisera
ideal
remov
antibodi
includ
isoagglutinin
larger
volum
sourc
materi
harder
manipul
may
requir
multipl
freez
thaw
cycl
obtain
aliquot
could
affect
product
stabil
requir
storag
space
method
sought
volum
reduc
sourc
materi
addit
antibodi
could
easili
remov
studi
designmethod
plastic
separ
devic
made
printer
creat
two
compart
insert
ml
tube
allow
ml
caviti
tube
base
sourc
materi
ad
tube
immedi
invert
frozen
min
hour
creat
ice
column
ic
cap
separ
devic
tube
remov
freezer
immedi
centrifug
swing
bucket
rotor
minut
separ
devic
prevent
ic
enter
tube
base
yet
allow
solut
separ
ic
flow
tube
base
ic
decant
concentr
solut
cs
extract
separ
devic
insert
syring
blunt
needl
total
protein
measur
via
bradford
assay
resultsfind
sampl
test
ic
mean
mass
initi
plasma
mass
yet
contain
mean
total
protein
tabl
cs
mean
mass
initi
plasma
mass
recov
mean
total
protein
describ
new
method
ice
use
reduc
mass
sourc
materi
concentr
protein
develop
point
care
aptamerbas
coagulopathi
sensor
scott
ferguson
aptitud
medic
system
backgroundcas
studi
coagulopathi
trauma
result
increas
mortal
sinc
death
caus
condit
occur
within
first
hour
rapid
detect
aggress
correct
significantli
improv
patient
outcom
fibrinogen
play
crucial
role
vulner
coagul
factor
hemorrhag
reach
critic
low
level
earlier
factor
fibrinogen
deficit
strong
predictor
tic
independ
predictor
mortal
fibrinogen
replac
improv
surviv
howev
blanket
administr
feasibl
due
potenti
transfusionrel
complic
high
cost
limit
suppli
cryoprecipit
fibrinogen
concentr
result
prompt
measur
datadriven
replac
fibrinogen
part
current
european
guidelin
manag
hemorrhag
coagulopathi
increasingli
advoc
us
unfortun
rapid
pointofcar
poc
test
current
exist
fibrinogen
standard
clauss
method
typic
slow
turnaround
time
min
miss
golden
hour
current
fibrinogen
test
suffici
simpl
rapid
robust
perform
prehospit
set
studi
designmethod
address
need
develop
first
poc
fibrinogen
sensor
sensor
exploit
novel
highaffinityspecif
aptam
fibrinogen
microfluid
electrochem
architectur
analog
glucos
test
strip
aptam
wellsuit
poc
given
chemic
thermal
stabil
eas
synthesi
high
consist
aptam
selfreport
probe
enabl
reagentless
detect
greatli
reduc
assay
time
complex
sensor
electrod
function
redoxlabel
aptam
fibrinogenaptam
bind
yield
chang
redox
current
correspond
concentr
sensor
character
buffer
plasma
whole
blood
sampl
use
fibrinogen
standard
demonstr
proof
concept
resultsfind
novel
fibrinogen
aptam
exhibit
k
nm
minim
cross
reactiv
nontarget
protein
includ
fibrinogen
degrad
product
prototyp
sensor
quantit
fibrinogen
accur
rapidli
across
clinic
rang
mgml
lod
mgml
cv
min
develop
handheld
reader
integr
smartphon
portabl
potentiostat
interrog
sensor
data
display
analyz
smartphon
via
custom
app
conclus
demonstr
prototyp
sensor
enabl
measur
fibrinogen
directli
plasma
whole
blood
min
outcom
support
product
develop
success
sensor
could
ultim
deploy
ambul
ed
periop
environ
improv
patient
outcom
protein
backgroundcas
studi
abo
blood
group
system
cognat
antibodi
foundat
transfus
transplant
medicin
serolog
test
method
remain
essenti
unchang
year
reli
visual
interpret
agglutin
increas
rate
abo
incompat
aboi
hematopoiet
stem
cell
hsct
solid
organ
transplant
new
test
modal
necessari
aboi
hsct
patient
requir
extens
monitor
antiabo
antibodymedi
morbid
includ
graft
reject
passeng
lymphocyt
syndrom
pl
aim
develop
novel
serolog
test
antiabo
antibodi
use
set
aboi
transplant
studi
designmethod
biolay
interferometri
bli
optic
assay
measur
interfer
pattern
light
reflect
two
surfac
develop
blibas
assay
measur
abo
antibodi
human
plasma
sampl
determin
lower
limit
detect
serial
dilut
monoclon
antia
antibodi
ab
plasma
valid
assay
volunt
blood
donor
plasma
sampl
lastli
assay
plasma
sampl
preand
posttranspl
patient
undergo
aboi
hsct
resultsfind
serial
dilut
monoclon
antia
antibodi
ab
plasma
determin
lower
limit
detect
ngul
peak
absorb
valu
posit
strongli
correl
antibodi
concentr
r
backgroundcas
studi
alloimmun
one
main
side
effect
blood
transfus
could
sever
complic
red
blood
cell
transfus
especi
patient
diseas
requir
multipl
transfus
convent
blood
group
phenotyp
hemagglutin
assay
carri
pretransfus
unsuit
certain
clinic
situat
molecular
type
offer
altern
method
allow
deduct
blood
group
phenotyp
genotyp
howev
current
method
requir
long
turnaround
time
perform
onsit
limit
applic
emerg
situat
rapid
decis
need
test
perform
near
onsit
advantag
studi
designmethod
work
report
develop
novel
rapid
multiplex
molecular
method
visual
identif
seven
allel
three
clinic
relev
blood
group
system
fy
fy
fy
gypb
gypb
jk
jk
assay
design
carri
unitari
test
specif
clinic
situat
pretransfus
test
patient
serolog
method
fail
emerg
situat
test
use
dryreag
allelespecif
later
flow
biosensor
prepcr
handl
dna
extractionfre
procedur
includ
multiplex
linearaftertheexponenti
late
pcr
amplif
perform
directli
whole
blood
singlestrand
amplicon
migrat
dryreag
allelespecif
nucleic
acid
lateralflow
dipstick
gold
nanoparticl
use
report
permit
detect
blood
group
snp
gener
red
dot
visibl
nake
eye
assay
paramet
optim
test
valid
blood
donor
sampl
known
phenotyp
resultsfind
optim
assay
includ
multiplex
latepcr
paramet
primer
concentr
cycl
number
later
flow
paramet
migrationhybrid
temperatur
buffer
composit
final
protocol
enabl
determin
deduc
phenotyp
total
process
time
one
hour
receiv
blood
sampl
valid
show
concord
rate
deduc
phenotyp
standard
serolog
phenotyp
allel
investig
transfus
servic
bed
commun
hospit
system
immedi
initi
util
psoralen
treat
platelet
begin
march
transfus
servic
maintain
dual
inventori
psoralen
treat
pa
platelet
addit
solut
nonpsoralen
treat
plasmabas
plateletpheresi
product
clinician
provid
option
electron
order
psoralen
treat
product
transfus
rather
order
fulfil
platelet
manag
exclus
transfus
servic
laboratori
staff
base
primarili
product
expir
date
patient
blood
type
compat
studi
designmethod
retrospect
analysi
conduct
compar
incid
transfus
reaction
involv
psoralentr
platelet
versu
transfus
reaction
involv
nonpsoralen
treat
platelet
march
februari
resultsfind
two
year
studi
period
total
transfus
perform
across
system
patient
includ
exactli
plateletpheresi
transfus
total
plateletpheresi
transfus
period
psoralen
treat
plateletpheresi
product
nonpsoralen
treat
plateletpheresi
product
studi
period
total
transfus
reaction
associ
psoralen
treat
platelet
transfus
result
incid
rate
studi
period
total
transfus
reaction
associ
nonpsoralen
treat
platelet
transfus
result
incid
rate
conclus
psoralen
treat
platelet
success
introduc
bed
commun
hospit
system
march
subsequ
two
year
psoralen
treat
nonpsoralen
treat
platelet
util
rate
rel
equival
clinic
signific
differ
p
incid
transfus
reaction
psoralen
treat
versu
nonpsoralen
treat
platelet
product
patient
experienc
sever
transfus
reaction
platelet
product
report
bacteri
contamin
associ
platelet
transfus
entir
evalu
period
thu
introduct
psoralen
treat
platelet
within
hospit
system
impact
overal
incid
transfus
reaction
platelet
backgroundcas
studi
despit
introduct
leukodeplet
blood
compon
shown
donor
leukocyt
engraft
transfusionassoci
microchimer
tam
remain
longterm
consequ
red
blood
cell
rbc
transfus
patient
group
mechan
donor
leukocyt
surviv
follow
blood
transfus
unclear
specul
genet
factor
may
one
possibl
reason
studi
conduct
determin
whether
associ
individu
genet
profil
establish
tam
blood
transfus
recipi
studi
designmethod
australian
trauma
patient
n
transfus
rbc
unit
injuri
sever
score
greater
recruit
twelv
patient
found
tam
date
whole
exom
sequenc
conduct
four
patient
tam
four
patient
without
tam
align
exom
data
human
genom
refer
sequenc
assembl
conduct
analysi
differenti
genet
variat
carri
variat
uniqu
least
patient
group
investig
primari
focu
gene
associ
immun
regul
resultsfind
preliminari
analysi
perform
mani
chang
found
four
patient
tam
present
highli
heterogen
gene
includ
zinc
finger
protein
gene
human
leukocyt
antigen
gene
hlab
interest
chang
found
gene
unknown
function
variant
addit
chang
found
follow
gene
gene
variant
id
role
regul
prolifer
tcell
gene
chr
variant
id
chemokin
contribut
tumor
associ
leukocyt
remov
conclus
next
gener
whole
exom
sequenc
technolog
allow
explor
genet
variat
across
differ
popul
group
provid
clue
potenti
indic
mechan
tam
may
establish
certain
patient
preliminari
analysi
provid
potenti
genet
chang
could
involv
gene
role
tcell
regul
prolifer
expect
analysi
expand
patient
number
allow
genom
data
explor
detail
australian
govern
fund
australian
red
cross
blood
servic
provid
blood
blood
product
servic
australian
commun
pamela
lopert
bobbi
carlin
mehraboon
irani
sharon
graminsk
scott
brook
neeta
rugg
jose
cancela
terumo
bct
bloodcent
wisconsin
hoxworth
blood
center
backgroundcas
studi
apheresi
platelet
store
either
plasma
portion
plasma
replac
platelet
addit
solut
pa
platelet
store
pa
may
reduc
risk
sever
plasmaassoci
advers
transfus
reaction
allerg
reaction
immun
reaction
trigger
cellular
mediat
plasma
potenti
transfusionrel
acut
lung
injuri
trali
object
studi
quantifi
vivo
radiolabel
recoveri
surviv
apheresi
platelet
collect
trima
accel
system
terumo
bct
lakewood
co
store
day
solut
freseniu
kabi
bad
homburg
germani
studi
designmethod
prospect
openlabel
multicent
studi
involv
healthi
adult
particip
donat
singl
hyperconcentr
platelet
product
trima
accel
system
product
dilut
pa
immedi
collect
via
autopa
meter
attain
plasma
carryov
intersol
store
day
standard
condit
day
whole
blood
wb
drawn
prepar
fresh
control
platelet
test
control
platelet
label
either
cr
randomli
assign
particip
simultan
infus
autolog
radiolabel
platelet
per
biomed
excel
safer
transfus
best
method
venou
wb
sampl
collect
day
infus
follow
day
recoveri
surviv
abstract
transfus
test
control
platelet
calcul
use
multipl
hit
model
cost
softwar
resultsfind
twentyfour
evalu
data
point
includ
analysi
day
evalu
test
product
platelet
concentr
platelet
yield
evalu
test
product
neg
bacteri
test
test
per
site
standard
practic
confirm
day
day
product
ph
shown
tabl
recoveri
test
platelet
greater
control
surviv
greater
control
onesid
confid
limit
conclus
hyperconcentr
platelet
collect
trima
accel
system
store
intersol
day
met
unit
state
fda
accept
criteria
platelet
recoveri
surviv
compar
fresh
control
similarli
plasma
type
ab
donor
key
resourc
trauma
resuscit
requir
abotyp
specif
howev
donor
pool
limit
remov
antiab
antibodi
would
significantli
increas
suppli
univers
plasma
match
fwb
walk
donor
thu
greatli
simplifi
transfus
logist
object
research
program
develop
costeffici
filter
specif
remov
antia
b
antibodi
fwb
plasma
sourc
studi
designmethod
human
whole
blood
plasma
unit
collect
cpd
obtain
region
blood
donor
center
human
whole
blood
assess
within
day
collect
plasma
obtain
frozen
thaw
prior
use
whole
blood
plasma
pass
porou
polym
bead
contain
novel
modif
design
remov
antia
antib
blood
group
antibodi
plasmablood
polym
ratio
sampl
collect
pre
postfiltr
analyz
remov
blood
group
antibodi
blood
type
reagent
red
cell
standard
gelcard
agglutin
assay
ortho
clinic
effect
coagul
hemostat
activ
measur
aptt
pt
assay
stat
coagul
analyz
diagnostica
stago
teg
analyz
haemonet
inc
respect
complet
blood
cell
count
cbc
measur
hemavet
hematolog
analyz
drew
scientif
antibodi
remov
effici
calcul
lowest
dilut
agglutin
reagent
red
cell
start
donor
titer
rang
antia
antib
resultsfind
treatment
plasma
function
b
polym
reduc
antibodi
titer
mean
sd
respect
nonfunction
control
polym
display
titer
reduct
antia
antib
antibodi
respect
treatment
whole
blood
function
b
polym
reduc
antibodi
titer
respect
condit
result
progress
declin
platelet
qualiti
due
ongo
metabol
activ
platelet
activ
current
platelet
storag
bag
compos
either
polyvinylchlorid
pvc
polyolefin
optimis
provid
adequ
gasperm
howev
platelet
adher
surfac
may
promot
platelet
activ
new
materi
coat
support
platelet
respir
whilst
prevent
platelet
adhes
activ
may
enabl
platelet
storag
beyond
day
studi
examin
impact
store
platelet
pvc
bag
coat
recombin
serglycin
intracellular
proteoglycan
express
hematopoiet
endotheli
cell
human
serum
albumin
molecul
chosen
antiadhes
properti
differenti
glycosyl
profil
studi
designmethod
buffycoat
deriv
platelet
plasma
ssp
split
paediatrics
pvc
platelet
storag
bag
macopharma
either
uncoat
coat
serglycin
albumin
albumex
solut
serglycin
recombinantli
express
cell
purifi
condit
medium
via
anion
exchang
chromatographi
platelet
concentr
store
day
agit
platelet
metabol
activ
function
test
day
use
vitro
assay
resultsfind
platelet
concentr
ph
glucos
lactat
valu
similar
group
storag
express
platelet
glycoprotein
gpiib
gpiiia
unaffect
bag
coat
activ
profil
platelet
store
coat
uncoat
bag
similar
determin
bind
platelet
function
assess
viscoelast
test
teg
compar
group
storag
microscop
examin
inner
plastic
surfac
bag
day
demonstr
significantli
reduc
platelet
adhes
serglycin
albumin
coat
bag
compar
uncoat
pvc
bag
whilst
morpholog
adher
platelet
similar
conclus
storag
platelet
pvc
bag
coat
serglycin
albumin
support
platelet
metabol
advers
affect
platelet
phenotyp
function
extend
period
day
although
protein
test
reduc
platelet
activ
initi
find
provid
proofofconcept
develop
next
gener
platelet
storag
bag
biomimet
focu
evalu
pair
platelet
product
collect
test
site
test
product
day
day
ph
assur
product
ph
confid
onesid
confid
limit
test
product
noninferior
control
morpholog
score
day
storag
backgroundcas
studi
prophylact
platelet
concentr
pc
transfus
first
line
therapi
patient
hemorrhag
syndrom
puriti
function
transfus
pc
cornerston
effici
treatment
obtain
pc
whole
blood
sampl
blood
bank
current
use
hard
spin
centrifug
base
method
lead
poor
rest
platelet
yield
prolong
storag
also
issu
blood
bank
platelet
storag
lesion
order
improv
platelet
qualiti
preserv
therapeut
aim
develop
acousticbas
fraction
devic
isol
human
platelet
whole
blood
bag
alreadi
shown
acoust
platelet
separ
effici
method
fraction
blood
low
shear
stress
environ
puriti
yield
lead
minim
platelet
activ
preserv
platelet
respons
agonist
function
aim
studi
impact
acoust
fraction
platelet
storag
compar
qualiti
platelet
rich
plasma
prp
produc
acoustophoresi
soft
spin
centrifug
studi
designmethod
prp
obtain
soft
spin
centrifug
acoust
fraction
store
day
constant
agit
platelet
analyz
rest
condit
stimul
common
platelet
agonist
use
flow
cytometri
monitor
express
activ
marker
pselectin
annexin
v
phosphatidylserin
check
morpholog
metabol
characterist
platelet
day
storag
resultsfind
prp
obtain
soft
spin
acoust
fraction
show
compar
storag
respons
surfac
express
pselectin
phosphatidylserin
increas
upon
storag
type
prp
differ
surfac
level
platelet
activ
marker
two
type
prp
interestingli
platelet
prepar
acoustophoresi
retain
slightli
increas
respons
collagen
storag
compar
platelet
prepar
soft
spin
centrifug
tabl
averag
ppm
hemeonc
inpati
lowest
studi
period
select
transfus
platelet
low
pmp
content
observ
differ
ppm
studi
period
baselin
poststudi
period
statist
signific
studi
limit
use
averag
ppm
overal
assess
platelet
usag
may
account
patient
factor
known
contribut
platelet
transfus
requir
futur
studi
may
benefit
evalu
impact
pmp
individu
platelet
transfus
respons
clinic
outcom
backgroundcas
studi
mechan
onset
vvr
platelet
apheresi
difficult
elucid
withdraw
return
flow
affect
donor
complexli
therefor
monitor
indic
reflect
physiolog
chang
donor
effect
mean
observ
occurr
studi
use
laser
doppler
flowmetri
continu
monitor
blood
flow
puls
rate
heart
rate
platelet
collect
analyz
process
vvr
studi
designmethod
retrospect
studi
includ
high
risk
donor
vvr
vvr
case
experienc
percent
decreas
blood
flow
dbf
percent
decreas
heart
rate
dhr
calcul
physiolog
posit
certain
time
apheresi
plot
use
valu
dbf
x
use
valu
dhr
motion
dot
everi
second
observ
platelet
apheresi
xy
field
divid
area
central
changeless
area
n
increas
flow
decreas
heart
rate
dh
area
increas
heart
rate
ih
area
b
decreas
flow
df
ih
area
c
df
dh
area
posit
chang
abl
paint
give
color
area
pixel
exhibit
second
stay
posit
total
occup
rate
area
calcul
certain
period
apheresi
abstract
doubl
tripl
platelet
product
trima
accel
donat
product
store
per
standard
blood
bank
condit
day
collect
platelet
product
assess
residu
white
blood
cell
wbc
content
final
platelet
yield
resultsfind
two
hundr
seventynin
particip
donat
evalu
singl
doubl
tripl
platelet
product
mean
sd
residu
wbc
count
singl
doubl
tripl
platelet
product
respect
breakdown
platelet
product
show
singl
platelet
unit
wbc
count
less
million
doubl
platelet
unit
wbc
content
lower
million
tripl
platelet
unit
wbc
content
lower
million
determin
confid
singl
doubl
tripl
platelet
product
accept
residu
wbc
level
failur
collect
therefor
meet
unit
state
fda
accept
criteria
singl
doubl
tripl
platelet
product
mean
sd
platelet
yield
respect
singl
platelet
product
residu
platelet
yield
none
doubl
tripl
platelet
product
platelet
yield
respect
conclus
singl
doubl
tripl
platelet
product
collect
trima
accel
store
plasma
met
accept
criteria
residu
wbc
level
platelet
yield
understand
platelet
activ
statu
plateletpheresi
donor
optim
platelet
alloc
gerda
leitner
michaela
horvath
vera
kolovratova
andrea
tanzmann
elisabeth
maurerspurej
clinic
blood
group
serolog
transfus
medicin
medic
univers
vienna
univers
british
columbia
backgroundcas
studi
platelet
microparticl
known
indic
platelet
activ
earli
marker
inflammatori
autoimmun
condit
known
certain
donor
demograph
associ
platelet
activ
whether
repeat
donor
consist
activ
nonactiv
platelet
studi
aim
understand
platelet
activ
statu
plateletpheresi
donor
quantifi
chang
platelet
activ
statu
across
multipl
donat
two
collect
technolog
import
activ
platelet
andor
microparticl
fragment
could
affect
immun
hemostat
properti
platelet
transfus
backgroundcas
studi
taiwan
qualiti
monitor
blood
product
key
issu
ratio
leucocytereduc
lr
product
increas
prevent
seriou
transfus
reaction
febril
nonhemolyt
transfus
reaction
fnhtr
current
manual
count
nageottechamb
residu
wbc
rwbc
enumer
time
consum
requir
technic
skill
taiwan
blood
suppli
lrrcc
account
red
blood
cell
goal
full
lrrcc
achiev
autom
import
opportun
feasibl
studi
sysmex
new
blood
bank
applic
develop
qualiti
monitor
blood
product
report
basic
perform
applic
rwbc
use
routin
manufactur
lr
red
cell
concentr
lrrcc
studi
evalu
feasibl
sysmex
analysi
rwbc
lrrcc
sampl
studi
designmethod
evalu
three
item
repeat
stabil
correl
manual
countflow
cytometri
fcm
method
repeat
test
rwbc
use
lrrcc
sampl
stabil
test
stabil
sampl
pack
rwbc
use
lrrcc
sampl
sampl
run
correl
test
correl
manual
count
fcm
bd
use
lrrcc
sampl
resultsfind
repeat
rwbc
cv
rwbc
cv
stabil
confirm
rwbc
show
good
stabil
hour
correl
result
r
correl
formula
manual
count
fcm
respect
conclus
show
good
consist
manual
count
fcm
result
higher
count
abstract
transfus
may
due
gate
area
fcm
includ
rain
dot
refer
damag
cell
gate
exclud
suspect
artefact
damag
cell
exclud
manual
count
routin
possibl
perform
routin
residu
wbc
test
hematolog
analyz
platform
near
futur
believ
improv
workflow
qualiti
monitor
blood
product
shorten
tat
minutessampl
rais
qc
sampl
rate
rcc
pack
reduc
total
test
cost
includ
labor
charg
evalu
oper
effici
trima
accel
ayda
rodriguez
solanyi
forero
deissi
baquero
claudia
cruz
cri
ortegon
andrew
howel
logan
fender
lesle
simonblum
cruz
roja
terumo
bct
backgroundcas
studi
trima
accel
use
collect
platelet
pa
goal
collect
minimum
two
platelet
product
per
collect
collect
time
often
dictat
select
devic
use
product
collect
januari
center
began
use
newest
version
trima
accel
tcuff
accessori
terumo
bct
lakewood
co
trima
accel
design
meet
need
blood
center
access
manag
autoflow
featur
trima
accel
design
reduc
access
relat
alert
make
autom
adjust
flow
rate
base
donor
access
flow
system
pressur
issu
detect
trima
accel
devic
accessori
tcuff
pressur
cuff
design
encourag
donor
squeez
ensur
pressur
mmhg
donor
arm
addit
trima
accel
design
enhanc
platelet
collect
product
modif
platelet
collect
algorithm
improv
procedur
manag
studi
designmethod
trima
accel
devic
upgrad
version
softwar
januari
util
cadenc
system
terumobct
lakewood
co
procedur
data
captur
donat
march
test
addit
procedur
data
donat
collect
control
period
trima
accel
novemb
januari
comparison
platelet
product
yield
procedur
time
venou
access
alert
donor
inform
analyz
test
control
group
resultsfind
follow
softwar
instal
trima
accel
overal
platelet
collect
effici
increas
platelet
yield
note
test
procedur
versu
control
procedur
p
averag
procedur
time
drop
test
control
group
approxim
min
min
vs
min
p
improv
report
collect
yield
vs
p
statist
signific
differ
also
shown
averag
number
access
alert
donat
trima
accel
trima
accel
averag
number
access
alert
drop
per
procedur
control
period
per
procedur
test
period
p
valu
twice
mani
donat
complet
success
without
access
relat
alert
compar
test
period
control
period
p
valu
zero
donat
greater
alert
singl
donat
trima
period
compar
control
period
frequent
access
alert
singl
donat
p
valu
test
control
group
compar
total
blood
volum
versu
predon
platelet
count
versu
conclus
trima
accel
increas
platelet
collect
product
compar
current
trima
accel
trima
accel
also
dramat
reduc
number
access
relat
oper
alert
per
donat
implement
softwar
enabl
center
collect
platelet
compon
per
procedur
contribut
improv
cost
effect
mainten
adequ
inventori
loren
fast
samuel
sowemimocok
andrew
dunham
rhode
island
hospit
hemanext
backgroundcas
studi
hemanext
develop
technolog
long
term
storag
red
blood
cell
rbc
oxygenreduc
storag
condit
storag
rbc
condit
shown
improv
qualiti
cell
transfus
white
blood
cell
wbc
rbc
transfus
may
respons
caus
transfus
associ
graft
versu
host
diseas
tagvhd
immunocompromis
patient
gamma
irradi
leukocytereduct
blood
product
transfus
current
use
prevent
seriou
advers
effect
blood
transfus
unknown
effect
gamma
irradi
wbc
abrog
affect
reduc
oxygen
content
hemanext
rbc
therefor
present
studi
design
determin
effect
hemanext
rbc
storag
condit
qualiti
red
blood
cell
growth
prolifer
tlymphocyt
follow
gamma
irradi
studi
designmethod
two
unit
fresh
leukocyt
reduc
red
cell
concentr
lrrcc
obtain
rhode
island
blood
center
ribc
two
unit
pool
togeth
creat
homogen
pool
lrrcc
peripher
blood
mononuclear
cell
pbmnc
isol
one
two
unit
abo
match
nonleukocyt
red
cell
concentr
nlrrcc
use
ficol
gradient
antibodi
coat
magnet
bead
per
manufactur
instruct
use
pbmnc
isol
aliquot
blood
ad
back
pool
lrrcc
final
concentr
ml
equal
aliquot
pool
unit
ad
convent
pvc
red
cell
storag
bag
deoxygen
hour
room
temperatur
hemanext
red
cell
process
system
transfer
hemanext
bag
storag
day
vitro
metric
atp
hemolysi
etc
red
cell
qualiti
measur
process
storag
storag
day
ml
remov
bag
rbc
remain
bag
expos
gy
gamma
irradi
per
standard
protocol
ribc
pbmnc
isol
preand
postirradi
sampl
test
abil
respond
mitogen
limit
dilut
assay
resultsfind
percent
oxygen
satur
hemoglobin
hemanext
rbc
sampl
reduc
hemolysi
sampl
day
gamma
irradi
control
hemanext
result
show
signific
growth
prolifer
tlymphocyt
differ
level
nonirradi
control
hemanext
rbc
growth
prolifer
tlymphocyt
inhibit
least
fold
reduct
frequenc
respond
cell
follow
gamma
irradi
pbmnc
rcc
store
normal
convent
hemanext
rbc
storag
bag
result
indic
prolifer
wbc
present
rbc
process
hemanext
red
cell
process
system
store
hemanext
storag
bag
suscept
gamma
irradi
similar
fashion
store
current
convent
storag
condit
prospect
open
label
nonrandom
multicent
studi
evalu
safeti
efficaci
trima
accel
system
modifi
postcount
algorithm
softwar
healthi
adult
volunt
donor
consent
donat
either
singl
doubl
platelet
product
trima
accel
system
modifi
platelet
postcount
algorithm
softwar
particip
postprocedur
platelet
count
measur
confirm
collect
product
assess
residu
white
blood
cell
wbc
content
ph
resultsfind
one
hundr
twenti
particip
donat
evalu
singl
doubl
platelet
product
singl
doubl
platelet
collect
result
postcount
lower
onesid
confid
interv
singl
doubl
platelet
product
calcul
mean
differ
measur
postcount
trima
accel
predict
postcount
singl
doubl
collect
pvalu
pvalu
respect
thu
trima
predict
platelet
postcount
averag
lower
actual
measur
postcount
regard
collect
platelet
qualiti
evalu
platelet
unit
residu
wbc
specif
singl
platelet
unit
mean
residu
wbc
doubl
platelet
unit
mean
residu
wbc
platelet
ph
assess
day
collect
depend
site
standard
practic
product
ph
singl
doubl
final
advers
event
ae
report
particip
ae
rate
consist
prospect
clinic
studi
previou
version
trima
accel
postcount
algorithm
total
ae
total
particip
conclus
collect
singl
doubl
platelet
product
trima
accel
system
modifi
platelet
postcount
algorithm
softwar
safe
maintain
particip
post
procedur
platelet
count
backgroundcas
studi
decad
notion
transfus
medicin
would
holi
grail
find
vitro
assay
could
tell
happen
vivo
despit
great
effort
put
develop
assay
flow
cytometr
assess
pselectin
express
morpholog
score
microscopi
hypoton
shock
respons
hsr
extent
shape
chang
esc
other
none
routin
use
hospit
blood
bank
platelet
plt
inventori
manag
recent
detect
plt
microparticl
mp
introduc
assess
plt
activ
statu
clinic
valid
associ
high
mp
poor
outcom
still
progress
studi
compar
mp
content
morpholog
score
clinic
outcom
goal
reveal
challeng
inform
futur
studi
studi
designmethod
clinic
studi
conduct
vancouv
gener
hospit
canada
enrol
hematologyoncolog
patient
patient
baselin
data
includ
preand
posttransfus
plt
count
plt
transfus
characterist
includ
plt
activ
statu
prospect
collect
plt
activ
statu
measur
mp
content
mp
dynam
light
scatter
thrombolux
lightintegra
technolog
inc
canada
morpholog
score
obtain
phase
contrast
microscopi
nikon
japan
object
small
paraformaldehydefix
sampl
mp
singl
donor
plt
sdp
suspend
plasma
compar
morpholog
score
clinic
respons
measur
correct
count
increment
cci
resultsfind
patient
receiv
total
transfus
sdp
patient
male
year
age
diagnos
allaml
cmv
posit
test
posit
antihla
antibodi
baselin
plt
count
l
bleed
rare
sensit
analysi
reveal
major
abo
mismatch
complex
case
multipl
transfus
short
success
patient
test
posit
antihla
antibodi
patient
older
year
confound
factor
activ
statu
measur
mp
sdp
transfus
impact
confound
factor
n
show
moder
correl
cci
cmv
posit
patient
diagnos
aml
r
p
activ
plt
mp
morpholog
score
sdp
show
moder
invers
correl
r
p
correl
nonactiv
platelet
due
difficulti
differenti
nonactiv
platelet
accur
visual
inspect
conclus
contrast
rel
qualiti
control
paramet
pselectin
express
mp
content
morpholog
score
reflect
entir
histori
plt
donor
plt
unit
data
suggest
refin
question
might
lead
solut
rather
aim
predict
outcom
goal
might
predict
worst
outcom
plt
transfus
mp
low
morpholog
score
high
probabl
insuffici
increas
cci
cmv
aml
patient
thu
practic
approach
improv
overal
clinic
outcom
may
avoid
activ
plt
transfus
prophylaxi
evalu
product
trima
accel
burak
deveci
altunay
haydar
vesk
ercan
nogay
ihsan
karado
gan
alexandra
zelinskaya
logan
fender
antalya
medstar
hastanesi
terumo
bct
backgroundcas
studi
improv
platelet
apheresi
product
enabl
blood
center
maintain
adequ
inventori
short
shelf
life
product
improv
oper
cost
effect
trima
accel
terumo
bct
lakewood
co
design
enhanc
platelet
collect
product
modif
platelet
collect
algorithm
improv
procedur
manag
studi
designmethod
retrospect
studi
consist
donat
januari
juli
trima
accel
control
compar
donat
juli
march
trima
accel
test
trima
accel
procedur
data
captur
use
cadenc
system
terumo
bct
lakewood
co
platelet
product
yield
procedur
time
donor
inform
analyz
test
control
group
measur
differ
resultsfind
statist
signific
differ
platelet
collect
product
measur
trima
accel
trima
accel
averag
procedur
time
drop
test
control
group
approxim
min
vs
min
p
improv
report
collect
yield
vs
p
normal
donat
time
trima
accel
produc
increas
platelet
yield
hour
averag
versu
control
procedur
p
test
control
group
compar
total
blood
volum
predon
platelet
count
despit
statist
signific
differ
favor
larger
tbv
versu
p
higher
predon
platelet
count
versu
p
control
group
conclus
trima
accel
result
statist
signific
increas
platelet
collect
product
compar
current
trima
accel
trima
accel
may
enabl
blood
center
collect
platelet
compon
per
procedur
contribut
improv
blood
center
cost
effect
mainten
adequ
inventori
resultsfind
averag
ph
day
drop
day
day
drop
day
ph
unit
never
drop
cours
storag
platelet
count
per
bag
chang
significantli
storag
averag
volum
loss
neglig
day
day
bacteri
growth
detect
day
pathogen
inactiv
e
coli
saureau
unit
control
unit
backgroundcas
studi
review
test
packet
end
test
add
time
process
client
need
result
hour
sampl
receipt
everi
minut
import
qualiti
control
staff
separ
process
caus
issu
identifi
occur
result
addit
delay
rework
addit
physic
separ
depart
hinder
commun
faster
method
provid
qualiti
control
check
laboratori
test
need
laboratori
place
staff
within
test
lab
perform
qualiti
check
process
effect
turnaround
time
assess
studi
designmethod
first
laboratori
area
select
studi
viral
marker
test
includ
antibodi
test
hiv
htlv
iii
hcv
hbsag
hbc
chaga
team
assembl
review
identifi
critic
check
point
need
within
process
critic
check
point
assess
determin
could
perform
inprocess
comput
autom
could
perform
check
team
identifi
sampl
accept
extern
control
critic
check
perform
inprocess
work
station
place
within
laboratori
test
area
qualiti
staff
perform
inprocess
check
procedur
train
develop
addit
laboratori
inform
system
configur
algorithm
allow
automat
approv
test
result
critic
check
accept
resultsfind
batch
viral
marker
test
inprocess
check
take
minut
compar
minut
endofprocess
check
end
test
except
review
qualiti
control
staff
prior
result
releas
process
chang
result
improv
averag
turnaround
time
detail
tabl
specif
averag
turnaroundtim
viral
marker
test
decreas
atlanta
laboratori
san
antonio
laboratori
conclus
implement
inprocess
qualiti
control
review
reduc
time
result
releas
time
maintain
high
qualiti
review
result
releas
estim
implement
addit
area
reduc
turnaround
time
hour
reduct
review
time
allow
qualiti
control
staff
perform
detail
qualiti
verif
area
outsid
test
process
includ
facil
cleanli
appropri
label
storag
materi
train
safeti
tabl
transfus
protocol
follow
among
adult
report
common
incid
code
product
administ
conclus
total
incid
report
rate
pediatr
vs
adult
patient
significantli
differ
higher
rate
associ
pediatr
transfus
pediatr
patient
higher
number
protocol
follow
report
adult
patient
higher
number
administ
report
understand
patient
safeti
event
relat
blood
transfus
help
target
hemovigil
educ
intervent
appropri
patient
popul
backgroundcas
studi
softwar
electron
posit
patient
identif
eppid
blood
transfus
implement
novemb
inpati
ambulatori
transfus
hospit
technolog
util
barcod
wristband
barcod
print
blood
compon
label
implement
embrac
nurs
remov
manual
process
two
licens
independ
practition
verifi
patient
identif
mppid
blood
compon
transfus
intraop
intraop
transfus
exclud
initi
scope
studi
designmethod
multidisciplinari
committe
assembl
identifi
feasibl
util
eppid
intraop
transfus
address
remov
mppid
decreas
blood
compon
wastag
improv
complianc
blood
administr
document
pilot
design
eppid
instal
cardiac
surgeri
oper
room
or
train
includ
video
interact
handson
session
led
clinic
informat
superus
total
anesthesiologist
provid
train
pilot
includ
case
ran
week
onlin
survey
creat
solicit
feedback
provid
pilot
complet
januari
committe
recommend
expans
remain
or
provid
train
expans
complet
decemb
data
includ
pilot
number
n
case
use
eppid
blood
compon
n
scan
return
blood
bank
patient
safeti
risk
post
expans
transfus
n
use
eppid
compar
mppid
overal
complianc
day
massiv
transfus
event
exclud
resultsfind
pilot
case
complet
provid
transfus
use
eppid
unit
scan
return
onlin
survey
convey
provid
felt
eppid
improv
patient
safeti
decreas
blood
wastag
desir
use
eppid
transfus
follow
expans
transfus
audit
tabl
show
noncompli
due
user
error
eppid
softwar
post
expans
show
eppid
complianc
increas
compar
mppid
previou
audit
day
post
expans
use
mppid
transfus
decreas
later
audit
conclus
pilot
studi
show
feasibl
provid
accept
eppid
intraop
transfus
creat
momentum
expans
eppid
or
strong
collabor
stakehold
combin
step
implement
pilot
follow
expans
eppid
bar
scan
technolog
allow
increas
patient
safeti
workflow
effici
intraop
suit
backgroundcas
studi
appropri
util
blood
compon
crucial
patient
safeti
improv
outcom
base
multipl
random
control
trial
hemoglobin
hgb
threshold
prophylact
rbc
transfus
lower
gdl
howev
guidelin
emphas
use
hgb
level
sole
criterion
make
transfus
decis
institut
current
threshold
coincid
hgb
critic
valu
gdl
critic
valu
defin
life
threaten
laboratori
valu
requir
time
provid
notif
prompt
clinician
take
action
avoid
signific
morbid
mortal
hypothesi
critic
valu
notif
affect
provid
decis
transfus
alert
hgb
level
gdl
aim
determin
critic
valu
low
hgb
valu
threshold
prophylact
transfus
lead
overutil
rbc
transfus
backgroundcas
studi
hospitalbas
blood
bank
high
volum
laboratori
process
approxim
specimen
per
year
blood
bank
specimen
unaccept
unlabel
unsign
miss
necessari
patient
identifi
document
case
new
specimen
request
drawn
per
protocol
attempt
decreas
number
unaccept
specimen
immedi
notif
nurs
manag
nm
prompt
debrief
process
staff
initi
june
decreas
number
unaccept
specimen
implement
addit
qualiti
improv
process
studi
designmethod
april
new
patient
safeti
initi
establish
rolledout
facil
wide
multidisciplinari
effort
includ
nurs
educ
hospit
qualiti
laboratori
medicin
includ
awar
campaign
mind
draw
patient
specimen
mind
accur
patient
id
begin
two
slogan
use
print
teeshirt
worn
project
champion
blood
bank
also
redesign
specimen
requisit
form
reflect
initi
new
requisit
form
includ
remind
import
step
patient
identif
id
specimen
collect
process
stop
sign
use
anchor
form
along
slogan
instruct
includ
prompt
bring
label
requisit
form
patient
bedsid
minim
disrupt
ie
close
curtain
check
patient
identifi
document
label
tube
bedsid
two
staff
remain
patient
room
procedur
complet
two
signatureindepend
patient
id
resultsfind
chart
repres
unaccept
specimen
averag
monthli
unaccept
specimen
identifi
blood
bank
half
data
prior
half
first
quarter
postin
upon
review
unaccept
specimen
sinc
januari
implement
new
initi
led
decreas
averag
number
unaccept
specimen
per
month
sinc
kickoff
april
conclus
mind
initi
awar
campaign
led
signific
decreas
number
unaccept
specimen
identifi
blood
bank
step
map
remind
polici
relat
specimen
collect
patient
id
heighten
awar
correct
patient
specimen
label
improv
patient
safeti
patient
experi
backgroundcas
studi
inventori
manag
depart
imd
blood
center
distribut
roughli
unit
annual
found
six
distribut
hub
standard
oper
depart
qualiti
error
investig
increas
percent
two
year
cost
depart
estim
labor
identifi
trend
depart
began
investig
use
leansix
sigma
methodolog
defin
process
base
valu
ad
step
outcom
decreas
error
qualiti
studi
designmethod
imd
identifi
increas
process
investig
result
high
potenti
loss
product
revenu
imd
implement
leansix
sigma
methodolog
reevalu
procedur
find
defect
process
begin
repres
blood
center
six
distribut
hub
map
process
complet
current
imd
util
qualiti
improv
tool
publish
tool
time
healthcar
langford
intern
inc
team
began
system
analysi
identifi
process
defect
impact
custom
upon
conclus
discoveri
workshop
found
six
hub
oper
manner
slight
varianc
process
creat
opportun
error
team
use
process
benchmark
tool
identifi
distribut
hub
oper
differ
upon
complet
activ
determin
standard
oper
procedur
need
updat
includ
specif
step
elimin
document
resultsfind
seventeen
distribut
depart
standard
oper
procedur
rewritten
inclus
hub
includ
definit
direct
process
team
identifi
execut
across
organ
result
depart
saw
decreas
product
qualiti
investig
almost
two
yearsa
total
cost
save
nearli
conclus
inventori
manag
depart
dedic
continu
improv
plan
motiv
posit
result
seen
calendar
year
distribut
depart
plan
continu
evalu
procedur
base
leansix
sigma
methodolog
frequenc
caus
standard
oper
procedur
deviationsa
year
review
linda
mamon
amna
iftikhar
edward
j
yoon
moham
alsammak
backgroundcas
studi
standard
oper
procedur
sop
critic
standard
laboratori
test
result
blood
bank
per
aabb
standard
except
polici
process
procedur
must
warrant
clinic
situat
requir
justif
preapprov
medic
director
gener
uncommon
event
individu
may
rais
concern
system
action
issu
order
better
understand
incid
context
deviat
identifi
potenti
area
improv
educ
compon
ongo
qualiti
assur
control
qaqc
sought
review
institut
prior
occurr
sop
deviat
backgroundcas
studi
rare
occas
symptom
hypotens
lead
transfus
reaction
tr
occur
receiv
salvag
autolog
blood
autotransfus
team
process
investig
possibl
reason
reaction
due
infrequ
tr
workup
procedur
sop
lack
organ
continu
work
flow
hinder
confid
staff
biennial
sop
review
recogn
rare
use
process
revis
five
year
earli
appli
lean
tool
improv
process
increas
effici
studi
designmethod
three
trainer
appli
lean
techniqu
month
sort
set
order
shine
standard
sustain
framework
elimin
obsolet
excess
document
sop
improv
locat
number
suppli
need
complet
workup
educ
tool
creat
practic
team
assist
trainer
revis
sop
implement
compet
assess
perform
employe
event
monitor
chang
implement
survey
present
employe
measur
satisfact
revis
resultsfind
new
step
practic
wet
lab
employe
garner
opinion
comfort
level
practic
scenario
trainer
gather
question
team
includ
train
modul
futur
employe
sop
written
recip
format
action
step
result
three
page
step
elimin
sop
time
perform
process
drop
four
hour
two
hour
sever
time
measur
premad
tr
kit
elimin
reduc
wast
suppli
kept
organ
locat
access
compet
assess
pass
employe
five
event
relat
miss
step
process
implement
new
sop
zero
event
report
satisfact
survey
show
prior
implement
scale
highest
averag
employe
comfort
level
four
revis
process
took
effect
employe
rate
chang
seven
scale
conclus
util
techniqu
reduc
wast
decreas
time
need
complet
work
intraop
tr
increas
staff
comfort
level
new
process
zero
event
report
implement
new
sop
recogn
streamlin
result
increas
compet
gaug
employe
comfort
level
import
factor
determin
chang
process
increas
accuraci
confid
level
among
staff
backgroundcas
studi
proper
storag
vapor
phase
nitrogen
freezer
vpnf
liquid
phase
nitrogen
freezer
lpnf
essenti
ensur
qualiti
cryopreserv
hematopoiet
stem
cell
product
aabb
fact
accredit
progenitor
cell
process
lab
defici
incid
cryostorag
process
respons
recent
wellpublic
cryostorag
failur
want
determin
product
truli
safe
previous
believ
studi
designmethod
oper
qualiti
medic
staff
critic
review
equip
monitor
system
process
procedur
perform
failur
mode
effect
analysi
fmea
determin
cryostorag
system
could
fail
resultsfind
vpnf
lpnf
reli
proper
vacuum
insul
lid
seal
maintain
level
temperatur
proper
function
solenoid
valv
enabl
vpnf
automat
fill
current
process
control
detect
insul
lid
solenoid
malfunct
includ
temperatur
oxygen
level
monitor
redund
alarm
check
detect
freezer
integr
failur
manufactur
prevent
mainten
recommend
intend
prevent
failur
eg
biannual
solenoid
replac
follow
manual
level
measur
manual
fill
backup
assur
adequ
level
autom
failur
lpnf
accumul
sludg
frost
make
manual
level
measur
difficult
could
lead
failur
detect
chang
consumpt
indic
compromis
freezer
integr
procedur
includ
standard
instruct
level
measur
condit
current
process
control
ensur
ampl
suppli
includ
stand
order
manifold
connect
freezer
multipl
tank
monitor
tank
level
critic
reexamin
onsit
disast
plan
suppli
reveal
extern
access
therefor
readili
avail
lastli
failur
respond
alarm
addit
potenti
failur
mode
use
electron
monitor
system
contact
design
personnel
respons
obtain
addit
procedur
clearli
delin
parti
respons
respond
alarm
select
staff
enhanc
secur
clearanc
may
inhibit
alarm
longer
minut
therefor
confid
alarm
would
trigger
appropri
action
conclus
fmea
allow
us
conclud
product
safe
store
risk
unrecogn
temperatur
excurs
well
manag
opportun
improv
would
enhanc
safeti
product
provid
addit
peac
mind
success
identifi
backgroundcas
studi
healthcar
imper
provid
optim
care
without
wast
resourc
crossmatch
follow
rbc
transfus
tx
within
hour
repres
potenti
area
resourc
optim
concurr
antibodi
screen
unexpectedli
convert
tx
request
may
result
potenti
avoid
delay
patient
care
assess
issu
institut
perform
audit
antibodi
screen
crossmatch
order
determin
whether
follow
tx
within
hour
studi
designmethod
antibodi
screen
crossmatch
order
sampl
receiv
institut
blood
bank
review
one
month
period
depart
dpt
order
provid
obtain
via
electron
record
tx
record
patient
correspond
order
referenc
determin
patient
receiv
tx
within
hour
screen
crossmatch
order
effici
ratio
efr
calcul
divid
either
number
crossmatch
order
number
tx
event
result
order
number
antibodi
screen
order
number
nontx
event
follow
order
ratio
consid
optim
resultsfind
total
crossmatch
order
antibodi
screen
evalu
crossmatch
order
result
tx
within
hour
efr
antibodi
screen
order
follow
tx
order
efr
order
effici
differ
depart
emerg
medicin
em
worst
efr
crossmatch
order
intern
medicin
im
worst
efr
antibodi
screen
order
tabl
conclus
audit
crossmatch
order
lead
tx
common
antibodi
screen
order
follow
unplan
tx
suggest
former
might
signific
issu
focus
qualiti
improv
depart
requir
intervent
obgyn
hemeonc
dpt
provid
demonstr
highli
effici
order
practic
futur
work
includ
evalu
nonpati
factor
em
surgeri
dpt
protocol
standard
order
set
may
contribut
rel
ineffici
screen
crossmatch
order
practic
observ
terri
coyl
kristi
clymer
erik
scott
jame
r
stubb
mayo
clinic
backgroundcas
studi
facil
recent
implement
new
blood
donor
comput
system
collect
manufactur
valid
convert
data
donor
legaci
system
ls
new
system
ns
recommend
fda
guidanc
industri
blood
establish
comput
system
valid
user
facil
april
team
develop
convers
valid
plan
execut
use
dream
coder
excel
power
queri
pq
screen
print
comparison
convers
plan
includ
risk
assess
softwar
tabl
donor
data
dd
element
establish
number
screen
print
verifi
data
ls
ns
dream
coder
use
popul
inform
convert
data
ls
ns
use
vendor
provid
convers
file
studi
designmethod
sixtyfour
tabl
provid
tabl
convers
process
sixteen
tabl
use
data
convers
tabl
use
ls
fortyeight
tabl
load
valid
environ
verifi
copi
product
environ
pq
develop
use
ls
ns
databas
take
account
convers
data
element
ls
ns
pq
use
ensur
dd
come
ls
match
migrat
ns
fortyseven
pq
use
compar
dd
databas
pq
consist
ls
ns
merg
queri
merg
queri
filter
match
record
identifi
discrep
data
two
system
screen
print
review
confirm
convert
dd
popul
correct
field
ns
ls
data
migrat
per
week
ns
reject
file
pq
issu
review
inform
technolog
group
resolv
data
migrat
issu
file
review
vendor
could
resolv
issu
determin
data
migrat
script
need
chang
vendor
adjust
import
script
dd
migrat
six
import
script
need
correct
final
dd
migrat
three
reject
file
three
differ
import
script
pq
identifi
two
addit
dd
discrep
conclus
decad
worth
dd
move
ensur
data
correctli
convert
requir
deploy
new
comput
system
perform
data
extract
migrat
multipl
time
review
data
pq
abl
identifi
data
element
transfer
correctli
correct
import
script
discrep
resolv
prior
go
live
end
confid
dd
accur
convert
migrat
allow
high
degre
certainti
continu
provid
safest
blood
patient
protect
valuabl
blood
donor
ensur
desir
therapeut
dose
platelet
compli
qualiti
control
requir
necessari
quantifi
amount
harvest
platelet
obtain
apheresi
procedur
object
verifi
complianc
schedul
plateletsharvest
obtain
amicu
cell
separ
studi
designmethod
two
devic
amicu
separ
system
evalu
prior
verif
technic
support
servic
made
adjust
separ
platelet
yield
adjust
pya
effect
adjust
assess
verifi
perform
separ
amicu
simpl
schedul
harvest
correl
platelet
program
cellsepar
plateletharvest
obtain
qualiti
control
verifi
base
criteria
establish
manufactur
expect
bia
carri
statist
analysi
establish
protocol
clsi
document
platelet
count
qualiti
control
carri
use
cellcount
analyt
control
iso
accredit
regulatori
requir
mexico
harvest
platelet
singl
product
platelet
unit
unit
test
decid
make
comparison
demand
requir
aabb
plateletsunit
unit
test
evalu
distribut
plateletharvest
obtain
averag
bia
percentag
noncompli
requir
establish
obtain
account
resultsfind
perform
singl
procedur
procedur
averag
valu
harvest
platelet
respect
minimum
valu
maximum
averag
bia
separ
kurtosi
valu
valu
total
bia
process
accord
protocol
fulfil
comparison
schedul
harvest
harvest
obtain
measur
cell
counter
process
perform
separ
fulfil
criteria
establish
aabb
platelet
harvest
occur
process
analyz
separ
data
show
wide
variabl
program
platelet
harvest
obtain
complianc
although
confus
variabl
relat
donor
analyz
differ
could
relat
platelet
collect
system
well
fact
apheresi
system
estim
platelet
collect
measur
platelet
obtain
carri
cellcount
devic
analyt
control
would
explain
nonnorm
distribut
data
obtain
separ
would
question
use
protocol
employ
quantit
test
howev
separ
meet
requir
establish
aabb
respect
valid
perform
devic
singl
platelet
harvest
aborh
test
event
gel
test
methodolog
implement
staci
coleman
janet
dornfeld
ami
mata
camil
van
buskirk
backgroundcas
studi
octob
larg
hospitalbas
transfus
laboratori
switch
manual
test
methodolog
laboratori
tube
test
previou
year
prepar
chang
autom
platform
decis
made
convert
manual
test
first
gel
thought
standard
stabil
test
platform
test
error
would
decreas
howev
case
particular
manual
aborh
test
studi
designmethod
control
chart
maintain
display
event
test
perform
laboratori
includ
aborh
antibodi
screen
direct
antiglobulin
test
antibodi
identif
antigen
type
control
chart
set
upper
warn
limit
sd
control
limit
sd
upper
warn
limit
reach
indic
indepth
review
event
need
done
octob
limit
reach
aborh
test
analysi
event
perform
resultsfind
comparison
number
event
occur
octob
octob
doubl
per
aborh
test
upon
investig
half
event
pre
gel
implement
half
post
howev
look
closer
post
implement
event
impact
twice
number
patient
involv
two
patient
compar
pre
post
event
pre
implement
event
rang
forget
add
antid
miss
mix
field
problem
test
equip
would
solv
gel
technolog
post
implement
event
occur
technologist
perform
aborh
multipl
patient
card
interchang
read
enter
reaction
laboratori
inform
system
label
card
left
tech
prefer
minimum
need
two
patient
identifi
tech
train
verifi
specimen
label
prior
result
entri
use
process
pre
implement
special
emphasi
given
tech
verifi
gel
card
well
three
post
implement
event
two
identifi
test
tech
enter
result
third
caught
due
mismatch
autom
instrument
conclus
switch
gel
test
elimin
rang
defect
creat
new
one
rare
seen
tube
test
uptick
specif
type
event
lab
standard
tech
label
gel
card
requir
card
label
minimum
patient
initi
full
medic
record
number
addit
tech
requir
open
result
grid
card
rather
sampl
card
set
reason
card
must
reverifi
prior
result
sinc
standard
implement
similar
event
occur
time
public
process
improv
ensur
rh
immun
globulin
rhig
prophylaxi
postpartum
rhneg
women
jennif
woo
rosalin
elizabet
lome
ami
decourten
jennif
martinez
ashok
nambiar
morvarid
moayeri
ucsf
health
backgroundcas
studi
process
ensur
administr
prophylact
rh
immun
globulin
rhig
import
manag
rhneg
women
complianc
aabb
standard
determin
postpartum
rhig
prophylaxi
particularli
challeng
entail
test
mother
babi
result
evalu
togeth
clinic
decis
make
includ
reflex
test
addit
laboratori
studi
miss
test
deviat
test
procedur
result
failur
provid
appropri
adequ
dose
rhig
studi
designmethod
examin
error
deviat
relat
postpartum
immunohematolog
test
rhig
prophylaxi
hospit
error
aris
provid
side
includ
failur
use
electron
order
set
result
omiss
fetal
bleed
screen
test
rhig
order
blood
bank
error
includ
failur
perform
reflex
test
weak
test
rhneg
cord
blood
kleihauerbetk
assay
posit
invalid
fetal
bleed
screen
error
includ
perform
weak
indic
rhneg
babi
born
rhposit
mother
report
rhnegativeweak
dposit
babi
type
rhposit
report
invalid
posit
weak
result
initi
gener
daili
laboratori
inform
system
report
retrospect
audit
identifi
case
weak
test
miss
subsequ
order
prevent
miss
weak
test
also
address
addit
failur
point
system
design
implement
cord
blood
worksheet
technologist
complet
worksheet
cord
blood
test
use
algorithm
checklist
approach
perform
complet
requir
test
sampl
babi
mother
worksheet
also
captur
document
relat
time
order
provid
issu
rhig
blood
bank
resultsfind
sinc
implement
cord
blood
worksheet
note
error
relat
blood
bank
test
appropri
administr
postpartum
rhig
prophylaxi
worksheet
made
workflow
safer
help
ensur
facil
complianc
aabb
standard
cord
blood
worksheet
also
serv
valuabl
educ
tool
traine
graduat
medic
educ
program
conclus
util
cord
blood
worksheet
simpl
yet
effect
way
guid
accur
immunohematolog
test
prompt
provid
place
appropri
order
postpartum
rhig
prophylaxi
ensur
rhig
issu
blood
bank
time
manner
achiev
oper
excel
cultur
peopl
jason
siebert
mark
malon
rafael
portela
blood
system
inc
backgroundcas
studi
oper
excel
oe
applic
far
reach
benefit
organ
includ
reduc
signific
wast
empow
staff
becom
problem
solver
cost
save
despit
mani
benefit
oe
initi
struggl
roadblock
incorpor
oper
excel
oe
exist
busi
cultur
requir
effect
strateg
plan
studi
explor
strategi
use
success
incorpor
oper
excel
busi
cultur
studi
designmethod
oe
steer
committe
formul
member
variou
function
depart
develop
evalu
metric
track
gemba
walk
oe
huddl
effect
ascertain
oe
success
deploy
throughout
organ
metric
target
track
weekli
determin
gap
overcom
resultsfind
initi
train
particip
manag
low
function
depart
report
gemba
walk
given
month
addit
manag
perform
requir
number
gemba
walk
per
month
oe
huddl
preassess
score
oe
huddl
effect
post
assess
score
contribut
lack
staff
particip
roadblock
discuss
key
busi
metric
display
huddl
year
oe
signific
improv
made
function
depart
report
gemba
walk
manag
perform
requir
gemba
walk
per
month
addit
oe
huddl
preassess
score
due
increas
staff
particip
effect
busi
metric
huddl
group
began
review
roadblock
respect
countermeasur
conclus
particip
low
begin
variou
critic
oe
activ
low
particip
due
busi
prioriti
challeng
forc
oe
background
addit
manag
get
offic
observ
work
perform
manag
perform
gemba
walk
understand
principl
behind
final
natur
work
team
indic
train
understand
basic
principl
conduct
oe
huddl
cours
year
busi
start
incorpor
oe
cultur
success
contribut
coach
workshop
frequent
report
metric
encourag
improv
recognit
success
also
staff
better
understand
appli
oe
workplac
motiv
start
use
problem
solv
tool
pdsa
undesir
impact
implement
electron
medic
record
nikolina
dioufa
richard
morri
amna
iftikhar
edward
j
yoon
moham
alsammak
templ
univers
hospit
backgroundcas
studi
electron
medic
record
emr
computer
physician
order
entri
cpoe
facilit
laboratori
test
medic
imag
order
revolution
healthcar
across
countri
past
decad
advantag
includ
signific
decreas
drug
expenditur
improv
effici
diagnost
upgrad
record
report
bill
servic
decreas
bill
error
howev
cpoe
may
also
unexpect
neg
impact
laboratori
includ
blood
bank
bb
affect
test
volum
turnaround
time
tat
qualiti
metric
institut
stat
request
emerg
depart
ed
complet
within
minut
averag
implement
emr
averag
drop
significantli
mandat
analysi
identifi
caus
possibl
solut
improv
studi
designmethod
retrospect
review
number
stat
request
type
screen
ts
receiv
ed
prior
execut
emr
sampl
ed
patient
record
stat
order
nonconsecut
month
assess
clinic
justif
patient
present
complaint
requir
stat
ts
b
whether
patient
transfus
resultsfind
emr
bb
receiv
monthli
averag
hand
written
stat
ts
order
ed
execut
emr
averag
monthli
stat
order
increas
target
tat
met
order
review
nontrauma
patient
record
present
complaint
justifi
stat
ts
account
includ
acut
neurolog
cardiovascular
symptom
gi
obgyn
bleed
anemia
within
categori
major
patient
anemia
receiv
transfus
other
transfus
clinic
unjustifi
group
includ
patient
complaint
urolog
pain
dermatolog
symptom
local
infect
intoxicationnon
transfus
investig
show
ts
order
ed
includ
default
prepopul
order
set
default
stat
conclus
although
implement
emr
cpoe
facilit
appropri
priorit
effici
ts
order
come
without
pitfal
autom
preselect
menu
option
may
result
unnecessari
request
exponenti
increas
workload
could
lead
error
delay
result
issu
blood
product
disrupt
qualiti
program
close
monitor
educ
commun
clinic
team
develop
order
set
judici
use
default
set
use
evidencebas
best
practic
alert
bpa
may
help
earli
identif
mitig
undesir
impact
emr
implement
smartphon
app
calcul
minimum
blood
volum
need
laboratori
test
ray
zhang
washington
univers
school
medicin
backgroundcas
studi
blood
draw
laboratori
test
lead
iatrogen
anemia
morbid
risk
factor
pediatr
critic
ill
popul
calcul
minimum
volum
need
test
requir
laboratori
assist
typic
impract
clinician
goal
project
develop
smartphon
app
perform
calcul
bedsid
reduc
number
tube
volum
blood
drawn
atrisk
patient
studi
designmethod
smartphon
app
io
android
devic
develop
user
input
desir
test
select
larg
academ
medic
center
test
menu
app
output
mani
type
blood
collect
tube
need
well
minimum
blood
volum
requir
within
tube
instrument
dead
volum
hematocrit
correct
taken
account
test
may
optim
perform
blood
specimen
combin
calcul
quickselect
interfac
frequent
order
test
present
resultsfind
app
incorpor
test
panel
encompass
central
laboratori
instrument
system
collect
tube
type
specimen
type
hous
staff
nurs
pediatr
intens
care
unit
picu
integr
app
critic
care
workflow
usag
user
feedback
specimen
collect
pattern
patient
outcom
follow
report
preliminari
feedback
picu
central
laboratori
use
overwhelmingli
posit
conclus
app
tinyblood
greatli
simplifi
calcul
minimum
blood
volum
need
laboratori
test
receiv
overwhelmingli
posit
feedback
avail
free
io
android
hit
wide
use
increas
avail
univers
rbc
implement
program
often
prolong
difficult
journey
variabl
degre
success
effect
use
leadership
principl
avoid
project
pitfal
studi
describ
success
launch
program
use
strateg
phase
team
select
multidisciplinari
collabor
exceed
product
right
type
mix
rtm
goal
studi
designmethod
project
divid
phase
valid
rampup
steadi
state
growth
distinct
prioriti
approach
valid
phase
focus
quickli
accumul
requir
collect
meet
qualiti
paramet
therefor
approach
includ
care
select
donor
known
pool
commit
wb
donor
staff
technic
train
vendor
educ
onsit
support
rampup
phase
priorit
wb
donor
convers
approach
reli
core
team
select
train
staff
perform
manag
therefor
base
convers
rather
total
wb
procedur
rtm
goal
foster
collabor
remov
conflict
interest
recruit
collect
staff
group
receiv
credit
collect
regardless
procedur
type
steadi
state
would
priorit
donor
pool
manag
new
donor
convers
procedur
net
success
rtm
key
perform
indic
kpi
core
collect
team
select
wb
apheresi
pool
basi
technic
skill
also
posit
attitud
abil
commun
motiv
influenc
other
donor
team
member
train
includ
signific
vendor
support
encompass
technic
aspect
also
approach
donor
handl
respons
includ
roleplay
scenario
prior
collect
date
team
member
identifi
good
candid
collect
base
blood
type
size
preview
elig
notifi
everi
member
collect
staff
everi
staff
member
make
touchpoint
donor
particip
onsit
convers
daili
result
celebr
obstacl
face
collabor
backgroundcas
studi
industri
includ
blood
donor
center
experienc
challeng
dissemin
inform
time
effect
manner
maintain
minim
disrupt
oper
one
solut
mitig
commun
issu
team
huddl
prior
implement
weekli
huddl
monthli
meet
primari
mean
commun
howev
meet
attend
low
blood
collect
reduc
staff
survey
result
indic
commun
within
work
unit
need
improv
intent
weekli
huddl
posit
impact
commun
reach
staff
minim
disrupt
work
flow
commun
discuss
updat
issu
time
manner
provid
forum
staff
bring
forth
concern
ask
question
studi
designmethod
weekli
huddl
implement
late
two
minut
huddl
held
week
central
locat
within
work
area
blood
collect
reduc
huddl
follow
specif
agenda
templat
cover
updat
donor
appoint
schedul
mobil
schedul
train
equip
procedur
staff
recognit
addit
gener
updat
remind
discuss
staff
encourag
ask
question
bring
forth
concern
april
survey
sent
current
staff
gain
insight
perceiv
impact
weekli
huddl
well
commun
prefer
attend
record
monthli
meet
weekli
huddl
also
compar
resultsfind
survey
respons
rate
result
show
prefer
commun
method
email
follow
close
weekli
huddl
individu
facetofac
tie
second
mostfavor
commun
method
lessfavor
commun
method
includ
monthli
meet
signagejob
aid
offic
commun
huddl
improv
commun
within
work
unit
accord
survey
respond
indic
inform
share
huddl
keep
uptod
chang
occur
within
work
unit
addit
agre
huddl
provid
venu
bring
forth
concern
ask
question
overal
respond
feel
huddl
worthwhil
use
time
staff
attend
weekli
huddl
shown
increas
monthli
meet
attend
conclus
frequenc
effect
huddl
improv
commun
well
negat
need
tradit
monthli
staff
meet
focu
monthli
meet
shift
educ
opportun
recent
manag
staff
attend
educ
event
team
huddl
learn
new
tactic
incorpor
huddl
includ
huddl
board
display
inform
dashboard
share
relev
statist
schedul
huddl
throughout
week
reach
staff
improv
timeli
inform
deliveri
plan
implement
new
transfus
servic
alexandra
budhai
john
fallon
patricia
v
adem
westchest
medic
center
backgroundcas
studi
organ
undergon
dramat
chang
recent
year
evolv
singlesit
tertiaryquaternari
care
center
greater
bed
becom
headquart
bed
multisit
system
keep
institut
push
unifi
process
achiev
better
patient
outcom
conserv
limit
resourc
evalu
exist
arrang
within
clinic
laboratori
blood
product
pretransfus
test
medicaladministr
oversight
transfus
servic
current
provid
region
blood
center
contractu
arrang
began
mani
year
ago
facil
function
small
commun
hospit
evolut
medic
center
network
necessit
explor
develop
implement
insourc
transfus
servic
describ
process
involv
studi
designmethod
sought
develop
expand
global
vision
insourc
central
transfus
servic
serv
patient
need
main
hospit
across
network
gap
analysi
project
budget
gantt
chart
util
determin
minimum
necessari
requir
associ
expens
onetim
recur
timelin
deliver
resultsfind
gap
analysi
entail
assess
exist
infrastructur
softwar
system
personnel
laboratori
equip
adequaci
tandem
regulatori
personnel
equip
infrastructur
requir
necessari
safe
support
high
volum
transfus
servic
item
step
necessari
bridg
gap
catalog
budget
accordingli
propos
show
favor
return
invest
within
five
year
approv
hospit
administr
develop
gantt
chart
organ
deliver
coordin
task
timelin
make
apprais
appropri
window
task
complet
provid
aid
formul
evalu
deadlin
respect
task
requir
one
year
prior
goliv
continu
post
goliv
hold
weekli
meet
formal
minut
ensur
adher
schedul
prompt
attent
problem
mani
aspect
project
move
parallel
requir
care
choreograph
serial
approach
necessit
map
event
order
avoid
pitfal
unforeseen
hurdl
hire
procur
effort
briefli
stall
administr
confront
possibl
significantli
reduc
financi
alloc
state
conclus
care
plan
research
implement
new
transfus
servic
could
achiev
one
year
timelin
timefram
month
would
enabl
adequ
buffer
account
unforeseen
fund
regulatori
impedi
state
feder
level
backgroundcas
studi
draft
guidanc
bpac
fda
propos
method
mitig
risk
bacteri
contamin
platelet
extent
method
impact
platelet
avail
product
cost
must
evalu
herein
attempt
categor
product
financi
impact
associ
bacteri
detect
cultur
bd
studi
designmethod
model
built
assess
product
econom
impact
bacteri
safeti
method
describ
background
blood
center
bc
hospit
abstract
bc
impact
discuss
month
platelet
collect
data
one
bc
analyz
determin
split
rate
sr
total
result
apheresi
platelet
compon
bacteri
safeti
method
method
collect
optim
ensur
maximum
platelet
compon
product
maximum
unit
elig
pr
without
impact
sr
also
calcul
permut
direct
indirect
cost
incur
collect
compon
process
test
releas
assess
static
indirect
cost
eg
administr
includ
revenu
base
sell
price
bd
pr
compon
bc
applic
upcharg
cmv
irradi
averag
direct
cost
associ
dlvc
bd
ad
upcharg
resultsfind
conclus
implement
bacteri
safeti
measur
impact
platelet
avail
day
usabl
shelf
life
product
cost
perform
pr
product
feasibl
bc
without
impact
avail
sr
pr
may
offset
financi
loss
associ
bacteri
safeti
measur
higher
valu
pr
gener
tie
broad
safeti
profil
replac
cmv
irradi
bc
must
select
product
method
consider
hospit
custom
need
willingness
perform
poi
test
bd
use
data
maxim
staff
util
nanett
johnson
kathi
j
kaherl
lean
ziebel
sandra
j
nanc
american
red
cross
american
red
cross
american
rare
donor
program
backgroundcas
studi
well
document
laboratori
workforc
shrink
due
diminish
influx
medic
technolog
mt
medic
laboratori
technician
mlt
graduat
immin
retir
babi
boomer
competit
new
graduat
fierc
applic
experienc
mtmlt
immunohematolog
refer
laboratori
irl
job
larg
metropolitan
area
rare
workload
referr
lab
increas
hospit
outsourc
antibodi
work
workload
staf
larg
irl
increas
respect
staff
retent
rate
sinc
multipl
complianc
risk
factor
prompt
intens
execut
leadership
scrutini
oversight
deep
dive
caus
complianc
risk
identifi
need
stratifi
workforc
map
task
appropri
job
posit
studi
designmethod
complex
task
time
exercis
perform
return
staff
util
figur
irl
respect
optim
staff
util
target
indic
staff
stretch
beyond
maximum
capac
data
exercis
staff
tabl
organ
review
three
largest
irl
two
high
complianc
risk
individu
staff
interview
observ
perform
independ
parti
familiar
laboratori
process
procedur
resultsfind
two
irl
b
c
higher
complianc
risk
spent
twice
much
time
nontest
task
train
compet
assess
equip
qualif
test
task
number
virtual
ident
irl
good
stand
irl
good
stand
three
four
time
staff
support
role
two
irl
higher
complianc
risk
data
analysi
recommend
independ
review
result
addit
two
lab
assist
two
oper
support
specialist
technic
trainer
administr
assist
assum
nontest
task
increas
supervisori
presenc
lab
cultur
qualiti
focus
first
time
right
implement
allow
laboratori
quickli
reach
regulatori
complianc
sustain
month
count
conclus
time
studi
coupl
map
task
job
descript
essenti
exercis
maxim
product
certifi
technic
staff
ad
staff
lower
compens
rate
effect
increas
manpow
product
without
ad
expens
abil
certifi
technic
staff
focu
test
task
increas
supervisori
oversight
enhanc
regulatori
complianc
rais
moral
staff
joshua
flerching
roger
godic
raleigh
krigbaum
carol
dumont
suzann
bakdash
cleveland
clinic
backgroundcas
studi
intraop
cell
salvag
periop
autotransfus
servic
util
either
onboard
machin
wall
suction
vacuum
regul
collect
blood
surgic
field
exist
regul
requir
costli
timeconsum
annual
prevent
mainten
pm
outsid
vendor
addit
function
verif
tech
regul
sent
annual
pm
unavail
sever
week
inoper
return
requir
replac
altern
vacuum
regul
lower
cost
less
time
laborintens
pm
identifi
evalu
exist
regul
studi
designmethod
vacuum
regul
design
cell
salvag
new
vacuum
regul
nvr
obtain
trial
compar
exist
gener
use
vacuum
regul
current
vacuum
regul
cvr
guidelin
avail
perform
comparison
attempt
simul
condit
daili
use
one
regul
model
attach
hospit
wall
vacuum
system
set
aspir
normal
salin
basin
initi
set
use
one
aspirationanticoagul
set
ana
set
yankauer
suction
tip
time
long
took
entir
aspir
content
basin
sinc
surgic
team
commonli
request
two
ana
set
util
one
aspir
field
process
repeat
two
ana
set
one
line
use
aspir
content
basin
left
open
atmospher
resultsfind
use
one
ana
set
regul
model
clear
salin
basin
second
use
two
ana
set
one
line
use
second
open
atmospher
cvr
model
aspir
salin
second
nvr
model
clear
basin
second
find
reproduc
repeat
test
acquisit
cost
nvr
model
higher
cvr
model
howev
cost
analysi
prove
replac
cvr
nvr
would
yield
return
invest
sinc
nvr
model
warranti
annual
pm
requir
given
oper
test
result
high
rate
eas
use
tech
anticip
time
labor
save
favor
cost
analysi
exist
cvr
model
replac
nvr
implement
new
nvr
signific
decreas
complaint
surgeon
weak
suction
reduc
need
troubleshoot
case
chang
note
cell
salvag
qualiti
control
paramet
switch
backgroundcas
studi
improv
commun
known
posit
affect
healthcar
oper
patient
safeti
blood
bank
bb
oper
significantli
impact
interrupt
due
phone
call
neg
impact
laboratori
workflow
potenti
affect
patient
care
report
experi
newli
form
oper
taskforc
improv
intern
workflow
interdepartment
commun
studi
designmethod
aim
studi
improv
commun
nurs
personnel
outpati
infus
center
institut
specif
reduc
number
phone
call
unit
time
spent
bb
staff
address
concern
oper
taskforc
blood
bank
ambassador
assembl
bridg
commun
gap
clarifi
workflow
nurs
personnel
group
form
supervisor
specialist
medic
director
intervent
strategi
includ
establish
platform
safe
share
idea
identifi
champion
chang
side
outlin
address
signific
concern
team
clarifi
common
goal
ownership
establish
baselin
followup
metric
initi
meet
held
blood
bank
ambassador
nurs
team
compos
nurs
manag
qualiti
improv
personnel
bedsid
nurs
inform
technolog
specialist
follow
addit
clarif
regular
commun
via
email
preand
postintervent
metric
number
call
bb
estim
time
spent
bb
staff
clarifi
issu
concern
rais
nurs
personnel
resultsfind
baselin
data
show
averag
call
per
month
octob
made
nurs
infus
center
serv
outpati
hematolog
oncolog
servic
institut
approxim
hour
per
month
spent
clarifi
issu
relat
bb
workflow
nurs
unit
common
issu
discuss
transfus
requir
requisit
agre
patient
file
transfus
guidelin
specimen
problem
request
addit
specimen
test
turnaroundtim
blood
product
avail
duplic
order
first
interdepartment
meet
follow
addit
clarif
via
email
call
number
reduc
per
month
decreas
averag
call
per
month
four
consecut
month
januari
april
repres
reduct
baselin
call
number
estim
time
spent
phone
call
conclus
blood
bank
ambassador
significantli
improv
interdepartment
commun
assert
common
leadership
goal
intern
workflow
posit
affect
dramat
reduct
phone
call
time
spent
clarifi
concern
experi
team
may
reveal
key
factor
success
implement
organiz
chang
backgroundcas
studi
acquir
hemophilia
aha
due
spontan
format
autoantibodi
factor
viii
acquir
bleed
disord
signific
morbid
mortal
therapi
includ
immunosuppress
bleed
control
erad
inhibitor
treatment
underli
condit
bleed
patient
hightit
inhibitor
bypass
medic
recombin
activ
factor
vii
rfviia
activ
prothrombin
complex
concentr
apcc
initi
promptli
fdaapprov
treatment
advantag
disadvantag
exampl
rfviia
recombin
product
thu
theoret
less
risk
transfusiontransmit
infect
known
unknown
agent
compar
human
plasmaderiv
product
apcc
howev
cost
rfviia
significantli
higher
thu
develop
econom
model
rigor
examin
cost
effect
rfviia
apcc
scenario
studi
designmethod
markov
decis
analyt
model
develop
simul
hypothet
cohort
adult
patient
bleed
due
aha
treat
either
rfviia
apcc
day
regardless
treatment
model
develop
patient
transit
differ
health
state
continu
bleed
thrombosi
stop
bleed
death
patient
model
bleed
initi
thu
enter
model
stage
depend
probabl
treatment
efficaci
advers
event
subsequ
day
patient
either
remain
state
enter
state
model
absorb
state
mean
patient
transit
state
enter
one
state
patient
experienc
thrombot
event
assum
event
sever
addit
rfviia
apcc
given
also
assum
rebleed
event
cohort
model
paramet
includ
probabl
health
util
index
cost
gather
medic
literatur
except
cost
apcc
rfviia
obtain
institut
data
resultsfind
period
treatment
cost
rfviia
substanti
cost
apcc
vs
averag
qualiti
adjust
life
day
qald
gain
rfviia
slightli
lower
compar
apcc
vs
overal
apcc
prevail
rfviia
suggest
increment
costeffect
ratio
sensit
analysi
also
confirm
robust
model
across
test
rang
input
variabl
conclus
hightit
aha
patient
bleed
apcc
costeffect
compar
rfviia
thu
apcc
use
patient
avail
contraind
clinic
backgroundcas
studi
work
fast
pace
surgic
set
make
difficult
establish
reliabl
staf
level
unpredict
hour
lead
larg
amount
overtim
callback
time
extra
hour
work
put
stress
employe
also
sourc
high
burnout
rate
januari
autotransfus
team
implement
multipl
staf
tool
accommod
high
pace
surgic
environ
creat
improv
worklif
balanc
twelv
technician
studi
designmethod
team
collect
data
case
perform
blood
salvag
procedur
determin
potenti
chang
staf
model
data
includ
averag
length
time
patient
oper
room
hour
averag
number
surgic
case
period
case
data
analysi
defend
follow
addit
schedul
five
hour
shift
convert
hour
shift
third
oncal
technician
two
design
late
shift
cover
potenti
overtim
addit
schedul
chang
implement
pointsystem
commun
sbar
sheet
assist
determin
staf
shift
chang
august
day
current
surgic
case
assign
point
translat
mani
staff
need
end
schedul
shift
eg
one
one
point
process
withdrew
emot
determin
staff
requir
stay
overtim
resultsfind
slight
increas
atstaf
case
overtim
decreas
oncal
hour
increas
howev
minim
increas
callback
hour
per
oncal
posit
tabl
pointsystem
data
indic
end
first
shift
approxim
eight
point
assign
schedul
surgic
case
number
point
specifi
averag
four
technician
need
staff
day
prior
implement
tool
number
technician
need
staff
vari
decid
even
shift
technician
conclus
introduc
staf
workload
tool
abl
make
chang
staf
model
improv
staf
model
result
decreas
overtim
less
callback
hour
per
shift
posit
worklif
balanc
richard
gammon
rita
reik
oneblood
inc
backgroundcas
studi
blood
center
bc
transit
tradit
model
therapeut
phlebotomi
tb
perform
donor
servic
creation
medic
group
oper
licens
medic
clinic
mc
associ
hospit
allow
perform
bill
profession
nurs
physician
consult
servic
associ
tb
mc
serv
whose
diagnos
allow
crossov
phlebotom
product
allogen
inventori
summar
oper
financi
regulatori
process
studi
designmethod
project
champion
chief
medic
offic
cmo
support
bc
senior
execut
manag
sec
multidisciplinari
work
group
establish
includ
bc
project
manag
physician
train
procedur
writer
therapeut
apheresi
nurs
tan
market
financ
qualiti
assur
inform
technolog
facil
extern
consult
bill
credenti
specialist
healthcar
attorney
credenti
mc
physician
center
medicar
medicaid
servic
contract
privat
carrier
need
complet
payment
mc
need
inspect
licens
agenc
health
care
administr
procedur
written
accord
appropri
law
regul
new
electron
medic
record
emr
creat
allow
patient
inform
enter
one
tablet
sync
across
devic
method
collect
insur
copay
createdallow
credit
card
process
cash
check
accept
pilot
program
launch
use
exist
bc
space
modif
reconfigur
recept
area
ensur
emr
visibl
patient
bc
physician
tan
staf
mc
account
receiv
ar
review
resultsfind
workflow
follow
prior
patient
schedul
appoint
walkin
accept
insur
prescript
verifi
copay
confirm
day
presentationcheckin
copay
health
screen
includ
vital
perform
tan
backgroundcas
studi
us
presid
emerg
plan
aid
relief
pepfar
program
integr
blood
safeti
activ
key
strategi
countri
high
preval
hiv
weak
blood
safeti
system
goal
strengthen
blood
transfus
servic
decreas
hiv
transfusiontransmit
infect
tti
provid
univers
access
safe
blood
standard
screen
program
implement
countri
nation
region
blood
center
encompass
questionnair
screen
hivrisk
behavior
exclud
potenti
highrisk
blood
donor
univers
laboratori
test
hiv
tti
current
major
gap
quantifi
impact
pepfar
hiv
transmiss
risk
blood
donat
studi
designmethod
world
health
organ
global
databas
blood
safeti
data
analyz
select
pepfarsupport
countri
subsaharan
africa
asia
caribbean
statist
analysi
perform
use
aim
aid
impact
model
goal
modul
spectrum
softwar
version
laboratori
qualiti
hiv
test
assum
sensit
specif
countryspecif
incid
rate
hiv
calcul
preval
rate
hiv
infect
transmit
blood
transfus
infect
blood
donat
time
impact
laboratori
test
program
blood
donat
hiv
transmiss
risk
blood
transfus
determin
estim
number
new
hiv
infect
avert
sinc
implement
pepfar
program
resultsfind
result
indic
hiv
incid
rate
blood
donat
show
decreas
trend
subsaharan
african
countri
cambodia
haiti
follow
pattern
observ
wide
ushap
trend
ghana
lesotho
guyana
revers
jshape
ethiopia
invert
wide
ushap
tajikistan
backgroundcas
studi
detail
inform
transfus
whole
blood
blood
compon
electron
health
record
ehr
record
inform
standard
blood
transplant
isbt
code
system
unit
state
us
code
system
add
sensit
granular
blood
surveil
code
system
bill
reimburs
code
may
lack
us
food
drug
administr
fda
center
biolog
effect
research
cber
recent
establish
biolog
effect
safeti
best
initi
part
cber
sentinel
program
aim
studi
character
preval
whole
blood
blood
compon
transfus
use
code
particip
data
partner
best
initi
studi
designmethod
explor
approxim
million
patient
record
three
ehr
databas
columbia
univers
stanford
univers
regenstrief
institut
along
librari
code
assess
transfus
whole
blood
blood
compon
red
blood
cell
plasma
cryoprecipit
platelet
resultsfind
transfus
trend
blood
compon
vari
total
transfus
event
red
blood
cell
rbc
account
half
event
platelet
plasma
cryoprecipit
whole
blood
compris
remain
event
observ
increas
rbc
transfus
event
suggest
increas
administr
cryoprecipit
rel
consist
use
plasma
overal
downward
trend
administr
platelet
whole
blood
usag
minim
becam
obsolet
studi
period
conclus
demonstr
use
code
system
feasibl
wellcaptur
within
best
ehr
databas
incorpor
code
cber
blood
surveil
system
enhanc
hemovigil
activ
afford
fda
abil
activ
monitor
blood
compon
util
transfusionrel
advers
event
compar
two
method
estim
hiv
hcv
incid
repeat
unit
state
blood
donor
whitney
steel
lauren
crowder
jame
hayn
ed
p
notari
roger
dodd
susan
l
stramer
american
red
cross
american
red
cross
holland
laboratori
backgroundcas
studi
incid
rate
ir
alway
number
case
divid
total
persontim
pt
risk
popul
question
incid
method
im
way
case
determin
pt
calcul
repeat
blood
donor
often
vari
investig
recent
paper
model
differ
im
hiv
use
simul
donat
infect
data
found
im
use
investig
sinc
elm
extend
lookback
method
result
bias
estim
differ
im
cm
convent
method
prefer
ir
estim
brambilla
transfus
assess
im
perform
actual
donor
data
calcul
hiv
hcv
ir
five
estim
interv
ei
organ
tabl
cm
ir
usual
doubl
ir
elm
correspond
pt
million
million
method
respect
pattern
gener
seen
hcv
except
year
cm
elm
ir
closer
conclus
contrast
analysi
use
simul
data
cm
popul
actual
rpt
donor
produc
consist
higher
ir
compar
elm
advantag
elm
posit
donor
identifi
ei
util
concern
correspond
increas
pt
entir
popul
compens
find
elm
identifi
incid
donor
cm
elm
pt
usual
pt
cm
number
incid
donor
captur
elm
greater
larger
denomin
without
equal
increas
numer
result
lower
elm
ir
simul
attempt
model
differ
condit
chang
donat
frequenc
number
posit
donat
may
match
actual
chang
donor
popul
observ
given
rapid
shift
donor
collect
recent
year
differ
method
difficult
model
thu
incid
method
like
continu
use
howev
blood
product
avail
limit
mani
patient
throughout
world
order
improv
access
blood
product
crucial
provid
countri
enough
detail
transfus
need
enabl
target
invest
determin
need
transfus
servic
countri
level
diseas
preval
inform
well
diseas
specif
transfus
rate
requir
diseas
preval
estim
avail
global
burden
diseas
gbd
studi
countri
sex
age
time
propos
use
administr
data
determin
transfus
rate
gbd
caus
appli
rate
gbd
preval
estim
order
determin
blood
product
need
countri
time
studi
designmethod
initi
step
analysi
use
truven
analyt
marketscan
databas
hcup
nationwid
inpati
sampl
determin
pack
red
blood
prbc
platelet
transfus
proport
diseas
categori
inpati
encount
diseas
categori
defin
base
global
burden
diseas
caus
list
inpati
encount
princip
diagnosi
use
determin
like
indic
transfus
transfus
event
defin
least
one
pack
red
blood
cell
platelet
transfus
procedur
code
code
per
inpati
encount
resultsfind
common
inpati
encount
least
one
prbc
platelet
transfus
cancer
relat
anemia
inpati
encount
acut
blood
loss
anemia
hereditari
nutrit
hemolyt
bone
marrow
failur
anemia
gastrointestin
bleed
event
chronic
liver
diseas
among
cancer
relat
anemia
leukemia
multipl
myeloma
highest
proport
admiss
least
one
transfus
conclus
popul
level
requir
blood
product
depend
locat
specif
epidemiolog
diseas
profil
use
administr
dataset
indic
transfus
determin
next
step
analysi
determin
diseas
specif
transfus
rate
appli
transfus
rate
diseas
preval
estim
global
burden
diseas
studi
countri
estim
number
need
blood
transfus
contrast
current
transfus
avail
report
global
databas
blood
safeti
backgroundcas
studi
atrial
fibril
af
common
cardiac
arrhythmia
affect
individu
develop
world
year
age
af
like
underdiagnos
result
therapeut
delay
increas
complic
risk
pilot
program
screen
af
mobil
electrocardiogram
ecg
applic
institut
commun
blood
center
benefit
donor
alert
possibl
af
seek
medic
evalu
studi
designmethod
follow
blood
collect
donor
age
older
invit
volunt
screen
af
give
inform
consent
complet
anonym
demograph
medic
histori
form
af
screen
ecg
applic
load
onto
tablet
devic
use
assess
heart
rhythm
result
normal
unclassifi
unread
possibl
af
record
subject
possibl
af
result
reciev
copi
heart
trace
advis
consult
health
provid
particip
also
complet
evalu
incorpor
fivelevel
likert
scale
unfavor
favor
resultsfind
total
donor
averag
age
screen
major
femal
caucasian
allogen
donor
health
provid
minor
subject
report
previou
af
evalu
interpret
normal
two
plu
one
unsur
previou
af
diagnosi
deni
current
af
thirti
plu
one
unsur
report
irregular
puls
histori
possibl
af
result
total
seven
none
previous
evalu
af
though
two
report
irregular
puls
histori
averag
age
possibl
af
less
normal
screen
refer
tabl
cohort
character
user
report
interest
opportun
likert
scale
found
result
usefulhelp
thought
devic
easi
use
like
rescreen
major
recommend
continu
offer
screen
conclus
pilot
af
screen
program
commun
blood
center
well
receiv
donor
particip
gener
possibl
af
result
studi
older
donor
popul
screen
af
prior
qualifi
blood
collect
warrant
also
correl
diagnost
outcom
possibl
af
screen
would
valuabl
granulocyt
colonystimul
factor
gcsf
breastmilk
nurs
donor
hematopoiet
progenitor
cell
hpc
mobil
randin
c
nelson
nation
institut
health
backgroundcas
studi
peripher
blood
hematopoiet
progenitor
cell
hpc
transplant
common
product
hpc
transplant
peripher
blood
hpc
donor
receiv
recombin
human
granulocyt
colonystimul
factor
gcsf
stimul
product
releas
hpc
peripher
blood
apheresi
collect
among
concern
lactat
gcsfmobil
peripher
blood
hpc
donor
unknown
potenti
harm
child
via
ingest
potent
growth
factor
nurs
two
studi
previous
describ
excret
gcsf
human
milk
leav
transplant
commun
limit
inform
make
appropri
safeti
recommend
nurs
hpc
donor
studi
gcsf
level
measur
lactat
gcsfmobil
hpc
donor
studi
designmethod
serial
plasma
milk
sampl
collect
volunt
peripher
blood
hpc
donor
gcsf
concentr
sampl
measur
use
enzymelink
immunoassay
elisa
resultsfind
peak
concentr
gcsf
donor
milk
ml
hour
first
dose
gcsf
given
gcsf
remain
detect
donor
milk
hour
final
dose
gcsf
conclus
compar
previou
report
higher
peak
concentr
gcsf
donor
breast
milk
mobil
identifi
addit
gcsf
still
detect
breast
milk
day
last
dose
time
even
conserv
guidelin
would
allow
donor
resum
breastfeed
underscor
need
cautious
counsel
lactat
hpc
donor
regard
presenc
gcsf
breast
milk
unknown
risk
pose
nurs
infant
red
blood
cell
go
nationwid
analysi
rbc
use
taiwan
lingi
hsu
yunyuan
chen
jenwei
chen
depart
research
head
offic
taiwan
blood
servic
foundat
backgroundcas
studi
understand
usag
red
blood
cell
rbc
componentscan
facilit
demand
plan
clinic
suppli
period
review
audit
blood
util
first
step
patient
blood
manag
futurein
studi
aim
nationwid
analysi
red
cell
transfus
clinic
indic
studi
designmethod
nation
health
insur
nhi
program
place
taiwan
sinc
rbc
identifi
diseas
diagnos
surgic
procedur
retriev
nhi
databas
compris
inform
blood
transfus
countri
resultsfind
total
person
transfus
red
cell
unit
adjust
ml
whole
bloodderiv
rbc
equival
unit
medic
center
metropolitan
hospit
commun
hospit
clinic
rbc
transfus
medic
center
transfus
metropolitan
commun
hospit
transfus
clinic
total
rbc
unit
transfus
medic
indic
transfus
surgic
indic
obstetr
gynecolog
compar
rbc
transfus
transfus
unit
medic
obstetricsgynecolog
remain
steadi
year
transfus
unit
surgic
procedur
decreas
breakdown
data
show
hematolog
oncolog
disord
account
rbc
transfus
respect
gastrointestin
vascular
cardiothorac
surgeri
also
common
indic
rbc
transfus
rbc
usag
vari
hospit
approxim
rbc
unit
transfus
cancer
patient
medic
center
less
cancer
patient
metropolitan
commun
hospit
hand
significantli
higher
percentag
rbc
usag
gastrointestin
surgeri
respiratori
diseas
observ
metropolitan
commun
hospit
compar
medic
center
intern
medic
procedur
number
rbc
unit
transfus
per
hospit
similar
hospit
howev
signific
variat
observ
surgic
procedur
hospit
conclus
first
comprehens
populationbas
analysi
rbc
usag
taiwan
studi
identifi
clinic
area
red
cell
unit
transfus
countri
data
import
futur
plan
provid
inform
realiz
patient
blood
manag
hrunit
avail
altern
transfus
immun
backgroundcas
studi
hrrare
blood
group
rh
encod
differ
allel
also
encod
partial
e
call
hr
phenotyp
often
segreg
allel
encod
partial
thu
hrsubject
like
develop
alloantibodi
respons
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hrunit
scarc
donor
test
reagent
procedur
accur
screen
antigen
weaken
commonli
seen
report
case
hrpregnant
women
differ
antibodi
profil
least
incompat
unit
select
studi
designmethod
standard
hemagglutin
genom
techniqu
use
resultsfind
patient
week
pregnanc
fetal
distress
report
rhd
darrhc
cear
homozyg
immun
antihr
reactiv
iatpapain
antihr
titer
unit
propos
iut
high
risk
antid
immun
ten
day
later
due
sever
renal
failur
patient
fetu
die
cover
postpartum
hemorrhag
two
option
possibl
rr
unit
would
incompat
iat
r
r
unit
would
incompat
iatpapain
without
prevent
antid
immun
best
scenario
would
r
r
unit
avail
deliv
patient
rhd
darrhc
cear
homozyg
immun
antid
antihr
antihr
deliveri
respect
titer
rr
r
r
unit
consid
reactiv
use
r
r
unit
bare
reactiv
passiv
antibodi
found
newborn
antid
antihr
babi
harbor
partial
discov
hbss
r
r
cevf
rh
unit
reactiv
iatpapain
even
though
r
r
unit
nonreact
order
prevent
anti
immun
cevfunit
consid
best
option
easier
collect
unit
patient
normal
deliveri
rd
pregnanc
antihr
titrat
antihr
weakli
reactiv
untreat
rbc
r
r
unit
select
mother
mother
blood
propos
newborn
luckili
transfus
need
two
year
later
new
pregnanc
th
month
emerg
deliveri
perform
fetal
distress
antihr
titer
birth
hemoglobin
emerg
transfus
done
fresh
r
r
unit
follow
exchang
transfus
use
phenotyp
patient
normal
antibodi
anti
antic
antihr
antihr
titer
perform
rr
r
r
r
r
rbc
respect
lost
first
newborn
month
week
could
carri
last
pregnanc
term
unit
hr
dor
rh
null
suitabl
transfus
conclus
transfus
hrimmun
individu
hrunit
avail
follow
phenotyp
test
rr
r
r
r
r
cevfor
rh
null
depend
antibodi
strength
clinic
histori
avail
unit
best
altern
decid
close
cooper
clinic
team
essenti
set
earliest
stage
pregnanc
case
illustr
urgent
need
implement
effici
procedur
donor
test
pick
hrunit
well
donor
recruit
campaign
target
hrindividu
next
gener
sequenc
base
abo
subtyp
organ
donor
bharat
thyagarajan
claudia
cohn
kayla
hansen
shelley
william
christin
henzler
univers
minnesota
fairview
hospit
backgroundcas
studi
organ
procur
transplant
network
optn
recommend
routin
subtyp
group
kidney
donor
donor
express
lower
amount
antigen
use
recipi
blood
type
b
despit
guidanc
kidney
transplant
sinc
decemb
subtyp
quarter
organ
procur
organ
opo
report
issu
subtyp
serolog
base
abo
type
subtyp
blood
type
may
inform
patient
receiv
pretranspl
transfus
advent
next
gener
sequenc
ng
technolog
allow
rapid
scalabl
method
molecular
determin
abo
blood
type
subtyp
may
address
limit
serolog
method
enabl
widespread
adopt
subtyp
kidney
transplant
studi
designmethod
develop
ng
base
method
specif
amplifi
enrich
sequenc
exon
abo
gene
follow
short
read
sequenc
use
either
miseq
platform
illumina
inc
raw
sequenc
data
process
use
custom
bioinformat
pipelin
allow
infer
abo
blood
type
subtyp
combin
sequenc
inform
popul
base
frequenc
variou
allel
concord
observ
abo
genotyp
serolog
determin
use
data
individu
match
abo
genotypeserolog
inform
concord
subtyp
determin
use
data
individu
match
subtyp
genotypeserolog
inform
resultsfind
exon
complet
sequenc
use
custom
ng
base
assay
observ
concord
abo
genotyp
correspond
serolog
individu
unambigu
genotyp
subtyp
avail
case
case
allel
could
unambigu
distinguish
allel
eight
case
serotyp
one
case
serotyp
combin
sequenc
data
inform
public
databas
allow
us
success
infer
genotyp
case
concord
among
patient
unambigu
subtyp
four
discrep
case
two
case
patient
allel
identifi
serolog
two
case
serolog
indic
subtyp
allel
identifi
genotyp
conclus
studi
demonstr
feasibl
use
molecular
techniqu
routin
subtyp
donor
patient
await
renal
transplant
understand
reason
observ
discrep
genotyp
serolog
improv
genotyp
determin
may
need
routin
implement
abo
genotyp
clinic
laboratori
backgroundcas
studi
deleteri
variant
affect
cybb
gene
region
associ
loss
nicotinamid
adenin
dinucleotid
phosphateoxidas
nadph
function
chronic
granulomat
diseas
cgd
directli
upstream
cybb
gene
xk
gene
encod
kx
transmembran
protein
red
blood
cell
loss
kx
protein
greatli
reduc
express
kell
system
antigen
refer
mcleod
mld
phenotyp
mld
neuroacanthocytosi
syndrom
includ
chronic
anemia
late
onset
neuromuscular
complic
mld
syndrom
cgd
rare
describ
cooccur
patient
delet
affect
cybb
xk
two
black
male
halfbroth
age
present
separ
brother
hospit
multifoc
lung
consolid
year
old
receiv
four
granulocyt
transfus
cgd
therapi
hospit
chronic
right
lung
fungal
pneumonia
produc
antikx
year
old
brother
receiv
three
red
blood
cell
unit
anemia
produc
antibodi
perform
serolog
dna
studi
individu
illustr
fuller
pictur
red
cell
phenotyp
identifi
caus
genet
variant
studi
designmethod
antik
antikp
b
pool
human
sera
region
tile
genom
pcr
strategi
use
detect
larg
region
x
chromosom
delet
publish
xchromosom
primer
gassner
et
al
use
amplifi
genom
pcr
target
span
mbp
region
contain
cybb
xk
gene
follow
finemap
use
stepwis
custom
primer
strategi
resultsfind
brother
red
blood
cell
found
weakli
reactiv
cellano
kp
b
antisera
contigu
pcr
amplicon
fail
amplifi
consist
larg
delet
fine
map
stepwis
pcr
strategi
identifi
approxim
xchromosom
delet
affect
gene
xk
cybb
conclus
studi
halfbroth
mld
phenotyp
cgd
identifi
previous
unreport
xchromosom
delet
affect
least
function
gene
includ
xk
cybb
evalu
patient
either
cgd
mld
syndrom
consid
evalu
syndrom
syndrom
suspect
genet
studi
includ
method
capabl
detect
type
loss
function
variat
identifi
extent
xchromosom
delet
transfus
exposur
minim
whenev
possibl
case
due
risk
provok
antikx
respons
carolina
bonet
bub
maria
giselda
aravechia
leandro
santo
eduardo
basto
marilia
sirianni
thiago
costa
jose
kutner
lilian
castilho
hospit
israelita
albert
einstein
hemocentro
unicamp
backgroundcas
studi
appropri
classif
rhd
phenotyp
crucial
correct
indic
antid
immunoglobulin
rhig
pregnant
women
serolog
distinct
weak
partial
phenotyp
often
doubt
make
genet
analysi
rhd
gene
highli
recommend
pregnant
women
addit
properli
defin
rhd
phenotyp
one
import
aspect
matern
medicin
predict
whether
rhd
variant
alloimmun
pregnant
woman
order
indic
appropri
use
antid
rhig
base
analyz
rhd
gene
cohort
pregnant
women
multiethn
popul
southeast
brazil
serolog
weak
phenotyp
evalu
implic
variant
found
alloimmun
studi
designmethod
select
total
prenat
patient
sampl
sampl
show
weak
reactiv
type
routin
antigen
express
evalu
tube
gel
hemagglutin
four
monoclon
antid
reagent
laboratorydevelop
dna
test
ldt
rhd
beadchip
bioarray
solut
immucor
sequenc
use
identifi
rhd
allel
resultsfind
standard
serolog
reactiv
identifi
could
predict
type
variant
would
identifi
agglutin
vari
molecular
analys
show
pregnant
women
rhd
weak
type
potenti
risk
antid
rhd
weak
type
risk
antid
patient
previous
gestat
antid
ig
prophylaxi
patient
show
neg
antibodi
screen
follow
conclus
result
show
weak
type
far
frequent
type
variant
select
prenat
patient
multiethn
popul
serolog
weak
phenotyp
accord
literatur
obstetr
patient
risk
antid
candid
rhig
accord
result
use
rhd
genotyp
could
prevent
unnecessari
inject
rhig
pregnant
women
serolog
weak
phenotyp
howev
antid
immun
observ
cohort
pregnant
women
weak
type
even
use
rhig
previou
gestat
challeng
rh
genotyp
match
brazilian
patient
sickl
cell
diseas
scd
tamir
delfino
do
santo
sheila
de
perecin
menegati
mayra
dorigan
de
macedo
simon
gilli
lilian
castilho
hemocentro
unicamp
backgroundcas
studi
knowledg
preval
rh
variant
support
develop
strategi
match
rh
avoid
rh
alloimmun
risk
hemolyt
transfus
reaction
andor
poor
transfus
outcom
molecular
rh
type
perform
identifi
rh
alter
allel
play
import
role
expand
match
scd
patient
donor
rh
system
studi
examin
transfus
request
rhmatch
donor
unit
compar
rhce
allel
scd
patient
rh
allel
frequenc
donor
popul
addit
number
potenti
compat
donor
assess
per
request
aim
identifi
rh
genotyp
lack
insuffici
donor
cohort
studi
designmethod
request
rh
genotyp
match
donor
januari
januari
evalu
patient
donor
rhd
rhce
allel
determin
laboratori
develop
test
ldt
rhd
rhce
sequenc
use
determin
rhdce
genotyp
among
patient
african
brazilian
blood
donor
consid
total
red
blood
cell
unit
request
patient
number
donat
per
year
evalu
number
potenti
compat
donor
resultsfind
evalu
transfus
request
patient
antihr
b
two
antihr
antihr
b
antihr
b
also
rh
alloantibodi
found
differ
combin
rhce
variant
allel
predict
partial
antigen
lack
high
preval
antigen
hrband
hrsin
patient
frequent
allel
rhce
rhce
c
ce
rhce
cear
although
rh
allel
also
found
donor
number
donor
homozyg
rh
genotyp
insuffici
fulfil
transfus
request
conclus
although
common
hrband
c
ce
allel
associ
rh
genotyp
match
request
uncommon
donor
abil
identifi
unit
fill
transfus
request
challeng
fill
request
hrsunit
special
challeng
phenotyp
much
less
frequent
donor
develop
strategi
screen
donor
optim
identif
donor
rh
variant
allel
critic
support
scd
patient
rh
genotyp
match
unit
novel
solubl
effici
neutral
high
titer
antibodi
matteo
binda
vincenzo
favaloro
norbert
piel
jodi
berri
peter
schwind
medion
grifol
diagnost
grifol
diagnost
solut
inc
backgroundcas
studi
novel
drug
use
treatment
multipl
myeloma
daratumumab
dara
interfer
diagnost
screen
identif
unexpect
antibodi
caus
panreact
reagent
red
blood
cell
rrbc
complic
detect
underli
alloantibodi
potenti
clinic
relev
moment
strategi
overcom
problem
howev
sever
drawback
aim
studi
evalu
diagnost
use
novel
recombin
particular
emphasi
dilut
effect
solubl
detect
unexpect
antibodi
studi
designmethod
fusion
protein
contain
extracellular
domain
express
mammalian
cell
purifi
evalu
diagnost
function
spike
donor
plasma
contain
alloantibodi
mix
vari
volumesconcentr
pb
control
incub
minut
antibodi
detect
perform
indirect
antiglobulin
test
iat
convent
tube
techniqu
dg
gel
techniqu
resultsfind
ratio
recombin
nomin
concentr
per
plasma
allow
complet
inhibit
respect
inhibit
spike
alloantibodi
antid
e
c
cw
k
fya
jka
lua
cob
bare
detect
amount
daraspik
donor
plasma
could
readili
detect
sampl
contrast
demonstr
dg
gel
techniqu
incub
dilut
prepar
respect
simul
dara
plasma
spike
antibodi
could
still
detect
present
result
show
inhibit
therapeut
plasma
concentr
daratumumab
use
novel
small
volum
without
interfer
alloantibodi
detect
addit
data
confirm
success
neutral
subsequ
antibodi
detect
requir
highli
concentr
neutral
plasma
screen
avail
routin
techniqu
tube
gel
techniqu
enabl
complet
inhibit
minim
dilut
plasma
highli
concentr
present
work
may
provid
combin
iat
rapid
accur
screen
identif
method
even
weakli
react
alloantibodi
mask
hand
glycophorin
e
gpe
express
erythrocyt
membran
glycophorin
famili
gene
call
gypa
gypb
gype
locat
chromosom
high
homolog
normal
antigen
sensit
proteas
proteaseresist
antigen
prm
identifi
st
gpzan
en
uk
kikuchi
uchikawa
et
al
report
novel
prm
low
molecular
weight
studi
perform
immunochem
serolog
molecular
genet
analysi
novel
prm
antigen
confirm
prm
present
gp
eb
hybrid
molecul
studi
designmethod
prm
screen
blood
donor
perform
japanes
red
cross
kanto
koshinetsu
block
blood
center
june
novemb
mn
blood
type
determin
autom
blood
group
machin
monoclon
antim
red
blood
cell
rbc
suspend
bromelin
solut
posit
reaction
observ
n
antigen
examin
standard
tube
method
rbc
membran
protein
analyz
immunoblot
antim
flow
cytometr
analysi
ss
antigen
rbc
perform
polyclon
anti
anti
identifi
molecular
mechan
novel
prm
antigen
reticulocyt
mrna
genom
dna
prmposit
donor
analyz
pcr
clone
follow
sequenc
genom
fragment
span
mspecif
sequenc
exon
downstream
exon
upstream
exon
downstream
exon
amplifi
gdna
pcr
sequenc
backgroundcas
studi
abo
type
recipi
donor
import
optim
transfus
transplant
outcom
although
serolog
abo
type
highli
reliabl
limit
discord
forward
revers
type
addit
live
solid
organ
stem
cell
donor
evalu
often
involv
buccal
swab
prevent
upfront
serolog
abo
type
combin
dna
base
genotyp
solut
use
help
resolv
serolog
abo
discord
well
screen
transplant
donor
abo
method
laborintens
requir
interpret
subject
matter
expert
sought
develop
target
abo
next
gener
sequenc
ng
assay
along
companion
interpret
softwar
autom
data
process
abo
type
known
abo
allel
studi
designmethod
target
long
rang
pcr
base
dna
enrich
abo
gene
achiev
evalu
seri
pcr
primer
combin
use
blood
buccal
swab
isol
dna
pcr
product
run
agaros
gel
agil
bioanalyz
determin
product
size
qualiti
promis
pcr
product
underw
illumina
trusight
ng
librari
prepar
sequenc
use
illumina
miseq
investig
previous
creat
curat
allel
databas
http
bloodantigenscom
custom
bloodtyp
interpret
softwar
determin
blood
group
whole
genom
sequenc
data
previou
effort
improv
upon
curat
abo
allel
ad
ng
sequenc
read
base
cistran
phase
bloodtyp
softwar
determin
full
abo
allel
haplotyp
resultsfind
pcr
primer
evalu
show
reproduc
pcr
product
span
abo
exon
blood
sampl
buccal
swab
yield
good
qualiti
ng
data
exon
encod
major
abo
specif
includ
abo
subtyp
ax
weak
antigen
aw
ael
hybrid
allel
cisab
b
verifi
abo
ng
assay
combin
blood
buccal
swab
sampl
test
found
concord
serolog
abo
type
sanger
sequenc
weak
subtyp
hybrid
allel
sampl
found
case
target
abo
ng
result
could
fulli
resolv
cistran
phase
genotyp
allow
unambigu
allel
determin
interpret
softwar
conclus
target
abo
ng
base
assay
develop
optim
blood
buccal
swab
isol
dna
companion
interpret
softwar
autom
ng
abo
analysi
develop
correctli
determin
abo
type
compar
serolog
sanger
sequenc
assay
softwar
interpret
repres
new
improv
standard
dna
base
abo
test
allow
abo
type
blood
sampl
avail
resolut
weak
subtyp
hybrid
abo
allel
backgroundcas
studi
recombin
blood
group
protein
rbgp
solubl
protein
deriv
eukaryot
express
system
mimic
red
cell
blood
group
antigen
studi
evalu
rbgp
potenti
use
red
cell
immunohaematolog
rci
laboratori
elucid
complex
antibodi
pretransfus
antenat
test
current
laboratori
method
use
resolv
complex
case
multipl
antibodi
antibodi
high
frequenc
antigen
antibodi
high
titr
low
avid
htla
natur
cumbersom
investig
requir
great
deal
oper
expertis
may
lead
delay
provis
suitabl
red
cell
unit
transfus
previou
studi
involv
rbgp
shown
signific
potenti
reduc
turnaround
time
antibodi
investig
subsequ
provis
red
cell
unit
patient
complex
antibodi
studi
evalu
use
rbgp
rci
laboratori
studi
designmethod
sampl
contain
complex
antibodi
test
use
appropri
rbgp
imusyn
inhibit
assay
use
per
manufactur
instruct
plasma
incub
rbgp
inhibit
specif
antibodi
cognat
blood
group
antigen
follow
indirect
antiglobulin
test
biorad
gel
card
method
resultsfind
sampl
test
contain
htla
type
antibodi
success
inhibit
use
rbgp
sampl
contain
antibodi
high
frequenc
antigen
success
inhibit
lower
frequenc
antibodi
also
test
use
rbgp
result
includ
tabl
conclus
recombin
blood
group
protein
novel
effect
way
manag
sampl
pretransfus
antenat
test
inhibit
assay
quick
straightforward
method
facilit
fast
antibodi
identif
allow
rapid
effect
provis
suitabl
unit
patient
requir
transfus
also
stratif
risk
due
antibodi
implic
hdfn
two
notabl
case
observ
wherebi
rbgp
allow
prompt
identif
specif
includ
antidob
antibodi
thu
facilit
provis
suitabl
unit
expedi
note
high
percentag
htla
type
antibodi
inhibit
success
howev
note
accur
assign
specif
ambigu
type
antibodi
thalassemia
patient
classif
hbb
hfe
dna
profil
leansequenc
asim
qidwai
kristoph
fernandez
ghazala
hashmi
afzal
memori
thalassemia
foundat
biomolecular
analyt
skh
foundat
backgroundcas
studi
blood
transfus
therapi
standard
care
manag
anemia
thalassemia
patient
mani
recipi
lead
accumul
excess
iron
hemochromatosi
inherit
iron
storag
disord
increas
risk
develop
iron
overload
mutat
hfe
highf
gene
impair
molecular
mechan
remov
excess
iron
thalassemia
patient
routin
character
mutat
hbb
gene
encod
betaglobin
screen
hfe
mutat
current
part
workup
explor
preval
hfe
mutat
chronic
transfus
pediatr
adolesc
thalassemia
patient
pakistan
evalu
dna
profil
hbb
hfe
gene
mutat
object
improv
thalassemia
patient
manag
studi
designmethod
pediatr
adolesc
patient
treat
afzal
memori
thalassemia
foundat
amtf
hospit
screen
singl
assay
use
novel
leansequenc
process
develop
biomolecular
analyt
panel
includ
set
thalassemia
bp
delet
cd
g
g
g
g
c
ttct
c
c
g
g
sickl
cell
hb
c
e
hemochromatosi
hfe
mutat
duplic
barcod
buccal
swab
sampl
collect
crude
extract
prepar
without
dna
purif
patel
et
al
crude
extract
amplifi
multiplex
pcr
reaction
hbb
hfe
gene
analyz
leansequenc
also
analyz
group
patient
extend
set
red
blood
cell
antigen
present
data
elsewher
proceed
resultsfind
patient
homozyg
heterozyg
hfe
mutat
normal
hbb
g
c
common
mutat
group
homozyg
compound
heterozyg
mostli
codon
g
ivsi
g
hb
e
also
common
codon
g
homozyg
compound
heterozyg
g
c
g
ttct
patient
identifi
bp
delet
homozyg
heterozyg
ttct
patient
compound
het
hb
e
sickl
cell
mutat
patient
normal
hb
hb
c
mutat
conclus
hfe
gene
mutat
uncommon
pakistani
thalassemia
patient
routin
screen
mutat
would
provid
addit
input
design
individu
proactiv
transfus
therapi
especi
pediatr
patient
name
routin
provid
cell
select
accord
patient
extend
rbc
antigen
profil
minim
risk
alloimmun
reduc
preval
condit
report
increas
frequenc
transfus
likewis
reduc
risk
iron
overload
leansequenc
mutat
new
york
blood
center
backgroundcas
studi
discrep
test
method
whether
autom
versu
tube
serolog
versu
dna
led
identif
novel
jk
allel
thirti
allel
code
alter
silenc
express
jk
multipl
ethnic
known
investig
jk
donor
jk
b
serolog
discord
current
histor
type
patient
jk
phenotyp
differ
jk
predict
dna
studi
designmethod
rbc
type
perform
standard
tube
method
monoclon
antijk
clone
jk
b
clone
genom
dna
isol
wbc
hea
precisetyp
perform
patient
jk
code
exon
amplifi
sequenc
resultsfind
sampl
south
asian
male
donor
rbc
current
donat
type
jk
b
histor
record
indic
jk
tube
test
rbc
weakli
reactiv
immucor
antijk
b
nonreact
biorad
seraclon
antijk
b
rbc
also
jk
sequenc
result
sampl
heterozyg
p
predict
jk
ab
addit
novel
chang
c
encod
identifi
chang
exom
aggreg
consortium
exac
rare
frequenc
sampl
year
old
caucasian
femal
patient
rbc
type
jk
hea
precisetyp
predict
jk
addit
test
found
rbc
nonreact
immucor
biorad
seraclon
antijk
rbc
also
type
jk
b
jk
sequenc
exon
confirm
jk
b
also
reveal
novel
chang
found
dbsnp
exac
databas
sequenc
snpspecif
primer
link
new
chang
jk
jk
identifi
patient
whose
rbc
type
jk
multipl
reagent
predict
locat
transmembran
ramsey
et
al
transfus
impact
protein
express
difficult
predict
sampl
insuffici
adsorptionelut
studi
determin
allel
encod
jk
null
phenotyp
low
level
jk
antigen
number
discord
identifi
serolog
dna
studi
show
combin
power
serolog
molecular
type
test
patient
donor
survey
abo
allel
associ
weak
lectin
reactiv
rbc
waseem
q
anani
kathleen
bens
michael
schanen
cindi
piefer
madelin
knier
emili
roeger
gregori
denomm
backgroundcas
studi
identif
group
solid
organ
evalu
red
blood
cell
rbc
allow
abo
incompat
aboi
transplant
group
b
recipi
classif
determin
use
lectin
manufactur
extract
dolicho
biflori
seed
dilut
differenti
human
group
rbc
subgroup
weak
reactiv
observ
rbc
use
either
two
fdalicens
reagent
manufactur
reagent
state
weak
reaction
occur
rbc
understand
implic
weak
lectin
rbc
type
subgroup
classif
evalu
incid
weak
hemagglutin
two
licens
lectin
reagent
associ
abo
allel
use
genom
dna
sequenc
exon
studi
designmethod
lectin
type
perform
use
two
licens
reagent
accord
manufactur
protocol
valid
use
known
reagent
rbc
weak
reactiv
defin
hemagglutin
either
lectin
reagent
sampl
abo
group
use
standard
licens
antisera
b
rbc
genom
dna
extract
subject
abo
exon
sequenc
use
intron
flank
primer
exon
two
overlap
fragment
exon
standard
sanger
dideoxi
sequenc
perform
use
bigdy
termin
could
rule
given
none
sampl
weakli
reactiv
licens
antia
thu
three
abo
allel
could
assign
sequenc
data
abo
one
abo
one
abo
abo
allel
pair
abo
one
abo
abo
one
abo
one
abo
one
abo
three
unassign
abo
allel
control
consist
three
group
donor
rbc
hemagglutin
along
two
group
donor
one
ab
donor
rbc
nonreact
test
use
lectin
sequenc
control
sampl
reveal
three
consensu
abo
three
abo
one
abo
conclus
weak
equivoc
result
lectin
rel
common
among
donor
analysi
abo
exon
sequenc
data
reveal
abo
common
allel
reveal
nucleotid
chang
associ
weak
lectin
reactiv
weak
reactiv
lectin
link
abo
allel
name
abo
abo
small
survey
express
group
carbohydr
chain
among
abo
allel
systemat
evalu
acut
reject
abo
kidney
aboi
recipi
suggest
addit
biochem
studi
warrant
mutat
effect
hpa
antigen
sudan
tao
ji
fame
zhu
wei
hu
xiaofan
zheng
huap
zhou
feng
chen
zhejiang
provinci
key
laboratori
blood
safeti
research
blood
center
zhejiang
provinc
backgroundcas
studi
human
platelet
antigen
hpa
implic
fetomatern
alloimmun
thrombocytopenia
fmait
platelet
plt
refractori
post
transfus
purpura
until
type
hpa
identifi
approxim
half
hpa
report
caus
gene
mutat
three
singlesit
mutat
gene
identifi
lab
caus
substitut
respect
mutat
heterozyg
three
individu
unabl
determin
effect
point
mutat
hpa
antigen
directli
studi
recombin
express
plasmid
wildtyp
gpiiia
three
variant
construct
vitro
recombin
protein
extract
coupl
luminex
bead
test
platelet
antibodi
use
luminex
xmap
technolog
determin
whether
three
point
mutat
effect
hpa
antigen
studi
designmethod
fulllength
cdna
wildtyp
amplifi
ligat
vector
ligat
plasmid
transfect
chines
hamster
ovari
cell
cho
respect
stabli
express
cell
select
screen
protein
extract
confirm
western
blot
use
tag
antibodi
protein
coupl
micro
bead
respect
coupl
bead
valid
anti
human
igg
serum
sampl
test
use
coupl
bead
bead
react
serum
sampl
respect
beadantigenantibodi
complex
subject
flow
cytometr
analysi
standard
serum
use
posit
control
three
neg
sera
without
hpa
antibodi
prepar
ab
type
blood
donor
use
neg
control
resultsfind
western
blot
analysi
reveal
establish
cell
line
express
gpiiia
molecul
molecular
weight
wt
similarli
protein
identifi
cell
prematur
stop
mutat
luminex
mfi
show
three
bead
coupl
gpiiia
protein
wt
respect
exhibit
similar
result
react
sarum
impli
new
mutat
affect
antigen
hpa
serum
sampl
one
posit
consist
result
measur
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
conclus
report
recombin
express
four
gpiiia
molecular
found
mutat
affect
express
protein
luminex
bead
use
coupl
recombin
protein
detect
hpa
antibodi
show
mutat
effect
antigen
hpa
compar
wild
type
result
consist
maipa
assay
work
sponsor
nation
natur
scienc
foundat
china
scienc
research
foundat
zhejiang
healthi
bureau
heather
simmon
martha
r
comb
nichola
bandarenko
jessica
poisson
duke
univers
hospit
backgroundcas
studi
inconclus
reactiv
solid
phase
sprca
antibodi
screen
identif
led
develop
follow
workflow
effici
manag
pretransfus
sampl
larg
academ
tertiari
care
center
autom
sprca
screen
panreact
screen
cell
sampl
antibodi
screen
absc
repeat
polyethylen
glycol
peg
tube
patient
histori
antibodi
peg
absc
neg
absc
interpret
neg
patient
may
elig
comput
crossmatch
compat
blood
risk
move
peg
tube
test
failur
identifi
antibodi
reactiv
sprca
studi
quantifi
often
workflow
use
antibodi
detect
failur
consequ
studi
designmethod
retrospect
review
absc
result
perform
januari
decemb
sprca
perform
immucor
readi
screen
norcross
ga
usa
result
correct
neg
peg
absc
identifi
review
antibodi
identif
ab
id
subsequ
antibodi
screen
clinic
insignific
alloand
autoantibodi
exclud
detail
immunohematolog
workup
collect
includ
transfus
reaction
direct
antiglobulin
test
dat
acid
eluat
test
tube
peg
tube
method
respect
resultsfind
absc
perform
neg
peg
absc
identifi
new
antibodi
found
sampl
peg
absc
twenti
seven
patient
new
signific
alloantibodi
peg
absc
identifi
antijk
commonli
detect
antibodi
tabl
twentythre
antibodi
detect
within
week
initi
correct
peg
absc
eleven
patient
receiv
rbc
transfus
correct
result
new
ab
id
time
ab
id
dat
result
posit
acid
eluat
neg
posit
dat
one
delay
transfus
reaction
identifi
patient
howev
transfus
preced
posit
sprca
screen
conclus
workflow
defer
peg
absc
miss
clinic
signific
alloantibodi
serolog
clinic
consequ
rare
transfus
infrequ
initi
correct
screen
detect
alloantibodi
benefit
workflow
labor
suppli
save
posit
spcra
screen
signific
antibodi
identifi
address
concern
miss
antibodi
threshold
move
peg
absc
adjust
result
cell
sampl
sprca
screen
conclus
sever
dhtr
nonscd
pt
unusu
recognit
treatment
nearli
untransfus
pt
requir
daili
clinic
commun
first
welldescrib
exampl
highli
clinicallysignific
antibodi
pt
poorlycharacter
variant
like
modifi
hy
strength
perhap
respons
novel
hi
antibodi
success
lung
transplant
recipi
antibodi
gustaaf
de
ridder
brandi
bottig
lorenzo
zaffiri
jessica
poisson
duke
health
patholog
duke
health
anesthesiolog
duke
health
medicinepulmonari
backgroundcas
studi
abo
antibodi
detect
blood
type
lung
transplant
patient
occasion
frequenc
time
detect
persist
descript
clinic
outcom
presenc
antibodi
report
studi
designmethod
singl
center
retrospect
review
lung
transplant
recipi
antibodi
januari
decemb
perform
avail
relev
clinic
patholog
transfus
serolog
data
collect
electron
medic
record
resultsfind
four
recipi
identifi
among
total
lung
transplant
descript
patient
procedur
characterist
four
recipi
seen
tabl
lung
alloc
score
rang
recipi
abo
type
rhd
one
addit
antii
cold
agglutinin
lung
donor
abo
type
present
transplant
transplant
recipi
persist
strength
recipi
vari
greatli
tabl
intraop
transfus
support
minim
three
patient
total
product
fourth
requir
massiv
resuscit
product
two
patient
treat
suspect
humor
reject
one
new
donorspecif
hla
antibodi
one
empir
base
radiolog
spirometr
find
length
stay
rang
transbronchi
biopsi
two
patient
acut
cellular
reject
acr
singl
biopsi
one
one
one
patient
two
biopsi
one
patient
acr
followup
rang
mo
patient
live
graft
viabl
conclus
lung
transplant
across
blood
group
mismatch
occur
occas
appear
antibodi
prior
transplant
appear
correl
graft
dysfunct
cellular
antibodymedi
reject
case
seri
patient
strongest
persist
antibodi
titer
requir
massiv
transfus
also
cold
agglutinin
activ
infect
longer
followup
larger
multicent
trial
need
better
understand
outcom
titer
confirm
en
fin
weak
nuk
type
gp
ab
hybrid
short
nterminu
gpa
segment
en
uk
en
rbc
decreas
sialic
acid
loss
wr
b
express
gpaband
antien
caus
hemolysi
allogen
rbc
en
donor
extrem
rare
worldwid
addit
genet
inform
highli
desir
studi
designmethod
serolog
test
perform
routin
method
dnabas
blood
group
phenotyp
employ
hea
immucor
norcross
ga
gypa
analyz
longrang
amplif
sequenc
exon
resultsfind
woman
evalu
histori
broad
rbc
incompat
age
cholecystectomi
age
uterin
hemorrhag
miscarriag
pregnanc
never
transfus
born
lahor
pakistan
parent
remot
cousin
allahabad
india
group
b
plasma
panreact
solidphas
polyethylen
glycol
antiigg
lowion
salin
solut
antiigg
ficinrbc
antiigg
method
direct
antiglobulin
test
neg
rbc
phenotyp
en
wr
reactiv
glycin
soja
lectin
indic
reduc
sialic
acid
plasma
nonreact
en
rbc
consist
antien
fr
ficinresist
en
literatur
pakistaniborn
us
patient
report
immunohematol
demograph
serolog
extend
rbc
phenotyp
publish
histori
patient
discuss
confirm
subject
report
rbc
gpa
detect
human
monoclon
antisera
immunoblot
time
genet
done
test
hea
interrog
gypa
exon
c
predict
phenotyp
backgroundcas
studi
abo
subgroup
express
b
antigen
weakli
rbc
due
inherit
alter
abo
gene
affect
either
efficaci
specif
concentr
ab
glycosyltransferas
report
investig
abo
patient
ukrain
show
suspect
mixedfield
appear
dual
popul
rbc
upon
test
antib
routin
serolog
studi
designmethod
flow
cytometr
analysi
routin
abo
genotyp
includ
analysi
upstream
cbfnfybind
enhanc
region
involv
determin
transcript
rate
certain
tissu
carri
genet
analysi
perform
dna
sequenc
abo
exon
includ
base
pair
adjac
intron
proxim
promot
abstract
resultsfind
dna
analysi
show
patient
genotyp
abo
normal
consist
group
b
sequenc
analysi
abo
exon
reveal
unexpect
chang
code
sequenc
explain
weak
phenotyp
pcr
analysi
upstream
cbfnfybind
enhanc
region
show
homozygos
expect
four
repeat
consist
genotyp
howev
sequenc
abo
promot
unravel
substitut
g
posit
flow
cytometr
analysi
show
express
normal
h
antigen
level
biphas
chimeralik
pattern
observ
antib
although
cell
intermedi
level
antigen
express
also
present
type
pattern
previous
report
subgroup
caus
mutat
regulatori
region
locat
intron
investig
parent
dna
show
mother
abo
extend
match
includ
rhd
rhce
variant
allel
consid
total
red
blood
cell
unit
request
patient
number
donat
per
year
compat
donor
fulfil
need
patient
level
match
patient
level
consid
rh
variant
much
difficult
find
compat
donor
patient
scd
besid
challeng
fulfil
request
multipl
neg
antigen
rh
match
unit
cost
effect
practic
minim
risk
alloimmun
remain
controversi
partli
patient
develop
alloantibodi
despit
extens
exposur
donor
rbc
antigen
order
optim
use
genotypematch
unit
patient
genotyp
patient
genet
marker
could
potenti
help
classif
respond
nonrespond
scd
patient
studi
evalu
abil
practic
avoid
product
rbc
antibodi
neg
consequ
alloimmun
follow
year
studi
designmethod
total
nonalloimmun
patient
scd
homozyg
hb
receiv
rang
rbc
unit
enrol
studi
nine
patient
cytokin
gene
polymorph
previous
associ
risk
alloimmun
transfus
extend
match
rbc
unit
level
match
patient
rhag
gene
polymorph
previous
associ
risk
rh
aloimmun
patient
genet
risk
factor
associ
rbc
alloimmun
transfus
rh
k
match
unit
conclus
although
patient
develop
antibodi
low
preval
antigen
one
patient
develop
practic
improv
abil
find
antigenmatch
compon
transfus
support
nonalloimmun
patient
benefit
patient
observ
lack
develop
common
alloantibodi
transfus
follow
two
year
show
transfus
strategi
effici
keep
patient
hb
baselin
level
fine
specif
kidd
antibodi
made
patient
novel
jk
allel
silenc
jk
b
allel
suggest
novel
antigen
christin
lomasfr
andrew
rossin
judith
aeschlimann
kim
hueroy
sunitha
vege
conni
westhoff
new
york
blood
center
immunohematolog
genom
laboratori
new
york
blood
center
backgroundcas
studi
year
old
e
asian
man
recent
transfus
present
chronic
anemia
dyspnea
antibodi
react
panel
cell
jk
ab
rbc
autolog
control
rbc
type
jk
ab
plasma
contain
appar
test
done
investig
plasma
reactiv
determin
jk
genotyp
studi
designmethod
antibodi
identif
antigen
type
perform
standard
method
licens
inhous
reagent
eluat
made
gamma
elukit
ii
immucor
genom
dna
isol
wbc
hea
precisetyp
perform
jk
code
exon
amplifi
sequenc
eluat
made
first
set
rbc
use
adsorpt
react
jk
jk
b
rbc
thu
contain
appar
surprisingli
jk
w
b
rbc
donor
homozyg
jk
jk
weakli
incompat
patient
plasma
peg
iat
conclus
describ
patient
partial
jk
detect
adsorptionelut
encod
novel
jk
tran
silenc
jk
b
encod
jk
initi
plasma
reactiv
consist
adsorpt
shown
contain
separ
antijk
jk
b
base
eluat
result
third
antibodi
specif
nonreact
jk
ab
patient
rbc
express
low
level
jk
suggest
antibodi
incompat
patient
plasma
rbc
donor
express
jk
encod
jk
show
recogniz
differ
protein
encod
allel
new
jk
encod
show
avail
jk
genotyp
rbc
enabl
precis
determin
antibodi
specif
inform
transfus
practic
backgroundcas
studi
abo
arguabl
import
blood
group
system
transfus
medicin
laboratori
typic
use
serolog
method
perform
abo
type
howev
serolog
signific
limit
includ
recent
transfus
patient
may
exhibit
mix
field
agglutin
wherein
patient
recent
donor
antigen
detect
ii
forward
revers
type
must
perform
may
yield
discord
result
limit
problemat
phenotyp
involv
weakli
express
antigen
laboratori
overcom
drawback
combin
genotyp
solut
ssp
sequenc
etc
method
timeand
laborconsum
requir
interpret
subject
matter
expert
aim
studi
evalu
altern
abo
realtim
pcr
base
genotyp
solut
recent
introduc
thermo
fisher
scientif
studi
designmethod
thermo
fisher
scientif
solut
base
link
eq
realtim
pcr
technolog
develop
year
ago
genotyp
complex
human
leukocyt
antigen
hla
system
link
eq
abo
analyz
reaction
identifi
multipl
relev
snp
locat
within
abo
gene
evalu
solut
analyz
archiv
dna
sampl
includ
blood
blank
sampl
serotyp
fail
produc
discord
result
sampl
deceas
solid
organ
donor
resultsfind
genotyp
result
gener
link
eq
concord
type
obtain
tradit
methodolog
sever
case
serolog
provid
conclus
result
includ
five
discord
serolog
six
indermin
lectin
reaction
case
link
eq
abl
provid
conclus
result
agreement
sanger
sequenc
result
avail
link
eq
overcom
major
challeng
molecular
type
provid
robust
autom
approach
increas
laboratori
product
reduc
turnaround
time
less
minut
handson
setup
oper
intervent
reagent
softwar
fulli
autom
analysi
link
eq
deliv
genotyp
predict
phenotyp
result
approxim
minut
conclus
conclud
link
eq
provid
simpl
effect
robust
method
abo
type
includ
accur
subgroup
monoclon
therapi
first
experi
interfer
antibodi
identif
christin
howardmenk
jason
e
crane
laura
doshi
mona
papari
itxmlifesourc
advoc
lutheran
gener
hospit
backgroundcas
studi
human
monoclon
antibodi
target
treatment
bcell
lymphoma
solid
tumor
marker
identifi
broadli
express
cell
surfac
protein
regul
phagocytosi
studi
designmethod
patient
year
old
femal
histori
bcell
lymphoma
statu
post
allogen
peripher
blood
stem
cell
transplant
octob
admit
hospit
gdl
hemoglobin
patient
previou
histori
cold
warm
autoantibodi
panagglutinin
use
gel
technolog
detect
hospit
sampl
sent
immunohematolog
refer
laboratori
complet
workup
transfus
histori
medic
initi
avail
initi
test
gel
show
revers
abo
discrep
panagglutinin
neg
dat
tube
test
use
peg
liss
enzym
select
continu
identif
strong
agglutin
strength
seen
agt
use
reagent
patient
plasma
test
cell
treat
ficin
dtt
glycin
acidedta
cord
cell
age
cell
batteri
rare
cell
base
patient
race
antibodi
reactiv
reaction
cell
test
though
dat
neg
eluat
perform
identifi
autoantibodi
demonstr
panagglutinin
titrat
plasma
versu
phenotyp
match
cell
show
reactiv
greater
alloabsorpt
use
human
stroma
ficintr
perform
panagglutinin
remov
resolv
abo
discrep
four
cold
alloabsorpt
remov
reactiv
reactiv
remain
test
addit
alloabsorpt
perform
remov
remain
reactiv
test
igg
coomb
resultsfind
result
suggest
potent
antibodi
high
frequenc
antigen
mind
sever
test
perform
use
cell
rare
phenotyp
complet
histori
obtain
found
patient
clinic
trial
monoclon
antibodi
therapi
target
literatur
review
antibodi
identifi
specif
igg
coomb
sera
clone
requir
resolv
reactiv
clone
lack
use
gamma
clone
monoclon
cell
previous
react
clone
contain
longer
react
antibodi
test
success
complet
use
gamma
clone
antiigg
sera
agt
omit
phase
abo
test
complet
cold
alloabsorb
stroma
conclus
addit
monoclon
therapi
continu
emerg
case
highlight
need
extens
commun
blood
bank
clinic
servic
regard
use
treatment
rbc
antigen
determin
thalassemia
patient
pakistan
use
leansequenc
process
ghazala
hashmi
asim
qidwai
anwari
syeda
neelam
mansoor
kristoph
fernandez
michael
seul
biomolecular
analyt
skh
foundat
afzal
memori
thalassemia
foundat
backgroundcas
studi
thalassemia
common
inherit
disord
pakistan
overal
carrier
frequenc
approxim
children
diagnos
year
disord
patient
receiv
transfus
support
manag
symptom
anemia
develop
antibodi
red
blood
cell
rbc
antigen
lead
increas
transfus
frequenc
zaidi
design
program
manag
transfus
therapi
patient
object
reduc
risk
alloimmun
therebi
ultim
lower
util
transfus
benefit
routin
use
rbc
genotyp
determin
extend
antigen
profil
patient
well
donor
studi
designmethod
thalassemia
patient
support
amtf
hospit
major
ethnic
pathan
sindhi
punjabi
baluchi
urdu
screen
determin
rbc
antigen
mn
rhce
lu
kel
fy
jk
di
yt
co
along
rhce
allel
describ
hashmi
et
al
duplic
barcod
buccal
swab
sampl
collect
crude
extract
prepar
patel
et
al
sampl
analyz
novel
leansequenc
process
biomolecular
analyt
achiev
scalabl
simultan
determin
multipl
variant
multipl
sampl
use
pcr
capillari
electrophoresi
genotyp
determin
phenotyp
predict
use
proprietari
softwar
resultsfind
patient
neg
k
ytb
e
n
fyb
includ
instanc
gata
silenc
mutat
jkb
doa
dob
fya
c
jka
c
e
k
yta
none
patient
variant
rhce
allel
encod
partial
phenotyp
also
character
patient
set
thalassemia
hemochromatosi
mutat
report
mutat
frequenc
separ
abstract
conclus
first
comprehens
genotyp
analysi
transfusiondepend
pakistani
thalassemia
patient
show
allel
divers
group
limit
small
number
gene
encod
princip
rbc
antigen
antigenneg
phenotyp
frequenc
e
c
k
jkb
similar
report
asian
fyb
jka
c
closer
frequenc
report
african
frequenc
antigen
includ
n
fyb
appear
differ
report
major
ethnic
group
rel
limit
allel
divers
compar
say
individu
african
heritag
bode
well
program
proactiv
provid
transfus
support
design
minim
sensit
risk
leansequenc
streamlin
protocol
use
crude
extract
buccal
swab
sampl
facilit
rapid
character
transfus
recipi
well
donor
need
support
object
examin
correl
hepat
c
infect
interferon
therapi
red
blood
cell
alloimmun
human
david
gibb
kevin
pelland
jeann
hendrickson
christoph
tormey
yale
univers
yale
school
medicin
backgroundcas
studi
studi
red
blood
cell
rbc
alloimmun
reveal
increas
risk
alloantibodi
product
patient
chronic
inflamm
remain
howev
littl
understand
inflammatori
pathway
promot
product
alloantibodi
patient
recent
studi
demonstr
specif
group
inflammatori
cytokin
type
interferon
ifn
promot
transfusioninduc
bcell
differenti
rbc
alloantibodi
develop
mice
given
transfus
vol
supplement
abstract
hepat
c
viru
hcv
infect
diseas
manag
ifn
therapi
hypothes
ifntreat
patient
hcv
may
elev
rate
rbc
alloimmun
thu
undertook
retrospect
examin
alloimmun
amongst
patient
hcv
studi
designmethod
alloimmun
subject
extract
preexist
databas
subject
queri
electron
medic
record
histori
hcv
infect
histori
report
follow
subsequ
collect
evid
ifn
therapi
rbc
antibodi
specif
sex
parallel
randomlyselect
nonalloimmun
rbc
transfus
patient
extract
gener
databas
establish
rate
hcv
infect
well
ifn
therapi
amongst
nonoverlap
control
group
chisquar
test
yate
correct
continu
fisher
exact
test
use
statist
comparison
pvalu
consid
signific
resultsfind
total
alloimmun
subject
histori
hcv
infect
major
individu
male
form
singl
alloantibodi
anti
kcjk
common
specif
comparison
randomlyselect
nonalloimmun
patient
transfus
rbc
histori
hcv
proport
alloimmun
subject
histori
hcv
significantli
higher
proport
control
nonimmun
transfus
patient
hcv
vs
addit
proport
alloimmun
subject
receiv
ifn
therapi
significantli
differ
transfus
control
hcv
conclus
substanti
portion
alloimmun
nonalloimmun
patient
cohort
histori
hcv
neither
hcv
infect
receipt
type
ifn
therapi
associ
increas
rate
rbc
alloimmun
larger
scale
multisit
studi
may
help
rigor
investig
whether
type
ifn
therapi
hcv
infect
diseas
may
impact
likelihood
alloimmun
follow
rbc
transfus
estim
risk
neg
women
give
birth
posit
child
jen
kjeldsenkragh
klau
j
olsen
univers
region
laboratori
region
larix
backgroundcas
studi
fetal
neonat
alloimmun
thrombocytopenia
fnait
platelet
counterpart
hemolyt
diseas
fetu
newborn
common
usual
sever
case
fnait
caus
neg
women
give
birth
posit
child
risk
becom
women
posit
higher
risk
compar
women
lack
hla
allel
aim
studi
estim
risk
posit
neg
women
give
birth
posit
child
studi
designmethod
literatur
search
conduct
identifi
prospect
fnait
studi
risk
becom
postpartum
calcul
use
bay
theorem
singl
trial
contain
need
inform
data
also
use
prevfnait
studya
recent
complet
larg
prospect
fnait
studi
poland
result
type
european
caucasian
nation
marrow
donor
program
use
estim
frequenc
allel
gener
popul
resultsfind
women
posit
risk
deliveri
posit
child
estim
confid
interv
ci
contrast
estim
immun
risk
ci
women
neg
neg
conclus
women
neg
posit
risk
ci
deliveri
posit
child
time
higher
women
neg
thu
risk
posit
women
rang
risk
rhdimmun
rhd
neg
women
deliveri
rhd
posit
child
mother
receiv
rhd
prophylaxi
clinic
cost
efficaci
molecular
rhd
genotyp
linda
mamon
ian
l
jame
edward
j
yoon
moham
alsammak
backgroundcas
studi
serolog
weak
test
patient
option
howev
work
group
colleg
american
pathologist
aabb
recommend
rhd
genotyp
rhdg
perform
discord
serolog
rhd
type
result
encount
andor
serolog
weak
identifi
goal
identif
true
candid
rhig
inject
andor
rhd
neg
rbc
institut
adopt
test
process
rhd
test
perform
two
method
gel
tube
identifi
serolog
discrep
henc
candid
rhdg
previous
conclud
process
posit
predict
valu
detect
variant
howev
costefficaci
rhdg
yet
establish
sought
evalu
cost
efficaci
molecular
rhdg
institut
studi
designmethod
result
rhdg
perform
retrospect
review
patient
age
gender
race
clinic
present
use
rhig
inject
transfus
also
review
cost
analysi
perform
resultsfind
analyz
period
type
screen
perform
blood
bank
sampl
includ
studi
sent
rhdg
due
serolog
discrep
initi
result
rhd
neg
major
patient
type
partial
type
kept
rhd
neg
remain
type
weak
variant
chang
rhd
posit
patient
transfus
subsequ
twenti
patient
pregnant
receiv
rhig
cost
see
tabl
demograph
patient
receiv
rhig
unnecessari
weak
would
save
approxim
assum
least
vialspati
cost
molecular
sendout
approxim
total
cost
patient
includ
studi
cost
rhd
neg
posit
prbc
unit
supplier
conclus
phase
rhdg
daili
transfus
medicin
practic
remain
advanc
challeng
topic
patient
popul
major
serolog
type
discrep
identifi
method
attribut
partial
variant
patient
treat
rhd
neg
thu
cost
effect
molecular
rhdg
question
probabl
reserv
specif
clinic
situat
patient
popul
abstract
transfus
neurodegener
neuroacanthocytosi
central
nervou
system
cn
manifest
associ
elev
cpk
level
weak
undetect
kell
system
antigen
absenc
kx
antigen
rbc
approxim
differ
xk
gene
mutat
report
appear
grow
awar
syndrom
investig
xk
four
male
patient
three
diagnos
acanthocythosi
one
fever
infect
present
antikx
studi
designmethod
rbc
type
perform
standard
tube
method
licens
unlicens
inhous
reagent
genom
dna
isol
wbc
xk
gene
amplifi
sequenc
resultsfind
proband
summar
tabl
rbc
four
show
depress
kell
system
antigen
kk
w
kp
ab
w
rbc
type
rbc
also
type
antikx
identifi
patient
plasma
albumin
papain
peg
iat
evalu
involuntari
jerk
movement
blood
film
show
acanthocyt
red
cell
neg
test
antikl
xk
gene
sequenc
reveal
novel
allel
proband
nucleotid
delet
posit
result
frameshift
prematur
stop
codon
sampl
intron
g
splice
site
mutat
predict
associ
altern
splice
nonsens
mutat
posit
result
prematur
stop
codon
missens
mutat
posit
result
amino
acid
chang
conclus
report
molecular
genet
basi
mcleod
phenotyp
four
proband
result
nucleotid
delet
caus
prematur
stop
splice
site
mutat
nonsens
mutat
missens
mutat
allelespecif
amplif
label
pool
amplicon
readout
capillari
sequenc
protocol
use
analyz
genom
dna
blind
sampl
previous
genotyp
extend
rbc
antigen
set
licens
method
data
analyz
phenotyp
predict
use
novel
algorithm
rhce
allel
determin
resultsfind
thirtyon
sampl
found
express
partial
c
c
partial
e
e
name
c
singl
c
encod
allel
pair
ce
allel
e
singl
e
encod
allel
pair
ce
allel
predict
weak
phenotyp
u
v
gata
silenc
fyb
uncommon
antigen
neg
u
e
yta
jsb
ceag
hrb
pair
ce
allel
rhce
allel
pair
previous
determin
name
rhce
ceag
homozyg
rhce
ceag
pair
ce
ce
ce
cemo
ceti
rhce
cesceti
five
discrep
note
one
predict
vv
comparison
assay
v
w
vsbi
leansequenc
detect
rhce
cear
detect
refer
assay
four
discrep
lu
c
mn
n
due
threshold
set
leansequenc
softwar
adjust
backgroundcas
studi
human
monoclon
antibodi
known
interfer
serolog
blood
bank
test
previous
report
success
gammaclon
antihuman
globulin
ahg
adsorpt
allogen
papaintr
rr
rbc
alway
reproduc
increas
enrol
patient
clinic
trial
solid
tumor
lymphoma
reliabl
effici
solut
need
human
platelet
concentr
hpc
use
adsorb
hla
antibodi
present
platelet
report
novel
use
hpc
adsorb
studi
designmethod
sampl
receiv
novemb
postdrug
day
march
postdrug
day
april
postdrug
day
yearold
femal
relaps
nonhodgkin
lymphoma
enrol
phase
ib
clinic
trial
rituximab
histor
blood
type
posit
neg
antibodi
screen
pregnanc
transfus
sampl
screen
commerci
reagent
cell
immedi
spin
ahg
liss
ahg
peg
ahg
salin
incub
except
reaction
compon
prewarm
minut
mix
follow
hpc
direct
insert
procedur
use
avail
plasma
sampl
perform
sequenti
adsorpt
evalu
reactiv
prewarm
peg
ahg
patient
sampl
spike
jk
antiserum
hpc
adsorb
verifi
expect
alloantibodi
reactiv
resultsfind
first
sampl
forward
type
posit
consist
histor
data
revers
type
b
cell
autocontrol
ac
direct
antiglobulin
test
dat
neg
antibodi
screen
reactiv
neg
ahg
use
gammaclon
antiigg
serolog
phenotyp
obtain
second
sampl
show
similar
abo
dat
ac
result
screen
reactiv
liss
w
peg
ahg
despit
use
gammaclon
ahg
three
hpc
adsorpt
success
remov
reactiv
ahg
third
sampl
abo
dat
ac
result
ahgphas
test
diminish
reactiv
remov
hpc
adsorpt
patient
specimen
spike
antijk
show
expect
reactiv
conclus
adsorpt
hpc
effici
remov
reactiv
ahg
previous
report
rbc
reduc
reactiv
note
fewer
adsorpt
requir
blood
drawn
drug
dose
use
hpc
adsorpt
knowledg
drugdos
time
may
offer
improv
effici
test
ahg
phase
blood
type
phenotyp
prior
initi
drug
dose
well
phenotypicallymatch
blood
remain
critic
optim
test
patient
extend
blood
group
platelet
phenotyp
predict
whole
genom
sequenc
impact
alloimmun
state
qatar
celina
montemayor
nagarajan
kathiresan
harvey
g
klein
zohreh
tatari
calderon
ena
wang
ccdtm
nih
sidra
medicin
nih
backgroundcas
studi
one
manifest
worldwid
genet
variat
divers
ethnic
distribut
blood
group
antigen
lead
uniqu
challeng
transfus
support
popul
although
genom
project
yield
import
insight
global
red
blood
cell
rbc
antigen
distribut
middl
east
popul
remain
underrepres
current
worldwid
largescal
sequenc
databas
genet
structur
qatari
popul
profoundli
impact
ancestr
popul
high
level
consanguin
migratori
flow
present
fantast
exampl
genet
divers
middl
east
north
africa
mena
region
describ
first
time
predict
extend
rbc
platelet
phenotyp
whole
genom
next
gener
sequenc
wg
qatari
individu
studi
designmethod
pairedend
wg
perform
qatari
nation
particip
larger
qatargenomeproject
studi
align
data
analyz
use
rylan
red
cell
leukocyt
antigen
predict
ng
queri
known
singl
nucleotid
indel
variant
red
blood
cell
rbc
platelet
antigen
gene
resultsfind
highest
variant
nucleotid
frequenc
observ
fy
fy
b
b
loci
respect
follow
promot
silenc
variant
fifteen
particip
carri
hbb
predict
kp
js
antigen
also
present
among
other
analysi
also
reveal
one
lu
yt
ab
co
b
jr
instanc
heterozygos
null
kidd
allel
total
particip
carri
differ
weak
kidd
antigen
variant
includ
homozyg
state
select
region
bcam
gene
fail
qualiti
filter
less
sampl
plateletspecif
antigen
frequenc
allel
compar
european
countri
relativelyhigh
frequenc
variant
compar
africa
identifi
detect
platelet
bw
antigen
conclus
wg
data
analysi
reveal
uniqu
combin
blood
group
platelet
antigen
qatari
popul
distinct
continent
blood
group
distribut
extract
genom
project
qatari
popul
possess
highest
frequenc
fy
variant
outsid
africa
suggest
natur
select
resist
malaria
clinic
high
preval
alloimmun
observ
qatar
might
relat
high
frequenc
polymorph
weak
kidd
antigen
latter
possibl
lead
discord
serolog
result
qatar
popul
compos
expatri
qatari
nation
circumst
rbc
antigen
discrep
donor
recipi
differ
genet
background
lead
alloimmun
rare
blood
group
frequent
found
qatar
studi
genom
data
stratifi
qatari
popul
ancestri
popul
bedouin
persian
arab
help
refin
knowledg
blood
group
divers
mena
region
gener
qatar
particular
import
step
toward
optim
precis
transfus
strategi
region
fyx
gata
variant
found
ci
jessica
keller
trina
horn
shannon
c
jenkin
jan
r
hamilton
margaret
keller
american
red
cross
american
red
cross
nation
molecular
laboratori
american
red
cross
blood
servic
backgroundcas
studi
genet
variat
also
known
darc
associ
fy
blood
group
system
well
appreci
promot
variant
destroy
bind
site
erythroid
transcript
factor
though
report
fy
allel
typic
inherit
fy
allel
silenc
express
fy
b
two
singl
nucleotid
polymorph
snp
locat
exon
associ
weaken
antigen
express
fy
typic
found
fy
weaken
fyb
term
fyx
gata
variant
common
individu
african
descent
fyx
variant
often
found
individu
caucasian
descent
though
found
fy
fy
allel
found
ci
report
blood
donor
gata
fyx
variant
inherit
ci
studi
designmethod
peripher
blood
old
african
american
male
blood
donor
test
panel
blood
group
antigen
variant
use
precisetyp
hea
molecular
beadchip
immucor
part
routin
test
panel
found
donor
homozyg
heterozyg
softwar
result
donor
possibl
variant
pv
fy
fy
b
donor
histori
serolog
type
fy
ab
genom
dna
reextract
peripher
blood
mononuclear
cell
sanger
sequenc
exon
perform
result
sequenc
align
consensu
variant
compar
allel
tabl
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
resultsfind
sanger
sequenc
confirm
genotyp
identifi
heterozygos
synonym
snp
conclus
rbc
genotyp
panel
use
algorithm
integr
genotyp
result
multipl
snp
popul
frequenc
predict
antigen
phenotyp
sinc
snp
associ
fyx
coinherit
promot
snp
destroy
gata
bind
site
immucor
softwar
result
donor
phenotyp
pv
fy
fy
b
sanger
sequenc
confirm
donor
carri
one
fy
allel
along
novel
allel
encod
fyx
silenc
gata
variant
case
illustr
highthroughput
screen
blood
donor
follow
serolog
confirm
uncov
new
blood
group
allel
serolog
import
optim
recognit
manag
weak
partial
prenat
patient
use
rhd
genotyp
commun
hospit
experi
cristin
f
clement
do
santo
zeenath
asma
elmhurst
memori
hospit
backgroundcas
studi
partial
weak
antigen
weak
discrep
reaction
serolog
test
despit
use
fda
approv
reagent
technolog
addit
test
distinguish
partial
weak
follow
clinic
manag
practic
current
variabl
gener
prenat
patient
discrep
reaction
categor
manag
rh
neg
addit
patient
test
rh
posit
actual
partial
phenotyp
recogn
possibl
risk
alloimmun
need
rhig
prophylaxi
elmhurst
memori
hospit
blood
bank
discrep
type
sampl
evalu
molecular
test
help
blood
bank
identifi
patient
despit
type
rh
posit
elig
rhig
immunoprophylaxi
studi
designmethod
period
fourteen
month
januari
april
seven
prenat
patient
sampl
reaction
strength
discrep
autom
gel
methodolog
manual
tube
method
antigen
addit
subject
rhd
genotyp
screen
weakparti
autom
gel
methodolog
erytra
analyz
grifol
diagnost
use
primari
type
tube
test
includ
immedi
spin
ahg
phase
perform
commerci
avail
panel
monoclon
antid
seraclon
monoclon
antid
blend
biorad
medic
diagnost
use
retyp
forward
type
perform
retyp
genom
dna
evalu
grifol
immunohematolog
tx
resultsfind
seven
prenat
patient
identifi
reaction
strength
discrep
autom
gel
test
manual
tube
test
subject
rhd
genotyp
patient
found
weak
type
patient
found
partial
one
patient
demonstr
partial
type
cs
previous
type
rh
neg
differ
laboratori
second
patient
identifi
partial
type
viii
previous
type
rh
posit
differ
facil
patient
deliv
rh
posit
infant
patient
partial
type
cs
receiv
rhig
week
gestat
postpartum
patient
partial
type
viii
receiv
rhig
week
postpartum
neg
antibodi
screen
time
deliveri
physician
advis
genet
test
find
recommend
made
rhig
prophylaxi
rhig
prophylaxi
indic
weak
subtyp
conclus
rhd
complex
serolog
profil
depend
express
antigen
red
cell
surfac
technic
condit
test
result
type
discrep
autom
technolog
manual
monoclon
antid
reagent
use
serolog
type
combin
genotyp
result
optim
rhig
prophylaxi
patient
popul
might
otherwis
receiv
prophylaxi
prevent
allommunn
suppress
kidd
antigen
express
use
molecular
red
cell
genotyp
resolv
discrep
serolog
test
debra
l
moor
sandi
wortman
lauri
sutor
carter
bloodcar
ut
southwestern
medic
center
backgroundcas
studi
serolog
phenotyp
test
express
surfac
rbc
antigen
wherea
molecular
genotyp
test
inherit
dna
allel
laboratori
may
util
techniqu
help
resolv
discrep
indic
need
test
jk
ab
phenotyp
extrem
rare
common
among
polynesian
studi
designmethod
complex
antibodi
identif
workup
perform
use
patient
plasma
rbc
standard
tube
pegliss
gel
methodolog
inform
obtain
urea
lysi
test
compar
serolog
phenotyp
molecular
genotyp
result
resultsfind
sampl
plasma
red
cell
receiv
year
old
femal
diagnos
ovarian
cancer
report
transfus
histori
direct
antiglobulin
test
dat
show
polyspecif
antihuman
globulin
ahg
antiigg
includ
neg
albumin
control
gel
antibodi
screenpanel
eluat
reactiv
cell
test
tube
test
screen
cell
potenti
peg
liss
also
panreact
patient
rbc
treat
edtaglycin
acid
ega
iggblock
obtain
dat
neg
cell
cell
subsequ
test
patient
serum
react
peg
iat
indic
autoantibodi
serolog
phenotyp
jk
ab
confirm
use
multipl
manufactur
antisera
phenotyp
similar
jk
null
rbc
nonreact
tube
peg
eluat
initi
suggest
probabl
rare
frozen
unlicens
antisera
unexpectedli
test
patient
rbc
contradict
jk
null
serolog
phenotyp
serolog
phenotyp
also
contradict
lysi
patient
rbc
urea
jk
null
rbc
resist
urea
lysi
due
discrep
serolog
result
molecular
genotyp
test
perform
molecular
result
jk
jk
b
predict
phenotyp
jk
ab
kidd
gene
dna
sequenc
perform
jk
exon
reveal
known
polymorph
explain
serolog
phenotyp
product
patient
transfus
three
unit
jk
ab
rbc
without
report
incid
conclus
case
illustr
molecular
genotyp
benefit
patient
discrep
serolog
test
result
predict
molecular
phenotyp
allud
possibl
suppress
antigen
express
compar
molecular
genotyp
result
serolog
phenotyp
result
rare
clinic
present
reveal
blood
util
optim
wast
rare
neg
blood
product
conclus
ng
analys
sampl
unexpectedli
found
two
snv
present
ci
previous
defin
distinct
jk
allel
variant
similarli
common
individu
african
ancestri
ng
approach
provid
addit
genom
inform
confirm
phase
snv
propos
determin
phase
perform
possibl
accur
annot
allel
amount
platelet
transfus
gc
polymorph
gene
posit
platelet
antibodi
product
analyz
resultsfind
age
sex
percentag
patient
benign
diseas
percentag
patient
homozygot
c
allel
posit
gene
similar
respond
nonrespond
also
similar
patient
hematolog
diseas
patient
nonhematolog
diseas
percentag
patient
hematolog
diseas
respond
lower
nonrespond
vs
p
although
amount
platelet
pheresi
transfus
patient
hematolog
diseas
higher
nonhematolog
diseas
vs
p
detect
rate
platelet
antibodi
lower
patient
hematolog
diseas
patient
nonhematolog
diseas
vs
p
compar
patient
hematolog
diseas
patient
nonhematolog
diseas
ci
fold
rel
risk
platelet
antibodi
product
conclus
studi
found
associ
gene
polymorph
platelet
antibodi
product
patient
hematolog
diseas
lower
risk
platelet
antibodi
product
patient
nonhematolog
diseas
backgroundcas
studi
human
gene
encod
glycoprotein
express
duffi
blood
group
antigen
fy
duffi
protein
act
receptor
distinct
proinflammatori
cytokin
malaria
parasit
p
vivax
p
knowlesi
aim
identifi
long
rang
allel
gene
possibl
includ
regulatori
element
without
ambigu
autochthon
popul
malaria
endem
area
studi
designmethod
collect
blood
sampl
healthi
volunt
ethiopia
southwestern
low
altitud
tropic
region
assay
devis
amplifi
gene
singl
amplicon
determin
genom
sequenc
haplotyp
resolv
nucleotid
cover
code
sequenc
cd
gene
includ
untransl
region
utr
intron
flank
region
comput
phase
genotyp
data
ethiopian
individu
individu
genom
project
use
input
markov
chainbas
haplotyp
mach
resultsfind
ethiopian
analyz
singl
nucleotid
polymorph
snp
distinct
genotyp
pattern
observ
except
gata
box
mutat
snp
encod
nonsens
mutat
found
physic
evid
allelespecif
amplif
sequenc
fragment
analysi
allow
us
discern
allel
chromosom
analyz
allel
detect
carri
snp
found
common
fy
b
phenotyp
clinic
relev
fy
allel
african
consist
allel
allel
repres
fy
allel
fy
b
fy
allel
fy
b
w
phenotyp
respect
nonsynonym
snp
found
comput
model
indic
chang
neutral
physic
confirm
allel
allel
correctli
predict
mach
softwar
allel
miss
anoth
haplotyp
actual
occur
among
ethiopian
cohort
predict
mach
singl
occurr
dataset
snp
list
gene
mach
predict
haplotyp
present
ethiopian
cohort
conclus
describ
distinct
allel
autochthon
eastafrican
popul
high
frequenc
fy
allel
studi
similar
studi
conduct
african
region
adjunct
human
refer
genom
assembl
gold
standard
refer
comprehens
popul
specif
data
allel
use
templat
sequenc
allel
call
highthroughput
nextgener
sequenc
precis
medicin
approach
null
phenotyp
associ
rhce
backgroundcas
studi
abo
type
import
compon
pretransfus
test
amino
acid
substitut
caus
abo
gene
mutat
usual
predict
impact
glycosyltransferas
function
may
caus
abo
blood
group
discrep
identifi
two
novel
mutat
exon
b
glycosyltransferas
gene
respons
weak
b
variant
howev
influenc
two
mutat
unclear
studi
effect
aminoacid
substitut
catalyt
activ
region
b
glycosyltransferas
caus
novel
mutat
gtb
express
explor
vitro
system
import
recogn
abo
subtyp
molecular
method
studi
designmethod
abo
antigen
serum
antibodi
proband
detect
serolog
method
sequenc
abo
gene
amplifi
pcr
sequenc
bidirect
fulllength
cdna
wildtyp
abo
mutant
b
allel
obtain
gene
synthesi
clone
vector
topo
ta
eukaryot
express
construct
recombin
plasmid
recombin
plasmid
transfect
hela
cell
lipofectamin
stabl
express
cell
harvest
use
select
stabl
express
cell
stimul
sodium
butyr
induc
erythroid
differenti
flow
cytometri
perform
use
phycoerythrin
pe
conjug
murin
antib
antibodi
hela
cell
transfect
agglutin
test
stabl
express
cell
also
examin
resultsfind
one
proband
identifi
bw
phenotyp
proband
identifi
b
phenotyp
heterozyg
site
code
region
abo
gene
identifi
directli
sequenc
analysi
haplotyp
analysi
show
proband
b
phenotyp
carri
novel
b
allel
c
p
proband
bw
phenotyp
carri
anoth
novel
b
allel
g
aminoacid
substitut
posit
two
novel
mutat
locat
catalyt
activ
region
blood
group
bglycosyltransferas
enzym
eukaryot
express
vector
wildtyp
abo
two
mutat
success
construct
confirm
clone
sequenc
stabl
express
hela
cell
also
obtain
recombin
plasmid
transfect
select
backgroundcas
studi
encod
multipass
transmembran
protein
express
kidd
blood
group
antigen
signific
genet
variat
also
known
jk
includ
multipl
variant
jk
jk
allel
result
weak
null
jk
jk
b
antigen
express
respect
report
jk
allel
includ
snp
exon
appear
silenc
express
jk
studi
designmethod
peripher
blood
old
african
american
femal
blood
donor
test
panel
blood
group
antigen
variant
use
agena
hemoid
dq
agena
bioscienc
part
routin
test
panel
found
donor
heterozyg
thu
predict
donor
type
jk
ab
donor
histori
serolog
type
jk
ab
genom
dna
reextract
peripher
blood
mononuclear
cell
total
rna
extract
rbc
sequencespecif
primer
ssp
pcr
perform
exon
sequenc
base
known
null
mutat
gene
region
exon
cdna
pcr
product
subject
sanger
sequenc
analysi
result
sequenc
align
consensu
sequenc
variant
compar
allel
backgroundcas
studi
rh
locu
compos
two
highli
homolog
gene
rhd
rhce
compos
exon
distribut
opposit
orient
facilit
macro
micro
gene
convers
lead
absenc
high
frequenc
antigen
creat
hybrid
protein
encod
low
frequenc
antigen
creat
partial
antigen
current
rh
blood
group
system
compris
antigen
gene
convers
encod
variant
protein
socal
partial
phenotyp
numer
partial
phenotyp
usual
identifi
posit
person
make
alloantid
describ
partial
common
peopl
african
descent
report
case
caucasian
pregnant
woman
harbor
rhd
diiib
variant
allel
complex
antibodi
mixtur
studi
designmethod
standard
hemagglutin
techniqu
includ
allogen
autolog
adsorpt
rhdrhce
genom
dna
sequenc
exon
hous
techniqu
perform
antibodi
titrat
done
lissiatigg
columnagglutin
techniqu
rhd
type
perform
diaclon
aborh
use
instrument
resultsfind
patient
chechnya
admit
hospit
deliv
third
child
proper
followup
done
pregnanc
inform
avail
previou
pregnanc
type
group
ab
dcece
k
fy
ab
jk
ab
ss
rhd
weaken
notic
reaction
antibodi
screen
show
complex
mixtur
alloantibodi
antid
antic
anti
anti
antik
titer
respect
autoantibodi
high
frequenc
antigen
papaintr
rbc
also
identifi
molecular
work
undertaken
confirm
suspicion
partial
genom
test
found
patient
harbor
variant
allel
rhd
diiib
rhd
homozyg
like
hemizyg
state
sequenc
rhce
gene
show
alter
confirm
patient
rhce
ce
homozyg
state
type
g
neg
antig
individu
antid
antic
group
r
r
k
sunit
crossmatch
found
compat
urgent
call
made
collect
fresh
unit
newborn
type
group
ab
dcece
k
birth
dat
elut
show
panagglutin
investig
due
small
amount
sampl
receiv
level
hemoglobin
gdl
total
bilirubin
day
hemoglobin
drop
gdl
bilirubin
treat
phototherapi
day
discharg
hospit
outpati
follow
stop
month
babi
hemoglobin
gdl
backgroundcas
studi
go
antigen
low
frequenc
antigen
rh
system
associ
partial
antigen
categori
diva
report
found
approxim
black
individu
immunohematolog
refer
lab
encount
number
patient
alloantibodi
direct
antigen
unexpect
number
donor
either
confirm
suspect
go
posit
decid
screen
donor
ro
phenotyp
posit
antigen
neg
c
e
determin
group
higher
preval
go
antigen
studi
designmethod
period
week
segment
remov
red
blood
cell
rbc
unit
previous
found
neg
c
e
antigen
initi
ro
donor
test
without
consid
ethnic
later
decid
check
donor
record
identifi
selfreport
african
american
aa
ethnic
group
donor
test
gel
techniqu
use
unlicens
antisera
shown
reactiv
differ
reagent
cell
posit
go
nonreact
cell
posit
js
v
vs
stem
antigen
group
b
donor
test
gel
techniqu
eluat
prepar
cell
use
adsorb
plasma
contain
antigo
eluat
also
shown
reactiv
cell
posit
go
nonreact
cell
antisera
well
cell
posit
b
antigen
go
posit
donor
confirm
neg
direct
antiglobulin
test
dat
gel
resultsfind
pleas
refer
follow
tabl
conclus
result
show
aa
donor
ro
phenotyp
higher
expect
preval
go
antigen
statist
analysi
indic
suffici
evid
support
hypothesi
signific
level
expect
go
antigen
found
aa
donor
unexpect
find
larg
number
caucasian
ro
donor
caucasian
expect
ro
phenotyp
ro
donor
test
caucasian
like
reflect
predomin
caucasian
blood
donor
continu
underrepresent
minor
donor
base
effort
recruit
black
ro
donor
transfus
patient
sickl
cell
diseas
becom
success
may
see
increas
patient
develop
antibodi
low
frequenc
antigen
found
black
popul
studi
may
warrant
establish
preval
low
frequenc
antigen
ro
rbc
preferenti
transfus
patient
popul
even
though
subgroup
may
produc
unexpect
abo
antibodi
risk
naturalor
alloimmun
differ
abo
allel
report
studi
summar
data
collect
span
ten
year
correl
abo
allel
antibodi
format
chines
blood
center
studi
designmethod
sampl
discrep
red
cell
serum
group
categor
specif
subgroup
standard
serolog
method
unexpect
antib
identifi
use
b
red
cell
platelet
activ
statu
measur
microparticl
mp
content
thrombolux
lightintegra
technolog
inc
canada
optim
threshold
predict
plt
activ
singl
donor
platelet
sdp
suspend
plasma
previous
determin
specif
sensit
clinic
respons
activ
nonactiv
sdp
compar
hlaposit
hlaneg
studi
patient
resultsfind
twenti
one
patient
test
posit
antihla
antibodi
hlaposit
becam
refractori
insuffici
cci
follow
two
consecut
random
plt
transfus
patient
show
insuffici
cci
baselin
data
hlaposit
hlaneg
patient
compar
hlaposit
patient
male
year
age
diagnos
aml
cml
md
baselin
platelet
count
l
bleed
rare
howev
averag
length
stay
hlaposit
patient
compar
day
hlaneg
patient
hlaposit
patient
respond
nonactiv
plt
transfus
significantli
lower
platelet
recoveri
cci
hlaneg
patient
vs
signific
level
one
patient
yr
old
male
aml
receiv
hlamatch
plt
character
plt
activ
statu
first
treatment
day
patient
receiv
plt
transfus
increasingli
insuffici
cci
two
hla
match
transfus
unsuccess
nonactiv
plt
success
increas
cci
see
tabl
conclus
select
nonactiv
random
plt
transfus
hlaposit
patient
achiev
suffici
high
cci
hlaposit
patient
howev
nonactiv
hla
match
plt
restor
cci
one
alloimmun
patient
addit
studi
need
determin
whether
nonactiv
platelet
could
improv
success
rate
hlamatch
transfus
backgroundcas
studi
rh
system
polymorph
blood
group
system
human
second
immunogen
next
abo
system
rhd
polymorph
show
substanti
ethnic
variabl
partial
allel
divers
includ
dau
allel
evid
molecular
level
rhd
allel
rare
partial
variant
report
type
discrep
femal
blood
donor
initi
type
rh
neg
previou
donat
year
ago
studi
designmethod
type
perform
use
three
differ
fda
licens
reagent
fda
k
clear
devic
three
differ
manufactur
method
includ
micropl
hemagglutin
column
agglutin
techniqu
gel
test
tube
dnasequenc
rhd
exon
perform
use
sanger
bidirect
dna
sequenc
analysi
resultsfind
previou
type
use
micropl
hemagglutin
weak
test
use
tube
method
neg
subsequ
donat
micropl
hemagglutin
gave
posit
result
weak
test
addit
test
use
column
agglutin
method
neg
dnasequenc
result
reveal
presenc
rhd
exon
characterist
dau
cluster
two
modif
found
respect
rhd
exon
exon
presenc
mutat
characterist
presenc
rhd
predict
partial
weak
phenotyp
conclus
amino
acid
chang
locat
inner
boundari
red
blood
cell
rbc
membran
chang
affect
antigen
integr
proper
express
drastic
decreas
antigen
densiti
individu
react
differ
test
variou
antid
monoclon
antibodi
access
referr
laboratori
genom
test
import
time
identif
variant
backgroundcas
studi
demand
red
blood
cell
rbc
antigen
neg
product
continu
rise
trigger
studi
suggest
rbc
close
match
patient
may
decreas
likelihood
alloimmun
creat
need
blood
center
employ
highvolum
screen
method
addit
demand
highincid
antigen
neg
rbc
must
match
need
sever
method
appli
standard
tube
autom
serolog
micropl
mcp
molecular
hea
beadchip
hbc
hbc
strength
abil
test
mani
antigen
simultan
shortcom
includ
cost
limit
detect
mani
null
phenotyp
especi
rh
k
jk
system
detect
serolog
immunohematolog
refer
lab
reli
screen
serolog
mcp
initi
chosen
highvolum
capabl
focu
screen
common
antigen
cece
k
fy
fy
b
jk
jk
b
ss
algorithm
expand
includ
direct
test
base
ethnic
broad
test
highand
lowincid
antigen
base
antisera
avail
newli
encount
highincid
antigen
neg
donor
sent
test
hbc
studi
designmethod
rbc
unit
sort
base
three
ethnic
african
american
hispan
caucasian
unit
test
cece
k
kp
b
detect
k
donor
unit
neg
two
four
rh
k
antigen
test
fy
fy
b
jk
jk
b
ss
unit
k
regardless
rhce
type
test
k
mcp
unit
meet
criteria
test
african
american
hispan
ethnic
js
di
also
test
unit
type
js
di
test
js
b
di
b
respect
found
js
b
di
b
hbc
request
addit
unit
type
sswere
submit
hbc
total
antigen
test
mcp
screen
method
sever
unit
neg
highincid
antigen
k
js
b
u
discov
find
unit
null
phenotpy
rh
k
jk
system
conclus
use
combin
serolog
mcp
molecular
hbc
algorithm
allow
us
nimbl
adapt
specif
need
base
chang
patient
popul
mcp
method
instrument
support
everincreas
antigen
neg
unit
requir
low
resolut
molecular
screen
method
strength
increasingli
commonplac
serolog
screen
permit
detect
rare
donor
could
miss
molecular
method
provid
inexpens
screen
larg
number
donor
unit
number
like
prove
mcp
true
stalwart
method
relationship
antibodi
reactiv
strength
reactiv
monocyt
monolay
assay
mma
joan
l
maurer
sandra
j
nanc
pamela
nickl
ardp
american
red
cross
american
rare
donor
program
american
red
cross
backgroundcas
studi
mma
use
predict
clinic
signific
alloantibodi
antibodi
bind
sensit
rbc
determin
perform
indirect
antiglobulin
test
might
expect
strong
antibodi
would
like
result
posit
mma
weakli
reactiv
antibodi
would
like
result
neg
mma
studi
designmethod
mma
perform
use
antigen
posit
antigen
neg
red
blood
cell
case
known
antibodi
specif
select
rbc
incub
patient
serum
without
sourc
fresh
complement
present
red
blood
cell
test
also
incub
salin
salin
control
control
increas
reactiv
might
present
rbc
alon
rbc
sensit
perform
incub
tube
water
bath
one
hour
intermitt
mix
antiglobulin
test
perform
red
cell
sampl
use
antiigg
includ
salin
control
studi
focus
compar
reactiv
antibodi
coat
rbc
backgroundcas
studi
gene
chromosom
encod
kidd
jk
glycoprotein
carri
blood
group
system
antigen
jk
jk
b
protein
encod
gene
membran
transport
mediat
urea
transport
erythrocyt
jk
glycoprotein
consist
intramembran
domain
extracellular
loop
jk
jk
b
antigen
express
result
singl
nucleotid
polymorph
exon
antigen
locat
th
extracellular
loop
sever
mutat
identifi
exon
intron
respons
weaken
express
jk
antigen
report
novel
silenc
mutat
discov
due
discord
serolog
predict
molecular
jk
phenotyp
red
cell
donor
selfidentifi
white
hispan
studi
designmethod
genom
dna
extract
edta
whole
blood
sampl
use
autom
magnet
particl
nucleic
acid
purif
method
dna
test
multiplex
hea
molecular
beadchip
test
immucor
bioarray
solut
nj
usa
nucleotid
associ
jka
jkb
polymorph
present
predict
jk
ab
phenotyp
histor
serolog
phenotyp
two
separ
donat
show
phenotyp
jk
ab
third
serolog
type
new
sampl
use
monoclon
antijk
biorad
confirm
previou
jk
ab
phenotyp
subsequ
bidirect
sequenc
studi
perform
appli
biosystem
dna
analyz
use
termin
sequenc
kit
life
technolog
co
ca
usa
dna
analyz
use
geneiou
pro
biomatt
auckland
nz
bioinformat
softwar
platform
obtain
nucleotid
base
sequenc
compar
ncbi
refer
sequenc
resultsfind
sequenc
analysi
reveal
delet
exon
impact
downstream
nucleotid
sequenc
mutat
jk
exon
nb
locat
implic
presenc
aberr
weak
jk
antigen
may
may
detect
serolog
method
novel
infram
mutat
produc
abnorm
jk
rd
extracellular
loop
result
lack
express
jk
antigen
final
protein
conclus
novel
mutat
ensu
delet
discov
investig
jk
antigen
type
discrep
predict
molecular
phenotyp
serolog
express
phenotyp
mutat
shown
silenc
jk
antigen
express
test
need
better
understand
mechan
underli
aberr
effect
infram
mutat
antigen
express
signific
identifi
alloantibodi
one
rbca
two
three
frequenc
identifi
alloantibodi
antim
anti
antik
antid
antilea
antijka
antilua
antileb
anti
antikpa
antic
anti
antijkb
conclus
show
overal
preval
antibodi
pediatr
popul
alloantibodi
clinic
import
irregular
antibodi
identifi
rh
kell
duffi
kidd
ss
system
high
frequenc
antim
correl
age
present
antibodi
mainli
children
mostli
natur
extens
rbc
antigen
match
includ
rh
kell
system
consid
politransfus
patient
regardless
basal
diseas
order
avoid
alloimmun
hemolyt
transfus
reaction
backgroundcas
studi
children
transfus
depend
anemia
sickl
cell
diseas
scd
thalassemia
increas
risk
develop
red
blood
cell
rbc
alloantibodi
due
lifelong
need
transfus
therapi
advent
genotyp
extend
rbc
antigen
panel
success
incorpor
chronic
transfus
therapi
program
cttp
precis
match
blood
popul
patient
studi
designmethod
key
member
transfus
servic
ts
immunohematolog
refer
laboratori
irl
hematolog
clinic
hc
care
children
sickl
cell
diseas
thalassemia
hemoglobinopathi
met
develop
chronic
transfus
therapi
program
benefit
patient
help
minim
risk
red
cell
alloimmun
children
enrol
baselin
genotyp
perform
includ
rbc
antigen
well
detect
fy
bgata
mutat
possibl
signific
mutat
rh
system
form
develop
assist
commun
hc
ts
irl
transfus
interv
volum
patient
estim
obtain
freshest
less
week
blood
avail
match
rh
kell
system
neg
antibodi
screen
doubl
rbc
unit
collect
possibl
patient
requir
unit
singl
transfus
episod
patient
develop
rbc
alloantibodi
switch
phenotyp
match
rbc
prevent
develop
addit
antibodi
base
profil
resultsfind
sinc
incept
program
june
patient
follow
disord
enrol
scd
thalassemia
disord
enrol
rbc
alloantibodi
includ
scd
patient
anti
previous
receiv
cekphenotyp
match
blood
found
variant
e
antigen
genotyp
children
without
alloantibodi
enrol
develop
antibodi
anti
follow
provis
rbc
match
rh
kell
system
antibodi
receiv
extendedmatch
unit
none
develop
addit
alloantibodi
conclus
genotyp
success
incorpor
cttp
provid
precis
match
blood
reduc
risk
rbc
alloantibodi
develop
much
inform
provid
genotyp
compar
tradit
serolog
phenotyp
without
expens
cell
separ
techniqu
recent
transfus
patient
prevent
rbc
antigen
sensit
help
avoid
costli
serolog
workup
prevent
delay
hemolyt
transfus
reaction
improv
blood
manag
addit
benefit
includ
improv
avail
blood
patient
otherwis
rare
blood
type
particularli
gata
mutat
present
backgroundcas
studi
gold
standard
compat
test
histor
base
upon
serolog
test
tube
gel
solid
phase
methodolog
detect
red
cell
agglutin
sever
condit
howev
serolog
reli
upon
determin
safest
blood
transfus
molecular
test
human
blood
group
antigen
provid
reliabl
method
accur
predict
phenotyp
transfus
recipi
without
extens
serolog
test
addit
ad
insight
variant
blood
group
antigen
creat
new
arena
match
blood
donor
patient
transfus
abstract
describ
molecular
test
incorpor
blood
collect
facil
influenc
chang
immunohematolog
laboratori
practic
studi
designmethod
sixti
donor
record
multipl
donat
without
full
phenotyp
molecular
genotyp
select
week
test
outsid
contract
laboratori
molecular
result
electron
transfer
blood
establish
comput
system
bec
staff
immunohematolog
refer
laboratori
irl
valid
result
transmit
rare
unit
uniqu
antigen
ad
frozen
blood
inventori
report
american
rare
donor
program
ardp
resultsfind
end
year
fulli
phenotyp
donor
databas
expand
includ
fulli
test
donor
addit
identifi
rare
donor
recruit
add
rare
frozen
unit
report
ardp
see
tabl
discuss
addit
donor
perform
molecular
test
patient
improv
medic
care
major
patient
sickl
cell
diseas
scd
area
molecular
genotyp
perform
enabl
irl
provid
phenotyp
similar
rbc
unit
effort
prevent
alloimmun
irl
also
select
patient
molecular
genotyp
autoimmun
hemolyt
anemia
drug
interfer
ie
daratumumab
multipl
transfus
phenotyp
match
prevent
alloimmun
simplifi
process
provid
best
match
blood
avail
patient
irl
also
provid
blood
collect
rare
donor
identifi
molecular
genotyp
blood
center
patient
need
rare
blood
conclus
unlik
genotyp
fulli
replac
serolog
test
prove
complementari
adjunct
immunohematolog
servic
hemovigil
focu
mani
associ
manag
care
patient
transfus
molecular
genotyp
aid
provid
blood
scd
patient
signific
autoimmun
diseas
medic
condit
molecular
genotyp
enorm
potenti
revolution
practic
blood
center
establish
larg
donor
pool
fulli
type
donor
well
identifi
mani
donor
rare
blood
group
backgroundcas
studi
incid
hdfn
caus
rh
antigen
reduc
markedli
low
level
develop
countri
still
pose
challeng
health
care
system
develop
countri
present
convent
test
tube
ctt
method
recommend
perform
titrat
antibodi
antenat
case
ctt
increasingli
replac
gel
microcolumn
agglutin
gma
system
offer
mani
advantag
transfus
laboratori
studi
topic
clear
guidelin
establish
precis
method
titrat
antenat
case
gma
studi
designmethod
sampl
rh
neg
antenat
femal
evalu
period
yearsthes
initi
subject
indirect
agglutin
test
iat
ctt
use
polyspecif
ahg
well
gma
cell
antibodi
screen
panel
posit
sampl
subject
identif
antibodi
use
cell
antibodi
identif
panel
presenc
antig
antibodi
rule
use
doubl
adsorpt
method
subject
titrat
ctt
gma
igg
rabbit
inhous
prepar
r
r
rbc
singl
donor
use
titrat
titrat
ctt
carri
use
liss
incub
time
min
well
normal
salin
incub
time
min
make
rbc
suspens
similarli
titrat
gma
carri
use
liss
incub
time
min
well
normal
salin
incub
time
min
recommend
earlier
studi
better
correl
two
method
titer
correl
clinic
context
recent
histori
antid
administr
intervent
like
iut
perform
outcom
pregnanc
resultsfind
antenat
case
test
posit
ict
gma
case
also
test
posit
tube
method
test
posit
gma
histori
antid
antibodi
identifi
antid
case
combin
anticantid
case
titrat
tube
method
use
liss
gave
posit
result
titrat
gma
use
normal
salin
ns
result
mix
field
reaction
two
method
includ
analysi
titer
obtain
ctt
use
ns
gma
use
liss
includ
analysi
titrat
perform
total
differ
sampl
obtain
antenat
case
valu
evalu
karl
pearson
coeffici
correl
evalu
pvalu
sampl
includ
suggest
moder
correl
case
involv
singl
antibodi
antid
evalu
p
suggest
strong
correl
case
undergon
iut
case
report
iufd
titer
valu
patient
note
least
ctt
gma
conclus
gma
highli
sensit
precis
method
titrat
antenat
case
prospect
report
titer
gma
along
ctt
evalu
treat
clinician
made
awar
result
two
method
ctt
gma
better
correl
singl
antibodi
present
year
old
man
extens
cardiac
past
medic
histori
present
acut
append
refus
surgeri
treat
antibiot
day
piperacillintazobactam
follow
ten
day
ampicillinclavulan
acid
return
er
day
discharg
ruptur
appendix
underw
urgent
surgeri
treat
empir
piperacillintazobactam
admiss
hour
hb
fell
gdl
gdl
accompani
marker
acut
hemolysi
ldh
ul
haptoglobin
gdl
indirect
bilirubin
mgdl
indirect
coomb
test
reveal
panagglutinin
dat
posit
igg
eluat
neg
strong
suspicion
diiha
piperacillintazobactam
held
sampl
blood
sent
new
york
blood
center
reveal
antibodi
piperacillin
detect
immun
complex
method
addit
antielik
specif
observ
weakli
reactiv
peg
iat
igg
gel
test
papaintr
panel
rbc
interestingli
patient
posit
e
antigen
phenotyp
patient
develop
acut
renal
failur
oliguria
requir
dialysi
subsequ
went
acut
respiratori
failur
requir
mechan
ventil
repeat
dat
neg
day
initi
dat
check
clinic
condit
improv
day
hematocrit
improv
back
baselin
howev
patient
dialysi
depend
month
prior
improv
renal
function
conclus
unlik
penicillin
cephalosporin
piperacillin
induc
hemolyt
anemia
typic
complement
mediat
induc
brisk
sever
hemolysi
dat
test
usual
posit
due
rbcbound
complement
igg
case
demonstr
piperacillin
induc
brisk
sever
hemolyt
anemia
absenc
detect
complement
rapid
withdraw
piperacillin
essenti
recoveri
end
organ
damag
may
delay
recoveri
investig
conduct
upon
detect
antigen
type
discrep
current
previou
donat
process
improv
implement
time
impact
frequenc
type
discrep
evalu
studi
designmethod
blood
establish
comput
system
bec
provid
correl
current
test
result
previou
result
retrospect
review
donor
antigen
type
discrep
flag
bec
complet
discrep
flag
hous
prior
label
classifi
intern
discrep
antigen
type
repeat
hospit
custom
report
discrep
classifi
extern
discrep
discrep
investig
determin
caus
identifi
discrep
postimplement
process
chang
evalu
resultsfind
period
discrep
detect
involv
genet
rh
variat
fyx
associ
weak
blood
group
antigen
type
detect
commerci
fda
licens
reagent
investig
reveal
process
failur
multipl
depart
also
contribut
donor
antigen
type
discrep
includ
collect
data
entri
technic
procedur
inform
system
key
process
improv
includ
implement
selfadminist
donor
health
histori
electronicallycaptur
identif
point
develop
job
aid
investig
duplic
donor
test
procedur
revis
includ
process
obtain
segment
unit
test
incub
maximum
time
recommend
manufactur
requir
confirm
second
manufactur
reagent
e
neg
antigen
type
genotyp
perform
sampl
type
discrep
key
identifi
genet
variat
level
antigen
express
result
process
chang
nonabod
antigen
type
discrep
decreas
approxim
collect
collect
year
period
conclus
donor
type
discrep
frequenc
reduc
implement
process
improv
across
multipl
depart
system
inform
system
function
compar
current
previou
test
critic
featur
label
histor
nonabod
antigen
genet
variant
frequent
caus
test
discrep
warrant
investig
investig
discrep
recogn
sourc
error
respond
process
improv
crucial
implement
robust
system
label
histor
nonabod
blood
group
antigen
backgroundcas
studi
antigen
pr
seri
associ
sialic
acid
residu
glycophorin
proteasesialidasesent
antipr
also
report
specif
determin
resid
side
chain
attach
mn
sialoglycoprotein
major
pr
specif
antibodi
gener
cold
agglutinin
react
optim
lower
temperatur
rare
igg
iga
biphas
properti
case
autoantipr
caus
sever
hemolyt
anemia
report
case
report
patient
gammaglobulinemia
high
titertherm
amplitud
antipr
show
obviou
evid
hemolysi
studi
designmethod
test
perform
routin
tube
method
use
peg
liss
salin
untreat
ficin
neuraminidasetr
cell
acid
eluat
prepar
test
reagent
red
cell
iat
method
heat
eluat
prepar
cold
adsorb
plasma
use
madsorb
cell
heat
eluat
test
neuraminidasetr
red
cell
also
test
muntreat
cell
autolog
cell
test
patient
plasma
hour
salin
settl
method
obtain
thermal
capac
plasma
treat
dtt
also
test
reagent
red
cell
differenti
igm
igg
resultsfind
patient
hemoglobin
gdl
hematocrit
total
bilirubin
mgdl
within
normal
rang
laboratori
test
ldh
haptoglobin
retic
count
perform
hemolysi
suspect
clinic
transfus
need
admiss
igm
detect
serum
protein
electrophoresi
spep
pleas
see
tabl
reaction
plasma
eluat
differ
cell
dat
weakli
posit
antiigg
autocontrol
strongli
posit
room
temperatur
rt
nonreact
iat
antibodi
titer
follow
conclus
keep
rariti
jk
variant
yield
clinic
signific
variant
seri
highli
select
case
rel
low
patient
jk
ab
patient
antibodi
associ
suspect
variant
jk
jk
phenotyp
guid
select
unit
rbc
transfus
patient
heterozyg
phenotyp
antigenneg
unit
match
antibodi
may
given
concern
alloimmun
antithet
jk
antigen
patient
homozyg
phenotyp
jk
ab
jk
ab
antigenneg
transfus
defer
like
presenc
least
one
convent
allel
risk
exposur
antithet
foreign
antigen
conclud
real
valu
molecular
test
lie
identifi
patient
without
clinic
signific
variant
unnecessari
restrict
rbc
unit
select
lift
especi
patient
multipl
alloantibodi
tube
agglutin
method
use
commerci
monoclon
biorad
germani
polyclon
reagent
genom
dna
extract
whole
blood
use
qiaamp
dna
blood
kit
qiagen
germani
red
cell
genotyp
perform
hea
rhce
kit
immucorbioarray
solut
warren
nj
usa
sinc
phenotyp
genotyp
result
discord
sampl
character
sequenc
ten
rhce
exon
flank
intron
region
use
sanger
sequenc
resultsfind
patient
dphenotyp
refer
suspicion
antihr
alloantibodi
hea
kit
predict
cephenotyp
rhce
kit
identifi
alter
allel
addit
patient
rbc
nonreact
multipl
commerci
antic
anti
includ
antic
includ
anti
includ
monoclon
reagent
sequenc
analysi
rhce
gene
indic
individu
cece
howev
patient
also
appar
homozyg
mutat
posit
exon
predict
encod
prematur
stop
codon
p
molecular
mechan
consist
aberr
rhce
ce
sequenc
abolish
c
e
express
rhce
allel
report
isbt
genom
databas
conclus
case
describ
novel
polymorph
exon
rhce
gene
caus
silenc
c
e
express
woman
dphenotyp
although
dna
genotyp
predict
blood
group
great
valu
genotyp
alway
consist
phenotyp
mani
genet
event
may
caus
appar
discrep
result
hemagglutin
dna
genotyp
sequenc
remain
gold
standard
studi
complex
rh
molecular
variant
one
case
abnorm
type
b
blood
group
identifi
use
microcolumn
gel
card
test
tube
method
determin
blood
group
respect
detect
blood
group
substanc
saliva
use
anticoagul
whole
blood
extract
dna
qiaamp
blood
kit
sequenc
invitrogen
corpor
two
gener
pedigre
investig
activ
glycosyltransferas
erythrocyt
membran
serum
measur
blood
donor
sampl
blood
sampl
transform
vitro
use
udpgalactos
serum
normal
type
b
resultsfind
bm
subtyp
confirm
blood
group
serolog
test
genotyp
sequenc
result
new
mutat
site
mutat
exon
famili
survey
result
show
father
sister
normal
type
blood
group
mother
type
bmmutant
similarli
weakli
express
b
antigen
includ
mutat
exon
gac
tag
suggest
mutat
herit
mutat
led
prematur
termin
protein
code
exon
signific
decreas
activ
glycosyltransferas
serum
treatment
udpgalactos
could
convert
bm
subtyp
blood
group
normal
type
b
blood
group
vitro
conclus
bm
subtyp
blood
group
result
new
herit
mutat
site
found
blood
group
examin
udpgalactos
combin
normal
type
b
serum
correct
effect
bm
subtyp
blood
group
suggest
abnorm
blood
group
correct
chang
activ
glycosyltransferas
improv
safeti
blood
transfus
clinic
signific
natur
occur
antin
anti
alloantibodi
blood
donor
sheetal
malhotra
gita
negi
aseem
tiwari
depart
transfus
medicin
india
institut
medic
scienc
depart
transfus
medicin
medantath
medic
backgroundcas
studi
alloimmun
trigger
individu
lack
particular
antigen
expos
antigen
transfus
pregnanc
caus
format
immun
antibodi
addit
exogen
exposur
underli
inflammatori
auto
immun
condit
may
lead
format
unexpect
antibodi
studi
designmethod
herein
case
natur
occur
antin
anti
alloantibodi
healthi
blood
donor
rh
posit
blood
group
report
case
signifi
import
incorpor
indirect
antiglobulin
test
iat
blood
unit
routin
protocol
alloadsorpt
perform
select
cell
confirm
presenc
alloantibodi
dtt
dithiothretiol
test
demonstr
igm
igg
natur
antibodi
antibodi
show
dosag
phenomena
reactiv
decreas
enzym
papain
treatment
donor
red
cell
phenotyp
mn
system
mnss
igm
igg
antibodi
titer
antin
anti
antibodi
respect
gel
card
techniqu
post
dtt
treatment
igg
antibodi
titer
antin
anti
conclus
present
case
clinic
signific
natur
occur
antin
anti
antibodi
react
wide
thermal
amplitud
detect
donor
serum
publish
report
natur
occur
antin
anti
antibodi
healthi
donor
popul
mn
system
antim
known
commonest
natur
occur
antibodi
igm
natur
react
salin
phase
antin
rel
less
common
anti
mostli
immun
natur
igg
type
reactiv
mani
small
center
especi
develop
countri
iat
done
rh
neg
blood
group
donor
order
rule
presenc
antid
alloantibodi
primarili
due
financi
constraint
case
author
want
emphas
protocol
iat
test
blood
donor
irrespect
rh
statu
incorpor
blood
bank
improv
safeti
blood
transfus
servic
patient
altern
iat
test
pool
cell
done
donor
initi
screen
procedur
antibodi
screen
three
cell
panel
put
iat
posit
case
thu
pave
way
better
transfus
practic
reduc
risk
advers
reaction
backgroundcas
studi
explor
feasibl
rh
blood
group
antigen
detect
precis
transfus
applic
rh
antigen
detect
technolog
comput
inform
identif
technolog
laboratori
blood
group
autoanalysi
softwar
system
blood
transfus
inform
manag
softwar
system
studi
designmethod
red
blood
cell
rbc
patient
donor
detect
abo
rh
antigen
c
c
e
e
use
laboratori
blood
type
automat
analysi
system
result
upload
transfus
inform
manag
system
tim
comput
recognit
technolog
automat
chose
appropri
blood
compat
abo
rh
antigen
blood
crossmatch
done
polybren
microcylind
gel
card
antiglobulin
method
mgcagh
reduc
incid
anti
antic
antirh
antibodi
avoid
repeat
crossmatch
incompat
due
unknown
rh
system
antigen
clinic
practic
realiz
precis
blood
transfus
resultsfind
blood
transfus
precis
program
implement
recipi
could
achiev
complet
compat
transfus
abo
type
rh
antigen
transfus
reaction
occur
within
first
minut
infus
hour
infus
blood
routin
examin
blood
biochemistri
measur
hour
infus
hb
increas
averag
serum
bilirubin
signific
chang
patient
receiv
unit
red
cell
suspens
repeat
infus
ineffect
rate
red
blood
cell
transfus
rate
delay
hemolyt
reaction
advers
reaction
transfus
occur
occurr
rate
blood
group
irregular
antibodi
significantli
reduc
patient
multipl
blood
transfus
compar
patient
implement
precis
blood
transfus
program
case
irregular
antibodi
posit
proport
antibodi
rh
system
decreas
significantli
previou
period
prior
implement
precis
blood
transfus
protocol
conclus
implement
rh
blood
group
antigen
detect
technolog
achiev
clinic
precis
blood
transfus
avoid
product
rh
system
antibodi
also
reduc
occurr
advers
reaction
blood
transfus
improv
abil
solv
difficult
blood
crossmatch
safeti
blood
transfus
therapi
perform
evalu
differ
descript
predict
phenotyp
found
instanc
relat
categor
weak
partial
rh
blood
group
antigen
report
presenc
fyb
gata
allel
true
discrep
found
one
antigen
type
predict
idcor
xt
current
system
dna
sequenc
amplicon
includ
gypa
exon
identifi
two
snp
intron
region
prevent
bind
idcor
xt
forward
primer
target
site
tabl
conclus
predict
rbc
antigen
express
obtain
idcor
xt
genotyp
system
current
use
show
high
degre
concord
singl
fals
neg
antigen
report
idcor
xt
unlik
clinic
import
weak
partial
antigen
express
specifi
predict
phenotyp
report
rh
blood
group
antigen
idcor
xt
may
clinic
applic
select
patient
popul
gata
mutat
promot
region
fyb
allel
identifi
genotyp
report
system
presenc
report
predict
phenotyp
idcor
xt
may
lead
unnecessari
transfus
fybneg
rbc
patient
mutat
use
predict
phenotyp
report
red
cell
alloimmun
pregnant
women
impact
systemat
inject
rhig
studi
laurin
laget
carolin
izard
elisabeth
durieuxroussel
isabel
dettori
julia
gouvitso
jacqu
chiaroni
virgini
ferreratourenc
backgroundcas
studi
red
blood
cell
rbc
alloimmun
pregnanc
rare
still
major
problem
depend
specif
antibodi
implic
hemolyt
diseas
fetu
newborn
mild
sever
alloimmun
may
requir
need
phototherapi
transfus
neonat
rarest
case
need
utero
transfus
studi
designmethod
object
studi
present
result
global
red
blood
cell
alloimmun
pregnant
women
period
year
french
region
provenc
alp
cote
dazur
cors
number
alloimmun
relat
number
birth
region
determin
preval
alloimmun
pregnanc
also
evalu
impact
recommend
nation
colleg
obstetrician
implement
sinc
systemat
inject
rhig
week
amennorhea
studi
incid
antid
alloimmun
cohort
resultsfind
year
analys
pregnanc
alloimmun
ie
pregnant
women
antibodi
implic
hemolyt
diseas
fetu
antid
antic
antikel
antibodi
implic
hemolyt
diseas
newborn
antic
anti
anti
antifya
antibodi
incid
pregnanc
antil
also
evalu
effect
systemat
inject
rhig
dpregnant
women
week
amennorhea
studi
incid
number
new
case
alloimmun
antid
year
period
observ
signif
decreas
incid
sinc
integr
recommend
followup
practic
incid
antid
alloimmun
stabil
result
compar
countri
also
practic
routin
inject
begin
quarter
conclus
result
broad
period
year
show
differ
preval
antibodi
pregnant
women
compar
countri
inde
franc
respect
rhk
phenotyp
transfus
young
woman
decreas
number
alloimmun
women
system
addit
sinc
recommend
nation
colleg
obstetrician
routin
inject
rhig
week
amenorrhea
incid
antid
alloimmun
significantli
decreas
stabil
test
backgroundcas
studi
hemaquebec
provid
blood
product
provinc
quebec
serv
popul
million
also
play
role
immunohematolog
refer
laboratori
irl
resolv
complex
antibodi
identif
case
refer
hospit
annual
receiv
roughli
request
hospit
blood
bank
investig
antibodi
identif
case
pregnanc
followup
transfus
reaction
variou
discrep
among
servic
provid
within
irl
antibodi
identif
investig
exclud
pregnanc
followup
repres
two
third
activ
softwar
haemonet
implement
manag
clinic
case
receiv
sampl
report
result
serv
electron
databas
present
studi
survey
red
blood
cell
rbc
antibodi
provid
valuabl
inform
antibodi
combin
work
frequenc
studi
designmethod
data
extract
databas
use
aggreg
serolog
investig
specif
code
june
implement
march
result
excel
file
manual
analys
resultsfind
yearperiod
data
exclud
pregnanc
follow
up
compil
case
receiv
averag
requestscas
consid
unev
regard
blood
unit
select
case
lack
antibodi
case
consid
nonspecif
reaction
cold
agglutinin
antibodi
rbc
media
nonspecif
antibodi
without
clinic
signific
underli
antibodi
antibodi
daratumumab
case
show
antibodi
blood
group
antigen
specif
without
clinic
signific
rhig
knop
data
regard
two
type
unexpect
rbc
antibodi
alloantibodi
autoantibodi
calcul
sampl
infer
could
make
evalu
case
addit
sole
antibodi
rh
specif
e
specif
evalu
classifi
unev
categori
whenev
autoantibodi
consid
clinic
signific
alloantibodi
total
case
show
blood
group
antigen
specif
clinic
signific
among
case
show
uniqu
antibodi
rh
specif
antibodi
found
case
case
least
one
antirh
case
antibodi
case
least
one
antirh
overal
present
antirh
anti
frequent
case
follow
antic
case
antik
case
antic
combin
anti
observ
case
repres
frequent
rh
antibodi
combin
conclus
studi
summar
last
year
antibodi
identif
workup
irl
exclud
pregnanc
work
up
clearli
show
antirh
remain
major
burden
patient
manag
rare
case
also
unrev
work
exampl
case
antiu
case
antipel
identifi
intend
produc
comprehens
portrait
investig
case
whole
pictur
lost
workload
urgenc
behind
request
also
serv
demonstr
relev
antibodi
work
up
order
prevent
transfus
reaction
favor
patient
outcom
backgroundcas
studi
introduct
immunoprophylaxi
rhd
neg
pregnant
women
drastic
reduc
incid
hemolyt
diseas
fetu
newborn
howev
immunoglobin
administr
risk
free
high
cost
discoveri
circul
free
fetal
dna
cffdna
prompt
introduct
noninvas
fetal
rhd
genotyp
matern
plasma
approach
increasingli
adopt
sever
countri
sinc
avoid
treatment
substanti
proport
rhd
neg
woman
give
birth
rhd
neg
child
purpos
studi
valid
method
antenat
noninvas
determin
fetal
rhd
statu
use
cffdna
matern
plasma
present
preliminari
data
ongo
valid
studi
designmethod
consequ
analyz
sampl
rhd
neg
pregnant
women
week
gestat
unknown
posit
rhd
partner
genom
dna
extract
matern
plasma
separ
qiaamp
circul
nucleic
acid
kit
qiagen
valencia
ca
us
use
automat
extract
qiasymphoni
order
determin
fetal
rhd
genotyp
use
taqman
primer
probe
detect
exon
rhd
gene
realtim
pcr
free
dna
fetal
kit
rhd
institut
de
biotechnolog
jacqu
boy
biorad
foster
citi
ca
intern
control
ad
maiz
dna
biorad
extract
use
primersprob
set
specif
maiz
dna
result
antenat
fetal
genotyp
compar
obtain
postnat
cord
blood
rh
phenotyp
resultsfind
sampl
rhd
posit
rhd
neg
sampl
process
avail
genotypephenotyp
comparison
agreement
three
sampl
inconclus
due
miss
data
birth
conclus
fetal
rhd
genotyp
matern
plasma
promis
tool
manag
rhd
neg
pregnant
women
data
confirm
larger
seri
non
invas
approach
reduc
risk
mother
babi
reduc
unnecessari
antirhdig
immunoprophylaxi
design
establish
platelet
donor
databas
known
hla
hpa
genotyp
nan
area
china
lilan
li
mei
yu
hengcong
li
xianggeng
su
fang
lu
guoguang
wu
nan
institut
transfus
medicin
nan
blood
center
backgroundcas
studi
platelet
transfus
therapi
patient
immun
platelet
transfus
refractoi
ptr
immun
thrombocytopenia
transfus
antigenneg
matchedplatelet
key
obtain
effect
treatment
patient
establish
known
antigen
platelet
donor
databas
could
provid
fast
conveni
way
find
antigenneg
matchedplatelet
donor
rel
immun
patient
hla
hpa
import
antigen
caus
platelet
alloimmun
diseas
popul
differ
area
polymorph
charact
hla
hpa
nan
import
comprehens
transport
hub
citi
locat
southwestern
china
million
peopl
aim
studi
design
establish
platelet
donor
databas
known
hla
hpa
genotyp
could
suitabl
popul
nan
area
china
provid
guarante
treatment
patient
immun
ptr
immun
thrombocytopenia
well
studi
designmethod
total
unrel
random
healthi
individu
use
popul
studi
hpa
polymorph
nan
area
china
individu
china
marrow
donor
program
use
popul
studi
hlaa
b
polymorph
nan
area
base
data
popul
studi
optim
size
platelet
donor
databas
predict
set
goal
design
establish
platelet
donor
databas
known
hla
hpa
genotyp
nan
area
name
nan
area
platelet
donor
databas
known
hla
hpa
genotyp
hlaa
b
genotyp
donor
databas
detect
pcrssp
pcrsso
respect
resultsfind
accord
popul
studi
hpa
polymorph
hlaa
b
polymorph
nan
area
follow
calcul
deriv
platelet
donor
databas
size
donor
approxim
patient
could
find
hpa
backgroundcas
studi
reduc
reagent
use
treat
plasma
order
distinguish
igm
igg
antibodi
remov
treat
plasma
prior
antibodi
test
common
dialyz
plasma
overnight
method
ultrafiltr
devic
use
drug
analysi
also
use
remov
day
test
method
b
studi
evalu
two
method
statist
differ
studi
designmethod
eleven
blood
sampl
alloantibodi
select
method
remov
method
use
nmwl
cellulos
dialysi
tube
method
b
use
kda
nmwl
ultrafiltr
devic
centrifre
ultrafiltr
devic
ultracel
ymt
milliporesigma
burlington
remov
specimen
method
titrat
test
igm
igg
abo
isohemaglutinin
level
manual
tube
test
confirm
previous
identifi
alloantibodi
treatment
also
perform
ensur
clinic
signific
antibodi
still
detect
method
treat
plasma
dialyz
overnight
phosphat
buffer
salin
recov
tube
method
b
treat
plasma
ad
devic
sampl
chamber
spun
fix
angl
centrifug
minut
ultrafiltr
devic
free
plasma
solut
filter
across
cellulos
membran
filter
plasma
recov
sampl
chamber
filter
doubl
dilut
perform
analyt
test
parallel
tube
method
determin
igm
abo
isohemagglutinin
level
achiev
room
temperatur
incub
igg
level
c
incub
four
time
autom
wash
antihuman
globulin
endpoint
titrat
determin
last
tube
reaction
statist
analysi
titrat
concentr
normal
last
tube
dilut
reaction
differ
dialyz
filter
plasma
endpoint
use
pair
ttest
determin
signific
differ
resultsfind
signific
differ
method
igm
igg
abo
isohemaglutinin
titer
hypothes
mean
differ
reject
previous
identifi
alloantibodi
still
detect
treatment
conclus
plasma
sampl
treat
show
statist
differ
dialyz
filter
plasma
use
ultrafiltr
devic
allow
day
test
accept
remov
maintain
immunoglobulin
backgroundcas
studi
high
titer
antibodi
coat
cognat
antigen
rare
caus
falseneg
red
blood
cell
rbc
antigen
phenotyp
event
refer
block
phenomenon
block
antigen
phenomenon
bap
hemolyt
diseas
fetu
newborn
hdfn
bap
complic
laboratori
workup
fetal
phenotyp
help
confirm
caus
hemolysi
treat
cord
rbc
ethylen
glycin
arginin
ega
remov
bap
maintain
express
antigen
except
k
case
hdfn
bap
k
antibodi
publish
despit
report
hdfn
involv
antik
case
chloroquin
diphosph
cdp
use
resolv
bap
effect
one
publish
comparison
elut
method
cdp
fail
remov
rbc
coat
antibodi
time
frequent
heat
elut
given
efficaci
greater
applic
ega
laboratori
longer
maintain
inventori
cdp
report
case
sever
hdfn
bap
due
antik
use
modifi
gentl
heat
elut
remov
bap
case
report
multipar
femal
present
week
pregnanc
complic
hightit
k
antibodi
ultrasound
evid
fetal
anemia
cesarean
section
perform
emerg
postdeliveri
neonat
exchang
transfus
sever
hdfn
test
result
preexchang
neonat
blood
specimen
typic
found
hdfn
howev
initi
neonat
rbc
phenotyp
k
antigen
neg
studi
designmethod
serolog
test
done
use
standard
procedur
modifi
gentl
heat
elut
method
equal
part
pack
rbc
albumin
heat
minut
use
dissoci
suspect
block
k
antibodi
rbc
repeat
k
phenotyp
perform
room
temperatur
incub
confirmatori
genotyp
perform
refer
laboratori
use
bioarray
platform
immucor
inc
norcross
ga
resultsfind
modifi
gentl
heat
elut
procedur
result
success
remov
bap
antik
preserv
rbc
k
antigen
type
tabl
genotyp
confirm
neonat
rbc
k
antigen
posit
conclus
although
infrequ
consid
heat
elut
use
bap
rare
situat
simpl
frequent
effect
cdp
remov
rbc
coat
antibodi
involv
readili
avail
suppli
modifi
gentl
heat
elut
mitig
decreas
antigen
express
effect
remov
bap
allow
accur
k
phenotyp
provid
person
red
cell
unit
use
nextgener
sequenc
case
studi
hongzhi
xu
antonia
moor
menchu
ong
lsu
health
scienc
center
univers
hospit
system
backgroundcas
studi
molecular
technolog
increasingli
use
transfus
medicin
predict
phenotyp
base
blood
group
genet
especi
tradit
serolog
assay
fail
accur
identifi
rare
complex
antigen
report
present
case
identif
antigen
dombrock
system
use
nextgener
sequenc
ng
studi
designmethod
patient
clinic
symptom
laboratori
find
includ
blood
bank
laboratori
workup
studi
resultsfind
patient
year
old
male
past
medic
histori
sickl
cell
anemia
hemoglobin
sc
diseas
complic
bilater
hip
avascular
necrosi
acut
chest
syndrom
requir
full
red
blood
cell
rbc
exchang
transfus
histori
multipl
transfus
besid
sever
histor
anti
antifi
antibodi
patient
found
antibodi
high
preval
antigen
dombrock
system
resembl
antiholley
antibodi
howev
sampl
submit
red
cell
genotyp
use
microarraybas
id
core
xt
grifol
indic
patient
genotyp
holley
antigen
sinc
antiholley
antibodi
may
induc
partial
holley
antigen
rbc
surfac
ng
perform
character
particular
antigen
mutat
detect
ng
studi
suggest
antibodi
initi
identifi
less
like
antiholley
antibodi
clinic
signific
unknown
antibodi
later
assess
use
monocyt
monolay
assay
mma
result
indic
antibodi
clinic
insignific
rbc
unit
issu
accordingli
conclus
present
studi
possibl
antiholley
antibodi
suggest
tradit
antibodi
panel
studi
could
confirm
rule
tradit
microarraybas
rbc
genotyp
method
use
ng
technolog
molecular
profil
antigeninquest
determin
clinic
decis
abl
make
base
result
case
highlight
valu
ng
transfus
servic
offer
comprehens
evalu
genet
variat
thu
provid
person
rbc
unit
recipi
research
correl
irregular
antibodi
screen
posit
ineffect
transfus
yanhua
jin
huili
chai
ying
yu
xin
tong
zhao
liu
first
hospit
harbin
backgroundcas
studi
repeat
blood
transfus
due
differ
allogen
antigen
system
stimul
bodi
produc
type
immun
respons
antibodi
exogen
erythrocyt
result
ineffect
red
blood
cell
transfus
import
reason
inefficaci
red
blood
cell
transfus
irregular
antibodi
detect
applic
routin
pretransfus
detect
method
detect
rate
irregular
antibodi
normal
popul
posit
rate
method
sensit
studi
designmethod
case
blood
transfus
collect
male
femal
age
year
abo
rh
homolog
blood
transfus
accord
blood
transfus
indic
cross
match
blood
medic
record
compar
valu
hemoglobin
blood
transfus
nt
rise
expect
valu
reexamin
within
hour
infus
red
blood
cell
prepar
elimin
blood
loss
blood
dilut
reason
clinic
sign
hemolyt
transfus
reaction
name
ineffect
blood
transfus
use
enhanc
detect
method
carri
irregular
antibodi
identif
patient
ineffect
blood
transfus
backgroundcas
studi
blood
group
chimer
rare
phenomenon
occur
either
congenit
acquir
case
describ
literatur
sinc
case
present
major
clinic
manifest
usual
recogn
time
blood
group
type
mixedfield
agglutin
discrep
cell
type
serum
type
requir
evalu
differenti
abo
subgroup
cisab
blood
group
chimer
studi
designmethod
describ
case
femal
twin
abo
rh
antigen
chimer
detect
routin
donor
abo
type
resolv
serolog
molecular
studi
resultsfind
red
blood
cell
rbc
mixedfield
reaction
detect
femal
donor
type
routin
doubl
popul
gel
column
antia
antib
antibodi
serum
type
identifi
antibodi
ask
new
blood
collect
togeth
rel
father
mother
twin
new
blood
serum
saliv
sampl
collect
father
type
b
posit
mother
posit
none
discrep
detect
twin
blood
type
reproduc
result
initi
detect
saliv
studi
show
presenc
b
substanc
secret
cisab
abo
subgroup
hypothesi
exclud
mother
father
rh
fenotyp
show
r
r
type
twin
fenotyp
also
demonstr
r
r
howev
doubl
popul
c
antigen
detect
twenti
one
short
tandem
repeat
str
loci
evalu
extract
dna
blood
confirm
blood
group
chimer
use
powerplex
fusion
pcr
amplif
kit
promega
corpor
usa
chimermark
softwar
softgenet
least
six
loci
vwa
tpox
show
one
two
addit
peak
besid
main
tall
str
peak
consist
presenc
chimer
conclus
rare
case
perman
chimer
involv
two
blood
system
presenc
separ
group
ab
c
c
rbc
character
discrep
rbc
type
achiev
str
molecular
test
despit
rare
phenomenon
diagnost
suspicion
necessari
order
resolv
type
discrep
provid
compat
blood
transfus
sever
resultsfind
five
therapeut
plasmapheresi
session
perform
albumin
replac
improv
pictur
hospit
discharg
month
patient
paresthesia
lower
limb
addit
treatment
dose
ivig
indic
first
dose
blood
product
patient
present
sever
intravascular
hemolysi
mark
anemia
reticulocytosi
total
receiv
three
dose
ivig
howev
follow
two
dose
patient
mild
anemia
immunohematolog
studi
show
patient
cekand
antic
serum
second
third
dose
ivig
antic
anti
auto
anti
identifi
gel
test
liss
enzym
administ
fourth
dose
immunoglobulin
serolog
test
immunoglobulin
perform
show
presenc
anti
autoigg
backgroundcas
studi
maspat
solidphas
base
assay
platelet
crossmatch
find
compat
donor
platelet
transfus
patient
serum
test
sever
donor
platelet
rapid
simpl
way
purpos
wide
use
hospit
well
blood
servic
institut
flow
cytometri
use
screen
platelet
antibodi
patient
serum
long
time
two
method
respect
advantagesw
compar
crossmatch
result
flow
cytometri
assay
maspat
elucid
pattern
differ
two
studi
designmethod
patient
compat
platelet
transfus
chosen
randomli
serum
patient
test
platelet
abocompat
donor
respect
ie
patientdonor
pair
total
use
flow
cytometri
assay
result
compar
maspat
routin
use
crossmatch
shanghai
blood
center
flow
cytometri
assay
wash
platelet
incub
serum
room
temperatur
wash
time
follow
incub
fitclabel
antihuman
antibodi
platelet
wash
subject
flow
cytometri
sampl
fitc
median
fluoresc
intens
mfi
platelet
gate
greater
twice
neg
control
healthi
ab
donor
serum
determin
posit
maspat
well
result
elucid
perform
accord
manufactur
manual
resultsfind
among
patient
sampl
ident
result
donor
method
term
patientdonor
pair
inconsist
two
method
ie
coincid
rate
neg
flow
cytometri
posit
maspat
situat
rest
contrari
posit
flow
cytometri
neg
maspat
situat
result
discrep
minor
differ
signific
differ
situat
remark
differ
despit
high
inconsist
two
method
final
choic
compat
unit
inconsist
patient
total
conclus
comparison
two
method
platelet
crossmatch
demonstr
maspat
result
posit
predict
probabl
due
nonspecif
adheres
fact
one
patient
treat
drug
situat
prove
platelet
antibodi
use
test
howev
sensit
demand
specif
choos
compat
unit
maspat
popular
due
simplic
rapid
discrep
investig
carri
elucid
method
accur
use
theoret
clinic
inter
cept
control
unit
sampl
c
amustalinegsh
pr
system
rbc
approv
commerci
use
post
shipment
test
postdon
lactat
lower
hct
na
glucos
similar
c
c
atp
molg
hb
indic
effect
rbc
viabil
throughout
storag
hemolysi
compar
c
shipment
hemolysi
lower
compar
c
tabl
conclus
amustalinegsh
pr
rbc
success
qualifi
region
blood
center
support
larg
phase
trial
pr
rbc
compon
met
us
criterion
hemolysi
end
storag
shipment
measur
vitro
paramet
amustalinegsh
rbc
indic
suitabl
transfus
backgroundcas
studi
human
anellovirus
smallest
particl
size
smallest
genom
size
least
complex
genet
organ
human
pathogen
establish
chronic
persist
infect
infanc
earli
childhood
produc
constantli
detect
load
plasma
thereaft
studi
suggest
ubiquit
present
human
popul
immun
surveil
requir
control
level
viru
load
studi
designmethod
use
quantit
dna
pcr
assay
recent
develop
target
conserv
region
anelloviru
genom
examin
viral
load
plasma
hivneg
blood
donor
hiv
carrier
pittsburgh
pennsylvania
resultsfind
blood
donor
posit
averag
load
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
hiv
carrier
posit
averag
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
conclus
result
valid
pcr
assay
develop
confirm
detect
viral
load
around
copi
present
blood
donor
survey
addit
hiv
infect
appear
reset
anelloviru
load
averag
carrier
approxim
order
magnitud
higher
broad
rang
load
approx
copiesml
hiv
carrier
investig
correl
immun
health
statu
backgroundcas
studi
cell
dose
extend
predictor
posttranspl
hematopoiet
recoveri
delay
recoveri
despit
suffici
number
common
suggest
factor
play
role
kinet
process
effect
total
nucleat
cell
tnc
engraft
remain
unclear
sever
studi
shown
conflict
result
object
studi
analyz
impact
tnc
engraft
surviv
studi
designmethod
singlecent
analysi
januari
decemb
includ
hematopoiet
stem
cell
transplant
hsct
procedur
autolog
allogen
patient
pt
male
femal
main
reason
hsct
acut
leukemia
allogen
hsct
multipl
myeloma
autolog
hsct
haploident
cordblood
transplant
exclud
condit
regimen
prior
allogen
hsct
myeloabl
pt
nonmyeloabl
nma
main
sourc
stem
cell
peripher
blood
resultsfind
median
tnc
infus
kg
kg
respect
autolog
hsct
found
higher
tnc
dose
correl
faster
neutrophil
engraft
p
spearman
correl
coeffici
higher
cell
dose
effect
allogen
hsct
group
higher
tnc
dose
correl
faster
platelet
engraft
p
either
nma
group
cell
dose
predict
faster
engraft
pt
receiv
kg
tnc
observ
shorter
median
time
neutrophil
engraft
autolog
group
shorter
time
platelet
recoveri
allogen
group
tabl
statist
differ
surviv
outcom
observ
group
regard
tnc
dose
number
conclus
seri
strong
associ
higher
tnc
cell
dose
shorter
time
engraft
observ
could
demonstr
effect
cell
dose
impact
surviv
observ
regard
tnc
cell
dose
backgroundcas
studi
west
nile
viru
wnv
transfusiontransmiss
viru
northern
hemispher
wnv
lineag
primarili
respons
human
diseas
endem
australia
although
less
virul
wnv
kunjin
strain
endem
tropic
northern
region
australia
perform
wnv
donor
screen
potenti
transfusiontransmiss
tt
risk
associ
donor
return
endemicoutbreak
countri
estim
risk
develop
probabilist
model
mont
carlo
simul
appli
eu
neighbour
countri
wnv
transmiss
season
studi
designmethod
input
paramet
countri
probabl
acquir
asymptomat
wnv
infect
period
observ
deriv
number
report
wn
fever
wnf
case
countri
ratio
symptomat
asymptomat
infect
donor
visit
outbreak
countri
period
observ
deriv
proport
australian
donor
popul
visit
countri
period
observ
return
donor
donat
viraem
base
number
return
donor
donat
within
week
leav
outbreak
countri
donat
use
clinic
backgroundcas
studi
transfusionrel
acut
lung
injuri
trali
potenti
fatal
complic
transfus
preclin
studi
sever
clinic
studi
trali
relat
loss
product
qualiti
red
blood
cell
storag
call
storag
lesion
donor
characterist
exampl
age
genet
sex
influenc
storag
lesion
investig
relat
donor
characterist
onset
trali
hypothes
donor
sex
age
blood
type
relat
trali
incid
studi
designmethod
perform
secondari
analysi
donor
data
two
cohort
studi
combin
one
largest
cohort
trali
patient
date
first
cohort
consist
retrospect
nest
case
control
studi
icu
patient
second
cohort
consist
prospect
case
control
studi
cardiac
surgeri
patient
suspect
trali
defin
use
consensu
definit
ali
obtain
donor
sex
age
blood
type
nation
blood
bank
use
kruskalw
test
compar
number
transfus
product
chisquar
test
compar
proport
trali
patient
transfus
control
valid
extern
standard
approach
three
differ
extern
standard
solut
prepar
b
c
test
use
nine
differ
chip
experi
design
evalu
reproduc
output
result
chip
lefthand
side
inlet
fill
standard
righthand
side
inlet
fill
either
standard
b
c
rightleft
flow
rate
ratio
use
analyt
output
signal
rcc
sampl
differ
storag
age
analyz
use
extern
standard
approach
compar
respect
deform
resultsfind
flow
rate
record
left
right
inlet
compar
chip
betweenchannel
coeffici
variat
cv
within
chip
lower
demonstr
high
homogen
channel
mask
use
fabric
pdm
chip
evalu
chiptochip
manufactur
reproduc
left
inlet
chip
fill
standard
flow
rate
compar
cv
deem
within
accept
rang
final
signific
differ
record
flow
rate
standard
b
c
overal
flow
rate
extern
standard
solut
determin
nl
cv
similar
flow
rate
observ
rcc
sampl
previou
studi
conclus
microfluid
method
believ
suitabl
precis
sensit
rbc
deform
analysi
develop
appropri
extern
standard
approach
use
address
chiptochip
variabl
use
dyedop
carboxyl
polystyren
microspher
found
reproduc
method
dexamethason
mg
mg
tablet
also
prescrib
hour
prior
collect
donor
without
histori
eye
diseas
complet
blood
count
perform
prior
mobil
postmobil
post
apheresi
granulocyt
concentr
allogen
blood
donor
criteria
use
qualifi
granulocyt
donor
statist
analysi
wilcoxson
ranksum
test
use
compar
distribut
follow
paramet
age
weight
pre
gcsf
wbcgranulocyt
platelet
count
post
gcsf
wbcplatelet
count
postapheresi
wbcplatelet
count
donor
tbv
tbv
process
run
time
collect
prefer
granulocyt
concentr
volumetot
wbchematocritanc
collect
effici
increas
wbc
granulocyt
post
gcsf
decreas
wbcplatelet
post
apheresi
bmi
group
statist
analysi
perform
use
r
version
statist
test
use
signific
adjust
made
multipl
test
resultsfind
first
time
femal
donor
normal
bmi
overweight
obes
four
paramet
found
statist
signific
weight
p
donor
total
blood
volum
p
granulocyt
concentr
volum
p
wbc
content
granulocyt
concentr
hematocrit
major
granulocyt
concentr
collect
three
bmi
group
paramet
list
statist
signific
conclus
conclud
increas
bmi
correl
greater
increas
wbc
mobil
gcsf
dexamethason
first
time
femal
donor
increas
bmi
correl
larger
volum
granulocyt
concentr
collect
increas
total
white
cell
content
found
fulli
autom
apheresi
machin
allow
us
minim
red
cell
contamin
optim
granulocyt
collect
data
analys
extend
male
donor
well
repeat
femalemal
donor
confirm
find
hiv
donor
base
antibodi
specif
donor
age
gender
recommend
donor
manag
strategi
studi
designmethod
studi
retrospect
cohort
studi
repeat
adult
volunt
allogen
blood
donor
electron
donat
histori
larg
commun
blood
center
donor
birthdat
gender
donat
date
antibodi
screen
result
antibodi
specif
obtain
via
electron
queri
donat
occur
januari
june
antibodi
categor
persist
recurr
evanesc
base
antibodi
screen
result
histori
mean
time
antibodi
evanesc
calcul
group
mean
compar
use
ttest
anova
pvalu
less
consid
signific
differ
resultsfind
signific
differ
mean
time
antibodi
evanesc
compar
donor
gender
age
number
antibodi
specif
donor
age
significantli
less
like
evanesc
antibodi
compar
younger
donor
mean
time
antibodi
evanesc
significantli
longer
antibodi
specif
kell
blood
group
system
antigen
compar
direct
rh
kidd
duffi
mn
blood
group
system
antigen
p
among
donor
antibodi
evanesc
mean
time
evanesc
day
mean
persist
day
suggest
averag
donor
antibodi
evanesc
group
becam
undetect
month
follow
initi
posit
donat
howev
twenti
percent
donor
posit
antibodi
screen
repeat
posit
donat
donor
least
two
posit
donat
mean
time
evanesc
day
result
studi
suggest
younger
donor
like
result
neg
antibodi
screen
subsequ
donat
compar
donor
year
old
data
suggest
possibl
initi
deferr
year
donor
two
consecut
posit
antibodi
screen
aggress
deferr
period
older
donor
antibodi
direct
antigen
kell
system
six
platelet
crossmatch
hla
type
posit
antigen
patient
hla
antibodi
therefor
platelet
incompat
given
high
pra
mfi
platelet
crossmatch
result
repeat
use
plasma
dilut
explor
prozon
phenomena
could
observ
resultsfind
platelet
crossmatch
result
use
plasma
dilut
yield
reactiv
platelet
one
incompat
platelet
posit
patient
mfi
antigen
approxim
respect
second
incompat
platelet
posit
mfi
approxim
respect
platelet
crossmatch
result
use
plasma
dilut
yield
reactiv
one
platelet
incompat
platelet
result
addit
dilut
posit
antigen
patient
antibodi
mfi
approxim
three
compat
platelet
use
plasma
dilut
dilut
posit
antigen
two
posit
antigen
one
posit
antigen
antibodi
mfi
result
antibodi
approxim
respect
show
antibodi
detect
normal
dilut
plasma
regardless
mfi
conclus
exampl
platelet
crossmatch
use
solid
phase
methodolog
show
low
sensit
prozon
effect
backgroundcas
studi
panther
system
fulli
autom
platform
nucleic
acid
amplif
test
use
blood
screen
grifol
diagnost
holog
assay
eg
hiv
hcv
hbv
zikv
typic
perform
plasma
ml
volum
assay
limit
detect
lod
low
iuml
case
viral
load
plasma
blood
compart
expect
low
adequ
sampl
volum
avail
sought
determin
whether
test
multipl
ml
replic
rep
system
program
perform
automat
use
ml
input
sampl
could
enhanc
sensit
detect
studi
designmethod
proof
concept
replic
test
could
detect
low
viral
load
use
aptima
quant
assay
test
plasma
elit
control
antibodyposit
natneg
blood
donor
artsuppress
hivinfect
individu
aptima
procleix
zika
viru
assay
test
edta
plasma
lyse
whole
blood
wb
zikvinfect
blood
donor
follow
longitudin
year
index
donat
hiv
sampl
ml
test
rep
zikv
plasma
ml
lyse
wb
ml
sampl
test
rep
respect
total
platelet
crossmatch
perform
use
sdp
sampl
taken
prior
pi
treatment
inclus
patient
sampl
crossmatch
repeat
use
postpi
treatment
sampl
reaction
strength
crossmatch
grade
strong
posit
w
weak
posit
neg
compar
origin
nonpi
treat
sampl
post
pi
treatment
sampl
donor
unit
abo
sdp
consider
reaction
strength
crossmatch
compar
platelet
antibodi
screen
test
previous
done
patient
sampl
posit
hla
antibodi
posit
hla
platelet
antibodi
neg
serum
plasma
patient
sampl
includ
use
test
resultsfind
patient
sampl
chang
crossmatch
reactiv
sampl
show
chang
hlaplatelet
antibodi
hla
antibodi
sampl
antibodi
neg
decreas
reactiv
strength
seen
pathogen
reduc
sampl
crossmatch
reaction
becom
neg
crossmatch
reaction
increas
strength
aabb
current
studi
tb
test
room
temperatur
ship
wb
donat
apheresi
product
blood
sampl
tube
studi
designmethod
mimic
freshli
collect
product
wb
collect
bag
reveo
lr
terumobct
fill
ml
salin
addit
apheresi
platelet
concentr
pc
plasma
bag
trima
collect
set
terumobct
blood
sampl
tube
fill
ml
ml
ml
salin
respect
monitor
probe
insert
insid
salinefil
bag
record
temperatur
profil
either
one
eight
reveo
wb
unit
pack
tb
solidphas
pcm
cryopak
apheresi
product
one
singl
pc
plasma
four
doubleplatelet
donat
pc
plasma
use
minim
maxim
load
test
maxim
ship
delay
singl
blood
sampl
tube
pack
tb
repres
limit
condit
tb
configur
expos
extrem
winter
summer
condit
design
experi
resultsfind
tb
use
pcm
allow
rapid
cool
blood
product
min
maintain
intern
temperatur
one
eight
reveo
wb
donat
extrem
extern
temperatur
use
pcm
allow
minim
maxim
apheresi
donat
product
stay
within
accept
hold
temperatur
rang
expos
extrem
winter
summer
condit
respect
final
blood
tube
expos
extern
temperatur
condit
maintain
intern
temperatur
respect
conclus
vip
box
pcm
allow
thermoregul
box
system
use
extend
ship
period
extrem
temperatur
condit
increas
intern
volum
box
accept
product
expens
addit
pcm
increas
total
weight
conclus
thermoregul
box
system
design
use
combin
pcm
meet
specif
requir
regard
packag
transport
blood
product
especi
winter
condit
determin
fresh
erythrocyt
concentr
reson
raman
spectroscopi
herbert
g
korsten
tatsuro
yoshida
dirk
de
kort
depart
product
process
develop
sanquin
blood
bank
new
health
scienc
inc
sanquin
research
landstein
laboratori
backgroundcas
studi
support
research
improv
erythrocyt
storag
low
oxygen
tension
po
haemoglobin
oxygen
satur
fresh
erythrocyt
concentr
rcc
measur
noninvas
studi
designmethod
blind
frozen
bacteri
test
panel
prepar
panel
compris
three
level
bacteri
speci
reconstitut
platelet
sampl
one
member
limit
detect
lod
pgd
assay
low
one
member
slightli
lod
assay
mid
one
lod
pgd
assay
high
backgroundcas
studi
platelet
apheresi
use
plateletaddit
solut
pa
allow
collect
platelet
reduc
plasma
content
divers
plasma
creat
plasma
compon
transfus
addit
benefit
collect
free
plasma
compon
reduc
incid
plasmaassoci
reaction
report
backgroundcas
studi
present
studi
conduct
find
preval
viral
hepat
marker
among
blood
donor
defer
basi
histori
hepat
relat
risk
factor
compar
preval
accept
blood
donor
assess
impact
deferr
blood
safeti
know
natur
histori
hbv
hcv
asymptomat
window
period
chronic
carrier
stage
genet
divers
mutant
crypticoccult
infect
potenti
transmiss
blood
transfus
remain
therefor
need
garner
data
evid
support
deferr
elicit
histori
presenc
risk
factor
relat
develop
hepat
interest
blood
safeti
realiz
studi
designmethod
observ
studi
recruit
defer
blood
donor
defer
basi
histori
hepat
relat
risk
factor
carri
serolog
idnat
hepat
b
hepat
c
obtain
written
inform
consent
histori
jaundic
tattoo
bodi
pierc
surgerydent
extract
contact
person
hepat
high
risk
behavior
blood
transfusionstransplant
immunoglobulin
administr
studi
particip
voluntari
nonrandom
studi
protocol
approv
ethic
committe
institut
resultsfind
defer
blood
donor
reactiv
elisa
reactiv
hbsag
wherea
antihcv
antibodi
initi
reactiv
idnat
discrimin
test
hbv
hcv
reactiv
hepat
b
concord
posit
hbsag
elisa
nat
wherea
one
nat
yield
one
seroyield
hepat
b
reactiv
histori
jaundic
one
histori
tattoo
one
histori
high
risk
behavior
hepat
c
reactiv
concord
antihcv
elisa
nat
reactiv
sero
yield
two
nat
yield
defer
donor
reactiv
hepat
c
major
histori
jaundic
follow
high
risk
behavior
total
donor
viral
marker
either
hepat
b
hepat
c
present
studi
therefor
potenti
deferr
histori
hepat
relat
risk
factor
could
interdict
hbv
andor
hcv
reactiv
blood
donor
enter
quarantin
blood
suppli
per
donor
correl
atp
dpg
poor
addit
except
suggest
rewir
rapoportlueb
shunt
specif
addit
addit
deamin
purin
hypoxanthin
predict
hemolysi
morpholog
alter
guanosin
supplement
paggsm
fuel
atp
gener
feed
nonoxid
pentos
phosphat
pathway
via
phosphoribolysi
decreas
urat
hypoxanthin
ratio
observ
alkalin
addit
sugget
decreas
gener
urat
purin
degrad
consequ
less
format
hydrogen
peroxid
xanthin
oxidas
activ
despit
mani
benefit
observ
purin
redox
metabol
alkalin
addit
prevent
accumul
free
fatti
acid
oxid
byproduct
open
window
futur
alkalin
formul
includ
lipophil
antioxid
conclus
alkalin
via
differ
strategi
replac
chlorid
anion
either
high
bicarbon
high
citratephosph
membran
imperm
glucon
result
differ
metabol
outcom
case
superior
current
canon
addit
result
metabol
analys
indic
superior
preserv
rbc
alkalin
addit
gener
alkalin
addit
nonalkalin
sagm
paggsm
particular
dpg
atp
gener
mainten
well
purin
metabol
redox
homeostasi
especi
ppp
nonoxid
phase
byproduct
favor
alkalin
addit
comparison
sagm
paggsm
howev
observ
metabol
benefit
extend
prevent
storageinduc
fatti
acid
releas
lipid
oxid
result
present
studi
provid
addit
insight
metabol
benefit
alkalin
storag
addit
like
guid
formul
novel
addit
near
futur
posit
id
posit
id
posit
id
posit
id
posit
andeannorth
andeanori
caribbean
andeannorth
pacif
andeansouth
nation
id
indetermin
backgroundcas
studi
transmiss
bacteria
transfus
remain
signific
problem
transfus
medicin
disinfect
clean
venipunctur
site
hand
surfac
key
compon
success
control
hygien
blood
bank
includ
cord
blood
bank
besid
bacteri
enumer
monitor
bacteri
pathogen
perform
reduc
risk
transfusionassoci
septic
refer
hygien
standard
disinfect
hospit
china
convent
method
cultur
biochem
method
inconveni
time
experi
requir
identifi
presenc
pathogen
bacteriath
aim
studi
develop
isotherm
realtim
recombinaseaid
amplif
rtraa
assay
improv
effici
bacteri
pathogen
identif
studi
designmethod
studi
design
specif
primer
fluoresc
probe
conserv
region
four
pathogen
bacteria
staphylococcu
aureu
salmonella
spp
hemolyt
streptococcu
pseudomona
aeruginosa
rtraa
assay
dna
four
baceria
isol
aliquot
cultur
medium
effici
extract
method
raa
reaction
conduct
constant
temperatur
simul
vivo
dna
recombin
min
evalu
sensit
method
four
pathogen
bacteria
cultur
variou
concentr
cfuml
inocul
surfac
sampl
amplifi
detect
rtraa
assay
specif
valid
use
bacteria
fungi
perform
rtraa
assay
evalu
skin
surfac
sampl
taken
steril
swab
blood
collect
product
obtain
microbiolog
profil
manufactur
condit
result
compar
cultur
biochem
method
standard
resultsfind
combin
fluoresc
probe
realtim
detect
raa
assay
could
reliabl
detect
cfuml
pure
cultur
four
pathogen
bacteria
constant
temperatur
within
min
sensit
convent
method
assay
success
use
amplifi
detect
dna
sampl
taken
skin
surfac
crossreact
test
bacteria
fungi
sixti
sampl
thirti
skin
sampl
surfac
sampl
respect
analyz
convent
cultur
method
rtraa
assay
skin
sampl
two
sampl
taken
hand
staff
detect
staphylococcu
aureu
rtraa
assay
consist
convent
method
conclus
data
present
studi
indic
rtraa
provid
rapid
sensit
specif
detect
pathogen
skin
surfac
sampl
without
prior
isol
character
bacteria
convent
method
rtraa
assay
serv
altern
tool
cultur
biochem
method
screen
pathogen
bacteria
result
obtain
rtraa
plate
count
base
cultur
method
show
environ
skin
surfac
area
blood
collect
product
potenti
contamin
pathogen
could
potenti
risk
blood
product
backgroundcas
studi
syphili
bacteri
infect
caus
treponema
pallidum
could
transmit
sexual
contact
blood
transfus
pregnanc
mother
fetu
sinc
colombia
mandatori
screen
pallidum
blood
donat
sever
studi
demonstr
activ
syphili
infect
potenti
transmiss
hiv
relat
higher
probabl
coinfect
pathogen
potenti
transmit
blood
aim
studi
identifi
syphili
coinfect
viru
associ
sexual
transmiss
colombian
blood
donat
studi
designmethod
retrospect
analysi
blood
donat
reactiv
syphili
hiv
hcv
hbv
htlv
collect
januari
decemb
certifi
blood
bank
nation
level
made
confirmatori
test
hiv
hcv
htlv
immunoblot
backgroundcas
studi
hemolysi
rate
end
storag
repres
import
qualiti
marker
red
cell
concentr
rcc
regulatori
agenc
establish
clear
standard
rcc
hemolysi
end
storag
howev
recommend
specif
methodolog
regard
supernat
hemoglobin
hb
measur
recent
studi
signific
differ
observ
rcc
hemolysi
rate
depend
analyt
approach
use
aim
studi
compar
rcc
hemolysi
result
obtain
differ
method
studi
designmethod
first
part
studi
sagmrcc
store
day
proceed
supernat
hb
measur
three
condit
seri
cbc
perform
hematolog
analyz
beckman
coulter
rcc
sampl
prior
centrifug
min
sampl
tube
seri
centrifug
seri
cbc
measur
omit
seri
sampl
subject
hard
spin
condit
shorter
time
min
seri
supernat
filter
hb
measur
use
hemocu
plasmalow
hb
system
follow
manufactur
recommend
second
part
studi
supernat
obtain
rcc
blood
sampl
mention
seri
harbo
method
uvvi
wavelength
nm
optic
path
length
hemocu
system
use
measur
free
hb
calcul
hemolysi
rate
resultsfind
averag
hb
valu
calcul
seri
gdl
slightli
higher
seri
gdl
seri
gdl
result
averag
hemolysi
seri
compar
seri
respect
importantli
seri
rcc
would
met
canadian
standard
endstorag
hemolysi
compar
seri
seri
harbo
vs
hemocu
studi
hb
averag
valu
gdl
gdl
respect
measur
averag
hemolysi
hemocu
higher
harbo
sampl
result
suggest
use
two
separ
tube
would
recommend
avoid
unfavor
bia
hemolysi
calcul
harbo
hemocu
plhb
compar
studi
suggest
signific
evid
userfriendli
hemocu
system
calibr
use
intern
council
standard
hematolog
refer
method
would
appropri
measur
method
free
hemoglobin
alexandra
tejadastrop
mohammad
zafrullah
saleem
kamili
susan
l
stramer
michael
purdi
cdc
american
red
cross
backgroundcas
studi
recent
increas
number
hepat
outbreak
unit
state
although
presenc
hav
rna
blood
donor
known
low
hav
antibodi
preval
popul
unknown
studi
designmethod
sampl
us
blood
donor
collect
primarili
midwestern
us
test
presenc
hav
igg
igm
antibodi
use
chemiluminesc
microparticl
immunoassay
architect
platform
abbott
laboratori
resultsfind
overal
preval
antihav
igg
previou
studi
use
sampl
collect
part
nation
health
nutrit
examin
survey
nhane
show
decreas
preval
howev
nhane
includ
individu
year
age
older
one
specimen
antihav
igm
posit
confirm
preval
specimen
hav
rna
neg
antihav
igg
preval
among
donor
year
drop
among
donor
age
year
increas
among
donor
age
year
high
preval
among
year
old
like
due
infant
vaccin
recommend
initi
differ
seen
sex
overal
antihav
igg
preval
male
femal
respect
among
five
state
highest
number
donor
antihav
igg
preval
missouri
significantli
higher
preval
illinoi
kentucki
p
differ
seen
antihav
igg
preval
among
individu
previous
test
posit
either
antihev
igm
igg
indic
correl
antihav
igg
statu
antihev
antibodi
statu
conclus
studi
demonstr
overal
high
rate
antihav
igg
us
blood
donor
low
risk
hav
transfus
transmiss
low
risk
support
hav
vaccin
polici
develop
sinc
defin
backgroundcas
studi
goal
staff
american
rare
donor
program
ardp
ensur
request
rare
blood
ardp
member
fill
import
know
request
rare
blood
fill
unfil
request
rare
blood
may
delay
patient
treatment
may
result
continu
low
hemoglobin
may
put
patient
risk
process
ardp
member
request
rare
unit
ardp
staff
send
two
fax
ardp
member
regist
rare
donor
type
request
complet
success
find
unit
email
request
recruit
sent
domest
ardp
member
regist
donor
request
still
unfil
next
step
would
consult
facil
ardp
medic
director
final
meet
fda
ind
requir
intern
request
patient
physician
permiss
autolog
donat
possibl
insuffici
elig
sibl
mma
result
request
made
intern
rare
donor
panel
studi
designmethod
review
unfil
request
perform
evalu
criteria
includ
phenotyp
aborh
number
unit
request
patient
diagnosi
resultsfind
research
request
respons
unfil
request
total
request
diagnosi
patient
sickl
cell
diseas
scd
phenotyp
preval
donor
african
descent
number
unit
request
rang
unit
averag
per
order
unfil
request
cancel
within
averag
day
fourteen
request
posit
unit
five
request
rh
allelematch
unit
igadefici
plasma
five
unfil
order
unit
neg
multipl
antigen
thirteen
antigen
high
preval
conclus
ardp
member
collabor
effect
fill
request
rare
blood
fill
rate
request
fill
monitor
unfil
request
import
determin
reason
request
remain
unfil
patient
popul
impact
data
collect
indic
unfil
request
patient
scd
major
request
associ
cancel
order
patient
discharg
without
transfus
impact
lack
transfus
patient
live
unknown
find
prompt
ardp
take
action
develop
implement
outcom
form
collect
inform
regard
impact
unfil
order
blood
bank
return
nontreponem
test
nt
david
bink
loui
katz
arlington
scientif
inc
america
blood
center
backgroundcas
studi
treponem
test
remain
posit
life
treatment
syphili
late
transfus
transmiss
nt
revert
neg
success
treatment
mani
late
infect
need
approxim
unit
blood
day
usa
less
popul
donat
unnecessari
deferr
donor
due
persist
reactiv
remot
noninfecti
identifi
follow
nt
revers
algorithm
need
reassess
revers
algorithm
replac
tradit
diagnost
algorithm
nt
test
confirm
transfus
medicin
autom
introduct
autom
nt
method
use
tradit
algorithm
evalu
prefer
method
screen
blood
donor
reduc
deferr
individu
past
longer
infecti
studi
designmethod
serum
plasma
specimen
concord
nt
result
test
asi
evolut
autom
rpr
analyz
use
asi
rpr
carbon
antigen
sampl
sourc
blood
bank
plasma
center
sampl
also
includ
nonreact
specimen
reactiv
specimen
pregnant
women
clinic
diagnos
reactiv
specimen
treat
untreat
public
health
depart
test
rpr
establish
expect
result
reactiv
sampl
rang
reactiv
minim
titer
titer
rpr
age
patient
rang
age
year
old
includ
male
femal
resultsfind
specimen
reactiv
specimen
nonreact
rpr
asi
evolut
identifi
reactiv
specimen
reactiv
nonreact
specimen
nonreact
posit
agreement
ci
neg
agreement
ci
conclus
year
nt
standard
screen
blood
donor
nt
displac
autom
avail
autom
nt
analyz
data
present
nt
test
reevalu
primari
donor
screen
test
decreas
deferr
rate
due
noninfecti
persist
reactiv
use
cell
count
refer
blood
bank
extern
qualiti
assess
region
flow
cytometri
unit
marc
cristian
moralesindiano
eva
alonso
marta
sara
vergara
minerva
raya
rosa
linio
laura
medina
carm
azqueta
jordi
sergi
querol
joan
ramon
grifol
backgroundcas
studi
flow
cytometri
unit
determin
peripher
blood
cell
count
hematopoiet
progenitor
cellapheresi
hpca
preapheresi
cell
count
procedur
start
preapheresi
sampl
analyz
afterward
stem
cell
process
laboratori
although
use
ukneqa
stem
cell
enumer
programm
extern
qualiti
assess
past
set
assess
correl
cell
count
obtain
flow
cytometri
unit
obtain
process
laboratori
order
replac
current
extern
qualiti
assess
costsav
measur
particularli
given
process
laboratori
also
subscrib
ukneqa
stem
cell
enumer
programm
studi
designmethod
retrospect
analyz
correl
cell
count
obtain
unit
stem
cell
process
laboratori
januari
april
flow
cytomet
antibodi
erythrocyt
lysi
solut
use
unit
cxp
softwar
clone
pe
clone
beckman
coulter
pharmlys
bectondickinson
flow
cytomet
antibodi
erythrocyt
lysi
solut
use
stem
cell
process
laboratori
facscalibur
cellquest
softwar
bectondickinson
clone
pe
clone
beckmancoult
bectondikinson
quicklysistm
absolut
cell
count
unit
use
flow
count
fluorospher
beckmancoult
process
laboratori
perfect
count
microspher
cytogno
passingbablok
regress
use
compar
two
laboratori
blandaltman
plot
use
assess
agreement
final
spearman
rank
correl
coeffici
use
determin
correl
result
obtain
flow
cytometri
unit
stem
cell
process
laboratori
resultsfind
passingbablok
regress
show
deviat
linear
two
laboratori
blandaltman
analysi
show
bia
cell
count
spearman
correl
coeffici
confid
interv
compon
divers
first
ml
whole
blood
postvenipunctur
establish
practic
effect
strategi
mitig
incid
skin
flora
relat
blood
product
contamin
previou
data
suggest
addit
sampl
divers
beyond
current
measur
would
reduc
bacteri
load
blood
collectionsepar
system
extens
studi
studi
sought
evalu
bacteri
content
blood
fraction
collect
contamin
sourc
inject
site
addit
ml
beyond
today
practic
divers
volum
ml
use
simpl
vitro
model
system
studi
designmethod
model
system
prepar
model
divers
line
similar
wagner
et
al
transfus
construct
use
inlet
line
doubl
needl
apheresi
platelet
collect
kit
freseniu
kabi
luer
lock
ad
place
sampl
divers
pouch
cm
past
second
ysite
test
articl
prepar
evalu
inject
site
steril
bag
contain
whole
blood
acda
anticoagul
inocul
minimum
cfu
overnight
epidermi
cultur
upon
dri
needl
model
divers
line
insert
inocul
area
aliquot
blood
taken
via
syring
luer
posit
place
divers
pouch
ml
aliquot
rd
sampl
line
seal
first
ysite
aliquot
drawn
second
luer
ml
aliquot
bacteria
concentr
fraction
determin
use
pour
plate
method
total
cfu
fraction
calcul
resultsfind
overal
result
total
cfu
fraction
show
continu
reduct
bacteri
load
increas
volum
collecteddivert
data
first
ml
collect
divers
line
consist
publish
wagner
et
al
show
bacteria
remov
first
fraction
collect
subsequ
fraction
show
continu
reduct
bacteri
load
result
addit
log
decreas
initi
ml
divers
conclus
studi
illustr
bacteri
load
reduct
continu
occur
past
standard
divers
volum
ml
vitro
model
divers
system
studi
requir
evalu
potenti
benefit
extend
divers
model
onlin
collect
system
practic
applic
impact
bacteri
growth
leukoreduc
red
cell
follow
hour
temperatur
excurs
toward
room
temperatur
stephen
wagner
cheryl
hapip
lenora
abel
american
red
cross
holland
lab
backgroundcas
studi
uncommon
power
interrupt
occur
blood
center
hospit
extrem
weather
event
backup
gener
fail
refriger
blood
warm
beyond
studi
evalu
level
sever
bacteria
refriger
leukodeplet
rbc
follow
temperatur
excurs
toward
room
temperatur
studi
designmethod
two
abo
rh
ident
leukoreduc
rbc
prepar
whole
blood
collect
consent
donor
fenwal
round
lake
unit
pool
mix
inocul
day
cfuml
quantit
plate
assay
p
fluorescen
enterocolita
marcescen
liquefacien
e
coli
aureu
pool
divid
equal
two
unit
store
day
one
two
unit
test
place
laboratori
bench
hour
surfac
temperatur
record
return
storag
unit
maintain
refriger
storag
control
detect
presenc
antibodi
along
antigen
blood
screen
reduc
risk
transfus
relat
hiv
infect
increas
sensit
coupl
high
specif
minim
donor
deferr
provid
public
safer
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
address
need
screen
assay
improv
autom
assay
detect
antibodi
antigen
develop
studi
designmethod
perform
immunoassay
detect
antibodi
antigen
evalu
next
gener
autom
platform
abbott
alin
reproduc
assess
day
use
posit
sampl
specif
evalu
sampl
obtain
random
blood
plasmapheresi
donor
sensit
evalu
use
presum
posit
sampl
antigen
viral
isol
seroconvers
sensit
evalu
commerci
seroconvers
panel
analyt
sensit
evalu
use
st
intern
standard
antigen
resultsfind
withinlaboratori
imprecis
less
cv
posit
sampl
day
specif
sensit
antigen
posit
sampl
sensit
antigen
posit
viral
isol
sampl
seroconvers
sensit
better
licens
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
analyt
sensit
rang
iuml
iuml
result
indic
new
autom
alin
hiv
agab
combo
assay
provid
accept
perform
specif
sensit
precis
also
assay
provid
better
seroconvers
sensit
licens
compar
assay
backgroundcas
studi
order
provid
plasma
compon
therapi
whole
blood
goe
seri
manufactur
step
visual
inspect
accept
standard
guid
perform
visual
inspect
would
benefici
improv
consist
regulatori
standard
plasma
color
red
blood
cell
rbc
concentr
plasma
necessari
first
determin
accept
cutoff
could
use
develop
visual
inspect
aid
studi
designmethod
determin
best
cutoff
accept
vs
unaccept
plasma
visual
represent
creat
plasma
unit
similar
size
color
inject
rbc
increment
volum
rang
plasma
unit
laid
increas
rbc
concentr
tech
manag
inspect
plasma
unit
determin
common
visual
cutoff
rbc
concentr
plasma
calcul
base
whole
blood
averag
hematocrit
rbcsml
doubl
unit
pack
rbc
determin
number
rbc
inject
unit
cutoff
determin
photo
taken
plasma
unit
use
creat
visual
inspect
aid
resultsfind
visual
cutoff
determin
tech
manag
fell
inject
plasma
unit
one
sourc
found
mention
limit
rbc
plasma
specif
rbcsml
packag
insert
pathogen
reduct
technolog
platelet
use
guidelin
unit
determin
concentr
rbcsml
visual
inspect
aid
produc
implement
compon
laboratori
initi
use
plasma
unit
inspect
plasma
pass
visual
inspect
aid
made
avail
two
hospit
blood
bank
sinc
initi
implement
flaw
calcul
discov
visual
cutoff
determin
concentr
rbcsml
survey
indic
respond
use
inspect
aid
believ
help
determin
plasma
accept
express
opinion
aid
improv
plasma
inspect
found
use
train
give
new
tech
confid
make
inspect
decis
conclus
develop
implement
plasma
visual
inspect
aid
provid
consist
visual
inspect
across
multipl
area
handl
plasma
prior
transfus
aid
accept
simpl
use
tool
tech
manag
result
addit
request
rbc
unit
lack
high
preval
antigen
includ
co
lu
b
di
b
jo
jr
ppip
k
ko
even
request
rbc
ab
recipi
univers
recipi
base
aborh
unabl
fill
due
rariti
type
eu
one
request
cekfi
rhce
allel
match
rhce
conclus
request
rbc
unit
rare
type
submit
specif
liquid
unit
fill
liquid
unit
unabl
fill
liquid
unit
involv
u
antigen
addit
involv
high
preval
antigen
request
frozen
rare
unit
util
fill
gap
liquid
unit
avail
without
frozen
unit
patient
would
receiv
transfus
time
manner
potenti
delay
associ
recruit
collect
rare
donor
ardp
advis
center
request
liquid
unit
review
patient
clinic
cours
determin
transfus
emin
requir
reconsid
frozen
unit
request
use
autom
solv
challeng
highthroughput
product
laboratori
steve
beeler
scott
jone
rachel
beddard
dian
hoover
ks
bailey
qualtex
laboratori
biobridg
global
abbott
abbott
transfus
medicin
backgroundcas
studi
blood
screen
laboratori
face
mani
challeng
today
chang
healthcar
environ
includ
ineffici
manual
process
shorten
turnaround
time
requir
staf
shortag
budget
constraint
advanc
autom
technolog
help
allevi
challeng
aim
studi
implement
autom
laboratori
track
system
product
laboratori
test
whole
blood
sourc
plasma
donor
sampl
metric
collect
determin
effect
implement
autom
track
laboratori
system
number
sampl
process
per
shift
time
perform
preanalyt
process
turnaround
time
sampl
test
qualiti
relat
issu
number
employe
requir
perform
test
studi
designmethod
implement
autom
product
laboratori
occur
two
phase
phase
one
integr
middlewar
across
primari
test
platform
phase
two
involv
fulli
autom
preanalyt
part
test
process
instal
track
autom
system
system
includ
autom
input
sampl
system
centrifug
decap
reseal
storag
sampl
tube
analyt
work
also
autom
place
chemistri
immunoassay
analyz
directli
track
system
resultsfind
tabl
show
data
preand
postimplement
track
autom
system
compar
metric
collect
preand
postimplement
track
autom
system
show
increas
number
sampl
process
per
shift
postimplement
also
decreas
averag
time
preanalyt
process
sampl
averag
turnaround
time
time
sampl
receiv
result
sent
client
decreas
two
hour
number
correct
report
gener
decreas
number
fulltim
employe
requir
perform
preanalyt
process
sampl
decreas
conclus
autom
donor
test
product
laboratori
enabl
us
test
sampl
increas
less
peopl
decreas
abl
report
result
shorter
period
time
hour
faster
averag
remov
manual
error
prone
process
allow
reduct
correct
report
test
sampl
effici
timeli
manner
without
addit
staff
stabil
factor
viii
pathogen
inactiv
pi
plasma
two
year
comparison
untreat
plasma
marco
amato
walter
nussbaum
univers
hospit
univ
hospit
innsbruck
backgroundcas
studi
due
long
possibl
storag
time
frozen
plasma
one
two
year
addit
safeti
step
implement
product
process
releas
transfus
approv
quarantin
storag
includ
retest
donor
hiv
hbv
hcv
month
one
routin
use
method
least
month
delay
possibl
releas
process
opposit
pathogen
inactiv
pi
techniqu
allow
immedi
use
treat
unit
two
three
day
howev
pi
mean
addit
manipul
plasma
possibl
loss
coagul
factor
product
subsequ
storag
therefor
studi
influenc
pi
methylen
blue
intercept
factor
viii
common
use
qualiti
paramet
frozen
plasma
compar
result
untreat
store
plasma
pair
system
studi
designmethod
produc
pool
plasma
unit
split
pool
three
arm
intercept
treat
plasma
methylen
blue
mb
treat
plasma
untreat
plasma
plasma
frozen
immedi
inactiv
fibrinogen
factor
viii
analyz
month
year
year
report
find
factor
loss
differ
pi
method
pi
treat
unit
howev
differ
also
signific
level
significantli
lower
p
stabil
factor
within
group
defin
chang
valu
month
year
freez
given
fibrinogen
p
factor
viii
p
three
arm
conclus
manipul
plasma
caus
pathogen
inactiv
techniqu
lead
signific
loss
factor
viii
compar
manipul
plasma
howev
addit
loss
frozen
state
year
similar
three
arm
therefor
increas
pi
techniqu
take
account
mean
volum
mb
treat
plasma
ml
wherea
treat
plasma
ml
total
content
factor
transfus
unit
significantli
higher
mb
group
influenc
total
number
transfus
unit
per
patient
method
cryopreserv
reagent
red
blood
cell
use
storag
condit
tracey
r
turner
jason
p
acker
centr
innov
canadian
blood
servic
depart
laboratori
medicin
patholog
univers
alberta
backgroundcas
studi
rare
red
cell
concentr
rcc
frequent
cryopreserv
store
use
high
glycerol
method
slow
freez
rate
prior
transfus
thaw
unit
must
glycerol
remov
methodolog
also
appli
reagent
red
blood
cell
rbc
provid
cell
test
purpos
avoid
liquid
nitrogen
storag
howev
deglycerol
process
rcc
requir
extens
wash
step
translat
small
ml
model
labour
intens
purpos
studi
evalu
simplifi
wash
process
provid
practic
deglycerol
method
reagent
small
volum
rbc
cryopreserv
studi
designmethod
rcc
glycerol
final
concentr
supernat
reduct
pre
post
glycerol
glycerol
rbc
aliquot
ml
volum
cryovial
place
freezer
minimum
hour
prior
deglycerol
sampl
thaw
water
bath
two
deglycerol
process
perform
process
involv
four
wash
step
salin
salin
two
wash
dextros
process
involv
three
wash
step
achiev
increas
volum
wash
solut
elimin
fourth
wash
step
rbc
sampl
suspend
post
process
hemoglobin
loss
hemoglobin
recoveri
glycerol
concentr
determin
addit
sampl
deglycerol
test
rbc
hemolysi
hour
hypotherm
storag
pointprocess
resultsfind
process
yield
approxim
ml
deglycerol
rbc
hematocrit
glycerol
concentr
sampl
hemoglobin
recoveri
process
compar
process
rbc
post
deglycerol
store
hour
prepar
use
process
hemolysi
respect
process
rbc
hemolysi
time
point
compar
process
sampl
store
correspond
time
point
signific
differ
observ
hour
p
conclus
simplifi
deglycerol
method
success
deglycerol
small
volum
rbc
rbc
suspend
post
process
sampl
store
hypotherm
day
increas
util
reagent
cell
small
volum
transfus
case
confirm
neutral
one
case
identifi
nonconfirm
hcv
eia
nat
hiv
eia
nat
one
case
confirm
two
case
identifi
indetermin
serolog
test
two
case
confirm
posit
us
armi
ranger
account
screen
event
roughli
us
armi
prescreen
event
ranger
regiment
elect
screen
blood
type
donor
elig
program
program
identifi
accuraci
selfreport
blood
type
us
armi
ranger
us
armi
ranger
present
program
blood
type
nonblood
group
conclus
screen
walk
blood
bank
donor
deploy
mitig
risk
transfusiontransmit
diseas
well
provid
identif
nonblood
group
donor
screen
walk
blood
bank
donor
inform
militari
medic
leader
front
line
assist
decis
regard
donor
elig
provid
fresh
whole
blood
fwb
farforward
auster
environ
use
fwb
point
injuri
poi
decreas
mortal
potenti
surviv
casualti
screen
potenti
donor
extend
avail
whole
blood
battlefield
backgroundcas
studi
project
focus
improv
whole
blood
compon
manufactur
includ
process
standard
increas
plasma
yield
reduc
wast
streamlin
workflow
introduc
compomat
product
studi
designmethod
comprehens
evalu
conduct
biolog
manufactur
team
process
includ
complet
sop
train
qualif
valid
implement
optim
equip
data
collect
use
oneblood
proprietari
bec
rsa
review
evalu
month
post
implement
plasma
volum
compar
manual
process
throughput
measur
time
oper
unload
complet
unit
reload
new
spun
wb
unit
multipl
unloadedreload
one
hour
allow
realist
full
day
labor
load
throughput
calcul
reduc
measur
data
data
evalu
month
post
implement
collect
two
site
resultsfind
custom
use
select
detector
test
bag
system
two
vendor
seven
compon
process
hardsoft
spin
sourc
leukocyt
pediatr
rbc
rbc
secondari
process
singl
cryo
singl
rdpsfsc
plasma
yield
increas
overal
compar
manual
process
yield
vari
process
type
centrifug
speed
site
use
hae
rcpl
bag
system
initi
soft
spin
secondari
hard
spin
rdp
increas
plasma
yield
achiev
use
hae
bag
system
initi
hard
spin
secondari
hard
spin
freezethaw
cryo
plasma
initi
increas
evalu
month
post
implement
site
averag
throughput
depend
averag
time
oper
unload
reload
unit
time
varianc
observ
depend
bag
system
complex
practic
number
use
two
oper
workload
produc
highest
throughput
secondari
process
singl
cryo
singl
rdp
unit
produc
per
hour
hard
spin
process
bag
type
two
oper
six
produc
backgroundcas
studi
plateletpheresi
unit
must
store
c
maintain
viabil
storag
make
unit
suscept
bacteri
growth
could
lifethreaten
fatal
patient
sinc
unit
collect
center
cultur
releas
identifi
unit
possibl
danger
transfus
recipi
review
process
illustr
effect
give
insight
risk
cultur
releas
process
studi
designmethod
product
record
review
june
cultur
process
initi
march
plateletpheresi
unit
held
hour
sampl
cultur
use
rapid
microbiolog
test
system
aerob
cultur
cultur
held
throughout
day
life
product
unit
avail
inventori
cultur
immedi
notif
system
fax
place
everi
custom
notif
unit
recal
need
notic
sent
immedi
sampl
becam
posit
cultur
bottl
give
posit
report
sent
nearbi
univers
microbiolog
laboratori
gram
stain
subcultur
identif
posit
evalu
probabl
sourc
gram
stain
subcultur
neg
growth
cultur
classifi
fals
posit
notif
cultur
outcom
sent
custom
ship
unit
report
transfus
fals
posit
unit
cultur
true
posit
total
waiv
cultur
except
releas
unit
requir
immedi
transfus
design
patient
test
unit
failur
process
discard
posit
cultur
product
trigger
action
includ
discard
blood
center
inventori
true
posit
collect
discard
process
notif
facil
receiv
posit
cultur
product
instruct
return
discard
unit
facil
notifi
regard
outcom
test
unit
report
transfus
collect
found
true
cultur
posit
alreadi
ship
five
collect
return
discard
five
posit
cultur
unit
transfus
notif
transfus
reaction
receiv
unit
conclus
notif
receiv
facil
true
posit
success
acknowledg
true
posit
like
skin
environment
contamin
group
contain
transfus
unit
signific
donorassoci
posit
cultur
collect
intercept
prior
shipment
remov
inventori
cultur
plateletpheresi
unit
hour
hold
conjunct
robust
commun
system
connect
facil
receiv
ship
blood
compon
effect
deterr
bacteri
contamin
advers
event
last
year
enhanc
cultur
techniqu
may
add
addit
assur
prevent
advers
event
contamin
platelet
water
salt
intak
blood
donat
reduc
vasovag
reaction
gender
age
group
whole
blood
donor
pierr
robillard
yve
backgroundcas
studi
new
donor
hemovigil
system
implement
octob
captur
sever
vasovag
reaction
vvr
program
donor
drink
water
eat
salt
snack
donat
implement
june
th
aim
studi
measur
effect
watersalt
snack
distribut
rate
vvr
without
loss
conscious
loc
studi
designmethod
preimplement
pre
period
prior
implement
sep
jun
postimplement
post
period
follow
implement
jun
mar
pre
donor
inform
registr
drink
water
donat
amount
mention
suppli
vari
empti
glass
donor
fill
water
tank
juic
box
water
bottl
noth
snack
offer
donat
mostli
sugari
june
th
program
introduc
collect
site
leaflet
poster
pictogram
inform
donor
import
drink
water
eat
salt
snack
given
water
bottl
bag
salt
pretzel
arriv
told
drink
whole
bottl
donat
eat
pretzel
check
point
monitor
consumpt
registr
interview
venipunctur
reinforc
made
check
point
bottl
empti
sever
vvr
report
standard
form
rate
vvr
vvrloc
calcul
per
donat
prepost
rate
compar
use
chisquar
test
resultsfind
signific
reduct
number
rate
vvr
see
tabl
risk
reduct
vvr
vvrloc
conclus
captur
sever
vvr
allow
quick
evalu
prevent
program
whole
blood
donor
structur
program
water
salt
snack
deliveri
blood
collect
site
significantli
reduc
incid
vvr
sex
age
group
improv
donor
safeti
make
donat
experi
better
like
donor
return
reactiv
may
mask
clinic
signific
underli
alloantibodi
dtt
treatment
welldocu
remedi
interfer
howev
blood
bank
struggl
bring
protocol
inhous
instead
send
test
refer
lab
great
expens
term
cost
turnaround
time
tat
purpos
studi
compar
inhous
dtt
protocol
versu
refer
lab
protocol
term
cost
turnaround
time
studi
designmethod
retrospect
review
blood
bank
patient
daratumumab
therapi
februari
april
includ
patient
type
screen
perform
studi
period
collect
follow
data
age
sex
date
daratumumab
start
total
number
type
screen
locat
test
tat
test
patient
type
screen
perform
exclud
analysi
februari
decemb
type
screen
sampl
sent
refer
laboratori
test
cost
approxim
per
test
januari
current
use
valid
dtt
inhous
protocol
test
cost
approxim
dollar
per
test
includ
tech
time
reagent
cost
resultsfind
studyperiod
notifi
daratumumab
patient
might
requir
transfus
exclud
patient
analysi
due
lack
type
screen
order
leav
patient
analysi
sampl
sent
refer
lab
time
test
hous
time
averag
tat
refer
lab
hour
minut
compar
inhous
tat
hour
minut
equat
time
save
hour
minut
averag
total
spent
approxim
sampl
test
refer
lab
versu
inhous
test
sampl
conclus
valid
inhous
dtt
protocol
significantli
decreas
tat
type
screen
daratumumab
patient
popul
addit
experienc
signific
cost
save
bring
dtt
test
inhous
compar
send
sampl
refer
laboratori
bring
test
inhous
also
significantli
reduc
time
blood
avail
patient
popul
signific
injuri
associ
vasovag
reaction
mari
j
townsend
hani
kamel
marjori
bravo
blood
system
inc
backgroundcas
studi
blood
donat
rel
safe
advers
event
occur
due
insert
larg
bore
needl
physiolog
respons
loss
roughli
ml
blood
andor
underli
condit
donor
common
advers
event
ae
vasovag
reaction
vvr
usual
resolv
spontan
minim
medic
intervent
loss
conscious
loc
accompani
vvr
donor
may
fall
risk
injuri
fall
result
signific
injuri
si
injuri
requir
medic
intervent
studi
designmethod
analyz
allogen
apheresi
wb
needlein
collect
month
vasovag
event
identifi
case
report
signific
injuri
base
classif
medic
director
consist
aabb
definit
report
signific
injuri
categori
includ
close
head
injuri
concuss
dental
injuri
fractur
lacer
motor
vehicl
accid
mva
record
review
perform
report
case
close
head
injuri
includ
diagnos
concuss
rate
signific
injuri
calcul
per
needlein
ni
allogen
donat
overal
proport
loc
event
resultsfind
allogen
needlein
donat
vvr
rate
ni
includ
loc
rate
ni
reaction
si
event
donat
rate
ni
donat
loc
reaction
highest
rate
lacer
ni
concuss
ni
lowest
mva
ni
femal
suffer
injuri
male
respect
young
donor
yo
injuri
older
donor
yo
respect
p
first
time
donor
injuri
repeat
donor
respect
p
signific
differ
injuri
young
male
young
femal
donor
older
male
older
femal
donor
fortythre
donor
sought
medic
intervent
injuri
except
donor
small
lacer
donor
broken
tooth
lost
followup
conclus
signific
injuri
rare
event
associ
loc
case
record
signific
injuri
almost
alway
requir
medic
intervent
result
incur
cost
continu
donor
vigil
safeti
measur
prevent
loc
help
mitig
potenti
avoid
event
specif
studi
verax
test
bacteria
platelet
lisa
shinefeld
nanci
best
miranda
william
erica
boudreau
adam
lousararian
mark
lamkin
remo
vallejo
verax
biomed
inc
backgroundcas
studi
pgdprime
rapid
test
bacteria
platelet
develop
improv
test
current
use
safeti
measur
platelet
transfus
design
provid
simpler
test
procedur
compar
current
product
current
pgd
test
employ
intact
igg
captur
detector
antibodi
vulner
low
rate
fals
posit
result
sampl
contain
high
level
heterophil
antibodi
rheumatoid
factor
new
pgdprime
test
incorpor
intact
igg
captur
f
ab
fragment
detector
antibodi
test
line
well
stringent
sampl
prepar
regim
reduc
alreadi
low
fals
posit
fp
rate
studi
designmethod
specif
new
test
evalu
limit
studi
test
cultureneg
individu
platelet
unit
pool
variou
type
sampl
type
includ
leukocytereduc
apheresi
platelet
plasma
leukocytereduc
whole
blood
deriv
platelet
lrwbdp
leukocytereduc
whole
blood
deriv
platelet
pool
lr
pool
prestorag
poststorag
nonleukocytereduc
whole
blood
deriv
platelet
nlrwbdp
poststorag
pool
nonleukocytereduc
whole
blood
deriv
platelet
nlr
pool
leukocytereduc
apheresi
platelet
platelet
addit
solut
pa
addit
frozen
plasma
sampl
accumul
year
platelet
unit
identifi
fals
posit
user
current
pgd
test
run
new
test
determin
suscept
sampl
result
backgroundcas
studi
blood
transfus
mani
part
world
reli
serolog
screen
hepat
b
surfac
antigen
hbsag
prevent
transfus
transmit
hbv
infect
sensit
hbsag
assay
must
capabl
cope
wide
rang
mutant
without
compromis
specif
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
address
need
screen
assay
improv
autom
assay
detect
hbsag
develop
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
confirm
hbsag
evalu
next
gener
autom
platform
abbott
alin
reproduc
assess
day
sensit
evalu
use
known
posit
sampl
commerci
avail
seroconvers
panel
rd
intern
hbsag
standard
hbsag
mutant
hbsag
genotyp
specimen
h
specif
evalu
sampl
obtain
random
blood
plasmapheresi
donor
resultsfind
within
laboratori
imprecis
less
cv
posit
sampl
day
test
overal
specif
sensit
presum
hbsag
posit
sampl
genotyp
mutant
detect
vs
licens
compar
assay
seroconvers
detect
compar
licens
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
analyt
sensit
rang
ngml
alin
hbsag
confirmatori
assay
confirm
posit
hbsag
specimen
includ
hbsag
mutant
sampl
confirm
licens
compar
hbsag
confirmatori
assay
new
autom
alin
hbsag
assay
provid
accept
perform
precis
specif
sensit
alin
assay
demonstr
gain
sensit
licens
compar
assay
detect
confirm
wider
rang
mutant
vasovag
reaction
blood
donat
requir
medic
attent
retrospect
studi
possibl
risk
factor
noorhayati
rahamat
avelina
ho
reuben
vamadevan
health
scienc
author
backgroundcas
studi
vasovag
sever
reaction
classifi
donor
sever
symptom
exampl
prolong
recoveri
faint
convuls
incontin
requir
medic
attent
mild
moder
reaction
accompani
injuri
also
includ
categori
donor
refer
hospit
observ
recent
year
number
sever
reaction
notic
rise
unpleas
undesir
trend
alarm
especi
advers
reaction
caus
blood
donor
injur
fall
fish
bone
diagram
use
identifi
factor
number
sever
reaction
age
gender
donat
histori
ethnic
highlight
studi
aim
analyz
preval
sever
reaction
past
year
find
differ
sever
reaction
demograph
variablesag
donat
histori
firsttimerepeat
donor
gender
malefemal
ethnic
chinesemalayindianoth
number
sever
reaction
studi
designmethod
retrospect
data
gather
hemovigil
report
whole
blood
donat
januari
octob
total
number
donat
perform
period
reaction
case
sever
reaction
requir
medic
attent
descript
analysi
inferenti
statist
use
chi
squar
use
find
differ
number
reaction
demograph
signific
threshold
set
resultsfind
incid
total
reaction
stood
number
sever
reaction
requir
medic
attent
hemovilgil
report
increas
percentag
sever
reaction
compar
vs
respect
rate
sever
reaction
higher
among
age
group
compar
age
group
vs
p
femal
experienc
sever
reaction
male
vs
p
repeat
donor
lesser
sever
reaction
firsttim
donor
vs
p
indian
highest
number
sever
reaction
compar
chines
malay
ethnic
group
vs
vs
vs
respect
despit
rise
trend
demograph
variabl
found
statist
signific
number
sever
reaction
even
still
need
good
commun
import
proper
rest
hydrat
blood
donat
reinforc
proper
donor
care
staff
donor
need
address
well
conclus
donor
experienc
sever
reaction
result
blood
donat
may
rise
howev
show
differ
demograph
variabl
number
sever
reaction
nevertheless
donor
safeti
quintessenti
factor
blood
donat
optim
target
minim
rate
reaction
recogn
vulner
cohort
donor
donat
staff
take
extra
measur
commun
pre
post
donat
advic
group
staff
would
also
abl
anticip
reaction
henc
monitor
close
backgroundcas
studi
form
partnership
import
strategi
promot
blood
donat
support
donor
center
entir
commun
donor
center
strive
engag
meaning
lesbian
gay
bisexu
transgend
queer
lgbtq
commun
also
compli
feder
regul
defer
male
sex
male
msm
last
month
univers
lgbtq
group
approach
campusbas
donor
center
idea
host
blood
drive
highlight
current
msm
donor
regul
provid
other
opportun
voic
opinion
fda
work
group
organ
blood
drive
also
maintain
feder
regul
blood
donat
knowledg
publish
report
donor
center
support
lgbtq
sponsor
blood
drive
herein
describ
develop
partnership
evalu
merit
studi
designmethod
collabor
initi
univers
lgbtq
group
email
commun
follow
inperson
meet
plan
blood
drive
prior
drive
recruit
donor
center
medic
staff
lgbtq
group
leadership
review
criteria
donor
elig
import
product
safeti
also
divers
sensit
educ
donor
selfidentif
guidelin
provid
donor
collect
staff
lgbtq
group
use
flier
social
media
public
drive
member
member
subsequ
pledg
donat
elig
recruit
other
donat
person
inelig
group
provid
regulatori
materi
msm
donat
member
recruit
prior
donat
day
drive
allianc
set
tabl
outsid
donor
center
provid
inform
interest
particip
msm
regul
opportun
sign
petit
fda
resultsfind
partnership
result
success
implement
collabor
blood
drive
lgbtq
group
repeat
second
year
first
lgbtq
blood
drive
donat
collect
first
day
drive
donat
second
day
second
year
lgbtq
blood
drive
held
one
day
donat
collect
valu
compar
averag
daili
collect
donat
per
month
resultsfind
total
student
survey
male
femal
donat
blood
previous
donor
donat
half
survey
student
thought
enough
knowledg
blood
donat
report
social
media
univers
main
sourc
knowledg
respect
educ
school
report
survey
student
influenc
parent
peer
report
respect
person
moral
altruism
report
awar
blood
bank
locat
blood
drive
report
squ
student
nonsqu
student
statist
signific
differ
motiv
discourag
factor
toward
blood
donat
squ
nonsqu
student
tabl
conclus
squ
student
report
higher
rate
motiv
lower
rate
discourag
factor
factor
toward
blood
donat
compar
nonsqu
student
reflect
influenc
increas
effort
improv
knowledg
blood
donat
recruit
among
student
squ
run
yearli
competit
colleg
blood
donat
need
extend
effort
societi
improv
awar
blood
donat
distinct
promot
strategi
adopt
increas
first
time
repeat
blood
donat
among
youth
altern
backgroundcas
studi
pgdprime
test
bacteria
platelet
later
flow
assay
develop
improv
test
current
use
safeti
measur
platelet
transfus
simplifi
test
procedur
current
product
robust
sampl
matrix
variat
challeng
test
neg
posit
sampl
variou
matrix
condit
compon
level
higher
lower
expect
normal
rang
platelet
sampl
studi
designmethod
platelet
sampl
produc
potenti
interfer
level
list
tabl
test
use
resultsfind
withinlaboratori
imprecis
less
posit
sampl
day
test
clinic
sensit
specif
blood
donor
popul
new
autom
alin
htlv
iii
assay
provid
specif
sensit
compar
licens
compar
assay
result
indic
new
alin
autom
htlv
iii
assay
provid
accept
perform
specif
sensit
precis
detect
malaria
dna
malaria
antibodi
nonreact
blood
donor
case
report
ramir
alcantara
hwee
huang
tan
health
scienc
author
blood
servic
group
backgroundcas
studi
transfus
transmit
malaria
remain
rare
seriou
complic
associ
blood
transfus
nonmalaria
endem
countri
like
singapor
recent
evid
suggest
main
risk
introduc
malaria
blood
suppli
nonendem
countri
donor
previou
resid
malaria
endem
area
donor
consid
semiimmun
low
level
parasitemia
asymptomat
malaria
antibodi
test
use
sever
nonendem
countri
identifi
semiimmun
blood
donor
prevent
transfus
transmit
malaria
report
detect
malaria
dna
pcr
malaria
antibodi
nonreact
donor
previou
resid
malaria
endem
area
studi
designmethod
donor
year
old
male
india
donat
st
time
singapor
deni
histori
malaria
infect
inform
blood
bank
last
visit
india
month
ago
donor
allow
donat
malaria
antibodi
test
pcr
perform
parallel
assess
malaria
risk
donor
resultsfind
result
show
malaria
antibodi
test
nonreact
plasmodium
dna
use
pcr
detect
donor
sampl
sampl
sent
refer
laboratori
plasmodium
vivax
identifi
donor
donat
discard
immedi
contact
senior
medic
staff
inform
result
new
sampl
collect
one
week
repeat
test
show
result
donat
follow
sampl
sent
anoth
laboratori
perform
malaria
antibodi
test
show
nonreact
result
use
differ
test
kit
result
investig
summar
tabl
donor
perman
defer
refer
infecti
diseas
clinic
evalu
manag
conclus
case
present
demonstr
transfus
transmit
malaria
still
occur
countri
perform
antibodi
test
screen
blood
donor
malaria
pcr
perform
parallel
antibodi
test
donat
donor
would
issu
use
may
transmit
malaria
patient
requir
blood
transfus
studi
requir
determin
incid
signific
antibodi
nonreact
pcr
posit
case
especi
nonendem
countri
wherein
signific
number
donor
previou
resid
malaria
endem
area
optim
deglycerol
manual
glycerol
red
blood
cell
use
autom
cell
processor
audrey
laforcelavoi
jessica
costanzoyanez
de
grandmont
marieclair
chevrier
marc
cloutier
backgroundcas
studi
inventori
contain
rare
red
blood
cell
rbc
glycerol
use
meryman
manual
method
current
unit
deglycerol
use
cobe
outdat
need
replac
shortli
although
autom
cell
processor
integr
activ
glycerol
deglycerol
rbc
yet
valid
deglycerol
manual
glycerol
rbc
unit
studi
aim
optim
deglycerol
manual
glycerol
unit
use
autom
cell
processor
system
sinc
unit
still
manual
glycerol
current
oper
optim
also
includ
determin
optim
age
rbc
unit
moment
freez
studi
designmethod
twenti
manual
glycerol
rbc
unit
inventori
frozen
approxim
ten
year
thaw
water
bath
deglycerol
use
autom
cell
processor
system
acp
haemonet
suspend
separ
experi
addit
rbc
unit
manual
glycerol
day
postcollect
per
group
unit
frozen
day
unit
thaw
deglycerol
acp
final
improv
recoveri
deglycerol
centrifug
step
test
compar
deglycerol
process
without
centrifug
pool
andsplit
experi
test
condit
rbc
vitro
qualiti
assess
hour
deglycerol
resultsfind
deglycerol
unit
test
met
criteria
hematocrit
steril
hour
storag
hemolysi
still
lower
typic
obtain
unit
deglycerol
cobe
unit
met
criteria
hemolysi
hemoglobin
unit
howev
addit
centrifug
step
recoveri
could
improv
lower
averag
hemolysi
age
unit
time
glycerol
influenc
hemolysi
upon
deglycerol
inde
hemolysi
significantli
higher
unit
frozen
day
collect
compar
frozen
day
result
justifi
need
evalu
optim
postcollect
time
unit
still
manual
glycerol
institut
set
experi
deglycerol
unit
compli
standard
hematocrit
hemoglobin
hemolysi
steril
long
glycerol
frozen
later
seven
day
postcollect
conclus
rbc
unit
manual
glycerol
deglycerol
acp
autom
cell
processor
suspend
store
hour
met
vitro
qualiti
standard
steril
hematocrit
standard
hemolysi
met
everi
unit
vastli
improv
compar
routin
obtain
cobe
difficulti
reach
standard
hemoglobin
might
relat
centrifug
volum
limit
inde
centrifug
step
remov
excess
supernat
prior
deglycerol
acp
seem
improv
blood
qualiti
red
blood
cell
yield
thu
autom
cell
processor
use
deglycerol
rbc
unit
manual
glycerol
provid
improv
sensit
detect
hcv
preseroconvers
window
serolog
test
provid
continu
detect
hcv
infect
individu
individu
resolv
infect
detect
hcv
rna
blood
plasma
center
requir
high
throughput
antihcv
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safeti
blood
plasma
suppli
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
address
need
screen
assay
improv
autom
assay
detect
antibodi
hcv
develop
studi
designmethod
perform
immunoassay
detect
antibodi
hcv
evalu
next
gener
autom
platform
abbott
alin
reproduc
assess
day
use
antihcv
posit
sampl
specif
evalu
sampl
obtain
volunt
blood
donor
plasmapheresi
donor
unit
state
sensit
evalu
use
preselect
antihcv
posit
antihcv
posit
chronic
infect
sampl
seroconvers
panel
confirm
repeatedli
reactiv
sampl
done
use
test
algorithm
consist
hcv
score
hcv
quantit
rna
assay
resultsfind
withinlaboratori
imprecis
less
cv
posit
sampl
test
day
clinic
sensit
preselect
specimen
seroconvers
sensit
better
licens
compar
evidenc
new
antihcv
assay
identifi
earlier
bleed
seroconvers
panel
specif
blood
donor
plasmapheresi
sampl
result
indic
new
autom
alin
antihcv
assay
provid
accept
perform
precis
specif
sensit
seroconvers
sensit
improv
relat
licens
compar
assay
although
current
confirm
report
transmiss
sarscov
asymptomat
individu
recent
research
data
indic
transfusiontransmit
sarscov
least
theoret
possibl
studi
aim
investig
efficaci
theraflex
mbplasma
system
inactiv
sarscov
human
plasma
theraflex
mbplasma
system
macopharma
use
methylen
blue
mb
combin
visibl
light
reduct
pathogen
infect
plasma
studi
designmethod
leukodeplet
plasma
prepar
whole
blood
use
standard
blood
bank
technolog
plasma
unit
spike
viru
suspens
vv
mblight
treatment
done
accord
manufactur
instruct
use
macotron
illumin
devic
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
standard
titer
sarscov
strain
frankfurt
determin
tissu
cultur
infect
dose
endpoint
titrat
vero
cell
atcc
resultsfind
spike
sarscov
titer
bag
bag
receiv
plasma
unit
alreadi
lowest
test
light
dose
merscov
inactiv
detect
limit
system
result
reduct
factor
bag
bag
conclus
result
demonstr
theraflex
mbplasma
procedur
effect
technolog
inactiv
sarscov
contamin
plasma
unit
haemovigil
taicang
district
jiangsu
provinc
china
wenbiao
liang
xiaofan
ye
jun
xu
weibin
tan
zhichao
chen
jiangsu
provinc
blood
center
suzhou
blood
center
pass
medic
technolog
compani
ltd
guangdong
backgroundcas
studi
establish
haemovigil
system
cover
entir
transfus
chain
import
ensur
safeti
suppli
blood
septemb
pilot
haemovigil
network
base
cloud
technic
built
oper
jiangsu
provinc
china
first
wide
area
haemovigil
network
hwan
china
studi
designmethod
hwan
softwar
standard
transfus
databas
develop
unifi
standard
collect
control
share
exchang
analyz
data
transfus
chain
mean
applic
middlewar
technolog
combin
manual
way
mechan
report
analyz
interv
transfus
advers
event
establish
oper
warn
inform
dispos
advic
issu
effici
emerg
respons
system
built
saa
servic
portal
connect
relev
particip
within
scope
hwan
resultsfind
septemb
end
march
taicang
blood
transfus
servic
issu
unit
blood
compon
unit
red
cell
unit
platelet
unit
total
ffp
unit
cryoprecipit
patient
transfus
unit
blood
compon
thu
blood
compon
pilot
site
trace
donor
recipi
vice
versa
donor
complic
among
blood
donat
patient
suffer
allerg
reaction
advers
incid
transfus
chain
report
captur
conclus
exemplari
hwan
cover
entir
transfus
chain
explor
work
perfectli
taicang
district
hv
cloud
china
first
region
hv
network
realiz
bidirect
veintovein
monitor
intervent
activ
whole
blood
transfus
chain
meaning
practic
hwan
china
survey
respons
onlin
motiv
interview
question
enhanc
blood
donat
intent
christoph
r
franc
jani
l
franc
ohio
univers
backgroundcas
studi
motiv
interview
effect
enhanc
blood
donor
retent
implement
may
costli
address
econom
challeng
conduct
two
studi
examin
impact
motiv
interview
content
donat
intent
deliv
onlin
survey
studi
designmethod
studi
one
respond
femal
mean
age
year
sd
year
complet
donat
commit
measur
randomli
assign
one
seven
motiv
interviewbas
question
noquest
control
group
studi
two
respond
femal
mean
age
year
sd
year
moder
level
donat
commit
randomli
assign
receiv
zerotofour
motiv
interviewbas
question
studi
futur
donat
intent
measur
immedi
follow
intervent
resultsfind
first
studi
reveal
signific
effect
interview
question
donat
intent
among
particip
moder
blood
donat
commit
f
p
among
low
commit
f
p
high
commit
f
p
studi
two
replic
signific
effect
interview
question
donat
intent
f
p
rel
noquest
control
condit
followup
analys
reveal
significantli
higher
donat
intent
question
combin
p
conclus
find
provid
initi
support
computeradminist
survey
question
model
motiv
interview
content
may
elicit
person
reflect
posit
impact
donat
intent
particularli
among
individu
moder
level
donat
commit
jennif
lider
unit
blood
servic
backgroundcas
studi
blood
center
see
increas
amount
apheresi
platelet
product
reject
high
platelet
concentr
increas
occur
steadili
period
two
year
two
year
timefram
blood
center
discontinu
run
predon
platelet
count
precount
prior
platelet
pheresi
procedur
process
discontinu
order
streamlin
process
elimin
paper
reduc
laboratori
staff
interrupt
precount
collect
day
donat
test
follow
day
averag
previou
three
platelet
count
use
program
instrument
current
donat
increas
platelet
reject
caus
decreas
amount
avail
product
loss
revenu
blood
center
studi
designmethod
team
led
qualiti
staff
develop
implement
plan
begin
obtain
day
donat
precount
donor
pro
con
collect
lab
staff
evalu
significantli
chang
process
depart
reintroduc
paper
record
process
determin
would
implement
trial
period
three
month
evalu
determin
product
cost
save
resultsfind
signific
reduct
high
platelet
concentr
reject
demonstr
blood
center
reject
approxim
product
per
month
project
implement
center
realiz
reduct
product
reject
per
month
result
save
blood
center
approxim
per
month
annual
conclus
implement
obtain
day
donat
donor
platelet
count
result
decreas
reject
platelet
pheresi
product
signific
cost
save
mobil
platelet
collect
hospitalbas
donor
center
david
anthoni
amber
lazareff
deborah
alter
alyssa
ziman
dawn
c
ward
divis
transfus
medicin
depart
patholog
laboratori
medicin
david
geffen
school
medicin
ucla
backgroundcas
studi
apheresi
platelet
ap
collect
hospitalbas
donor
center
limit
two
fix
collect
site
commun
blood
drive
limit
whole
blood
wb
donat
plan
commun
wb
drive
blood
center
evalu
opportun
hold
concurr
wb
ap
mobil
drive
discuss
hospit
baseddonor
center
first
combin
wb
ap
mobil
drive
step
maxim
effici
reduc
cost
mobil
platelet
drive
set
studi
designmethod
blood
donor
field
recruit
request
new
wb
mobil
drive
desir
region
counti
high
interest
ap
donat
day
request
oper
staff
visit
desir
mobil
collect
site
assess
space
donor
registr
donor
histori
segreg
wb
ap
collect
donor
recoveri
electr
outlet
locat
support
apheresi
machin
donor
center
leadership
set
weekli
meet
examin
feasibl
host
concurr
wb
ap
blood
drive
aspect
platelet
collect
requir
mobil
blood
drive
prerequisit
evalu
standard
oper
procedur
review
revis
includ
allow
ap
collect
mobil
drive
ap
suppli
equip
review
eas
transport
field
recruit
educ
recruit
adult
area
high
school
wb
drive
prescreen
abil
donat
multipl
product
hla
test
result
multipar
femal
donor
donat
historyr
blood
cell
loss
staf
mobil
drive
includ
wb
collect
staff
apheresi
oper
addit
oper
staff
mitig
unforese
issu
resultsfind
prescreen
donor
schedul
donat
time
slot
two
back
donor
one
backup
donor
ultim
donat
ap
donor
firsttim
ap
donor
total
product
collect
includ
seven
platelet
unit
doubl
product
singl
product
wb
donat
four
six
hour
respect
platelet
unit
result
cost
save
unit
purchas
outsid
blood
supplier
platelet
collect
bolster
inventori
normal
low
collect
day
postdriv
review
leadership
team
identifi
need
special
mobil
ap
collect
chair
conclus
hospitalbas
donor
center
success
held
combin
wb
ap
mobil
drive
first
time
time
initi
plan
implement
week
approach
ap
donor
select
result
increas
ap
product
cost
effici
manner
tale
three
autom
group
instrument
rane
wannarkafarling
scott
hammel
jennif
vriez
jame
r
stubb
manish
gandhi
mayo
clinic
backgroundcas
studi
obtain
fast
accur
test
result
essenti
hospit
base
donor
center
blood
product
label
avail
patient
use
sever
differ
autom
methodolog
avail
test
facil
want
compar
current
methodolog
solid
phase
autom
gel
system
studi
designmethod
compar
test
result
run
time
three
instrument
time
includ
put
sampl
rack
load
sampl
instrument
order
test
run
time
test
review
result
unload
sampl
aborh
test
includ
front
back
type
includ
weak
du
test
applic
confirm
test
forward
backgroundcas
studi
consist
blood
suppli
support
lifesav
transfus
reli
regular
repeat
volunt
blood
donat
studi
focus
donor
previous
defer
lowhemoglobin
hb
level
better
understand
valu
suppli
postdeferr
educ
inform
action
donor
took
base
deferr
studi
designmethod
anonym
nation
survey
activ
inact
donat
past
month
donor
group
defer
low
hemoglobin
level
conduct
survey
question
assess
postdeferr
donor
action
prefer
regard
post
deferr
educ
understand
deferr
demograph
inform
chisquar
analysi
perform
compar
categor
survey
result
donor
group
p
denot
statist
signific
resultsfind
survey
result
activ
inact
donor
respons
respect
activ
donor
like
recal
receiv
educ
materi
postdeferr
vs
take
iron
vitamin
supplement
vs
live
within
min
donor
site
vs
like
older
yr
vs
inact
donor
counterpart
activ
inact
donor
similar
p
anemia
histori
frequenc
femalegend
predomin
lowpreval
vegan
mix
interest
receiv
inform
rais
hemoglobin
level
conclus
activ
donor
frequent
recal
receiv
educ
materi
low
hemoglobin
deferr
like
take
action
improv
hemoglobin
altern
method
postdeferr
recruit
consid
given
uncertain
valu
postdeferr
inform
compar
activ
vs
inact
donor
donor
pregnanc
question
word
lauri
sutor
jeff
centilli
carter
bloodcar
backgroundcas
studi
larg
commun
blood
center
ask
allogen
blood
donor
histori
pregnanc
screen
risk
transfusionrel
acut
lung
injuri
health
histori
questionnair
almost
exclus
comput
rare
resort
manual
paper
donor
card
made
chang
word
question
pregnanc
adopt
recent
version
uniform
donor
histori
questionnair
late
studi
designmethod
answer
donor
pregnanc
question
januari
sept
review
compar
percent
women
age
answer
ye
whether
ever
pregnant
question
q
regard
pregnanc
reword
donor
screen
manual
exclud
studi
septemb
donor
ask
two
question
ever
pregnant
last
six
week
pregnant
pregnant
septemb
femal
donor
ask
one
combin
question
ever
pregnant
pregnant
look
two
subperiod
septemb
separ
singl
q
two
part
ever
pregnant
pregnant
occur
januari
resultsfind
first
studi
period
femal
donor
year
age
said
ye
ever
pregnant
second
studi
period
chang
q
number
drop
month
month
analysi
donor
respons
show
approxim
decreas
donor
answer
ye
question
ever
pregnant
follow
chang
format
question
two
separ
question
one
combin
question
pregnant
even
emphas
two
part
natur
new
q
minim
improv
observ
last
day
studi
period
femal
year
older
chang
answer
q
ye
hand
chang
answer
ye
precaut
blood
center
system
place
prevent
collect
apheresi
platelet
plasma
procedur
prevent
releas
transfus
plasma
product
return
femal
donor
previous
report
pregnant
even
answer
conclus
concern
femal
donor
either
confus
new
format
question
take
time
read
new
question
studi
could
reveal
effect
commun
strategi
relat
donor
questionnair
blood
shortag
holiday
vs
nonholiday
time
period
virginia
hugh
univers
delawar
backgroundcas
studi
blood
shortag
holiday
especi
challeng
donor
center
transfus
servic
cogent
effort
made
minim
elect
surgeri
holiday
due
decreas
blood
donat
studi
done
analyz
differ
among
four
region
unit
state
month
septemb
decemb
regard
blood
suppli
level
seventyfour
blood
center
studi
designmethod
data
access
america
blood
center
databas
month
indic
number
blood
center
region
follow
west
midwest
south
east
blood
suppli
data
categor
day
day
day
n
number
day
repeat
measur
analysi
varianc
dunnett
ttest
pair
ttest
conduct
use
spss
ascertain
differ
among
four
region
studi
repeat
measur
analysi
independ
variabl
region
depend
variabl
day
blood
suppli
resultsfind
month
septemb
dunnett
test
twosid
reveal
signific
among
four
region
p
analyz
day
blood
suppli
month
decemb
dunnett
ttest
also
reveal
signific
among
four
region
p
mean
day
blood
suppli
region
east
midwest
south
west
mean
day
blood
suppli
region
east
midwest
south
west
mean
day
blood
suppli
region
east
midwest
south
west
blood
center
midwest
region
affect
short
blood
suppli
level
decemb
compar
three
region
eighteen
percent
center
day
blood
suppli
three
occas
five
occas
blood
center
west
region
highest
blood
suppli
level
report
day
day
suppli
christma
day
east
region
report
day
suppli
blood
blood
center
remain
three
region
report
blood
suppli
pair
ttest
twotail
perform
blood
shortag
categori
day
day
day
compar
month
decemb
nonholiday
month
septemb
signific
found
midwest
south
region
three
blood
suppli
categori
east
region
reveal
signific
day
categori
west
region
reveal
signific
differ
blood
suppli
categori
conclus
studi
compar
blood
suppli
level
holiday
month
nonholiday
month
across
four
region
unit
state
dunnett
ttest
determin
differ
region
day
blood
suppli
signific
pair
ttest
reveal
signific
differ
septemb
decemb
blood
suppli
level
midwest
south
east
west
region
midwest
averag
blood
center
day
blood
suppli
month
decemb
septemb
region
studi
prudent
continu
track
blood
suppli
level
donat
transfus
servic
across
countri
identifi
region
vulner
blood
shortag
abstract
transfus
base
new
hypertens
guidelin
jeremi
housekeep
emili
chen
ling
li
yanyun
wu
bloodwork
backgroundcas
studi
gener
blood
donor
consid
healthi
popul
healthier
popul
part
blood
donor
screen
blood
pressur
check
qualifi
donor
blood
donat
criterion
blood
pressur
american
colleg
cardiologyamerican
heart
associ
task
forc
issu
new
blood
pressur
guidelin
new
guidelin
normal
blood
pressur
defin
mm
hg
work
tri
assess
rate
blood
donor
abnorm
blood
pressur
base
new
hypertens
guidelin
studi
designmethod
donor
inform
obtain
blood
center
donat
databas
period
januari
march
first
donat
time
use
donor
resultsfind
pleas
see
tabl
inform
blood
pressur
blood
donor
studi
period
variat
observ
differ
age
group
ethnic
background
conclus
base
snap
shot
studi
signific
number
blood
donor
abnorm
blood
pressur
base
new
hypertens
guidelin
studi
investig
need
confirm
find
assess
need
action
influenc
psycholog
care
anxieti
blood
donor
among
colleg
student
ya
gao
wuhan
blood
center
backgroundcas
studi
nowaday
psycholog
care
play
import
role
societi
colleg
student
major
blood
donat
popul
still
mani
easi
anxiou
advers
reaction
time
blood
donat
defici
medic
knowledg
accord
research
mental
stress
main
caus
advers
reaction
allevi
anxieti
blood
donor
among
colleg
student
becom
import
problem
research
aim
investig
influenc
psycholog
care
anxieti
medic
student
nonmed
student
explor
appropri
mode
promot
educ
voluntari
blood
donat
enhanc
proport
fix
blood
donor
colleg
blood
donor
ensur
blood
suppli
meet
clinic
use
demand
studi
designmethod
student
comprehens
univers
region
citi
age
volunt
donat
blood
randomli
divid
observ
group
control
group
student
group
observ
group
medic
student
nonmed
student
control
group
medic
major
student
nonmed
major
student
control
group
given
routin
blood
donat
nurs
observ
group
given
psycholog
care
treatment
control
group
observ
group
score
selfrat
anxieti
scale
sa
collect
case
advers
reaction
record
respect
resultsfind
observ
group
sa
score
collect
medic
student
nonmed
student
significantli
decreas
donat
p
respect
control
group
sa
score
obviou
chang
donat
p
whether
medic
student
nonmed
student
incid
advers
reaction
control
group
higher
observ
group
p
incid
advers
reaction
nonmed
major
volunt
higher
medic
major
volunt
observ
group
control
group
respect
p
incid
advers
reaction
medic
student
control
group
higher
medic
student
observ
group
p
conclus
psycholog
care
effect
allevi
anxieti
emot
volunt
univers
especi
nonmed
major
student
advers
reaction
prevent
donat
differ
method
nurs
includ
convent
care
psycholog
care
chosen
accord
actual
situat
time
effect
holist
psycholog
care
deserv
promot
allevi
anxieti
emot
incid
revers
reaction
volunt
necessari
establish
scientif
effect
mode
promot
educ
psycholog
counsel
voluntari
blood
donat
backgroundcas
studi
time
platelet
administr
drive
blood
bank
inventori
stabl
platelet
inventori
ensur
time
deliveri
lifesav
blood
product
challeng
maintain
tertiari
care
center
hospitalwid
demand
emerg
prophylact
platelet
transfus
ppt
activ
surgic
oncolog
unit
respect
high
volum
overnight
ppt
lead
earli
morn
inventori
shortag
last
hour
particularli
inventori
shipment
occur
regular
busi
hour
delay
transfus
emerg
situat
addit
overnight
ppt
increas
patient
sleep
interrupt
nonurg
reason
studi
designmethod
singl
inpati
oncolog
unit
found
highest
contributor
number
overnight
platelet
transfus
prophylact
transfus
medicin
oncolog
physiciansnurs
partner
leader
patient
well
initi
explor
patientcentr
reason
delay
overnight
ppt
analysi
demonstr
daili
lab
drawn
overnight
led
ppt
order
abnorm
cbc
result
hour
later
solut
postpon
lab
draw
implement
statist
analysi
signific
use
chisquar
test
perform
percentag
valu
resultsfind
postpon
lab
draw
inpati
oncolog
unit
led
signific
reduct
proport
overnight
platelet
transfus
ppt
also
decreas
frequenc
platelet
inventori
shortag
conclus
partnership
laboratori
clinic
staff
identifi
simpl
yet
impact
solut
reduc
overnight
ppt
postpon
laboratori
collect
time
chang
time
lab
draw
shift
time
platelet
administr
stabil
platelet
inventori
collabor
clinic
staff
oncolog
unit
well
lead
patient
well
initi
help
frame
project
goal
greater
patientcent
tabl
show
neg
antigen
frequenc
donor
popul
compar
publish
frequenc
gener
popul
except
c
fy
b
vel
higher
publish
antigen
frequenc
sort
donor
popul
caucasian
african
american
follow
antigen
neg
frequenc
higher
caucasian
popul
c
vel
importantli
african
american
donor
sever
antigen
higher
publish
neg
antigen
frequenc
includ
follow
c
e
v
vs
fy
co
b
yt
b
see
tabl
also
identifi
rare
donor
conclus
donorscreen
program
util
autom
molecular
assay
enabl
us
better
identifi
phenotypematch
donor
scd
patient
popul
rare
donor
identifi
report
serolog
phenotyp
confirm
american
rare
donor
program
ardp
plan
continu
screen
process
next
sever
year
major
donor
base
molecularli
genotyp
understand
autolog
unit
member
facil
extend
expir
date
beyond
year
rare
product
conclus
practic
vari
greatli
throughout
membership
howev
appear
consensu
high
preval
antigen
neg
unit
frozen
possibl
donor
recruit
specif
target
member
half
member
extend
expir
date
rare
unit
retain
rare
type
inventori
beyond
gener
use
storag
time
wesley
rubenstein
aaron
j
hard
patricia
kopko
elizabeth
allen
univers
california
san
diego
backgroundcas
studi
hemorrhag
event
clinician
often
stockpil
blood
product
bedsid
abrupt
end
massiv
transfus
protocol
mtp
return
product
result
temperaturerel
wast
rbc
wast
maintain
refriger
temperatur
plasma
brought
c
thaw
inevit
wast
cool
requir
c
implement
hemoroam
mobil
blood
storag
refriger
mbr
roemer
industri
sante
ca
highvolum
transfus
event
univers
health
system
includ
hospit
level
trauma
center
obstetr
servic
liver
transplant
servic
inpati
bed
transfus
volum
rbc
unit
annual
evalu
impact
blood
product
wastag
studi
designmethod
approv
fund
obtain
hospit
administr
mbr
purchas
valid
new
standard
oper
procedur
sop
mbr
implement
blood
issu
sop
updat
mbr
pilot
liver
transplant
program
usag
subsequ
expand
entir
health
system
includ
mtp
highvolum
transfus
event
upon
request
stakehold
includ
liver
transplant
team
oper
room
staff
receiv
train
use
mbr
usag
trend
temperaturerel
wast
rbc
plasma
unit
month
backgroundcas
studi
public
address
sustain
red
blood
cell
suppli
suffici
differ
dynam
red
blood
cell
apheresi
platelet
usag
consid
separ
review
experi
meet
inventori
demand
product
although
challeng
meet
group
red
blood
cell
inventori
overal
red
blood
cell
demand
reduc
significantli
effect
patient
blood
manag
apheresi
platelet
howev
demand
sustain
reflect
fact
indic
often
prophylact
sinc
effect
time
age
red
blood
cell
donor
base
collect
demonstr
decid
see
similar
consider
appli
apheresi
donor
base
also
decid
find
extent
recent
restrict
donat
women
histori
pregnanc
effect
particip
apheresi
platelet
donor
studi
designmethod
review
apheresi
platelet
donor
apheresi
platelet
distribut
record
donor
classifi
age
gender
number
donor
differ
age
bracket
express
percentag
annual
total
number
donor
year
also
express
percentag
contribut
age
bracket
made
annual
total
apheresi
platelet
inventori
resultsfind
age
bracket
includ
apheresi
platelet
donor
increas
progress
year
bracket
year
year
apheresi
platelet
donor
year
age
older
percentag
rose
respect
increas
relianc
see
tabl
older
donor
percent
contribut
annual
inventori
year
old
donor
decreas
half
first
full
year
restrict
femal
donor
histori
pregnanc
compar
male
donor
apheresi
platelet
contribut
annual
inventori
increas
femal
contribut
decreas
conclus
signific
age
apheresi
donor
base
relianc
older
donor
thwart
near
futur
like
patient
like
continu
apheresi
donor
restrict
femal
donor
signific
effect
particip
apheresi
donor
ensur
sustain
apheresi
platelet
inventori
program
understand
donor
age
domin
contributor
previous
rel
inaccess
donor
effect
temperatur
probe
placement
blood
shipper
valid
saravan
kumar
arif
rahman
balaji
jayakumar
tyler
rapp
maxq
research
llc
backgroundcas
studi
industri
standard
insul
shipper
design
maintain
red
blood
cell
rbc
unit
c
transport
use
wet
ice
cool
sourc
packout
rbc
bag
payload
direct
contact
wet
icether
detriment
effect
integr
red
blood
cell
maximum
allow
transport
durat
rbc
shipper
vari
base
packout
amount
type
locat
cool
materi
develop
determin
unit
freez
use
rare
product
frozen
facil
tool
use
recruit
long
unit
store
liquid
freez
codabar
unit
inventori
concern
unlicens
frozen
unit
extend
expir
date
valid
blood
center
case
shipper
valid
requir
measur
temperatur
payload
requir
period
time
expos
fulli
pack
shipper
differ
ambient
profil
howev
placement
temperatur
probe
standard
therefor
vari
across
blood
center
studi
aim
understand
demonstr
effect
payload
volum
temperatur
probe
placement
shipper
valid
studi
designmethod
seri
experi
perform
cardboardstyrofoam
shipper
pack
lb
wet
ice
repres
volum
dimens
water
bag
use
substitut
rbc
unit
number
payload
unit
vari
determin
effect
payload
volum
measur
payload
temperatur
payload
unit
place
vertic
insid
payload
holder
bag
wet
ice
place
top
payload
holder
insid
shipper
nist
calibr
temperaturemeasur
devic
use
record
temperatur
everi
minut
differ
locat
insid
shipper
shipper
place
insid
programm
environment
chamber
expos
transient
temperatur
profil
repres
summer
winter
condit
hour
simul
ambient
temperatur
transit
temperatur
payload
differ
locat
shipper
function
time
record
configur
numer
thermal
simul
use
finit
volum
method
fvm
softwar
also
perform
visual
temperatur
distribut
key
configur
comparison
insul
shipper
specif
design
phase
chang
materi
test
similar
ambient
condit
resultsfind
temperatur
record
cardboardstyrofoam
shipper
test
wet
ice
show
variat
payload
differ
locat
insid
shipper
summer
winter
ambient
test
respect
test
result
present
tabl
identifi
import
temperatur
probe
placement
shipper
valid
conclus
placement
temperatur
probe
signific
effect
shipper
valid
durat
data
corrobor
fvm
simul
demonstr
import
choos
appropri
point
temperatur
measur
also
consid
payload
volum
measur
method
appli
backgroundcas
studi
develop
nation
remot
area
transport
blood
often
inconveni
owe
poor
infrastructur
geograph
barrier
issu
blood
unit
taken
back
blood
bank
concern
short
shelf
life
cold
chain
thu
dilemma
blood
storag
hospit
remot
area
blood
storag
littl
blood
suppli
shortag
blood
storag
much
much
higher
blood
expir
wast
result
caus
bottleneck
blood
suppli
decreas
blood
avail
promot
blood
suppli
manag
effici
ensur
blood
avail
remot
area
internet
thing
iot
base
blood
cold
chain
monitor
system
develop
studi
designmethod
rfid
card
attach
red
blood
cell
unit
bag
monitor
cold
chain
red
blood
cell
unit
store
remot
hospit
due
expir
day
taken
back
redistribut
nearbi
hospit
necessari
test
studi
collect
data
use
new
monitor
system
four
island
hospit
analyz
data
blood
expir
statist
method
resultsfind
sinc
new
monitor
system
deploy
among
four
hospit
remot
island
inhabit
red
blood
cell
unit
storag
increas
incid
emerg
blood
collect
suppli
decreas
eight
year
prior
use
new
monitor
system
one
year
sinc
use
new
monitor
system
thu
blood
avail
increas
significantli
also
comparison
time
span
number
expir
red
blood
cell
unit
decreas
expiri
rate
declin
differ
expiri
rate
hospit
use
new
monitor
system
signific
p
advers
report
reus
takeback
blood
unit
applic
internet
thing
promot
blood
avail
blood
suppli
manag
effici
remot
area
blood
inventori
manag
king
hussein
cancer
center
blood
bank
salah
bohisi
maher
sughay
tamara
dabbagh
esraa
alkhateeb
aya
ataallah
mohammad
nour
ghanem
king
hussein
cancer
center
backgroundcas
studi
blood
inventori
manag
tricki
challeng
process
consid
absenc
real
constraint
control
blood
issu
upon
need
therefor
maintain
balanc
guarante
blood
avail
minim
wastag
continu
demand
make
sure
product
use
effect
effici
king
hussein
cancer
center
khcc
blood
bank
blood
unit
donat
year
cover
khcc
patient
demand
minimum
stock
limit
blood
type
govern
amount
donat
accept
daili
basi
accord
jordanian
abo
distribut
figur
daili
total
minimum
stock
limit
establish
base
current
patient
need
review
least
annual
blood
unit
adjust
twice
sinc
base
increas
demand
aim
studi
examin
khcc
inventori
manag
perform
order
consid
appropri
guidelin
best
practic
improv
effici
blood
bank
servic
unus
ffp
identifi
provid
one
unus
unit
one
two
unus
unit
one
three
unus
unit
one
seven
unus
unit
five
patient
expir
transfus
three
ffp
bag
broke
unus
platelet
sixteen
provid
fourteen
one
unus
unit
one
provid
two
unus
unit
one
provid
three
unus
unit
blood
bank
technologist
involv
three
addit
unus
platelet
unit
conclus
signific
reduct
rbc
discard
compar
two
prior
year
due
new
real
time
onlin
blood
product
order
system
real
time
onlin
blood
product
order
system
blood
supplier
lesser
sustain
reduct
platelet
wastag
ffp
platelet
major
reason
discard
unit
order
use
backgroundcas
studi
although
blood
program
number
differ
approach
provid
apheresi
platelet
inventori
hospit
includ
prohibit
return
larg
blood
center
elect
rotat
restock
apheresi
platelet
maintain
site
approxim
healthcar
facil
charg
servic
reli
mani
hospit
typic
experi
rel
high
daili
transfus
demand
apheresi
platelet
accept
shorter
date
unit
return
blood
center
daili
rotat
schedul
recent
howev
increas
number
request
facil
keep
onsit
inventori
apheresi
platelet
compli
anticip
matern
level
care
design
requir
massiv
transfus
protocol
trauma
level
design
background
continu
challeng
maintain
adequ
inventori
hospit
made
acut
increas
demand
product
age
apheresi
platelet
donor
base
decid
investig
rotat
restock
polici
close
want
pay
special
attent
proport
overal
apheresi
platelet
suppli
rotat
restock
manag
also
proport
inventori
eventu
lost
outdat
short
date
product
return
rotat
restock
hospit
transfus
busier
transfus
servic
studi
designmethod
review
annual
apheresi
platelet
suppli
rotat
nonrot
hospit
select
special
attent
rotat
hospit
return
apheresi
platelet
stock
daili
averag
determin
number
hour
outdat
remain
apheresi
platelet
issu
return
evalu
carri
return
platelet
eventu
percentag
outdat
resultsfind
apheresi
platelet
distribut
hospit
distribut
provid
rotat
restock
hospit
hospit
platelet
rotat
restock
program
util
less
platelet
ship
averag
hour
remain
platelet
ship
hour
remain
outdat
platelet
return
total
number
platelet
distribut
hospit
use
remain
return
ultim
outdat
conclus
opportun
improv
effici
rotat
restock
polici
depend
approv
extend
outdat
apheresi
platelet
beyond
current
permiss
day
regard
cold
store
platelet
much
longer
shelf
life
would
significantli
reduc
transport
deliveri
cost
associ
inventori
rotat
schedul
also
decreas
number
short
date
product
risk
outdat
redistribut
hour
shelf
life
remain
hospit
busi
transfus
servic
